

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTAL653RAW

PASSWORD:

***** RECONNECTED TO STN INTERNATIONAL *****
SESSION RESUMED IN FILE 'REGISTRY' AT 12:34:32 ON 07 OCT 2004
FILE 'REGISTRY' ENTERED AT 12:34:32 ON 07 OCT 2004
COPYRIGHT (C) 2004 American Chemical Society (ACS)

COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
1067.56	1067.77

=> Index biosci

FILE 'DRUGMONOG' ACCESS NOT AUTHORIZED
COST IN U.S. DOLLARS

FULL ESTIMATED COST

SINCE FILE ENTRY	TOTAL SESSION
1067.98	1068.19

INDEX 'ADISCTI', ADISINSIGHT, ADISNEWS, AGRICOLA, AQUALINE, ANABSTR, ANTE,

AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
BIOTECHNO, CABA, CANCERLIT, CAPUS, CEABA-VTB, CEN, CIV, CONFSCI, CROB,
CROPU, DISSABS, DFB, DDFU, DGENE, ... ENTERED AT 12:34:53 ON 07 OCT

2004

74 FILES IN THE FILE LIST IN STNINDEX

Enter SET DETAIL ON to see search term postings or to view
search error messages that display as 0 with SET DETAIL OFF.

=> s 11

0*	FILE ADISCTI
0*	FILE ADISINSIGHT
0*	FILE ADISNEWS
0*	FILE AGRICOLA
0*	FILE AQUALINE
0*	FILE ANABSTR
0*	FILE ANTE
0*	FILE AQUASCI
0*	FILE BIOBUSINESS
0*	FILE BIOCOMMERCE
0*	FILE BIOENG
0*	FILE BIOSIS
0*	FILE BIOTECHABS
0*	FILE BIOTECHDS
0*	FILE BIOTECHNO
0*	FILE CABA
0*	FILE CANCERLIT
0*	FILE CAPUS
0*	FILE CEABA-VTB
0*	FILE CEN

0*	FILE CIN
0*	FILE CONFSCI
0*	FILE CROB
0*	FILE CROPU
0*	FILE DISSABS
0*	FILE DFB
0*	FILE DDFU

=> set detail on
SET COMMAND COMPLETED

=> s 11

FILE 'ADISCTI'
'SQSP' IS NOT A VALID FIELD CODE
0 CIPNDGFTV[ANDQEGILMFSTV][EGKSY][PDENGLKSTV][RGW][LIRKNOQS
TV][LLEWY]/SQSP

FILE 'ADISINSIGHT'
'SQSP' IS NOT A VALID FIELD CODE
0 CIPNDGFTV[ANDQEGILMFSTV][EGKSY][PDENGLKSTV][RGW][LIRKNOQS
TV][LLEWY]/SQSP

FILE 'ADISNEWS'
'SQSP' IS NOT A VALID FIELD CODE
0 CIPNDGFTV[ANDQEGILMFSTV][EGKSY][PDENGLKSTV][RGW][LIRKNOQS
TV][LLEWY]/SQSP

FILE 'AGRICOLA'
'SQSP' IS NOT A VALID FIELD CODE
0 CIPNDGFTV[ANDQEGILMFSTV][EGKSY][PDENGLKSTV][RGW][LIRKNOQS
TV][LLEWY]/SQSP

FILE 'AQUALINE'
'SQSP' IS NOT A VALID FIELD CODE
0 CIPNDGFTV[ANDQEGILMFSTV][EGKSY][PDENGLKSTV][RGW][LIRKNOQS
TV][LLEWY]/SQSP

FILE 'ANABSTR'
'SQSP' IS NOT A VALID FIELD CODE
0 CIPNDGFTV[ANDQEGILMFSTV][EGKSY][PDENGLKSTV][RGW][LIRKNOQS
TV][LLEWY]/SQSP

FILE 'ANTE'
'SQSP' IS NOT A VALID FIELD CODE
0 CIPNDGFTV[ANDQEGILMFSTV][EGKSY][PDENGLKSTV][RGW][LIRKNOQS
TV][LLEWY]/SQSP

FILE 'AQUASCI'
'SQSP' IS NOT A VALID FIELD CODE
0 CIPNDGFTV[ANDQEGILMFSTV][EGKSY][PDENGLKSTV][RGW][LIRKNOQS
TV][LLEWY]/SQSP

FILE 'BIOBUSINESS'
'SQSP' IS NOT A VALID FIELD CODE
0 CIPNDGFTV[ANDQEGILMFSTV][EGKSY][PDENGLKSTV][RGW][LIRKNOQS
TV][LLEWY]/SQSP

FILE 'BIOCOMMERCE'
'SQSP' IS NOT A VALID FIELD CODE
0 CIPNDGFTV[ANDQEGILMFSTV][EGKSY][PDENGLKSTV][RGW][LIRKNOQS
TV][LLEWY]/SQSP

FILE 'BIOENG'
'SQSP' IS NOT A VALID FIELD CODE
0 CIPNDGFTV[ANDQEGILMFSTV][EGKSY][PDENGLKSTV][RGW][LIRKNOQS
TV][LLEWY]/SQSP

FILE 'BIOSIS'
'SQSP' IS NOT A VALID FIELD CODE
0 CIPNDGFTV[ANDQEGILMFSTV][EGKSY][PDENGLKSTV][RGW][LIRKNOQS
TV][LLEWY]/SQSP

```

'sosp' IS NOT A VALID FIELD CODE
0 C[PRNDGFTY][ANDDEGLMFPSTYV][EGKSY][PDENQGLKSTY][RGW][LIRKQOPS
TV][ILFWY]/SQSP
FILE 'BIOTECHAS'
'sosp' IS NOT A VALID FIELD CODE
0 C[PRNDGFTY][ANDDEGLMFPSTYV][EGKSY][PDENQGLKSTY][RGW][LIRKQOPS
TV][ILFWY]/SQSP
FILE 'BIOTECHDS'
'sosp' IS NOT A VALID FIELD CODE
0 C[PRNDGFTY][ANDDEGLMFPSTYV][EGKSY][PDENQGLKSTY][RGW][LIRKQOPS
TV][ILFWY]/SQSP
FILE 'BIOTECHNO'
'sosp' IS NOT A VALID FIELD CODE
0 C[PRNDGFTY][ANDDEGLMFPSTYV][EGKSY][PDENQGLKSTY][RGW][LIRKQOPS
TV][ILFWY]/SQSP
FILE 'CABA'
'sosp' IS NOT A VALID FIELD CODE
0 C[PRNDGFTY][ANDDEGLMFPSTYV][EGKSY][PDENQGLKSTY][RGW][LIRKQOPS
TV][ILFWY]/SQSP
FILE 'CANCERLIT'
'sosp' IS NOT A VALID FIELD CODE
0 C[PRNDGFTY][ANDDEGLMFPSTYV][EGKSY][PDENQGLKSTY][RGW][LIRKQOPS
TV][ILFWY]/SQSP
FILE 'CAPLUS'
'sosp' IS NOT A VALID FIELD CODE
0 C[PRNDGFTY][ANDDEGLMFPSTYV][EGKSY][PDENQGLKSTY][RGW][LIRKQOPS
TV][ILFWY]/SQSP
FILE 'CEABA-VTB'
'sosp' IS NOT A VALID FIELD CODE
0 C[PRNDGFTY][ANDDEGLMFPSTYV][EGKSY][PDENQGLKSTY][RGW][LIRKQOPS
TV][ILFWY]/SQSP
FILE 'CEN'
'sosp' IS NOT A VALID FIELD CODE
0 C[PRNDGFTY][ANDDEGLMFPSTYV][EGKSY][PDENQGLKSTY][RGW][LIRKQOPS
TV][ILFWY]/SQSP
FILE 'CIN'
'sosp' IS NOT A VALID FIELD CODE
0 C[PRNDGFTY][ANDDEGLMFPSTYV][EGKSY][PDENQGLKSTY][RGW][LIRKQOPS
TV][ILFWY]/SQSP
FILE 'CONFSCI'
'sosp' IS NOT A VALID FIELD CODE
0 C[PRNDGFTY][ANDDEGLMFPSTYV][EGKSY][PDENQGLKSTY][RGW][LIRKQOPS
TV][ILFWY]/SQSP
FILE 'CROB'
'sosp' IS NOT A VALID FIELD CODE
0 C[PRNDGFTY][ANDDEGLMFPSTYV][EGKSY][PDENQGLKSTY][RGW][LIRKQOPS
TV][ILFWY]/SQSP
FILE 'DISASBS'
'sosp' IS NOT A VALID FIELD CODE
0 C[PRNDGFTY][ANDDEGLMFPSTYV][EGKSY][PDENQGLKSTY][RGW][LIRKQOPS
TV][ILFWY]/SQSP
FILE 'DDFB'
'sosp' IS NOT A VALID FIELD CODE

```

```

0 C[PRNDGFTY][ANDDEGLMFPSTYV][EGKSY][PDENQGLKSTY][RGW][LIRKQOPS
TV][ILFWY]/SQSP
FILE 'DDFV'
'sosp' IS NOT A VALID FIELD CODE
0 C[PRNDGFTY][ANDDEGLMFPSTYV][EGKSY][PDENQGLKSTY][RGW][LIRKQOPS
TV][ILFWY]/SQSP
FILE 'DEBNE'
SEARCH NOT VALID, USE RUN GETSEQ
=> file home
'HOME' IS NOT A VALID FILE NAME
SESSION CONTINUES IN INDEX FILES 'ADISCTI, ADISINSIGHT, ADISENWS, AGRICOLA,
AQUALINE,
ANABSTR, ANTE, AQUASCI, BIOBUSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHAS,
BIOTECHDS, BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CEN, CIN, CONFSCI,
CROB, CROPU, DISASBS, DDFB, DEBNE, DRUGB, DRUGONOG2, INSURUGENWS, DRUGU,
IMRESEARCH, EMBAL, EMBASE, ESBIOBASE, FEDRIP, FOWAD, FOREGE, FROSTI, FSTA,
GENBANK, HEALSAFE, IIPAT, IMSPRODUCT, JICST-EBLUS, KOSMET, LIFESCI, MEDICINF,
MEDLINE, NIOSHTIC, NITS, NUTRACUT, OCEAN, PASCAL, PCTGEN, PHAR, PHARMAM, PHIC,
PHIN, PROMT, PROUSODR, RDISCLOSURE, SCISEARCH, STINTHLINE, TOXCENTER, USPATFULL,
USPAT2, VETB, VETU, WATER, WEIDS, WPIFY, WPIINDEX'
Enter "HELP FILE NAMES" at an arrow prompt (=>) for a list of files
that are available. If you have requested multiple files, you can
specify a corrected file name or you can enter "IGNORE" to continue
accessing the remaining file names entered.

```

```

=> file home
COST IN U.S. DOLLARS
FULL ESTIMATED COST
FILE 'HOME' ENTERED AT 12:36:28 ON 07 OCT 2004

```

```

=> log h
COST IN U.S. DOLLARS
FULL ESTIMATED COST

```

```

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:36:41 ON 07 OCT 2004
Connecting via Winsock to STN

```

```

Welcome to STN International! Enter x:x
LOGINID:SSSPTA1653RAW
PASSWORD:
***** RECONNECTED TO STN INTERNATIONAL *****
SESSION RESUMED IN FILE 'HOME' AT 12:38:07 ON 07 OCT 2004
FILE 'HOME' ENTERED AT 12:38:07 ON 07 OCT 2004
COST IN U.S. DOLLARS

```

```

SINCE FILE TOTAL
ENTRY SESSION
1070.11

```

FULL ESTIMATED COST 0.21 1070.11

=> file biosis caplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST 0.21

FILE 'BIOSIS' ENTERED AT 12:38:20 ON 07 OCT 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'CAPLUS' ENTERED AT 12:38:20 ON 07 OCT 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

=> s 11

'SQSP' IS NOT A VALID FIELD CODE

'SQSP' IS NOT A VALID FIELD CODE

L41 0 L1

=> log h

COST IN U.S. DOLLARS

FULL ESTIMATED COST 1.29

SESSION WILL BE HELD FOR 60 MINUTES

STN INTERNATIONAL SESSION SUSPENDED AT 12:38:57 ON 07 OCT 2004

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTAL653RAW

PASSWORD:

* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *

SESSION RESUMED IN FILE 'BIOSIS, CAPLUS' AT 12:40:39 ON 07 OCT 2004

FILE 'BIOSIS' ENTERED AT 12:40:39 ON 07 OCT 2004

Copyright (c) 2004 The Thomson Corporation.

FILE 'CAPLUS' ENTERED AT 12:40:39 ON 07 OCT 2004

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS

FULL ESTIMATED COST 1.29

=> file home

COST IN U.S. DOLLARS

FULL ESTIMATED COST 1.29

FILE 'HOME' ENTERED AT 12:40:48 ON 07 OCT 2004

=> file caplus

COST IN U.S. DOLLARS

FULL ESTIMATED COST 0.21

FILE 'CAPLUS' ENTERED AT 12:40:52 ON 07 OCT 2004

USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.

PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is held by the publishers listed in the PUBLISHER (PB) field (available for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications.

The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Oct 2004 VOL 141 ISS 15

FILE LAST UPDATED: 6 Oct 2004 (20041006/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 11

L42 5026 L1

=> s 12

L43 114 L2

=> s 13

L44 8 L3

=> s 142 or 143 or 144

L45 5029 L42 OR L43 OR L44

=> dup rem 145

PROCESSING IS APPROXIMATELY 20% COMPLETE FOR L45

PROCESSING IS APPROXIMATELY 42% COMPLETE FOR L45

PROCESSING IS APPROXIMATELY 65% COMPLETE FOR L45

PROCESSING IS APPROXIMATELY 87% COMPLETE FOR L45

PROCESSING COMPLETED FOR L45

L46 4761 DUP REM L45 (268 DUPLICATES REMOVED)

=> s 146 not wescott/in

L47 4761 S L46

L48 4761 L47 NOT WESCOTT/IN

=> s 148 not wescott/au

L49 4761 L48 NOT WESCOTT/AU

=> e wescott/in

AN 2003:719271 CAPLUS
 DN 139:263740
 TI KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy
 IN Sato, Aaron K.; Sexton, Daniel J.; Lader, Robert C.; Dransfield, Daniel
 T.; Swenson, Rolf E.; Marinelli, Edmund R.; Ramalingam, Kondasiddhar;
 Nunn, Adrian D.; Von Wronski, Mathew A.; Shrivastava, Ajay; Pochon,
 Sibylle; Bussat, Philippe; Abogast, Christoph; Filali, Radhakrishna;
 Fan, Hong; Linder, Karen E.; Song, Bo; Nanjappan, Palaniappa
 PA Dyna Corp., USA; Bracco International B.V., et al.
 SO PCT Int. Appl., 350 pp.
 DT Patent
 LA English
 FAN: CNT 2
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI WO 2003074005 A2 20030912 WO 2003-US6731 20030303
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH,
 GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
 LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MX, MY, NZ, NO, OM, PA,
 PE, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, SM, SN, SV,
 SW, SY, SZ, TD, TH, TJ, TM, TR, TT, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW,
 RU, TU, TM
 RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, RO, SE, SI, SK, TR, BF, BU, CF, CG, CI, CM, GA, GN, GQ,
 GW, ML, MR, NE, SN, TD, TG
 WO 2004065621 A1 20040805 WO 2003-US28787 20030911
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH,
 GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK,
 LR, LS, LT, LU, LV, MA, MD, ME, MG, MK, MN, MX, MY, NZ, NO, OM, PA,
 PE, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, SM, SN, SV,
 SW, SY, SZ, TD, TH, TJ, TM, TR, TT, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW,
 RU, TU, TM
 RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
 NL, PT, RO, SE, SI, SK, TR, BF, BU, CF, CG, CI, CM, GA, GN, GQ,
 GW, ML, MR, NE, SN, TD, TG
 PRAI US 2002-36081P P 20020301
 US 2003-44041P P 20030115
 WO 2003-382082 A2 20030303
 WO 2003-US6731 A2 20030303
 AB The present invention relates to polypeptides useful for detecting and
 targeting primary receptors on endothelial cells for VEGF, i.e., VEGF
 receptor 2, also known as kinase domain region (KDR) and fetal liver
 kinase-1 (Flk-1), and for imaging and targeting complexes formed by VEGF
 and KDR. The involvement of VEGF and KDR in angiogenesis makes the
 VEGF/KDR and KDR binding polypeptides of the present invention
 particularly useful for imaging important sites of angiogenesis, e.g.,
 neoplastic tumors, for targeting substances, e.g., therapeutic agents, including
 radiolabeled compounds, to such sites, and for treating certain disease states,
 including those associated with inappropriate angiogenesis. Disclosed are
 synthetic, isolated polypeptides capable of binding KDR or VEGF/KDR
 complex with high affinity (e.g., having a K_D of 10⁻⁹ M).

L53 ANSWER 3 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2003:464737 CAPLUS
 DN 139:12147
 TI Human colon and colon cancer-associated polynucleotides and polypeptides
 and their diagnostic and therapeutic applications
 IN Ruben, Steven M.; Barash, Steve C.; Birse, Charles E.; Rosen, Craig A.
 PA Human Genome Sciences, Inc., USA
 SO U.S. Pat. Appl. Publ., 174 pp., Cont.-in-part of Appl. No. PCT/US00/26524.
 DT Patent
 LA English
 FAN: CNT 3
 PATENT NO. KIND DATE APPLICATION NO. DATE
 PI US 2003109690 A1 20030612 US 2002-106698 20020327
 WO 2001022920 A2 20010405 WO 2000-US26524 20000928
 W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
 CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GR,
 HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
 LU, LV, MA, MD, ME, MG, MK, MN, MX, MY, NZ, NO, OM, PA, PE, PG,
 PH, PL, PT, RO, RU, SC, SD, SE, SG, SI, SK, SL, SM, SN, SV, SW, SY,
 SZ, TD, TH, TJ, TM, TR, TT, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW,
 RU, TU, TM
 RW: GH, GM, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, BG,
 CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT,
 RO, SE, SI, SK, TR, BF, BU, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE,
 SN, TD, TG
 US 2003109690 A1 20030612 US 2002-106698 20020327
 PRAI US 1999-157137P P 19991029
 US 1999-157137P P 19991029
 WO 2000-US26524 A2 20000928
 WO 2000-106698 A 20020327
 AB The present invention relates to 8354 novel colon- or colon cancer-related
 polynucleotides and the polypeptides encoded by these polynucleotides
 herein collectively known as "colon or colon cancer antigens," and the use
 of such colon or colon cancer antigens for detecting disorders of the
 colon, particularly the presence of colon cancer and colon cancer
 metastases. More specifically, isolated colon- or colon cancer-associated,
 nucleic acid molecules are provided encoding novel colon- or colon
 cancer-associated polypeptides. Novel colon or colon cancer polypeptides and
 antibodies that bind to these polypeptides are provided. Also provided
 are vectors, host cells, and recombinant and synthetic methods for
 producing human colon- or colon cancer-associated polynucleotides and/or
 polypeptides. The invention further relates to diagnostic and therapeutic
 methods useful for diagnosing, treating, preventing and/or prognosing
 disorders related to the colon, including colon cancer, and therapeutic
 methods for treating such disorders. The invention further relates to
 screening methods for identifying agonists and antagonists of
 polynucleotides and polypeptides of the invention. The present invention
 further relates to methods and/or compounds for inhibiting the production
 and function of the polypeptides of the present invention. [This abstract
 record is one of two records for this document necessitated by the large
 no. of index entries required to fully index the document and publication
 system constraints.]

L53 ANSWER 4 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 2001:697649 CAPLUS
 DN 135:328137
 TI Nucleic acids and their encoded polypeptides from human nervous system

IN Rosen, Craig A.; Barash, Steven C.; Ruben, Steven M.
PA Human Genome Sciences, Inc., USA
SO PCT Int. Appl., 1701 pp.
CO CODEN: PIXXD2

DT Patent
LA English

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001059063 A2		20010816	WO 2001-US1334	20010117
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GR, GU, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LU, LV, LY, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, BU, BU, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR				
PRAI US 2000-PV179065	20000131			
US 2000-PV180628	20000204			
US 2000-PV184664	20000224			
US 2000-PV186350	20000302			
US 2000-PV189874	20000316			
US 2000-PV190076	20000317			
US 2000-PV198123	20000418			
US 2000-PV205515	20000519			
US 2000-PV209467	20000607			
US 2000-PV214866	20000628			
US 2000-PV215135	20000630			
US 2000-PV216647	20000707			
US 2000-PV216880	20000707			
US 2000-PV217487	20000711			
US 2000-PV217496	20000711			
US 2000-PV218290	20000714			
US 2000-PV220963	20000726			
US 2000-PV220964	20000726			
US 2000-PV225757	20000814			
US 2000-PV225270	20000814			

AB

The present invention relates to novel nervous system-related polynucleotides, the polypeptides encoded by these polynucleotides herein collectively referred to as "nervous system antigens", and antibodies that immunospecifically bind these polypeptides, and the use of such nervous system polynucleotides, antigens, and antibodies for detecting, treating, preventing and/or prognosing disorders of the nervous system, including, but not limited to, the presence of nervous system cancer and nervous system metastases. More specifically, 3324 isolated nervous system cDNA mols. and 7200 genomic DNA mols. are provided encoding novel human nervous system polypeptides. Novel nervous system polypeptides and antibodies that bind to these polypeptides are provided. Also provided are vectors, host cells, and recombinant and synthetic methods for producing human nervous system polynucleotides, polypeptides and/or antibodies. The invention further relates to diagnostic and therapeutic methods useful for diagnosing, treating, preventing and/or prognosing disorders related to the nervous system, including nervous system cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of polynucleotides and polypeptides of the invention. The invention further relates to methods and/or compns. for inhibiting or

promoting the prodn. and/or function of the polypeptides of the invention. [This abstr. record is two of three records for this document necessitated by the large no. of index entries required to fully index the document and publication system constraints.]

L53 ANSWER 5 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:247142 CAPLUS
DN 134:306971
TI Colon and colon cancer associated cDNAs and proteins and their use in diagnosis and treatment of colon cancer
IN Ruben, Steven M.; Barash, Steven C.; Barse, Charles E.; Rosen, Craig A.
PA Human Genome Sciences, Inc., USA
SO PCT Int. Appl., 9787 pp.
CO CODEN: PIXXD2

DT Patent
LA English
FAN, CNT 3

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001022920	A2	20010405	WO 2000-US26524	20000928
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GR, GU, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NL, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, BG, BR, BU, BU, CF, CG, CH, CI, CM, CY, DE, DK, ES, FI, FR, GA, GB, GR, IE, IT, LU, MC, ML, MR, NE, NL, PT, SE, SN, TD, TG, TR				
AU 2000077215	A5	20010430	AU 2000-77215	20000928
EP 1265382	A2	20021218	EP 2000-966944	20000928
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL				
US 2003109690	A1	20030612	US 2002-106698	20020327
US 2003109690	A1	20030612	US 2002-106698	20020327
PRAI US 1999-157137P	P	19990929		
US 1999-163280P	P	19991103		
WO 2000-US26524	W	20000928		
US 2002-106698	A	20020327		

AB

This invention relates to newly identified colon or colon cancer related polynucleotides and the polypeptides encoded by these polynucleotides herein collectively known as "colon cancer antigens", and the use of such colon cancer antigens for targeting specific cell types and/or diagnosing, detecting, preventing and treating disorders of the colon, particularly the presence of colon cancer and colon cancer metastases. This invention relates to colon cancer antigens as well as vectors, host cells, antibodies directed to colon cancer antigens and the recombinant or synthetic methods for producing the same. Also provided are diagnostic methods for diagnosing and treating, preventing and/or prognosing disorders related to the colon, including colon cancer, and therapeutic methods for treating such disorders. The invention further relates to screening methods for identifying agonists and antagonists of colon cancer antigens of the invention. The present invention further relates to inhibiting the prodn. and function of the polypeptides of the present invention.

L53 ANSWER 6 OF 6 CAPLUS COPYRIGHT 2004 ACS on STN

AN 2001:35512 CAPLUS
 DN 134:249803
 TI Spe-29 encodes a small predicted membrane protein required for the initiation of sperm activation in *Caenorhabditis elegans*
 AU Nance, Jeremy; Davis, Elizabeth B.; Ward, Samuel
 CS Department of Molecular and Cellular Biology, University of Arizona, Tucson, AZ, 85721, USA
 SO Genetics (2000), 156(4), 1623-1633
 PB GENETICS: GENETICS: ISSN: 0016-6731
 DT Journal
 LA English
 AB *C. elegans* spermatids complete a dramatic morphogenesis to crawling spermatozoa in the absence of an actin- or tubulin-based cytoskeleton and without synthesizing new gene products. Mutations in 3 genes (*spe-6*, *spe-12*, and *spe-27*) prevent the initiation of this morphogenesis, termed activation. Males with mutations in any of these genes are fertile. By contrast, mutant hermaphrodites are self-sterile when unmated due to a failure in spermatid activation. Intriguingly, mutant hermaphrodites form functional spermatozoa and become self-fertile upon mating, suggesting that spermatids can be activated by male seminal fluid. Here we describe a mutation in a 4th gene, *spe-29*, which mimics the phenotype of *spe-8*, *spe-12*, and *spe-27* mutants. *Spe-29* sperm are defective in the initiation of hermaphrodite sperm activation, yet they maintain the ability to complete the morphogenetic rearrangements that follow. Mutant alleles of *spe-12*, *spe-27*, and *spe-29* exhibit genetic interactions that suggest that the wild-type products of these genes function in a common signaling pathway to initiate sperm activation. We have identified the *spe-29* gene, which is expressed specifically in the sperm-producing germ line and is predicted to encode a small, novel transmembrane protein.
 RE.CNT 39 THERE ARE 39 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> s 143 not e6
 5 "WESCOTT CHARLES R"/IN
 L54 112 L43 NOT "WESCOTT CHARLES R"/IN
 => s 154 and PY<1999
 18927350 PY<1999
 L55 16 L54 AND PY<1999
 => s 155 not 153
 16 L55 NOT L53
 => d 156 bib ab 1-16
 L56 ANSWER 1 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN
 AN 1999:125754 CAPLUS
 DN 130:178389
 TI Nucleic acids encoding human merosin, merosin fragments and uses thereof
 AU Engvall, Eva; Leivo, Ilmo
 CS La Jolla Cancer Research Foundation, USA
 SO U.S., 80 PP., Cont.-in-part of U.S. Ser. No. 919,951, abandoned.
 DT Patent

LA English
 FAI.CNT 3
 PATENT NO.
 P1 US 5872231 A 19990216 US 1993-125077 19930922
 CA 2172385 AA 19950330 CA 1994-2172385 19940921
 WO 9508628 A2 19950330 WO 1994-US10730 19940921
 WO 9508628 A3 19950511
 W: AM, AU, BE, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KR, KZ, LK, LV, MG, MN, NO, NZ, PL, RO, RU, SD, SK, UA, UZ, VN, RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BE, BJ, CF, CG, CI, CM, GA, GN, MT, MR, NE, SN, TD, TG
 AU 9478770 A1 19950410 EP 1994-78770 19940921
 EP 720651 A1 19960710 EP 1994-929860 19940921
 R: BE, CH, DE, DK, FR, GB, IT, LI, NL, SE
 JP 09505985 T2 19970617 JP 1995-509932 19940921
 US 5624905 A 19970429 US 1995-393250 19940921
 US 5837496 A 19981117 US 1995-460309 19950602
 PRAI US 1990-472319 B1 19900130
 US 1992-919951 B2 19920727
 US 1991-734201 B1 19910722
 US 1993-103032 B1 19930708
 US 1993-125077 A 19930922
 WO 1994-US10730 W 19940921
 AB This invention provides an isolated nucleic acid mol. encoding a subunit of a protein, the protein having an apparent mol. wt. of about 800 kDa, designated merosin (also known as laminin 2). Also provided are isolated nucleic acid mols. which encode merosin fragments. Anti-merosin antibodies, vectors for the recombinant prodn. of merosin, and the expression of recombinant proteins by use of a host vector system also are provided. The human merosin gene is mapped on human chromosome 6. The invention further provides the use of merosin to promote neurite growth and for certain diagnostic applications.
 RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
 ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 2 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN
 AN 1996:637403 CAPLUS
 DN 130:50229
 TI Allele frequencies of the STR locus HumFGA in an Italian population
 AU Buscemi, L.; Tagliabacchi, A.; Bianchi, F.; Paoli, M.; Saccaroli, C.; Rodriguez, D.; Gaetano, L.; Ponzano, E.; Cortivo, P.; Previtere, C.; Peloso, G.; Pierucci, G.; Bibbiani, R.; Nardone, M.; Spinetti, I.; Domenici, R.; Bargagna, M.
 CS University of Ancona, Italy
 SO International Congress Series (**1998**), 1167(Progress in Forensic Genetics 7), 249-251
 CODEN: EXMD44; ISSN: 0531-9131
 PB Elsevier Science B.V.
 DT Journal
 LA English
 AB Collaborative research on the polymorphism of the STR locus HumFGA was carried out by the Institutes of Legal Medicine in 4 Italian regions: (Marche, Veneto, Lombardy, and Tuscany). The aim was to establish a database of allelic frequencies with a view to applying HumFGA in forensic identification and paternity testing. The goal for each participating lab. was to study .storeq.100 genotypes of unrelated, locally residing

individuals. The results of statistical anal. were highly informative (PD = 0.96 and mean exclusion change = 0.71) suggesting that this system is a powerful tool for forensic routine.

RE CNT 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L56 ANSWER 3 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1996:681655 CAPLUS
DN 125:319487
TI Structure of the human laminin .alpha.2-chain gene (LAMA2), which is affected in congenital muscular dystrophy

AU Zhang, X.; Votaweano, Reetta; Tryggvason, Karl
CS Division Matrix Biology, Karolinska Institute, Stockholm, S-171 77, Sweden.
SO Journal of Biological Chemistry (**1996**), 271(44), 27664-27669
CODEN: JBCHA3; ISSN: 0021-9258

PA American Society for Biochemistry and Molecular Biology
DT Journal
LA English
AB We have detd. the structure and complete exon size pattern of the human laminin .alpha.2-chain gene (LA-M2), which has been shown to be affected in congenital muscular dystrophy (Helbling-Leclerc, A., Zhang, X., Topaloglu, H., Orsaud, C., Tesson, F., Weissensbach, J., Tome, F. M. S., Schwartz, K., Fardeau, M., Tryggvason, K., and Guicheney, P. (1995) Nat. Genet. 11:216-218). The gene is over 260,000 base pairs and contains 64 exons. The sequence of all exon-intron borders was detd. Two of the exons, i.e., exons 43 and 52, are extremely small in size, 6 and 12 base pairs, resp. Comparison of the exon pattern of the human LAMA2 gene with that of the Drosophila LAMA gene revealed that only 2 of 63 intron locations in the 5'-end of the human gene match the intron locations in the Drosophila gene, which contains 14 introns.

L56 ANSWER 4 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:824041 CAPLUS
DN 124:48609
TI Fibrinogen .alpha. genes: conservation of bipartite transcripts and carboxy-terminal-extended .alpha. subunits in vertebrates

AU Fu, Yiping; Cao, Yan; Herzberg, Kathe M.; Griendinger, Gerd
CS Lindsay F. Kimball Res. Inst. of the New York Blood Center, New York, NY, 10021, USA
SO Genomics (**1995**), 30(1), 71-6
CODEN: GNMCEP; ISSN: 0888-7543

PA Academic
DT Journal
LA English
AB All three well-studied subunits of the clotting protein fibrinogen (.alpha., .beta., .gamma.) share N-terminal structural homologies, but until recently only the .beta. and .gamma. chains were recognized as having similar globular C-terminal. With the discovery of an extra exon in the human fibrinogen .alpha. gene (exon VI), a minor form of the .alpha. subunit (.alpha.E) with an extended .beta.- and .gamma.-like C-terminus has been identified (Fu et al., Biochem. J., 1996, 1992). In the present study, the polymerase chain reaction has been used to identify sequences that encode counterparts to .alpha.E in chicken, rabbit, rat, and baboon. The basic six-exon structure of the fibrinogen .alpha. genes is shown to be conserved among mammals and birds, as are the intron positions. Bipartite transcripts still bearing an intron prior to the last exon-are found among the products of the various vertebrate fibrinogen .alpha.

genes. The last exon represents the largest conserved segment of the gene and, in each species examined, encodes exactly 236 amino acids. The C-termini of these .alpha.E chains align without a single gap and are between 76 and 99% identical. Since the exon VI-encoded domain of .alpha.E is as well conserved as the corresponding regions of the .beta. and .gamma. chains, it follows that it is equally important and that .alpha.E-fibrinogen plays a vital, if as-yet unrecognized physiol. role.

L56 ANSWER 5 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:667298 CAPLUS
DN 123:49265
TI Nucleic acids encoding human merosin, merosin fragments and uses thereof

AU Engvall, Eva; Leivo, Ilmo
PA La Jolla Cancer Research Foundation, USA
SO PCT Int. Appl., 65 pp.
CODEN: PIXND2

DT Patent
LA English
FAN CNT 3

PI PATENT NO. KIND DATE APPLICATION NO. DATE
WO 9508628 A2 19950330 WO 1994-US10730 19940921 <--
W: AM, AU, BE, BG, BR, BY, CA, CN, CZ, FI, GE, HU, JP, KE, KR, KW, LG, LV, MG, MN, NO, NZ, PL, RO, RU, SD, SK, UA, UZ, VN

US 5872231 A 19990216 19930922 <--
US 5872231 A 19990216 19930922 <--
AU 9478770 A1 19950410 AU 1994-78770 19940921 <--
EP 720651 A1 19960710 EP 1994-929860 19940921 <--
R: BE, CH, DE, DK, FR, GB, IT, LI, NL, SE

JP 09505985 T2 19970617 JP 1995-509932 19940921 <--
PRAI US 1993-125077 A 19930922
US 1990-472319 B1 19900130
US 1992-919951 B2 19920727
WO 1994-US10730 W 19940921

AB This invention provides an isolated nucleic acid mol. encoding a subunit of a protein, the protein having an apparent mol. wt. of about 800 kD, designated merosin. Also provided are isolated nucleic acid mols. which encode merosin fragments. Anti-merosin antibodies, vectors for the recombinant prodn. of merosin, and the expression of recombinant proteins by use of a host vector system also are provided. The human merosin gene is mapped on human chromosome 6. The invention further provides the use of merosin to promote neurite growth and for certain diagnostic applications.

L56 ANSWER 6 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1995:393761 CAPLUS
DN 123:248220
TI Cloning and expression of laminin .alpha.2 chain (M-chain) in the mouse

AU Berrier, Suzanne M.; Utani, Atsushi; Katsuhiko, Toshihiro
CS Laboratory of Developmental Biology, National Institute of Dental Research, Bethesda, MD, USA
SO Matrix Biology (**1995**), 14(6), 447-55
CODEN: MTBOEC; ISSN: 0945-053X

PB Fischer
 DT Journal
 LA English
 AB Laminins are a family of heterotrimeric glycoproteins specific to basement membranes. Laminin-2, consisting of .alpha.2, .beta.1, and .gamma.1 chains, was originally identified in the basement membranes of skeletal muscle and peripheral nerve. The authors have isolated and sequenced the full-length cDNA for the mouse laminin .alpha.2 chain. Four overlapping clones spanning 9,330 bp encode a predicted polypeptide of 3,106 amino acids having a calcd. mol. mass of 350 kDa including a 23-amino-acid signal peptide. The amino acid sequence of the .alpha.2 chain shares a 45.9% identity with that of the .alpha.1 chain. Similar to the structure of the .alpha.1 chain, the .alpha.2 chain consists of several domains beginning at the N-terminus with three globular domains alternating with three epidermal growth factor-like domains followed by two .alpha.1-helical domains and a C-terminal globular domain. The most N-terminal globular domain is highly conserved (77.3% identity) between the .alpha.2 and .alpha.1 chains, whereas the .alpha.1-helical domains have low homol. (30.3% identity). Northern blot and RNase protection anal. revealed expression of mRNA for the .alpha.2 chain in heart, kidney, liver, skin, lung and skeletal muscle of newborn mice. Such a tissue distribution suggests a role for the .alpha.2 chain and, consequently, laminin-2 or -4 not only in the organization and the function of nerve and muscle tissue but possibly also in the mesenchymal components of certain tissues.

L56 ANSWER 7 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1994:506510 CAPLUS
 DN 121:106510
 TI Synthetic peptides from fibrinogen and anti-peptide antibodies for use in immunoassay and treatment of fibrinolytic disorders
 IN Kraus, Michael; Stuebel, Werner
 PA Behringwerke AG, Germany
 SO Ger. Offen., 34 pp.
 CODEN: GXXXBX
 DT Patent
 LA German
 FAN.CNT.1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
DE 4242736	A1	19940623	DE 1992-4242736	19921217 <--
EP 605797	A1	19940713	EP 1993-119574	19931209 <--
EP 605797	B1	19990317		
R: AT, BE, CH, DE, DK, ES, FR, GB, IT, LI, LU, NL, PT, SE	E	19990415	AT 1993-119574	19931209
ES 2129487	T3	19990616	ES 1993-119574	19931209
AU 9352435	A1	19940630	AU 1993-52435	19931215 <--
AU 676859	B2	19970327		
US 559678	A	19970204	US 1993-166930	19931215 <--
CA 2111645	AA	19940618	CA 1993-2111645	19931216 <--
JP 06256388	A2	19940913	JP 1993-344306	19931217 <--
US 5861697	A	19991109	US 1996-727045	19961008
US 6441141	B1	20020827	US 1999-408172	19990929
PRAI DE 1992-4242736	A	19921217		
US 1993-166930	A3	19931215		
US 1996-727045	A3	19961008		

AB A method is described for obtaining synthetic peptides by plasmin cleavage of fibrinogen to yield C-terminal ends of the E fragment which are also

antigenic. The peptides are injected into rabbits to produce antibody-producing cells which are used to generate monoclonal antibodies for use in immunoassays or in the treatment of fibrinolytic disorders.

L56 ANSWER 8 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1994:126557 CAPLUS
 DN 120:126557
 TI Human laminin M chain (merosin): complete primary structure, chromosomal assignment, and expression of the M and A chain in human fetal tissues
 AU Vuolteenaho, Reetta; Nissinen, Marja; Salho, Kirsi; Byers, Mary; Eddy, Roger; Hirvonen, Harri; Shows, Thomas B.; Sariola, Hannu; Engvall, Eva; Tryggvason, Karl
 CS Biocent., Univ. Oulu, FIN-90970, Finland
 SO Journal of Cell Biology (***1994***), 124(3), 381-94
 CODEN: JCLB3J; ISSN: 0021-9525

DT Journal
 LA English
 AB The primary structure of the human laminin M chain was ded. from cDNA clones isolated from human placental libraries. The clones covered a total of 6942 bp, with 49-bp encoding a 5' end untranslated region and 6893-bp coding for a translated sequence. The complete human laminin M chain contains a 22-residue signal peptide and 3,068 residues of the mature M chain. The M chain has a domain structure similar to that of the human and mouse A chains. The homol. between the two human laminin heavy chains is highest in the short arm region and lowest in the long arm. helical domain I + II. Northern blot anal. of human fetal tissues showed that the M chain was expressed in most tissues such as cardiac muscle, pancreas, lung, spleen, kidney, adrenal gland, skin, testis, meninges, choroid plexus, and some other regions of the brain, but not in liver, thymus, and bone. In situ hybridization localized the expression of the M chain gene to cells of mesenchymal origin. In contrast, expression of the A chain was obsd. only in kidney, testis, neuroectoderm and some region of brain as dedcd. by Northern analyses. Epithelial and endothelial cells were neg. for both M and A chain gene transcripts. The gene for the human M chain (LMM) was localized to chromosome 6q22.1 (p12.1).

L56 ANSWER 9 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
 AN 1993:489199 CAPLUS
 DN 119:489199
 TI Carboxy-terminal-extended variant of the human fibrinogen .alpha. subunit: a novel exon conferring marked homology to .beta. and .gamma. subunits
 AU Fu, Yiping; Welsbach, Lawrence; Plant, Patricia W.; Odooux, Carole; Cao, Yapi; Liang, T. Joke; Roy, Samar N.; Redman, Colvin M.; Griendling, Gerald
 CS Lindsley F. Kimball Res. Inst., New York Blood Cent., New York, NY, 10021, USA
 SO Biochemistry (***1992***), 31(48), 11968-72
 CODEN: BICHAU; ISSN: 0006-2960

DT Journal
 LA English
 AB Similarities between the N-terminal regions of the three subunits of the clotting protein fibrinogen (.alpha., .beta., .gamma.) suggest that they evolved from a common progenitor. However, to date no human .alpha. chain has been found with the strong C-terminal homol. shared by the .beta. and .gamma. chains. The natural product of a novel fibrinogen .alpha. chain transcript bearing a sep. open reading frame that supplies the missing C-terminal homol. to the other chains is examd. Addtl. splicing leads to the use of this extra sequence as a sixth exon elongating the .alpha.

chain by 35%. Since the extended .alpha. chain (.alpha.2) is assembled into fibrinogen mols. and its synthesis is enhanced by interleukin-6, it suggests participation in both the acute phase response and normal physiol.

L56 ANSWER 10 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1992:544541 CAPLUS
DN 117:144541
TI Nucleotide sequences of the three genes coding for human fibrinogen
AU Chung, Dominic W.; Harris, Jeff E.; Davie, Earl W.
CS Dep. Biochem., Univ. Washington, Seattle, WA, 98195, USA
SO Advances in Experimental Medicine and Biology (***1990***),
281(Fibrinogen, Thromb., Coagulation, Fibrinolysis), 39-48
CODEN: AEMBAP; ISSN: 0065-2598
DT Journal General Review
LA English

The gene for the A.alpha. chain of human fibrinogen was isolated by plaque hybridization of recombinant lambda phage genomic libraries using cDNAs as hybridization probes. The A.alpha. gene is located at the 3' end of the .gamma. gene and consists of 5 exons. Three single nucleotide differences with the cDNA sequence were observed, but they do not change the amino acids encoded. The majority of the primary translation product (amino acids 153-625) is encoded in one large exon which also contains the tandem repeats unique to the A.alpha. chain. Another unique feature of this gene is that it contains a segment of 100 residues in Intron C that are exclusively pyrimidines and >70% T residues. The sequences of the B.beta. and .gamma. chain genes (E.W. Davie et al., 1983, 1985) are also discussed.

L56 ANSWER 11 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1985:573275 CAPLUS
DN 103:173275
TI Evolution and structure of the fibrinogen genes. Random insertion of
AU introns or selective loss?
AU Crabtree, Gerald R.; Comeau, Claudette M.; Fowlkes, Dana M.; Fornace,
Albert J., Jr.; Malley, James D.; Kant, Jeffrey A.
CS Med. Sch., Stanford Univ., Stanford, CA, 94305, USA
SO Journal of Molecular Biology (***1985***), 185(1), 1-19
CODEN: JMOBAK; ISSN: 0022-2836
DT Journal
LA English

Chromosomal linkage as well as sequence homologies provide unequivocal evidence that the genes for the .alpha., .beta., and .gamma. chains of fibrinogen arose by successive duplication of a single ancestral gene. Yet, when the 3 fibrinogen chains are aligned by amino acid homol., the positions of intervening colcoids at only 2 positions for all 3 chains. Whereas 1 adnl. intron occurs at a homologous site in the .beta. and .gamma. chains, none of the positions of the remaining 11 introns in the 3 genes is shared. This arrangement of introns in the 3 fibrinogen genes suggests that either introns were selectively lost, implying that there is essential information in the retained introns, or the common introns were present in the ancestral fibrinogen gene and introns have been randomly inserted since the triplication of the original gene. The more likely possibility of selective loss of introns implies that the ancestral gene, as it existed, approx. 1 billion years ago, must have been composed of numerous small exons.

L56 ANSWER 12 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1983:517030 CAPLUS
DN 99:117030
TI Partial mRNA sequences for human A.alpha., B.beta., and .gamma. fibrinogen
AU chains: Evolutionary and functional implications
AU Kant, Jeffrey A.; Lord, Susan T.; Crabtree, Gerald R.
CS Lab. Pathol., Natl. Cancer Inst., Bethesda, MD, 20205, USA
SO Proceedings of the National Academy of Sciences of the United States of
America (***1983***), 80(13), 3953-7
CODEN: PNAS6; ISSN: 0027-8424
DT Journal
LA English

Rat cDNA and genomic probes were used to screen a human liver cDNA library to isolate clones of 2274, 855, and 736 base pairs (bp) coding for the A.alpha., B.beta., and .gamma. chains of human fibrinogen. Sequence anal. reveals a hitherto unrecognized extension of 15 amino acids at the C-terminus of the A.alpha. chain, the terminal residue of which is proline. This brings the known length of the human A.alpha. chain to 625 amino acids. The 13-amino acid repeated region in the midportion of the A.alpha. chain clearly has arisen through an 8-fold duplication of a 39-bp genetic element, which itself appears to have been constructed from smaller 6-bp repeating units. Greater than 50% sequence homol. between B.beta. and .gamma. chain coding regions confirms that these genes have arisen by duplication and subsequent divergence of an ancestral gene. A comparison of human and rat .gamma. chain cDNAs shows >88% sequence homol. over the C-terminal 162 amino acids, implying strong selective pressures on these portions of the .gamma. chain gene.

L56 ANSWER 13 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1983:417447 CAPLUS
DN 99:17447
TI Characterization of a complementary deoxyribonucleic acid coding for the
AU .alpha. chain of human fibrinogen
AU Rixon, Mark W.; Chan, Wai Yee; Davie, Earl W.; Chung, Dominic W.
CS Dep. Biochem., Univ. Washington, Seattle, WA, 98195, USA
SO Biochemistry (***1983***), 22(13), 3237-44
CODEN: BICHAW; ISSN: 0006-2960
DT Journal
LA English

A human liver cDNA library was screened for the .alpha. chain of fibrinogen with a cDNA clone from the corresponding bovine mol. as a hybridization probe. Several human clones coding for the .alpha. chain were identified, and 1 of these was used to rescreen the entire cDNA library of 18,000 recombinants. Plasmids with the largest cDNAs were isolated, and their inserts were sequenced. The largest cDNA insert contained 2224 base pairs, including a noncoding region at the 5' end that was followed by a region coding for a signal peptide of 19 (or 16) amino acids and a mature protein of 625 amino acids, a stop codon of TAC, another noncoding region, and a poly(A) tail at the 3' end. Eight tandem repeats of 39 base pairs were observed, which started with nucleotide 905 (amino acid residue 270) and ended with nucleotide 1213 (amino acid residue 372). The identity in the nucleotide sequence in the tandem repeats ranged 72-95% when compared to a consensus sequence. The predicted amino acid sequence for the mature polypeptide chain was 15 amino acids longer at the C-terminal and than that of the .alpha. chain isolated from plasma fibrinogen and sequenced. Apparently, minor proteolysis of the C-terminus of the .alpha. chains had occurred, probably

during secretion or circulation of the protein in plasma.

L56 ANSWER 14 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
L58 AN 1981:16302 CAPLUS
DN 94:116302
T1 Human fibrinogen: sequence, sulfur bridges, glycosylation and some structural variants
AU Herschenz, A.; Lottspeich, F.; Souhan, C.; Toeffer-Petersen, E.
CS Max-Planck-Instit. Biochem., Martinsried D-8033, Fed. Rep. Ger.
SO Practices of the Biological Fluids (****1980**), 25th, 51-6
CODEN: BBPFA6, ISSN: 0079-7055

Human fibrinogen has the overall structure (A.alpha., B.beta., gamma, 2). The complete amino acid sequences of the 3 chains with 610, 461, and 411 residues have been elucidated. The chains are held together by 29 S₂ bonds, 3 of which link the half-molecules to each other. Carbohydrate side chains are present in the B.bet₂ and gamma₂-chains. Variants of the gamma-chain with considerably lower mol. wt. seem to be present in all individuals. The structural error in a new abnormal variant, fibrinogen Muenchen, has recently been identified as an Arg-74-->Asn exchange in position 3 of the alpha-chain.

L56 ANSWER 15 OF 16 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1980:17417 CAPLUS
DI 92:17417
TI The amino acid sequence of the .alpha.-chain of human fibrinogen
AU Doolittle, R. F.; Watt, K. W. K.; Cottrell, B. A.; Strong, D. D.; Riley,
M.
CS Dep. Chem., Univ. California, San Diego, CA, 92093, USA
SC Nature (London, United Kingdom) (***1979***), 280(5722), 464-8
CODEN: NATURE; ISSN: 0028-0836

AB The structure of human fibrinogen .alpha.-chain could be divided into 3 zones of .approx.200 residues, each of unique amino acid compn. The regions were designated ZN, ZM, and ZC and corresponded roughly to the amino-terminal third, the middle third, and the carboxy-terminal third, resp. ZM contained the 2 primary .alpha.-chain crosslinking acceptor sites and consisted of a series of internal duplications.

L56 ANSWER 16 OF 16 CAPLUS COPYRIGHT 2004 ACS ON STN
AN 1980:1856 CAPLUS
DN 92:1856
TI Amino acid sequence studies on the .alpha. chain of human fibrinogen
TI Overlapping sequences providing the complete sequence
AU Wate, K. W. K.; Cottrell, B. A.; Strong, D. D.; Doolittle, R. F.
CU Dep. Chem., Univ. California, La Jolla, CA 92093, USA
SO Biochemistry (1979) 18(24), 5410-16
50 CODEN: BICHAW; ISSN: 0006-2960

The complete amino acid sequence of the α_1 chain of human fibrinogen AB was deduced. It contains 610 amino acid residues and has a calcd. mol. wt. of 66,125. The chain has 10 methionines, and fragmentation with CNBr yielded 11 peptides. The arrangement of the 11 fragments was deduced by the isolation of peptide overlaps from plastic and staphylococcal protease

digests of fibrinogen and (or) .alpha. chains. Indeed, certain of the CNBr fragments, preliminary reports of whose sequences have appeared previously,¹ were reexamined to resolve several discrepancies. The .alpha. chain is homologous with the beta₂ and .gamma. chains of fibrinogen, although a large repetitive segment of unusual compn. is absent from the latter 2 chains. The existence of this unusual segment divides the sequence of the .alpha. chain into 3 zones of approx. 200 residues each that are readily distinguishable on the basis of amino acid compn. alone.

his
d
v
=

(FILE 'HOME' ENTERED AT 12:00:59 ON 07 OCT 2004)

```

1401 FILE "REGISTRY" ENTERED AT 12:01:08 ON OCT 07 OCT 2004
1402
1403 24910 S C[P]NODGKSTY [I]NODGKSTMPSTWV [I]EGASTY [I]PDNODGKSTY [I]GAM [I]LIRRO
1404 167 S C[P]NOST [I]NODGKSTMPSTWV [I]ESI [I]PDNOSTY [I]LIMNOSTV [I]FVY [I]SOS
1405 27 S [C]PNI [I]ANDGKSTLMPSTWV [I]ANQGLIPEPT [I]C[P]NOST [I]ANDGKSTLMPSTWV [I]
1406 0 S WIANODGKSTLMPSTWV [I]ANQGLIPEPT [I]C[P]NOST [I]ANDGKSTLMPSTWV [I]
1407 0 S WIAELMI [I]ALNU [I]CP [I]DEGAM [I]E [I]PENSI [I]LTI [I]FCW [I]DGHS [I]AGHS [I]SOSP
1408 0 S WIAELMI [I]ALNU [I]CP [I]DEGAM [I]E [I]PENSI [I]LTI [I]FCW [I]DGHS [I]AGHS [I]SOSP
1409 2 S CYS-SER-ASP-SER-GLN-TRP-LEU-TRP-CYS [I]SOSP
1410 2 S CYS-PRO-MET-SER-GLU-TRP-LEU-TRP-CYS [I]SOSP
1411 5 S CYS-PRO-TRP-GLU-SER-TRP-TRP-PHE-CYS [I]SOSP
1412 5 S CYS-GLN-GLU-GLU-PRO-GLU-PRO-TRP-LEU-PHE-CYS [I]SOSP
1413 5 S CYS-THR-GLU-GLU-PRO-GLU-PRO-TRP-LEU-PHE-CYS [I]SOSP
1414 2 S CYS-GLN-LEU-GLU-GLY-TRP-TRP-CYS [I]SOSP
1415 2 S CYS-ASP-GLY-GLU-PRO-TRP-LEU-PHE-CYS [I]SOSP
1416 2 S CYS-GLY-TRP-GLY-SER-TRP-LYS-PHE-CYS [I]SOSP
1417 2 S CYS-GLY-TRP-GLY-SER-GLY-LYS-LEU-CYS [I]SOSP
1418 3 S CYS-PRO-GLU-GLU-PRO-TRP-TRP-PHE-CYS [I]SOSP
1419 2 S CYS-PRO-GLY-GLY-TRP-TRP-PHE-CYS [I]SOSP
1420 2 S CYS-ARG-GLY-GLU-SER-TRP-PRO-TYR-CYS [I]SOSP
1421 2 S CYS-PRO-GLY-GLY-SER-TRP-PRO-TYR-CYS [I]SOSP
1422 2 S CYS-GLY-GLN-GLU-SER-ARG-TRP-PHE-CYS [I]SOSP
1423 2 S CYS-PHE-GLU-LYS-GLY-GLY-TRP-LEU-CYS [I]SOSP
1424 1 S CYS-GLU-LEU-CYS-SER-ASP-GLU-ASN-TRP-LEU-TRP-CYS [I]SOSP
1425 1 S CYS-THR-GLU-GLY-GLY-SER-ASP-GLU-ASN-TRP-LEU-TRP-CYS [I]SOSP
1426 1 S CYS-THR-MET-MET-CYS-PRO-MET-SER-GLY-TRP-LEU-TRP-CYS [I]SOSP
1427 4 S CYS-THR-GLU-GLU-PRO-TRP-GLU-SER-TRP-PHE-CYS [I]SOSP
1428 2 S CYS-ALA-PRO-CYS-GLN-GLU-GLU-PRO-TRP-LEU-PHE-CYS [I]SOSP
1429 1 S CYS-PRO-ARG-PRO-CYS-TRP-GLY-GLU-SER-GLY-LIE-PHE-CYS [I]SOSP
1430 1 S CYS-PRO-ARG-PRO-CYS-TRP-GLY-GLU-PRO-TRP-TRP-PHE-CYS [I]SOSP
1431 1 S CYS-GLN-ALA-CYS-GIN-GLY-GLU-PRO-TRP-PHE-CYS [I]SOSP
1432 1 S CYS-GLN-LEU-CYS-GLY-TRP-GLY-SER-TRP-LYS-PHE-CYS [I]SOSP
1433 1 S CYS-TRP-PHE-CYS-PRO-GLY-GLU-PRO-TRP-TRP-PHE-CYS [I]SOSP
1434 1 S CYS-TRP-PHE-CYS-PRO-GLY-GLU-PRO-TRP-TRP-PHE-CYS [I]SOSP
1435 1 S CYS-TRP-GLN-ALA-CYS-GIN-GLY-GLY-TRP-ARG-TRP-TRP-PHE-CYS [I]SOSP
1436 1 S CYS-TRP-PHE-CYS-PRO-GLY-GLU-PRO-TRP-SER-PHE-CYS [I]SOSP
1437 1 S CYS-TRP-ARG-PRO-CYS-ARG-GLY-GLU-SER-TRP-PRO-TRP-CYS [I]SOSP
1438 1 S CYS-TRP-ALA-CYS-PRO-GLY-TRP-LYS-ARG-GIN-PHE-CYS [I]SOSP
1439 1 S CYS-TRP-ARG-PRO-CYS-PRO-GLY-GLU-SER-ARG-TRP-PHE-CYS [I]SOSP
1440 1 S CYS-TRP-ARG-PRO-CYS-PHE-GLN-LYS-GLY-GLY-TRP-LEU-CYS [I]SOSP

```

INDEX, ADISCTI, ADISINSIGHT, ADISNEWS, AGRICOLA, AQUALINE, ANABSTR, ANTE

AQUASCI, BIOSUBSINESS, BIOCOMMERCE, BIOENG, BIOSIS, BIOTECHABS, BIOTECHDS,
BIOTECHNO, CABA, CANCERLIT, CAPLUS, CEABA-VTB, CIN, CONFSCI, CROPB,
CROPU, DISSABS, DDFB, DDFU, DGENE, ... ENTERED AT 12:34:53 ON 07 OCT 2004
SEA LI

0* FILE ADISCTI
0* FILE ADISINSIGHT
0* FILE ADISNEWS
0* FILE AGRIOLA
0* FILE AQUALINE
0* FILE ANABSTR
0* FILE ANTE
0* FILE AQUASCI
0* FILE BIOSUBSINESS
0* FILE BIOCOMMERCE
0* FILE BIOENG
0* FILE BIOSIS
0* FILE BIOTECHABS
0* FILE BIOTECHDS
0* FILE BIOTECHNO
0* FILE CABA
0* FILE CANCERLIT
0* FILE CAPLUS
0* FILE CEABA-VTB
0* FILE CIN
0* FILE CONFSCI
0* FILE CROPB
0* FILE CROPU
0* FILE DISSABS
0* FILE DDFB
0* FILE DDFU
SET DEFAULT ON
SEA LI

0* FILE ADISCTI
0* FILE ADISINSIGHT
0* FILE ADISNEWS
0* FILE AGRIOLA
0* FILE AQUALINE
0* FILE ANABSTR
0* FILE ANTE
0* FILE AQUASCI
0* FILE BIOSUBSINESS
0* FILE BIOCOMMERCE
0* FILE BIOENG
0* FILE BIOSIS
0* FILE BIOTECHABS
0* FILE BIOTECHDS
0* FILE BIOTECHNO
0* FILE CABA
0* FILE CANCERLIT
0* FILE CAPLUS
0* FILE CEABA-VTB
0* FILE CIN
0* FILE CONFSCI

0* FILE CROPB
0* FILE CROPU
0* FILE DISSABS
0* FILE DDFB
0* FILE DDFU

FILE 'HOME' ENTERED AT 12:36:28 ON 07 OCT 2004

L41 FILE 'BIOSIS, CAPLUS' ENTERED AT 12:38:20 ON 07 OCT 2004
0 S LI

FILE 'HOME' ENTERED AT 12:40:48 ON 07 OCT 2004

FILE 'CAPLUS' ENTERED AT 12:40:52 ON 07 OCT 2004

L42 3026 S LI
L43 114 S L2
L44 8 S L3
L45 5029 S L42 OR L43 OR L44
L46 4761 DUP REM L45 (268 DUPLICATES REMOVED)
L47 4761 S L46
L48 4761 S L46 NOT WESCOTT/IN
L49 4761 S L46 NOT WESCOTT/AU
L50 4761 S L46
L51 4759 S L46 NOT E6
L52 4757 S L51 NOT FIBRIN
L53 6 S L44 NOT E6
L54 112 S L43 NOT E6
L55 16 S L54 AND PY<1999
L56 16 S L55 NOT L53

=> 109 h
COST IN U.S. DOLLARS
FULL ESTIMATED COST
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
CA SUBSCRIBER PRICE

SINCE FILE	TOTAL
ENTRY	SESSION
74.12	1145.73
-15.40	-15.40

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 12:48:16 ON 07 OCT 2004
Connecting via Winsock to STN

Welcome to STN International! Enter xix

LOGINID:SSSF1653RAW

PASSWORD:
* * * * * RECONNECTED TO STN INTERNATIONAL * * * * *
SESSION RESUMED IN FILE 'CAPLUS' AT 13:27:02 ON 07 OCT 2004
FILE 'CAPLUS' ENTERED AT 13:27:02 ON 07 OCT 2004
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

COST IN U.S. DOLLARS SINCE FILE TOTAL
ENTRY SESSION
FULL ESTIMATED COST 74.12 1145.73
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS) SINCE FILE TOTAL
ENTRY SESSION
CA SUBSCRIBER PRICE -15.40 -15.40
=> S (17 or 18 or 19 or 110 or 111 or 112 or 113 or 114 or 116 or 117 or 118 or
119 or 120 or 121 or 122)
2 L7
1 L8
4 L9
2 L10
2 L11
2 L12
2 L13
2 L14
2 L16
2 L17
2 L18
2 L19
2 L20
2 L21
2 L22
L57 4 (L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14 OR L16 OR
L17 OR L18 OR L19 OR L20 OR L21 OR L22)
=> S (123 or 124 or 125 or 126 or 127 or 128 or 129 or 130 or 131 or 132 or 133
or 134 or 135 or 136 or 137 or 138 or 139 or 140)
2 L23
2 L24
4 L25
2 L26
2 L27
1 L28
2 L29
2 L30
2 L31
2 L32
2 L33
2 L34
2 L35
2 L36
2 L37
2 L38
2 L39
2 L40
L58 4 (L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31 OR
L32 OR L33 OR L34 OR L35 OR L36 OR L37 OR L38 OR L39 OR L40)
=> set detail off
SET COMMAND COMPLETED
=> S 157 or 158
L59 4 L57 OR L58

=> S 159 not e6
L60 5 "WESCOTT CHARLES R"/IN
2 L59 NOT "WESCOTT CHARLES R"/IN
=> d 160 bib ab
L60 ANSWER 1 OF 2 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2004:634089 CAPLUS
DN 141:167846
TI Binding peptides for the KDR receptor and vascular endothelial growth
factor/KDR complex and their use in diagnosis, therapy, and imaging of
angiogenesis-related disorders
IN Sato, Aaron K.; Sexton, Daniel J.; Dransfield, Daniel T.; Lader, Robert
C.; Arbogast, Christopher; Bussat, Philippe; Fan, Hong; Khurana, Sudha;
Linder, Karen E.; Marinelli, Edmund R.; Nanjappa, Palaniappan; Nunn,
Adrian; Pillai, Radhakrishna; Pochon, Sibylle; Ramalingam, Kondareddar;
Srinivasava, Vijay; Song, Bo; Swenson, Rolf E.; Von Wronski, Matthew A.
PA Dyax Corp., USA; Biaco International B.V.
SO PCT Int. Appl., 470 pp.
DI Patent
LA English
FAN.CNT 2
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2004065621 A1 20040905 WO 2003-0528787 20030911
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE,
GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SV, TJ, TM,
TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ,
BY, BG, BR, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GT, GW, ML, MR, NE, NG, SN, TD, TG
WO 2003074005 A2 20030912 WO 2003-056731 20030303
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH,
GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NI, NO, NZ,
OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW, AM, AZ, BY, BG, BR, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC,
NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GN, GT, GW, ML, MR, NE, NG, SN, TD, TG
PRAI US 2002-36081P P 20020301
US 2003-44041P P 20030115
US 2003-362082 A2 20030303
WO 2003-056731 A2 20030303
AB The present invention provides peptides, peptide dimers, and multimeric
complexes comprising at least one binding moiety for KDR receptor or
vascular endothelial growth factor (VEGF)/KDR complex, which have a

variety of uses whenever treating, detecting, isolating, or localizing angiogenesis is advantageous. Particularly disclosed are synthetic, isolated peptides capable of binding KDR or VEGF/KDR complex with high affinity (e.g., having a $KD < 1 \text{ nM}$), and dimer and multimeric constructs comprising these polypeptides. The involvement of VEGF and KDR in angiogenesis makes the binding peptides particularly useful for imaging important sites of angiogenesis, e.g., neoplastic tumors, for targeting substances, e.g., therapeutics, including radiotherapeutics, to such sites, and for treating certain disease states, including those associated with inappropriate angiogenesis.

THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> file home
cost in U.S. dollars
full estimated cost
discount amounts (for qualifying accounts)
ca subscriber price
since file
entry
total
since file
entry
total
file 'home' entered at 13:28:53 on 07 oct 2004
```

(FILE 'HOME' ENTERED AT 12:00:59 ON 07 OCT 2004)

```

File 'REGISTRY' entered at 12:01:08 on 07 OCT 2004
L1 24910 S C/PNDQGLSTV [ANDQGLIMPFV] [GSKY] [PNDQGLSTV] [RGW] [LXPR
L2 167 S C/PNDQGLSTV [ANDQGLIMPFV] [LEI] [PNDQGLSTV] [WILINGSV] [FVY] [/SQ
L3 27 S C/PNI [ANDQGLIMPFV] [WVWY] [ANDQGLIMPFV] [C/PNDQGLSTV] [ANDQGL
L4 0 W/ARNDQGLIMPFVSTVYV [ANDQGLIMPFV] [C/PNDQGLSTV] [ANDQGLIMPFVSTVYV]
L5 0 W/ACGLV [ALMP] [C/PIDEGMW] [E] [PBNUS] [LWU] [DGHGHS] [AGPVS] [/SQP
L6 0 S W/ACGLV [ALMP] [C/PIDEGMW] [E] [PBNUS] [LWU] [DGHGHS] [AGPVS] [/SQP
L7 2 S CYS-SER-ASP-GLU-ASN-TRP-LEU-TRP-CYS [/SQP
L8 1 S CYS-SER-ASP-GLU-ASN-TRP-LEU-TRP-CYS [/SQP
L9 5 S CYS-PRO-TRP-GLU-SER-TRP-TRP-PHE-CYS [/SQP
L10 3 S CYS-GLN-GLU-GLU-PRO-GLY-PRO-ILE-CYS [/SQP
L11 2 S CYS-TRR-GLY-GLU-TRR-ARG-TRR-TRP-CYS [/SQP
L12 2 S CYS-ASP-GLY-GLU-PRO-TRP-TRP-PHE-CYS [/SQP
L13 2 S CYS-GLY-TRR-GLY-SER-TRP-LYS-PHE-CYS [/SQP
L14 2 S CYS-GLY-TRR-GLY-SER-GLY-LYS-PHE-CYS [/SQP
L15 2 S CYS-PRO-GLY-GLU-PRO-TRP-TRP-PHE-CYS [/SQP
L16 3 S CYS-PRO-GLY-TRR-LEU-ARG-SER-LEU-CYS [/SQP
L17 2 S CYS-PRO-GLY-TRR-LEU-ARG-SER-LEU-CYS [/SQP
L18 2 S CYS-ARG-GLY-GLU-SER-TRP-PRO-TRP-CYS [/SQP
L19 2 S CYS-PRO-GLY-TRR-LYS-ARG-GLN-PHE-CYS [/SQP
L20 2 S CYS-GLY-GLN-GLU-SER-ARG-TRR-PHE-CYS [/SQP
L21 2 S CYS-PHE-GLN-LYS-GLY-GLY-TRR-PHE-CYS [/SQP
L22 1 S CYS-ASP-GLU-CYS-SER-ASP-GLU-ASN-TRP-LEU-TRP-CYS-TRP-PRO-HIS-GLY
L23 1 S TRP-MET-MET-CYS-PRO-MET-SER-GLU-TRP-LEU-TRP-CYS-TRP-SER-ALA-GLU
L24 4 S TRP-GLN-PRO-CYS-PRO-TRP-GLU-SER-TRP-THR-PHE-CYS-TRP-ASP-PRO-GLY
L25 4 S TRP-ALA-PRO-CYS-GLU-GLU-GLU-PRO-TRP-LEU-PHE-CYS-PHE-HIS-GLY
L26 1 S PRO-ARG-PRO-CYS-TRR-GLY-GLU-SER-GLY-ILE-PHE-CYS-TRP-TRP-LYS-GLY
L27

```

INDEX, ADICIT, ADINSIGHT, ADINSEMS, AGRICOLA, AQUILINE, ANASTR, ANE
AQUACEL, BIOBUSTINES, BLOOMBERG, BIOENG, BIOSIS, BIOTECNAB, BIOTECNAB,
BIOTECNO, CABLA, CANCERLIT, CAPULUS, CEMBA-VTS, CEN, CIN, CONFSCI, CROPB,
CROPU, DISSABS, DDBB, DDFU, DGEHE, ... * ENTERED AT 12:34:53 ON 07 OCT 2006

15

```

0* FILE ADISCTI
0* FILE ADISINSIGHT
0* FILE ADISNEWS
0* FILE AGRICOLA
0* FILE AQUALINE
0* FILE ANABSTR
0* FILE ANTE
0* FILE AQUASCI
0* FILE BIOBUSINESS
0* FILE BIOCOMMERCE
0* FILE BIOENG
0* FILE BIOSIS
0* FILE BIOTECHABS
0* FILE BIOTECHDS
0* FILE BIOTECHNO
0* FILE CABA
0* FILE CANCERLIT
0* FILE CAPUS
0* FILE CEBA-7VB
0* FILE CEN
0* FILE CIN
0* FILE CONFSCI
0* FILE CROPB
0* FILE CROPU
0* FILE DISSABS
0* FILE DDBB
0* FILE DDBU
0* FILE DETAIL ON
0* FILE LI
-----
0* FILE ADISCTI
0* FILE ADISINSIGHT
0* FILE ADISNEWS
0* FILE AGRICOLA
0* FILE AQUALINE
0* FILE ANABSTR
0* FILE ANTE
0* FILE ANTE

```

0* FILE AQUASCI
 0* FILE BIOSINNESS
 0* FILE BIOCOMMERCE
 0* FILE BIOENG
 0* FILE BIOSIS
 0* FILE BIOTECHAS
 0* FILE BIOTECHS
 0* FILE BIOTECHNO
 0* FILE CABAA
 0* FILE CANCERLIT
 0* FILE CAPUS
 0* FILE CEABA-VTB
 0* FILE CEN
 0* FILE CIN
 0* FILE CONFSCI
 0* FILE CROPR
 0* FILE CROPU
 0* FILE DISSABS
 0* FILE DDFB
 0* FILE DDFU

FILE 'HOME' ENTERED AT 12:36:28 ON 07 OCT 2004

FILE 'BIOSIS, CAPUS' ENTERED AT 12:38:20 ON 07 OCT 2004
 0 S LI

FILE 'HOME' ENTERED AT 12:40:48 ON 07 OCT 2004

FILE 'CAPUS' ENTERED AT 12:40:52 ON 07 OCT 2004

L42 5026 S L1
 L43 114 S L2
 L44 8 S L3
 L45 5029 S L42 OR L43 OR L44
 L46 4761 DUP REM L45 (268 DUPLICATES REMOVED)
 L47 4761 S L46
 L48 4761 S L46 NOT WESCOTT/IN
 L49 4761 S L48 NOT WESCOTT/IN
 L50 4761 S L46
 L51 4759 S L46 NOT E6
 L52 4757 S L51 NOT FIBRIN
 L53 6 S L44 NOT E6
 L54 112 S L43 NOT E6
 L55 16 S L54 AND PY<1999
 L56 16 S L55 NOT L53
 L57 4 S (L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14 OR L16 OR
 L58 4 S (L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
 SET DETAIL OFF
 4 S L57 OR L58
 L59 2 S L59 NOT E6
 L60

FILE 'HOME' ENTERED AT 13:28:53 ON 07 OCT 2004

=> file reg
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST
 SINCE FILE
 ENTRY
 TOTAL
 SESSION
 0.21
 1151.63

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
 CA SUBSCRIBER PRICE
 SINCE FILE
 ENTRY
 TOTAL
 0.00
 -16.10

FILE 'REGISTRY' ENTERED AT 13:29:38 ON 07 OCT 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 6 OCT 2004 HIGHEST RN 757927-15-4
 DICTIONARY FILE UPDATES: 6 OCT 2004 HIGHEST RN 757927-15-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
 conducting SmartSelect searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
 information enter HELP PROP at an arrow prompt in the file or refer
 to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> file home
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST
 SINCE FILE
 ENTRY
 TOTAL
 0.42
 1152.91
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
 CA SUBSCRIBER PRICE
 SINCE FILE
 ENTRY
 TOTAL
 0.00
 -16.10

FILE 'HOME' ENTERED AT 13:30:16 ON 07 OCT 2004

=> file reg
 COST IN U.S. DOLLARS
 FULL ESTIMATED COST
 SINCE FILE
 ENTRY
 TOTAL
 0.21
 1153.12
 DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
 CA SUBSCRIBER PRICE
 SINCE FILE
 ENTRY
 TOTAL
 0.00
 -16.10

FILE 'REGISTRY' ENTERED AT 13:30:50 ON 07 OCT 2004
 USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
 PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
 COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
 provided by InfoChem.

STRUCTURE FILE UPDATES: 6 OCT 2004 HIGHEST RN 757927-15-4
DICTIONARY FILE UPDATES: 6 OCT 2004 HIGHEST RN 757927-15-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registrys.html>

=> d 13 bib sqd3 ref

L3 ANSWER 1 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN

RN 599211-32-2 REGISTRY

FS PROTEIN SEQUENCE; STEREOSEARCH

SOL 19

NTE modified

type	location	description
terminal mod.	Trp-1	N-acetyl
terminal mod.	Lys-19	C-terminal amide
bridge	Cys-4	disulfide bridge
modification	Lys-19	undetermined modification

PATENT ANNOTATIONS (PNT):

Sequence | Patent

Source | Reference

Not Given|NO2003074005

| claimed

| SEQID 336

SEQ3 1 Trp-Gln-Pro-Cys-Pro-Tip-Gly-Ser-Tip-Thr-

11 Phe-Cys-Tip-Asp-Pro-Gly-Gly-Lys

HITS AT: 1-15

RELATED SEQUENCES AVAILABLE WITH SEQLINK

2 REFERENCES IN FILE CA (1907 TO DATE)

2 REFERENCES IN FILE CAPLUS (1907 TO DATE)

REFERENCE 1

AN 141:167846 CA

TI Binding peptides for the KDR receptor and vascular endothelial growth
factor/KDR complex and their use in diagnosis, therapy, and imaging of
angiogenesis-related disorders

IN Sato, Aaron K.; Sexton, Daniel J.; Dransfield, Daniel T.; Ladner, Robert
C.; Arbogast, Christophe; Busat, Philippe; Fan, Hong; Khurana, Sucha;
Linder, Karen E.; Martinelli, Edmund R.; Nanjappa, Palanippa; Nunn,
Adrian; Pillai, Radhakrishna; Pochon, Sibylle; Ramalingam, Kondareddi;
Shrivastava, Ajay; Song, Bo; Swenson, Rolf E.; Von Wronski, Matthew A.
PA Dyax Corp., USA; Bracco International B.V.
SO PCT Int. Appl., 470 pp.
CODEN: PIXXD2

DT Patent
LA English

PATENT NO. 2

PI WO 2004065621

W: AE, AG, AL, AM, AT, AU, AZ,

CO, CR, CU, CZ, DE, DK, DM,

GH, GM, GR, HU, ID, IL, IN,

IR, LS, LT, LU, LV, MA, MD,

OM, PG, PH, PL, PT, RO, RU,

TN, TR, TT, TZ, UA, UG, US,

UZ, VC, VN, ZA, ZM, ZW, AM, AZ,

BY, KG, KZ, MD

FW: GH, GM, KE, LS, MW, MZ,

SD, SL, SZ, TZ, UG, ZM, ZW,

AT, BE, BG,

CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT,

LU, MC,

NL, PT, RO, SE, SI, SK, TR,

BF, BJ, CG, CI, CM, GN, GQ,

GW, ML, MR, NE, SN, TD, TG

WO 2003074005 A2 20030912

W: AE, AG, AL, AM, AT, AU, AZ,

BA, BB, BG, BR, BY, BZ, CA,

CH, CN,

CO, CR, CU, CZ, DE, DK, DM,

DZ, EC, EE, EG, FI, GB, GE,

GH, GM, GR, HU, ID, IL, IN,

IS, JP, KE, KG, KP, KR, KZ,

LC, LK, LR,

LS, LT, LU, LV, MA, MD, ME,

MG, MK, MN, MX, MY, NZ, OM,

PH,

PL, PT, RO, RU, SC, SD, SE,

SG, SK, SL, TJ, TM, TR, TT,

TZ, UA, UG, US, UZ, VC, VN,

YU, ZA, ZM, ZW, AM, AZ, BY,

KG, KZ, MD,

RU, TJ, TM

FW: GH, GM, KE, LS, MW, MZ,

SD, SL, SZ, TZ, UG, ZM, ZW,

AT, BE, BG,

CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT,

LU, MC,

NL, PT, RO, SE, SI, SK, TR,

BF, BJ, CG, CI, CM, GN, GQ,

GW, ML, MR, NE, SN, TD, TG

FW: GH, GM, KE, LS, MW, MZ,

SD, SL, SZ, TZ, UG, ZM, ZW,

AT, BE, BG,

CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT,

LU, MC,

NL, PT, RO, SE, SI, SK, TR,

BF, BJ, CG, CI, CM, GN, GQ,

GW, ML, MR, NE, SN, TD, TG

FW: GH, GM, KE, LS, MW, MZ,

SD, SL, SZ, TZ, UG, ZM, ZW,

AT, BE, BG,

CH, CY, CZ, DE, DK, EE, ES,

FI, FR, GB, GR, HU, IE, IT,

LU, MC,

RE. CNT 4 THERE ARE 4 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

REFERENCE 2

AN 139:265740 CA

TI KDR and VEGF/KDR binding peptides and their use in diagnosis and therapy

IN Sato, Aaron K.; Sexton, Daniel J.; Ladner, Robert C.; Dransfield, Daniel

T.; Swenson, Rolf E.; Martinelli, Edmund R.; Ramalingam, Kondareddi;

Nunn, Adrian D.; Von Wronski, Matthew A.; Shrivastava, Ajay; Pochon,

Sibylle; Busat, Philippe; Arbogast, Christophe; Pillai, Radhakrishna;

Fan, Hong; Linder, Karen E.; Song, Bo; Nanjappa, Palanippa

PA Dyax Corp., USA; Bracco International B.V.; et al.

SO PCT Int. Appl., 350 pp.

CODEN: PIXXD2

DT Patent

RM: GH, GM, KE, LS, MM, NZ, SD, SI, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
US 2003109690 A1 20030612 US 2002-106698 20020327
PRAI US 1999-157137P 19990929
US 1999-16380P 19991103
WO 2000-US26524 20000928
US 2002-106698 20020327

L3 ANSWER 4 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 483015-78-7 REGISTRY
FS PROTEIN SEQUENCE
SQL 66

SEQ3 1 Met-Thr-Asn-Ser-His-Thr-His-Asn-Gly-Asp-
11 Arg-Ile-Tyr-Phe-Ile-Cys-Ser-Tyr-Gly-Asp-
21 Gly-Pro-Ile-Cys-Tyr-Gly-Met-Ala-Leu-Asp-
31 Leu-Ile-Gly-Gly-Ile-Ser-Leu-Ile-Ala-Phe-
41 Ser-Val-Leu-Leu-Val-Gly-Val-Ile-Phe-Phe-
51 Gly-Tyr-Phe-Gly-Ile-Phe-Pro-Lys-Val-Ile-
61 Arg-Arg-Lys-Leu-His-Asp
HITS AT: 13-27

RELATED SEQUENCES AVAILABLE WITH SEOLINK

L3 ANSWER 5 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-90-8 REGISTRY
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 15

SEQ3 1 Pro-Arg-Pro-Cys-Phe-Gln-Lys-Gly-Thr-
11 Leu-Cys-Tyr-Pro-Gly
HITS AT: 1-15

REFERENCE 1

AN 139:138721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wesco, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DT Patent
LA English
FAM.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 2003143158 A1 20030731 US 2001-34974 20011221
PRAI US 2001-34974 20011221
REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wesco, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAM.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 200205544 A2 20020718 WO 2001-US49534 20011221
WO 200205544 A3 20030327

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MX, MY, NA, NG, NI, NO, NZ, OM, PA,
PE, PG, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, SM, SN, ST, SV, SZ, TD,
TH, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TG, UG, ZM, ZW, AG, AZ, BY,
KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GN, GW,
ML, MR, NE, SN, TD, TG
EP 1348026 A2 20031001 EP 2001-997103 20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004523514 T2 20040805
PRAI US 2000-747403 20001223
WO 2001-US49534 20011221
JP 2002-556612 20011221

L3 ANSWER 6 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-89-9 REGISTRY
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 15

SEQ3 1 Pro-Arg-Pro-Cys-Gly-Gln-Glu-Ser-Arg-Thr-
11 Phe-Cys-Leu-Glu-Gly
HITS AT: 1-15

REFERENCE 1

AN 139:138721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wesco, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DT Patent
LA English
FAM.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 2003143158 A1 20030731 US 2001-34974 20011221

PRAI US 2001-34974 20011221

REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055544	A2	20020718	WO 2001-US49534	20011221
WO 2002055544	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SE, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1348026 A2 20031001 EP 2001-997103 20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004523514 T2 20040805 JP 2002-556612 20011221
PRAI US 2000-747403 20001223
WO 2001-US49534 20011221

L3 ANSWER 7 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-88-4 REGISTRY
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 15

SEQ3 1 Trp-Gln-Ala-Cys-Pro-Gly-Tyr-Lys-Arg-Gln-

11 Phe-Cys-Trp-Asp-Arg

HITS AT: 1-15

REFERENCE 1

AN 139:138721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE

PI WO 2002055544 A2 20020718 WO 2001-US49534 20011221
WO 2002055544 A3 20030327

REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055544	A2	20020718	WO 2001-US49534	20011221
WO 2002055544	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DO, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SE, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1348026 A2 20031001 EP 2001-997103 20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004523514 T2 20040805 JP 2002-556612 20011221
PRAI US 2000-747403 20001223
WO 2001-US49534 20011221

L3 ANSWER 8 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-87-3 REGISTRY
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 15

SEQ3 1 Pro-Arg-Pro-Cys-Arg-Gly-Glu-Ser-Trp-Pro-

11 Tyr-Cys-Trp-Gly-Gly

HITS AT: 1-15

REFERENCE 1

AN 139:138721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO

DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003143158	A1	20030731	US 2001-34974	20011221
PRAI US 2001-34974		20011221		

REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002055544	A2	20020718	WO 2001-US49534	20011221
WO 2002055544	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OC, ON, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HT, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OC, ON, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

EP 1348026 A2 20031001 EP 2001-997103 20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004523514 T2 20040805 JP 2002-556612 20011221
PRAI US 2000-747403 20001223
WO 2001-US49534 20011221

L3 ANSWER 9 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-86-2 REGISTRY
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 15

SEQ3 1 Ttp-Tyr-Phe-Cys-Pro-Gly-Glu-Pro-Tip-Ser-
11 Phe-Cys-Pro-Asp-Gly
HITS AT: 1-15

REFERENCE 1
AN 139:138721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.

PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003143158	A1	20030731	US 2001-34974	20011221
PRAI US 2001-34974		20011221		

REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002055544	A2	20020718	WO 2001-US49534	20011221
WO 2002055544	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OC, ON, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, HT, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OC, ON, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

EP 1348026 A2 20031001 EP 2001-997103 20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004523514 T2 20040805 JP 2002-556612 20011221
PRAI US 2000-747403 20001223
WO 2001-US49534 20011221

L3 ANSWER 10 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-86-1 REGISTRY
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 15

SEQ3 1 Ttp-Gln-Thr-Cys-Pro-Gly-Tyr-Leu-Arg-Ser-
11 Leu-Cys-Tip-Asp-Gly
HITS AT: 1-15

REFERENCE 1

AN 139:138721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 2003143158 A1 20030731 US 2001-34974 20011221
PRAI US 2001-34974 20011221

REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2002055544 A2 20020718 WO 2001-0549534 20011221
WO 2002055544 A3 20030327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, BU, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1348026 A2 20031001 EP 2001-997103 20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004523514 T2 20040805 JP 2002-556612 20011221
PRAI US 2000-747403 20001223
WO 2001-0549534 20011221

L3 ANSWER 11 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-84-0 REGISTRY
FS PROTEIN SEQUENCE; STEREORESEARCH
SQL 15

SEQ3 1 Trp-His-Phe-Cys-Pro-Gly-Glu-Pro-Tip-Thr-
11 Phe-Cys-Trp-Ala-Gly
HITS AT: 1-15

REFERENCE 1

AN 139:138721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 2003143158 A1 20030731 US 2001-34974 20011221
PRAI US 2001-34974 20011221

REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2002055544 A2 20020718 WO 2001-0549534 20011221
WO 2002055544 A3 20030327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, BU, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1348026 A2 20031001 EP 2001-997103 20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004523514 T2 20040805 JP 2002-556612 20011221
PRAI US 2000-747403 20001223
WO 2001-0549534 20011221

L3 ANSWER 12 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-83-9 REGISTRY
FS PROTEIN SEQUENCE; STEREORESEARCH
SQL 15

SEQ3 1 Cys-Tyr-Phe-Cys-Pro-Gly-Glu-Pro-Tip-Thr-
11 Phe-Cys-Cys-Asp-Asp
HITS AT: 1-15

HITS AT: 1-15

REFERENCE 1

AN 139:136721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltrzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 2003143158 A1 20030731 US 2001-34974 20011221
PRAI US 2001-34974 20011221

REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltrzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2002055544 A2 20020718 WO 2001-US49534 20011221
PRAI US 2000-747403 20001223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LG, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1348026 A2 20031001 EP 2001-997103 20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004523514 T2 20040805 JP 2002-556612 20011221
PRAI US 2000-747403 20001223
WO 2001-US49534 20011221

L3 ANSWER 13 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-82-8 REGISTRY
FS PROTEIN SEQUENCE; STEREOBANCH
SQ 15

SEQ3 1 Trp-Leu-Ser-Gly-Tyr-Gly-Ser-Gly-Tyr-

11 Leu-Cys-Leu-Gly-Val

HITS AT: 1-15

REFERENCE 1

AN 139:136721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltrzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 2003143158 A1 20030731 US 2001-34974 20011221
PRAI US 2001-34974 20011221

REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltrzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2002055544 A2 20020718 WO 2001-US49534 20011221
PRAI US 2000-747403 20001223

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LG, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1348026 A2 20031001 EP 2001-997103 20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004523514 T2 20040805 JP 2002-556612 20011221
PRAI US 2000-747403 20001223
WO 2001-US49534 20011221

L3 ANSWER 14 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-81-7 REGISTRY

FS PROTEIN SEQUENCE; STEREOSARCH
SQL 15

SEQ3 1 Trp-Asn-Gly-Cys-Gly-Trp-Gly-Ser-Trp-Lys-
11 Phe-Cys-Gly-Glu-Gly
HITS AT: 1-15

REFERENCE 1

AN 139:136721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DI Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003143158	A1	20030731	US 2001-34974	20011221
PRAI US 2001-34974		20011221		

REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DI Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002055544	A2	20020718	WO 2001-US49534	20011221
WO 2002055544	A3	20030327		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
FW: GH, GM, KE, LS, MW, MZ, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1348026	A2	20031001	EP 2001-997103	20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, LV, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
JP 2004523514	T2	20040805	JP 2002-556612	20011221
PRAI US 2000-747403		20001223		
WO 2001-US49534		20011221		

13 ANSWER 15 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-80-6 REGISTRY
FS PROTEIN SEQUENCE; STEREOSARCH
SQL 15

SEQ3 1 Trp-Lys-Phe-Cys-Asp-Gly-Glu-Pro-Trp-Leu-
11 Phe-Cys-Trp-Asp-Gly
HITS AT: 1-15

REFERENCE 1

AN 139:136721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DI Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI US 2003143158	A1	20030731	US 2001-34974	20011221
PRAI US 2001-34974		20011221		

REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DI Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PI WO 2002055544	A2	20020718	WO 2001-US49534	20011221
WO 2002055544	A3	20030327		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW				
FW: GH, GM, KE, LS, MW, MZ, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
EP 1348026	A2	20031001	EP 2001-997103	20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, LV, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

JP 2004523514 T2 20040805 JP 2002-556612 20011221
PRAI US 2000-747403 20001223
WO 2001-US49534 20011221

L3 ANSWER 16 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-79-3 REGISTRY
FS PROTEIN SEQUENCE/ STEREOSEARCH
SQL 15

SEQ3 1 Trp-Gln-Ala-Cys-Gln-Leu-Gly-Tyr-Arg-Thr-

11 Tyr-Cys-Trp-Asp-Gly

HITS AT: 1-15

REFERENCE 1

AN 139:138721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DT Patent
LA English
FAN CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 200143158 A1 20030731 US 2001-34974 20011221
PRAI US 2001-34974 20011221

REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN CNT 1

PATENT NO.

KIND DATE APPLICATION NO. DATE

PI WO 2002055544 A2 20020718 WO 2001-US49534 20011221
WO 2002055544 A3 20030327

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GU, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TW, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GK, KE, LS, MM, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, BR, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GU, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MM, MO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TW, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
GR, IE, IT, LU, MC, NL, PT, SE, TR, BE, BJ, CE, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1348026 A2 20031001 EP 2001-997103 20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CV, AL, TR

JP 2004523514 T2 20040805 JP 2002-556612 20011221
PRAI US 2000-747403 20001223
WO 2001-US49534 20011221

L3 ANSWER 17 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-71-5 REGISTRY
FS PROTEIN SEQUENCE/ STEREOSEARCH
SQL 19

NTE modified

type location description

terminal mod. Trp-1 - N-acetyl
terminal mod. Lys-19 - C-terminal amide

SEQ3 1 Trp-Ala-Pro-Cys-Gln-Glu-Glu-Pro-Trp-Leu-

11 Phe-Cys-Phe-His-Gly-Gly-Gly-Lys

HITS AT: 1-15

REFERENCE 1

AN 139:138721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DT Patent
LA English
FAN CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 2003143158 A1 20030731 US 2001-34974 20011221
PRAI US 2001-34974 20011221

REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2002055544 A2 20020718 WO 2001-US49534 20011221
WO 2002055544 A3 20030327

DC Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 200205544 A2 20020718 WO 2001-US49534 20011221
WO 200205544 A3 20030327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1348026 A2 20031001 EP 2001-997103 20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004523514 T2 20040805 JP 2002-556612 20011221
PRAI US 2000-747403 20001223
WO 2001-US49534 20011221
L3 ANSWER 20 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-66-8 REGISTRY
FS PROTEIN SEQUENCE; STEREORESEARCH
SQL 15
SEQ3 1 Trip-Lys-Ala-Oys-Pro-Gly-Glu-Asp-Trip-Leu-
11 Phe-Oys-Trip-Gly-Ser
HITS AT: 1-15
REFERENCE 1
AN 139:138721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 2003143158 A1 20030731 US 2001-34974 20011221
PRAI US 2001-34974 20011221
REFERENCE 2
AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.

PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 200205544 A2 20020718 WO 2001-US49534 20011221
WO 200205544 A3 20030327
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, GR, GU, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, NO, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1348026 A2 20031001 EP 2001-997103 20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004523514 T2 20040805 JP 2002-556612 20011221
PRAI US 2000-747403 20001223
WO 2001-US49534 20011221
L3 ANSWER 21 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-65-7 REGISTRY
FS PROTEIN SEQUENCE; STEREORESEARCH
SQL 15
SEQ3 1 Trip-Ala-Pro-Oys-Gln-Glu-Pro-Trip-Leu-
11 Phe-Oys-Phe-His-Gly
HITS AT: 1-15
REFERENCE 1
AN 139:138721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO
DT Patent
LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 2003143158 A1 20030731 US 2001-34974 20011221
PRAI US 2001-34974 20011221
REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXMD2

DT Patent
LA English
FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055544	A2	20020718	WO 2001-US49534	20011221
WO 2002055544	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CE, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1348026 A2 20031001 EP 2001-997103 20011221

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004523514 T2 20040805 JP 2002-556612 20011221

PRAI US 2000-747403 20001223
WO 2001-US49534 20011221

L3 ANSWER 22 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-64-6 REGISTRY
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 15

SEQ3 1 Tip-Gln-Pro-Cys-Pro-Tip-Glu-Ser-Tip-Thr-
11 Phe-Cys-Tip-Asp-Pro

HITS AT: 1-15

REFERENCE 1

AN 139:138721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO

DT Patent
LA English
FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PT US 2003143158	A1	20030731	US 2001-34974	20011221
PRAI US 2001-34974		20011221		

REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
CODEN: PIXMD2

DT Patent
LA English
FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055544	A2	20020718	WO 2001-US49534	20011221
WO 2002055544	A3	20030327		

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GR, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MY, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZM, ZW

RM: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CE, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG

EP 1348026 A2 20031001 EP 2001-997103 20011221

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR

JP 2004523514 T2 20040805 JP 2002-556612 20011221

PRAI US 2000-747403 20001223
WO 2001-US49534 20011221

L3 ANSWER 23 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-63-5 REGISTRY
FS PROTEIN SEQUENCE; STEREOSEARCH
SQL 15

SEQ3 1 Tip-Met-Met-Cys-Pro-Met-Ser-Glu-Tip-Ileu-
11 Tyr-Cys-Tip-Ser-Ala

HITS AT: 1-15

REFERENCE 1

AN 139:138721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXXCO

DT Patent
LA English
FAN CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
PT US 2003143158	A1	20030731	US 2001-34974	20011221
PRAI US 2001-34974		20011221		

PI US 2003143158 A1 20030731 US 2001-34974 20011221
PRAI US 2001-34974 20011221

REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
CODEN: FIXMD2

DT Patent
LA English

FAN.CNT 1

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2002055544 A2 20020718 WO 2001-US49534 20011221
WO 2002055544 A3 20030327

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GE, GD, GE, GH,
GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
BG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1348026 A2 20031001 EP 2001-997103 20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004523514 T2 20040805 JP 2002-556612 20011221
PRAI US 2000-747403 20001223
WO 2001-US49534 20011221

L3 ANSWER 24 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 442513-62-4 REGISTRY
FS PROTEIN SEQUENCE; STEREOSEARCH

SOL 15

SEQ3 1 Trip-Glu-Leu-Cys-Ser-Asp-Glu-Asn-Trip-Leu-

11 Trip-Cys-Trip-Pro-His

HITS AT: 1-15

REFERENCE 1

AN 139:138721 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA USA
SO U.S. Pat. Appl. Publ., 41 pp.
CODEN: USXKCO
DT Patent

LA English
FAN.CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI US 2003143158 A1 20030731 US 2001-34974 20011221
PRAI US 2001-34974 20011221

REFERENCE 2

AN 137:90279 CA
TI Fibrin binding moieties useful as imaging agents
IN Wescott, Charles R.; Beltzer, James P.; Sato, Aaron K.
PA Dyax Corp., USA
SO PCT Int. Appl., 89 pp.
CODEN: FIXMD2

DT Patent
LA English

PATENT NO. KIND DATE APPLICATION NO. DATE
WO 2002055544 A2 20020718 WO 2001-US49534 20011221
WO 2002055544 A3 20030327

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GE, GD, GE, GH,
GR, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR,
LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NZ, NO, NZ, OM, PH,
PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ,
UA, UG, US, UZ, VN, YU, ZA, ZM, ZW
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY,
BG, KZ, MD, RU, TJ, TM, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB,
GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA,
GN, GQ, GW, ML, MR, NE, SN, TD, TG
EP 1348026 A2 20031001 EP 2001-997103 20011221
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, MK, CY, AL, TR
JP 2004523514 T2 20040805 JP 2002-556612 20011221
PRAI US 2000-747403 20001223
WO 2001-US49534 20011221

L3 ANSWER 25 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 368931-76-4 REGISTRY
FS PROTEIN SEQUENCE

SOL 73

SEQ3 1 Pro-Glu-Ala-Ser-Pro-Phe-Lys-Lys-Thr-Pro-

11 Leu-Leu-Ile-Ser-Thr-Asn-His-Leu-Thr-Ala-

21 Ala-Ser-Pro-Phe-Cys-Ser-Phe-Asn-Thr-Thr-

31 Asp-Gln-His-Ser-Phe-Leu-Ile-Arg-Ala-Thr-

PATENT ANNOTATIONS (PNTS):

Sequence | Patent

Source | Reference

Not Given | WO2001059063

1 | SEQID 6020

41 Asn-Pro-Gly-Val-Val-Leu-Ala-Ser-Leu-Tip-
51 Arg-Met-Cys-Ser-Glu-Ser-Ser-Gly-Val-Leu-
61 Cys-Phe-Thr-Ile-Asp-Val-Arg-Gly-Leu-Lys-
71 Thr-Pro-Pro
HITS AT: 50-64

REFERENCE 1
AN 135:328137 CA
TI Nucleic acids and their encoded polypeptides from human nervous system
IN Rosen, Craig A.; Barash, Steven C.; Ruben, Steven M.
PA Human Genome Sciences, Inc., USA
SO PCT Int. Appl., 1701 pp.
CODEN: PIXXD2
DT Patent
LA English
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2001059063 A2 20000131 WO 2001-US1334 20010117
PRAI US 2000-PV179065 20000204
US 2000-PV180628 20000224
US 2000-PV184664 20000302
US 2000-PV186350 20000316
US 2000-PV189874 20000317
US 2000-PV190076 20000418
US 2000-PV198123 20000519
US 2000-PV205515 20000607
US 2000-PV209467 20000628
US 2000-PV214886 20000630
US 2000-PV215135 20000707
US 2000-PV216647 20000707
US 2000-PV216880 20000711
US 2000-PV217487 20000711
US 2000-PV217496 20000714
US 2000-PV218290 20000726
US 2000-PV220963 20000726
US 2000-PV220964 20000726
US 2000-PV225757 20000814
US 2000-PV225270 20000814

L3 ANSWER 26 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 334659-00-6 REGISTRY
FS PROTEIN SEQUENCE
SQL 61

PATENT ANNOTATIONS (PNT):
Sequence | Patent
Source | Reference
=====|=====
Not Given | WO2001022920
| claimed
| SEQID 6949

SEQ3
1 Arg-Lys-His-Gly-Arg-Thr-Cys-Tip-Tip-Gly-
11 Pro-Ser-Asn-Ile-Gln-Leu-Asn-Leu-Ser-Pro-
21 Pro-Ser-Ser-Pro-Val-Leu-Cys-Arg-Asp-Gly-
31 Ser-Arg-Leu-Leu-Cys-Gly-Leu-Asp-Ile-Ser-
41 Glu-Gln-Pro-Asn-Leu-Ala-Gly-Ile-Asn-Pro-
51 Lys-Gly-Thr-Gly-Leu-Arg-Gly-Gln-Glu-Leu-
61 Lys
HITS AT: 24-38

RELATED SEQUENCES AVAILABLE WITH SEQLINK
REFERENCE 1
AN 134:306971 CA
TI Colon and colon cancer associated cDNAs and proteins and their use in
IN diagnosis and treatment of colon cancer
PA Ruben, Steven M.; Barash, Steven C.; Birse, Charles E.; Rosen, Craig A.
SO PCT Int. Appl., 9787 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 3
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 2001022920 A2 20010405 WO 2000-US26524 20000928
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN,
CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR,
HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT,
LU, LV, MA, MD, MG, MK, MW, MX, NZ, NO, NZ, PL, PT, RO, RU,
SD, SE, SG, SI, SK, SL, TJ, TR, TT, TZ, UA, UG, US, UZ, VN,
YU, ZA, ZW, AM, AZ, BY, BG, KZ, MD, RU, TZ, UA, UG, US, UZ, VN,
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY,
DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ,
CF, CG, CI, CM, GN, GW, ML, MR, NE, SN, TD, TG
AU 2000077215 A5 20010430 AU 2000-77215 20000928
EP 1255582 A2 20021218 EP 2000-966944 20000928

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT,
IE, SI, LT, LV, FI, RO, WK, CY, AU
US 2003:09690 A1 20030612 US 2002-106698 20020327
US 2003:09690 A1 20030612 US 2002-106698 20020327
PRAI US 1999-157137P 19990929
US 1999-165280P 19991103
WO 2000-US26524 20000928
US 2002-106698 20020327

L3 ANSWER 27 OF 27 REGISTRY COPYRIGHT 2004 ACS on STN
RN 330969-43-2 REGISTRY
FS PROTEIN SEQUENCE
SQL 66

SEQ3
1 Met-Thr-Asn-Ser-His-Thr-His-Asn-Gly-Asn-
11 Arg-Ile-Tip-Phe-Ile-Cys-Ser-Tip-Glu-Asn-

FILE COVERS 1907 - 7 Oct 2004 VOL 141 ISS 11
FILE LAST UPDATED: 6 Oct 2004 (20041006/ED)

```
=> s 145 and py<=2001
      21560072 py<=2001
163      3057145 AND py<-300
```

References

```

52224 FIBRING?
L63      25 L62 AND FIBRING?

=> s l63 not e6
      5 "WESCOTT CHARLES R"/IN
L64      25 L63 NOT "WESCOTT CHARLES R"/IN

=> s l64 not "wescott charles r"/au
      19 "WESCOTT CHARLES R"/AU
L65      25 L64 NOT "WESCOTT CHARLES R"/AU

=> s l65 not l56
L66      14 L65 NOT L56

```

L66 ANSWER 1 OF 14 CAPLUS COPYRIGHT 2004 ACS on STM
AN 2004:769051 CAPLUS
T1 Cysteine-rich extracellular matrix signaling molecules, protein and cDNAs
Abstract Abstract and four secondary methods using x-ray photoelectron spectroscopy

PA Munin Corporation, USA
SO U.S., 61 pp., Cont.-in-part of U.S. Ser. No. 142,569.
CODEN: USXXAM

LA	English
FAN,CNT	3
PATENT NO.	KIND
	DATE
	APPLICATION NO.
	DATE

PI	US 67960606	B1	20040314	US 2000-454448	20000131
WO 9733995		A2	19970318	WO 1997-US4193	19970314
WO 9733995		A3	19960108		
W:	AL, AM, AT, AU, AZ, BE, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE,				

US 6413735.210	US 1995-142369	19990302
WO 2001035210	WO 2001-US3267	20010131
WO 2001035210	A3	

W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BX, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DA, DB, DC, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ.

AB Protein and cDNA sequences for mammalian extracellular matrix (ECM) signaling molecules affecting the cell adhesion, migration, and proliferation activities, namely Cytel, Fisp12, Ctgf, are provided. The polypeptide compns. comprise mammalian ECM signaling molecules, peptide fragments, inhibitory peptides capable of interacting with receptors for ECM signaling molecules, and antibody products recognizing Cytel. Also provided are methods for producing mammalian ECM signaling molecules. Further provided are methods for using mammalian ECM signaling molecules for screening modulators of cell migration as well as methods to modulate angiogenesis, chondrogenesis, and oncogenesis. Claimed is a method for screening modulators of cell migration using gel matrix comprising Cytel and human fibroblast cells presenting .alpha.6.beta.1 integrin.

RE.CNT 24 THERE ARE 24 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

166 ANSWER 2 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:851374 CAPLUS
DN 136:1597
TI Anti-angiogenic polypeptides derived from **fibrinogen** E and their use in cancer therapy
IN Lewis, Claire; Staton, Carolyn
PA University of Sheffield, UK
SO PCT Int. Appl., 41 pp.
CODEN: PLEXD2
DT Patent
LA English
FAN.CNT 1

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2001088129	A1	20011122	WO 2001-082079	20010514 <--
W:				
AE, AG, AL, AM, AT, AU, AZ, BA, BB, BC, BD, BE, BF, BG, BH, BI, BJ, BK, BL, BM, BN, BO, BP, BQ, BR, BS, BT, BU, BV, BW, BX, BY, BZ, CA, CB, CC, CD, CE, CF, CG, CH, CI, CJ, CK, CL, CM, CN, CO, CP, CQ, CR, CS, CT, CU, CV, CW, CX, CY, CZ, DA, DB, DC, DD, DE, DF, DG, DH, DI, DJ, DK, DL, DM, DN, DO, DP, DQ, DR, DS, DT, DU, DV, DW, DX, DY, DZ, EA, EB, EC, ED, EE, EF, EG, EH, EI, EJ, EK, EL, EM, EN, EO, EP, EQ, ER, ES, ET, EU, EV, EW, EX, EY, EZ, FA, FB, FC, FD, FE, FF, FG, FH, FI, FJ, FK, FL, FM, FN, FO, FP, FQ, FR, FS, FT, FU, FV, FW, FX, FY, FZ, GA, GB, GC, GD, GE, GF, GH, GI, GJ, GK, GL, GM, GN, GO, GP, GQ, GR, GS, GT, GU, GV, GW, GX, GY, GZ, HA, HB, HC, HD, HE, HF, HG, HH, HI, HJ, HK, HL, HM, HN, HO, HP, HQ, HR, HS, HT, HU, HV, HW, HX, HY, HZ, IA, IB, IC, ID, IE, IF, IG, IH, II, IJ, IK, IL, IM, IN, IO, IP, IQ, IR, IS, IT, IU, IV, IW, IX, IY, IZ, JA, JB, JC, JD, JE, JF, JG, JH, JI, JJ, JK, JL, JM, JN, JO, JP, JQ, JR, JS, JT, JU, JV, JW, JX, JY, JZ, KA, KB, KC, KD, KE, KF, KG, KH, KI, KJ, KK, KL, KM, KN, KO, KP, KQ, KR, KS, KT, KU, KV, KW, KX, KY, KZ, LA, LB, LC, LD, LE, LF, LG, LH, LI, LJ, LK, LM, LN, LO, LP, LQ, LR, LS, LT, LU, LV, LW, LX, LY, LZ, MA, MB, MC, MD, ME, MF, MG, MH, MI, MJ, MK, ML, MN, MO, MP, MQ, MR, MS, MT, MU, MV, MW, MX, MY, MZ, NA, NB, NC, ND, NE, NF, NG, NH, NI, NJ, NK, NL, NM, NO, NP, NQ, NR, NS, NT, NU, NV, NW, NX, NY, NZ, OA, OB, OC, OD, OE, OF, OG, OH, OI, OJ, OK, OL, OM, ON, OO, OP, OQ, OR, OS, OT, OU, OV, OW, OX, OY, OZ, PA, PB, PC, PD, PE, PF, PG, PH, PI, PJ, PK, PL, PM, PN, PO, PP, PQ, PR, PS, PT, PU, PV, PW, PX, PY, PZ, QA, QB, QC, QD, QE, QF, QG, QH, QI, QJ, QK, QL, QM, QN, QO, QP, QQ, QR, QS, QT, QU, QV, QW, QX, QY, QZ, RA, RB, RC, RD, RE, RF, RG, RH, RI, RJ, RK, RL, RM, RN, RO, RP, RQ, RS, RT, RU, RV, RW, RX, RY, RZ, SA, SB, SC, SD, SE, SF, SG, SH, SI, SJ, SK, SL, SM, SN, SO, SP, SQ, SR, SS, ST, SU, SV, SW, SX, SY, SZ, TA, TB, TC, TD, TE, TF, TG, TH, TI, TJ, TK, TL, TM, TN, TO, TP, TQ, TR, TS, TU, TV, TW, TX, TY, TZ, UA, UB, UC, UD, UE, UF, UG, UH, UI, UJ, UK, UL, UM, UN, UO, UP, UQ, UR, US, UT, UV, UW, UX, UY, UZ, VA, VB, VC, VD, VE, VF, VG, VH, VI, VJ, VK, VL, VM, VN, VO, VP, VQ, VR, VS, VT, VU, VV, VW, VX, VY, VZ, WA, WB, WC, WD, WE, WF, WG, WH, WI, WJ, WK, WL, WM, WN, WO, WP, WQ, WR, WS, WT, WU, WV, WW, WX, WY, WZ, XA, XB, XC, XD, XE, XF, XG, XH, XI, XJ, XK, XL, XM, XN, XO, XP, XQ, XR, XS, XT, XU, XV, XW, XX, XY, XZ, YA, YB, YC, YD, YE, YF, YG, YH, YI, YJ, YK, YL, YM, YN, YO, YP, YQ, YR, YS, YT, YU, YV, YW, YX, YY, YZ, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ.				

UZ, VN, VU, ZA, ZB, ZC, ZD, ZE, ZF, ZG, ZH, ZI, ZJ, ZK, ZL, ZM, ZN, ZO, ZP, ZQ, ZR, ZS, ZT, ZU, ZV, ZW, ZX, ZY, ZZ.

AB The invention relates to the anti-angiogenic effects of polypeptides derived from **fibrinogen** . Specifically, **fibrinogen** E peptides of amino acid 1-78 of .alpha. chain, 43-122 of .beta. chain, and 1-62 of .gamma. chain are identified and tested to inhibit angiogenesis, which are useful for cancer therapy.

RE.CNT 7 THERE ARE 7 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

166 ANSWER 3 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2001:262857 CAPLUS
DN 135:340130
TI Yersinia pestis pira shows biovar-specific differences and recent common ancestry with a Salmonella enterica serovar typh. plasmid
AU Prentice, Michael B.; James, Keith D.; Parkhill, Julian; Baker, Stephen G.; Stevens, Kim; Simmonds, Mark N.; Murgall, Karen L.; Churcher, Carol; Oyston, Peter C. F.; Tibbally, Richard W.; Wren, Brendan W.; Weir, John; Pickard, Derek; Hien, Tran Tinh; Farrar, Jeremy J.; Dougan, Gordon
CS Department of Medical Microbiology, St. Bartholomew's and the Royal London School of Medicine and Dentistry, London, EC1A 7BE, UK
SO Journal of Bacteriology (2001-0000), 193(8), 2586-2594
CODEN: JOBAAV; ISSN: 0021-9193
PB American Society for Microbiology
DT Journal
LA English
FAN.CNT 1

166 ANSWER 4 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 2000:871614 CAPLUS
DN 134:15618
TI ClfF, a novel cyclo-oxygenase factor, regulates the circadian oscillation of plasminogen activator inhibitor-1 gene expression
AU Mammura, Koji; De la Monte, Suzanne M.; Chih, Michael T.; Layne, Matthew D.; Hsieh, Chung-Ming; Yet, Shaw-Fang; Petralia, Mark A.; Lee, Xu-En

CS Cardiovascular Division, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, 02115, USA
SO Journal of Biological Chemistry (***2000***), 275(47), 36847-36851
CODEN: JBCHA3; ISSN: 0021-9238
PB American Society for Biochemistry and Molecular Biology
DT Journal
LA English
AB The onset of myocardial infarction occurs frequently in the early morning, and it may partly result from circadian variation of ***fibrinolytic*** activity. Plasminogen activator inhibitor-1 activity shows a circadian oscillation and may account for the morning onset of myocardial infarction. However, the mol. mechanisms regulating this circadian oscillation remain unknown. Recent evidence indicates that basic helix-loop-helix (bHLH)/PAS domain transcription factors play a crucial role in controlling the biol. clock that controls circadian rhythm. The authors isolated a novel bHLH/PAS protein, cycle-like factor (Clf) from human umbilical vein endothelial cells. Clf shares high homol. with Prosopila CYCLE, one of the essential transcriptional regulators of circadian rhythm. Clf is expressed in endothelial cells and neurons in the brain, including the suprachiasmatic nucleus, the center of the circadian clock. In endothelial cells, Clf forms a heterodimer with CLOCK and up-regulates the PAF-1 gene through E-box sites. Furthermore, period and Cryptochrome1, whose expression show a circadian oscillation in peripheral tissues, inhibit the PAF-1 promoter activation by the CLOCK:Clf heterodimer. These results suggest that Clf regulates the circadian oscillation of PAF-1 gene expression in endothelial cells. In addn., the results potentially provide a mol. basis for the morning onset of myocardial infarction.

RE.CNT 35 THERE ARE 35 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 5 OF 14 CAPLUS COPYRIGHT 2004 ACS on STM
AN 2000:133731 CAPLUS
DN 132:177254
TI ***Fibrinogen*** fragments, their production with recombinant cells, and their use in diagnosis and therapy
IN Griendinger, Gerdi; Aplegate, Dianne; Stolke-Stephen, Lara
PA The New York Blood Center, Inc., USA
SO Per Inc. Appl., 66 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 200003562 A1 20000224 WO 1999-US18412 19990812 <--
W: CA, JP
RW: AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE
EP 1105428 A1 20010613 EP 1999-941108 19990812 <--
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, FI
US 6410965 B1 20020709 US 1999-373157 19990812
US 2002187722 A1 20021114 US 2002-112527 20020329
PRAI US 1998-962109 P 19980812
US 1999-373157 A1 19990812
WO 1999-US18412 W 19990812

AB The invention provides novel .alpha.ECX cleavage fragments of ***fibrinogen*** and methods for detecting and purifying these fragments. The method of the invention also includes a diagnostic method for def. ***fibrinolytic*** states or atherogenesis in a mammal. Methods of treating disease characterized by ***fibrinogen*** metab. are also disclosed. In addn., the invention also provides monospecific antibodies which are specifically reactive with .alpha.ECX domain of ***fibrinogen***. Also provided, are DNA and RNA mols. that encode .alpha.ECX cleavage fragments of ***fibrinogen***. In addn., the present invention includes a vector and a host cell capable of expressing .alpha.ECX cleavage fragments of ***fibrinogen***. Thus, ***fibrinogen*** -420 was purified from human blood plasma. The behavior of ***fibrinogen*** -420 was similar to that of ***fibrinogen*** -340 in clot formation and proteolytic susceptibility. Plasmin rapidly released the .alpha.ECX domain of ***fibrinogen*** -420 and this fragment was resistant to further degran. In vitro, this .alpha.ECX fragment is detectable in the plasma of patients undergoing thrombolytic therapy.

RE.CNT 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT

L66 ANSWER 6 OF 14 CAPLUS COPYRIGHT 2004 ACS on STM
AN 1999:621254 CAPLUS
DN 132:118097
TI DNA sequence of the canine platelet .beta.3 gene from cDNA: comparison of canine and mouse .beta.3 to segments that encode alloantigenic sites and functional domains of .beta.3 in human beings
AU Lipscomb, Desiree L.; Bounie, Candace; Boudreau, Mary K.
CS Department of Pathobiology, College of Veterinary Medicine, Auburn University, Auburn, AL, 36849, USA
SO Journal of Laboratory and Clinical Medicine (***1999***), 134(3), 313-321
CODEN: JLCMAJ; ISSN: 0022-2143
PB Mosby, Inc.
DT Journal
LA English
AB The platelet glycoprotein complex .alpha.IIb.beta.3 is required for platelet- ***fibrinogen*** binding and platelet aggregation. This study was designed to characterize the nucleotide sequence of the canine platelet .beta.3 gene from cDNA. The nucleotide and deduced amino acid sequences of the canine .beta.3 gene were 92% and 96% homologous, resp., with the sequences previously established for the .beta.3 gene of human beings. Within the .beta.3 gene, the nucleotide sequence of cDNA prep. from canine platelets shared homol. of 98% for the cytoplasmic domain, 93% for the transmembrane domain, 92% for the extracellular domain, 94% for the arginine-glycine-aspartic acid (RGD) binding domain, and 97% for the region assoc. with Ca2+-dependent stabilization of the .alpha.IIb.beta.3 ***fibrinogen*** -binding pocket. The deduced amino acid sequence of canine .beta.3 was 100%, 97%, 96%, and 95% homologous with the cytoplasmic, transmembrane, extracellular, and RGD-binding domains, resp., and was 100% homologous with the region assoc. with Ca2+-dependent stabilization of the .alpha.IIb.beta.3 ***fibrinogen*** -binding pocket of .beta.3 in human beings. The canine platelet cDNA signal peptide segment of the .beta.3 gene encodes for 22 amino acids, as compared with 26 amino acids previously reported for human beings. The deduced amino acid sequence of canine .beta.3 corresponds to the high-frequency allelic

from human aortic adventitia (aneurysm-associated antigenic protein, 40 kDa [AAAP-40]) that is immunoreactive with Ig (19c) from the wall of abdominal aortic aneurysms (AAAs). It shares motifs with Ig .kappa. (which may act as a binding site for interaction with integrins), cytochrome b5 (which may be a mol. mimic in the pathogenesis of AAA), and vitronectin and the ***fibrinogen***. A cDNA library was constructed from the aortic adventitia of a AAA. The library was screened with either rabbit anti-vitronectin antibody or rabbit anti-***fibrinogen*** antibody. Pos. plaques were purified and expressed in a strain of Escherichia coli. The clone sequences were analyzed. The expressed proteins were sepd. by SDS/PAGE and the immunoblots were probed with either AAA IgG or anti-human Ig .kappa. antibody. Exptl. cell lines, transfected with the clones (clones 1 and 5), synthesized recombinant proteins (AAAP-CL1 and AAAP-CL5), detectable in Western immunoblots with AAA IgG. A prediction of the tertiary structure resembles well-characterized cell adhesion molts. These findings suggest that there is a novel family of matrix proteins that may use Ig motifs as binding sites for cellular integrins and that there are matrix proteins in addn. to AAAP-40 that may serve as autoantigens in the pathogenesis of AAA disease.

L66 ANSWER 10 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1993:554328 CAPLUS
DN 119:134328
TI A comparative analysis of cDNA-derived sequences for rat and mouse .beta.3 integrins (GP11A) with their human counterpart
AU Cleutaut, A. M.; Rosa, J. P.; Letourneur, F.; Poncz, M.; Rifat, S.
CS Hop. Lariboisiere, Paris, Fr.
SO Biochemical and Biophysical Research Communications (***1993***), 193(2): 771-8
CODEN: BBRCAG; ISSN: 0006-291X

LA English
AB .alpha.IIb.beta.3 (GP11b-IIla), the platelet receptor for .***fibrinogen***, is a member of the integrin superfamily. Cloning of the mouse and rat .beta.3 cDNAs is described here. These data represent the first available non-human .beta.3 sequences, allowing important comparative analyses. Both .beta.3 sequences are highly homologous with human .beta.3, well above the av. rodent-human protein homol. of 79%. The ligand binding domains (amino acids 109-171 and 204-229) are, resp., 90% and 100% homologous. The .beta.3 transmembrane and the cytoplasmic tail are surprisingly highly conserved, being 97% and 100% homologous, resp., but share little homol. with .beta.1, or .beta.2. This latter difference argues strongly in favor of a crucial .beta.3-specific function for these domains. In conclusion the first comparative anal. of .beta.3 chains demonstrates a high overall homol. The Biol. implications of these comparisons are discussed.

L66 ANSWER 11 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1991:37194 CAPLUS
DN 114:37194
TI Recombinant manufacture of soluble functional integrins
IN Bodary, Sarah C.; Gorman, Cornelia M.; McLean, John W.; Nappier, Mary A.
PA Genentech, Inc., USA
SO PCT Int. Appl., 47 pp.
CODEN: PIXXD2
DT Patent
LA English

PAT. CNT 1
PATENT NO. KIND DATE APPLICATION NO. DATE
PI WO 9006953 A2 19900628 WO 1989-US5743 19891220 <--
WO 9006953 A3 19900809

W: AU, JP
R: AT, BE, CH, DE, ES, FR, GB, IT, LU, NL, SE
AU 9048326 A1 19900710 AU 1990-48326 19891220 <--
AU 638964 B2 19930715
AU 452364 A1 19911023 EP 1990-901448 19891220 <--
EP 452364 B1 20020522
R: AT, BE, CH, DE, ES, FR, GB, IT, LU, NL, SE
JP 04502327 T2 19920423 JP 1990-501899 19891220 <--
JP 200211796 A2 20020416 JP 2001-257835 19891220 <--
EP 1201756 A2 20020502 EP 2001-124409 19891220 <--
EP 1201756 A3 20021030
R: AT, BE, CH, DE, ES, FR, GB, IT, LU, NL, SE
EP 1201757 A2 20020502 EP 2001-124410 19891220 <--
EP 1201757 A3 20020911
R: AT, BE, CH, DE, ES, FR, GB, IT, LU, NL, SE
AT 217687 E 20020615 AT 1990-901448 19891220 <--
ES 2176174 T3 20021201 ES 1990-901448 19891220 <--
CA 2006475 AA 19900622 CA 1989-2006475 19891221 <--
US 5726037 A 19980310 US 1995-444792 19950519 <--
US 5726290 A 19980310 US 1995-445042 19950519 <--
US 5837486 A 19981117 US 1995-445443 19950519 <--
PRAI US 1988-290224 A 19881222
US 1989-444490 A 19891201
EP 1990-901448 A3 19891220
JP 1990-501899 A3 19891220
WO 1989-US5743 A 19891220
US 1992-821337 B1 19920113
US 1994-218878 B1 19940328
US 1995-380227 B3 19950130

AB Human polypeptide receptors such as platelet glycoprotein GP11b-GP11a are manuf. as a functional, i.e. ligand-binding, sol. dimer by expression of cDNAs for analogs lacking the transmembrane and cytoplasmic domains of the polypeptides. These sol. derivs. have altered physiol. properties that make them therapeutically useful and as reagents for the detn. of their ligands. A cDNA for GP11b was cloned using an oligonucleotide probe and a cDNA for GP11a of the prior art obtained and modified to lower the G/C content of the 5' region. Expression vectors for the two cDNAs were introduced into 293S cells and transformants shown to produce the membrane-bound complex. The cDNAs were then modified to introduce stop codons into the sequence immediately before the coding sequences for the transmembrane domains. 293S cells transformed with the appropriate plasmids were shown to produce the sol. dimer. Clones stably expressing the genes were established. The protein was secreted as a dimer and was able to bind fibrinogen.

L66 ANSWER 12 OF 14 CAPLUS COPYRIGHT 2004 ACS on STN
AN 1990:212623 CAPLUS
DN 112:212623
TI Two contrary functions of tenascin: dissection of the active sites by recombinant tenascin fragments
AU Spring, Juerig; Beck, Konrad; Chiquet-Ehrismann, Ruth
CS Friedrich Miescher-Inst., Basel, CH-4002, Switz.

L25 4 S 'TRP-GLN-PRO-CYS-PRO-TRP-GLU-SER-TRP-THR-PHE-CYS-TRP-ASP-PRO
L26 2 S 'TRP-ALA-PRO-CYS-GLN-GLU-PRO-TRP-LEU-PHE-CYS-PHE-HIS-GLY
L27 1 S 'PRO-ARG-PRO-CYS-TYR-GLY-GLU-SER-GLY-ILE-PHE-CYS-TRP-LYS-VAL
L28 1 S 'PRO-ARG-PRO-CYS-THR-GLY-GLU-PRO-GLY-PRO-ILE-CYS-GLY-PRO-ARG
L29 1 S 'TRP-GLN-ALA-PRO-CYS-GLN-LEU-TYR-ARG-THR-TYR-CYS-TRP-ASP-GLY
L30 1 S 'TRP-LYS-PHE-CYS-ASP-GLY-TRP-PRO-LEU-PHE-CYS-TRP-ASP-GLY
L31 1 S 'TRP-ASN-GLY-CYS-GLY-TRP-GLY-SER-TRP-LYS-PHE-CYS-GLY-GLU-GLY
L32 1 S 'TRP-LEU-ASN-CYS-GLY-TRP-GLY-SER-GLY-LYS-LEU-CYS-LEU-GLU-GLY
L33 1 S 'CYS-TYR-PHE-CYS-PRO-GLY-GLU-PRO-TRP-THR-PHE-CYS-CYS-ASP-ASP
L34 1 S 'TRP-HIS-PHE-CYS-PRO-GLY-GLU-PRO-TRP-THR-PHE-CYS-CYS-ASP-ASP
L35 1 S 'TRP-GLN-THR-CYS-PRO-GLY-TYR-LEU-ARG-SER-LEU-CYS-TRP-ALA-GLY
L36 1 S 'TRP-TYR-PHE-CYS-PRO-GLY-GLU-PRO-TRP-SER-PHE-CYS-TRP-ASP-GLY
L37 1 S 'PRO-ARG-PRO-CYS-ARG-GLY-GLU-SER-TRP-TYR-CYS-PRO-ASP-GLY
L38 1 S 'TRP-GLN-ALA-CYS-PRO-GLY-TYR-LYS-ARG-GLN-PHE-CYS-TRP-ASP-GLY
L39 1 S 'PRO-ARG-PRO-CYS-GLY-GLU-GLU-SER-ARG-THR-PHE-CYS-LEU-GLU-GLY
L40 1 S 'PRO-ARG-PRO-CYS-PHE-GLN-GLN-LYS-GLY-THR-LEU-CYS-TRP-PRO-GLY

FILE 'HOME' ENTERED AT 12:36:28 ON 07 OCT 2004
FILE 'BIOSIS, CAPLUS' ENTERED AT 12:36:20 ON 07 OCT 2004
0 S L1

FILE 'HOME' ENTERED AT 12:40:48 ON 07 OCT 2004
FILE 'CAPLUS' ENTERED AT 12:40:52 ON 07 OCT 2004
5026 S L1
114 S L2
8 S L3
5029 S L42 OR L43 OR L44
4761 DUP REM L45 (268 DUPLICATES REMOVED)
4761 S L46
4761 S L46 NOT WESCOTT/TN
4761 S L48 NOT WESCOTT/NU
E WESCOTT/IN

L42 4761 S L46
L43 4759 S L46 NOT E6
L44 4757 S L51 NOT FIBRIN
L45 6 S L44 NOT E6
L46 112 S L43 NOT E6
L47 16 S L54 AND PY<1999
L48 16 S L55 NOT L53
L49 4 S (L7 OR L8 OR L9 OR L10 OR L11 OR L12 OR L13 OR L14 OR L16 OR
L50 4 S (L23 OR L24 OR L25 OR L26 OR L27 OR L28 OR L29 OR L30 OR L31
L51 SET DETAIL OFF
L52 4 S L57 OR L58
L53 2 S L59 NOT E6
L54
L55
L56
L57
L58
L59
L60

FILE 'HOME' ENTERED AT 13:28:53 ON 07 OCT 2004
FILE 'REGISTRY' ENTERED AT 13:29:38 ON 07 OCT 2004
FILE 'CAPLUS' ENTERED AT 13:30:01 ON 07 OCT 2004
FILE 'REGISTRY' ENTERED AT 13:30:12 ON 07 OCT 2004

FILE 'HOME' ENTERED AT 13:30:16 ON 07 OCT 2004
FILE 'REGISTRY' ENTERED AT 13:30:50 ON 07 OCT 2004
0 S L2 AND PY<=2001
L61
FILE 'CAPLUS' ENTERED AT 13:33:45 ON 07 OCT 2004
3057 S L45 AND PY<=2001
L62 25 S L62 AND FIBRIN?
L63 25 S L63 NOT E6
L64 25 S L64 NOT "WESCOTT CHARLES R"/AU
L65 14 S L65 NOT L56
L66
=> log h
COST IN U.S. DOLLARS
FULL ESTIMATED COST
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)
CA SUBSCRIBER PRICE
SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 13:36:15 ON 07 OCT 2004
Connecting via Winsock to STN

Welcome to STN International! Enter x:x
* * * * * STN Columbus * * * * *
FILE 'HOME' ENTERED AT 15:27:24 ON 07 OCT 2004
=> d hie
(FILE 'HOME' ENTERED AT 15:27:24 ON 07 OCT 2004)
=> file dgene
COST IN U.S. DOLLARS
FULL ESTIMATED COST
FILE 'DGENE' ENTERED AT 15:28:00 ON 07 OCT 2004
COPYRIGHT (C) 2004 THE THOMSON CORPORATION
FILE LAST UPDATED: 24 SEP 2004 <20040924/DP>
DGENE CURRENTLY CONTAINS 6,130,750 BIOSEQUENCES
>>> NEW DISPLAY FIELDS L5 AND L52 (LEGAL STATUS DATA FROM
THE INPADOC DATABASE) AVAILABLE IN DGENE - SEE NEWS <<<
>>> ONLINE THESAURUS AVAILABLE IN /PAO <<<

	SINCE FILE	TOTAL
ENTRY	44.74	1339.14
SESSION	-9.80	-25.90

	SINCE FILE	TOTAL
ENTRY	0.21	0.21
SESSION		

>>> ONLINE THESAURUS AVAILABLE IN /PAO <<<

```

>>> DOWNLOAD THE GENE WORKSHOP MANUAL:
http://www.stn-international.de/training_center/bioseq/dgene_km.pdf
>>> DOWNLOAD COMPLETE GENE HELP AS PDF:
http://www.stn-international.de/training_center/bioseq/dgene_help.pdf <<<
>>> DOWNLOAD GENE BLAST/GETSIM FREQUENTLY ASKED QUESTIONS:
http://www.stn-international.de/service/faq/dgenefaq.pdf <<<

=> run getseq C[PVQST][ANDQIGLMEPSTWV][ES][PDENQSTY][WILIMQSTV][FWI]/SQSP
RUN GETSEQ AT 21:27:38 ON 07 OCT 2004
COPYRIGHT (C) 2004 FITZ KARLSRUHE GMBH

L1 RUN STATEMENT CREATED
L1 334 C[PVQST][ANDQIGLMEPSTWV][ES][PDENQSTY][WILIMQSTV][FWI]/SQSP

=> dup rem l1
DUPLICATE IS NOT AVAILABLE IN 'DGENE'.
ANSWERS FROM THESE FILES WILL BE CONSIDERED UNIQUE
PROCESSING COMPLETED FOR L1
L2 334 DUP REM L1 (0 DUPLICATES REMOVED)

=> s l2 not "wescott charles r"/in
L3 334 S L2
0 "WESCOTT CHARLES R"/IN
L4 334 L3 NOT "WESCOTT CHARLES R"/IN

=> e wescott/in
E1 13 WESCHE H/IN
E2 4 WESCHKE W/IN
E3 0 --> WESCOTT/IN
E4 389 WESCOTT C R/IN
E5 17 WESLAKE R J/IN
E6 38 WESLOH R/IN
E7 12 WESNERG D/IN
E8 18 WESKAMP G/IN
E9 39 WESKE M/IN
E10 2 WESLEY B/IN
E11 8 WESLEY I V/IN
E12 42 WESLEY R D/IN

=> s l2 not e4
L5 334 S L2
389 "WESCOTT C R"/IN
L6 300 L5 NOT "WESCOTT C R"/IN

=> s l6 and py <=2001
2847180 PY <=2001
(PY<=2001)
L7 36 L6 AND PY <=2001

=> d l7 l1-36
L7 ANSWER 1 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABP07066 Protein DGENE

```

```

TI Novel human polypeptides and polynucleotides useful for diagnosing,
preventing and treating cardiovascular disease, neurodegenerative,
hyperproliferative disorders and autoimmune disorders
IN Shinketsu R A; Leach M D
PA (CURA-N) CURAGEN CORP.
PI ***WO 2001092523 A2 20011206 999p***
AI WO 2001-US10836 20010529
PRAI US 2000-206132P 20000530
DT US 2000-228716P 20000829
LA English
OS 2002-106308 (14)
CR N-PSDB: AAM22818
DESC Human ORFX protein sequence SEQ ID NO:14114.

L7 ANSWER 2 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AB89477 Protein DGENE
TI Novel 1405 isolated polypeptides, useful for diagnosis, treatment and
prevention of neural, immune system, muscular, reproductive,
gastrointestinal, pulmonary, cardiovascular, renal and proliferative
disorders -
IN Balse C E; Rosen C A
PA (HUMA-N) HUMAN GENOME SCI INC.
PI ***WO 2001090304 A2 20011129 999p***
AI WO 2001-US16450 20010518
PRAI US 2000-205515P 20000519
DT Patent
LA English
OS 2002-122018 (16)
CR N-PSDB: AB189886
DESC Human polypeptide SEQ ID NO 1853.

L7 ANSWER 3 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AA01405 protein DGENE
TI Novel isolated nucleic acid molecule which encodes a fibrinogen E
polypeptide which is useful for treating cancer, diabetic retinopathy,
obesity, hepatitis, pneumonia, glomerulonephritis, asthma and thyroiditis
IN Lewis C; Staton C
PA (UYSH-N) UNIV SHEFFIELD.
PI ***WO 2001088129 A1 20011122 41p***
AI WO 2001-GB2079 20010514
PRAI GB 2000-11464 20000513
GB 2000-14370 20000614
GB 2000-27396 20001109
DT Patent
LA English
OS 2002-062380 (08)
CR N-PSDB: AAK98254
DESC Human fibrinogen E-Fragment alpha-chain amino acids 1-78.

L7 ANSWER 4 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AB870490 Protein DGENE
TI New isolated nucleic acid detection reagent for detecting 1000 or more
genes from Drosophila and for elucidating cell signalling and cell-cell
interactions -
IN Venter J C; Adams M; Li P W D; Myers E W

```

PA	(PEKE)	PE CORP NY.		
PI	***WO 2001071042 A2	20010927		
AI	WO 2001-US9231	20010323	21p***	
PRAI	US 2000-191637P	20000323		
DT	Patent	US 2000-614150	20000711	
LA	English			
OS	2001-656860 [75]			
CR	N-PDB: ABL14593			
DESC	Drosophila melanogaster polypeptide SEQ ID NO 38262.			
L7	ANSWER 5 OF 36	GENE COPYRIGHT 2004 The Thomson Corp on STN		
AN	AB59448 Protein	GENE		
TI	New isolated nucleic acid detection reagent for detecting 1000 or more genes from Drosophila and for elucidating cell signalling and cell-cell interactions -			
IN	Venter J C; Adams M; Li P W D; Myers E W			
PA	(PEKE)	PE CORP NY.		
PI	***WO 2001071042 A2	20010927	21p***	
AI	WO 2001-US9231	20010323		
PRAI	US 2000-191637P	20000323		
DT	Patent	US 2000-614150	20000711	
LA	English			
OS	2001-656860 [75]			
CR	N-PDB: ABL03551			
DESC	Drosophila melanogaster polypeptide SEQ ID NO 5136.			
L7	ANSWER 6 OF 36	GENE COPYRIGHT 2004 The Thomson Corp on STN		
AN	ABG0414 Protein	GENE		
TI	New isolated polynucleotide and encoded polypeptides, useful in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits and to assess biodiversity -			
IN	Dranac R T; Liu C; Tang Y T			
PA	(HYSE-N)	HYSEQ INC.		
PI	***WO 2001075067 A2	20011011	103p***	
AI	WO 2001-US8631	20010330		
PRAI	US 2000-540217	20000331		
DT	Patent	US 2000-649167	20000823	
LA	English			
OS	2001-639362 [73]			
CR	N-PDB: AAS84601			
DESC	Novel human diagnostic protein #20405.			
L7	ANSWER 7 OF 36	GENE COPYRIGHT 2004 The Thomson Corp on STN		
AN	ABG1528 Protein	GENE		
TI	New isolated polynucleotide and encoded polypeptides, useful in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits and to assess biodiversity -			
IN	Dranac R T; Liu C; Tang Y T			
PA	(HYSE-N)	HYSEQ INC.		
PI	***WO 2001075067 A2	20011011	103p***	
AI	WO 2001-US8631	20010330		
PRAI	US 2000-540217	20000331		
DT	Patent	US 2000-649167	20000823	
LA	English			
OS	2001-639362 [73]			
CR	N-PDB: AAS84601			
DESC	Novel human diagnostic protein #20405.			
L7	ANSWER 8 OF 36	GENE COPYRIGHT 2004 The Thomson Corp on STN		
AN	ABG0222 Protein	GENE		
TI	New isolated polynucleotide and encoded polypeptides, useful in diagnostics, forensics, gene mapping, identification of mutations responsible for genetic disorders or other traits and to assess biodiversity -			
IN	Dranac R T; Liu C; Tang Y T			
PA	(HYSE-N)	HYSEQ INC.		
PI	***WO 2001075067 A2	20011011	103p***	
AI	WO 2001-US8631	20010330		
PRAI	US 2000-540217	20000331		
DT	Patent	US 2000-649167	20000823	
LA	English			
OS	2001-639362 [73]			
CR	N-PDB: AAS66409			
DESC	Novel human diagnostic protein #2213.			
L7	ANSWER 9 OF 36	GENE COPYRIGHT 2004 The Thomson Corp on STN		
AN	ABG5891 Protein	GENE		
TI	Isolated polypeptides, which may be peptide hormones, which are identified by high throughput genome-based biology which identifies genes and gene products as therapeutic targets for treatment of diseases such as diabetes and cancer -			
IN	Agarwal P; Murdoch P R; Rizvi S K; Smith R F; Xiang Z; Kabnick K S; Lai Y			
PA	(SMIK)	SMITHLINE BEECHAM PLC.		
PI	***WO 2001072961 A2	20011004	99p***	
AI	WO 2001-US9226	20010322		
PRAI	US 2000-192158P	20000324		
DT	Patent	US 2000-192688P	20000328	
LA	English		20000427	
OS	2001-639223 [73]			
CR	N-PDB: AAL67161			
DESC	Amino acid sequence of GSK gene Id 74552.			
L7	ANSWER 10 OF 36	GENE COPYRIGHT 2004 The Thomson Corp on STN		
AN	ABG5890 Protein	GENE		
TI	Isolated polypeptides, which may be peptide hormones, which are identified by high throughput genome-based biology which identifies genes and gene products as therapeutic targets for treatment of diseases such as diabetes and cancer -			
IN	Agarwal P; Murdoch P R; Rizvi S K; Smith R F; Xiang Z; Kabnick K S; Lai Y			
PA	(SMIK)	SMITHLINE BEECHAM CORP.		
PI	***WO 2001072961 A2	20011004	99p***	
AI	WO 2001-US9226	20010322		
PRAI	US 2000-192158P	20000324		

US 2000-19268P	20000328	
US 2000-200166P	20000427	
DT Patent		
LA English		
OS 2001-639223 (73)		
CR N-PSDB: AA167180		
DESC Amino acid sequence of GSK gene Id 74552.		
L7 ANSWER 11 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN		
AN AAB47569 Protein DGENE		
TI New polypeptide for treating gastrointestinal, cardiovascular and autoimmune disorders, comprising novel human proteases (PRTS) and polynucleotides -		
IN Yue H; Lu D A M; Policky J L; Deleage A M; Tribouley C M; Khan F A; Au-Yang J; Bandhan O; Lal P; Borowsky M L; Gandhi A R; Hillman J L; Tang Y T; Burford N; Baughn M R; Nguyen D B; Yao M G; Walla N K; He A; Hafalla A; Lu Y; Patterson C		
PA (INCY-N) INCYTE GENOMICS INC.		
PI ***WO 2001071004 A2 20010927	129P***	
AI WO 2001-US8441	20010316	
PAI US 2000-190708P	20000317	
US 2000-193182P	20000330	
US 2000-197086P	20000414	
US 2000-199022P	20000420	
US 2000-20027P	20000428	
DT Patent		
LA English		
OS 2001-611509 (70)		
CR N-PSDB: AA443522		
DESC Protease PRTS-11.		
L7 ANSWER 12 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN		
AN AAO11054 Protein DGENE		
TI Isolated nucleic acids and polypeptides, useful for preventing diagnosing and treating e.g. leukaemia, inflammation and immune disorders -		
IN Tang Y T; Liu C; Drmanac R T		
PA (HYSE-N) HYSEQ INC.		
PI ***WO 2001064835 A2 20010907	999P***	
AI WO 2001-US4927	20010226	
PAI US 2000-515126	20000228	
US 2000-577409	20000518	
DT Patent		
LA English		
OS 2001-514838 (56)		
CR N-PSDB: AA190385		
DESC Human polypeptide SEQ ID NO 24946.		
L7 ANSWER 13 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN		
AN AAU12295 Protein DGENE		
TI Isolated, secretory and transmembrane PRO polypeptide used to detect other PRO polypeptides, link bioactive molecules to cells expressing PRO polypeptides, and detect the presence of mammalian tumours e.g. lung, breast, prostate, cervical -		
IN Baker K P; Beresini M; DeForge L; Desnoyers L; Filvaroff E; Gao W; Gerlitsen M E; Goddard A; Godowski P J; Gurney A L; Sherwood S; Smith V; Stewart T A; Tumas D; Watanabe C K; Wood W I; Zhang Z		
PA (GEITH) GENENTECH INC.		
PI ***WO 2001040466 A2 20010607		813P***
AI WO 2000-US32878	20001201	
PAI WO 1999-US28301	19991201	
WO 1999-US28634	19991201	
WO 1999-US28551	19991202	
WO 1999-US28564	19991202	
WO 1999-US28565	19991202	
US 1999-170262	19991209	
US 1999-US30095	19991216	
WO 1999-US30911	19991220	
WO 1999-US30939	19991220	
WO 1999-US31243	19991230	
WO 2000-US277	20000106	
WO 2000-US376	20000106	
WO 2000-US3565	20000211	
WO 2000-US4341	20000218	
WO 2000-US4342	20000218	
WO 2000-US4414	20000222	
WO 2000-US4914	20000224	
WO 2000-US5004	20000224	
WO 2000-US5601	20000301	
WO 2000-US7377	20000320	
WO 2000-US7532	20000321	
WO 2000-US8439	20000330	
WO 2000-US13705	20000517	
WO 2000-US14042	20000522	
WO 2000-US14941	20000530	
WO 2000-US15264	20000602	
WO 2000-US30873	20001110	
DT Patent		
LA English		
OS 2001-408281 (43)		
CR N-PSDB: AAS21367		
DESC Human PRO6090 polypeptide sequence.		
L7 ANSWER 14 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN		
AN AAE00334 Protein DGENE		
TI Novel membrane bound protein, zsig60 isolated from pituitary gland, and anti-zsig60 antibodies which are useful for identifying or isolating cells of pituitary gland and to detect size and morphology of the gland -		
IN Presnell S R		
PA (ZYMO) ZYMOGENETICS INC.		
PI ***WO 2001023567 A1 20010405	89P***	
AI WO 2000-US26664	20000928	
PAI US 1999-156367	19990928	
DT Patent		
LA English		
OS 2001-26161 (27)		
DESC Human membrane-bound protein-60 alternative mature extracellular portion.		
L7 ANSWER 15 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN		
AN AAE00333 Protein DGENE		
TI Novel membrane bound protein, zsig60 isolated from pituitary gland, and anti-zsig60 antibodies which are useful for identifying or isolating cells of pituitary gland and to detect size and morphology of the gland -		
IN Presnell S R		
PA (ZYMO) ZYMOGENETICS INC.		

PI ***WO 2001023367 A1 20010405 89p***
 AI WO 2000-US26664 20000928
 PRAI US 1999-156367 19990928
 DT Patent
 LA English
 OS 2001-266161 [27]
 DESC Human membrane-bound protein-60 (Zsig60) mature extracellular portion.

L7 ANSWER 16 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAE00332 Protein DGENE
 TI Novel membrane bound protein, Zsig60 isolated from pituitary gland, and anti-Zsig60 antibodies which are useful for identifying or isolating cells of pituitary gland and to detect size and morphology of the gland - Presnell S R

IN (ZYMO) ZYMOGENETICS INC.
 PA ***WO 2001023367 A1 20010405 89p***
 PI WO 2000-US26664 20000928
 PRAI US 1999-156367 19990928
 DT Patent
 LA English
 OS 2001-266161 [27]
 DESC Human membrane-bound protein-60 alternative mature protein sequence.

L7 ANSWER 17 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAE00331 Protein DGENE
 TI Novel membrane bound protein, Zsig60 isolated from pituitary gland, and anti-Zsig60 antibodies which are useful for identifying or isolating cells of pituitary gland and to detect size and morphology of the gland - Presnell S R

IN (ZYMO) ZYMOGENETICS INC.
 PA ***WO 2001023367 A1 20010405 89p***
 PI WO 2000-US26664 20000928
 PRAI US 1999-156367 19990928
 DT Patent
 LA English
 OS 2001-266161 [27]
 DESC Human membrane-bound protein-60 (Zsig60) mature protein sequence.

L7 ANSWER 18 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAE00330 Protein DGENE
 TI Novel membrane bound protein, Zsig60 isolated from pituitary gland, and anti-Zsig60 antibodies which are useful for identifying or isolating cells of pituitary gland and to detect size and morphology of the gland - Presnell S R

IN (ZYMO) ZYMOGENETICS INC.
 PA ***WO 2001023367 A1 20010405 89p***
 PI WO 2000-US26664 20000928
 PRAI US 1999-156367 19990928
 DT Patent
 LA English
 OS 2001-266161 [27]
 DESC Human membrane-bound protein-60 (Zsig60) mature protein sequence.

L7 ANSWER 19 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAE0466 Protein DGENE
 TI Novel secreted protein 5' expressed sequence tag sequences used in

IN diagnostic, forensic, gene therapy, and chromosome mapping procedures
 PA (GENT) Dumas Milne Edwards J; Duclerc A; Giordano J
 PI ***WO 9953051 A2 19991021 837p***
 AI WO 1999-18712 19990409
 PRAI US 1998-57719 19980409
 DT Patent
 LA English
 OS 2000-038446 [03]
 CR N-PSDB: AA242480
 DESC Human 5' EST related polypeptide SEQ ID NO:1027.

L7 ANSWER 20 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAY94930 Protein DGENE
 TI New polynucleotides encoding secreted proteins, which may have e.g. nutritional, chemokine, immune stimulating or suppressing, hematopoiesis regulating, tissue growth, activin/inhibin antiinflammatory or tumor inhibition activity - Jacobs K; McCoy J M; LaVallie E R; Collins-Racie L A; Evans C; Marberg D; Treacy M; Agostino M J; Steininger R J; Spaulding V; Wong G G; Clark H F; Fechtel K

IN (GENY) GENETICS INST INC.
 PA ***WO 200009352 A1 20000224 641p***
 PI WO 1999-US18298 19990813
 PRAI US 1998-96815 19980817
 US 1998-96815 19980817
 US 1998-99229 19980904
 US 1998-105368 19981023
 US 1998-115234 19980108
 US 1998-119331 19980212
 US 1998-120375 19980218
 US 1999-132020 19990430
 US 1999-96622 19990811
 DT Patent
 LA English
 OS 2000-205979 [18]
 DESC Human secreted protein clone qa136_1 protein sequence SEQ ID NO:66.

L7 ANSWER 21 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAY82891 Protein DGENE
 TI New fragments of human fibrinogen, useful for treating conditions associated with fibrinogen metabolism - Giesinger G; Applegate D; Stoike-steben L

IN (NYB-N) NEW YORK BLOOD CENT INC.
 PA ***WO 200009562 A1 20000224 66p***
 PI WO 1999-US18412 19990812
 PRAI US 1998-96210 19980812
 DT Patent
 LA English
 OS 2000-205983 [18]
 CR N-PSDB: AA293039
 DESC Alpha2 subunit of human fibrinogen.

L7 ANSWER 22 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAB38373 Protein DGENE
 TI New nucleic acid molecules encoding 62 human secreted proteins for

diagnosing, preventing, treating or ameliorating medical conditions and used as food additives or preservatives -
 IN Ruben S M; Nl J; Komatsoulis G A; Rosen C A; Soppet D R; Shi Y; Lafleur D W; Olsen H S; Eder R; Florence K A; Moore P A; Birse C E; Young P E
 PA (HUMA-N) HUMAN GENOME SCI INC.
 PI ***WO 2000061623 A1 20001019 716p***
 WO 2000-058979 20000406
 PRAI US 1999-128693 19990409
 US 1999-130991 19990426
 DT Patent
 LA English
 OS 2000-647418 [62]
 DESC Human secreted protein encoded by gene 53 clone HPABG18.

L7 ANSWER 23 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAB18983 Protein DGENE
 TI New human transmembrane proteins are used to treat a disease or condition associated with decreased expression of functional HTP e.g. Tourette's disorder, angina and leukaemia -
 IN Yue H; Lal P; Tang Y T; Hillman J L; Reddy R; Bandman O; Baughn M R; Lu D A M; Azimzai Y; Yang J
 PA (INCYTE-N) INCYTE PHARM INC.
 PI ***WO 2000056891 A2 20000928 130p***
 WO 2000-057817 20000322
 PRAI US 1999-125537 19990322
 US 1999-139565 19990616
 DT Patent
 LA English
 OS 2000-579485 [54]
 CR N-PSDB: AAB6498
 DESC Amino acid sequence of a human transmembrane protein.

L7 ANSWER 24 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAB54135 Protein DGENE
 TI New nucleic acid that is a pancreatic cancer antigen for preventing, treating, or ameliorating a medical condition, particular pancreatic cancer, or for use in assays for diagnosing a pathological condition -
 IN Rosen C A; Ruben S M
 PA (HUMA-N) HUMAN GENOME SCI INC.
 PI ***WO 2000055320 A1 20000921 999p***
 WO 2000-055989 20000308
 PRAI US 1999-124270 19990312
 DT Patent
 LA English
 OS 2000-579444 [54]
 CR N-PSDB: AAC9890
 DESC Human pancreatic cancer antigen protein sequence SEQ ID NO:587.

L7 ANSWER 25 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAB19796 Protein DGENE
 TI Purified laminin 2 protein, useful for research and therapeutic purposes including peripheral nerve regeneration, treatment of degenerative muscle disorders, angiogenesis regulation, and ex vivo cell therapy -
 IN Yurchenco P
 PA (UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
 PI ***WO 2000066730 A2 20001109 305p***
 WO 2000-US11378 20000428

PRAI US 1999-131720 19990430
 US 1999-139198 19990615
 US 1999-143289 19990712
 US 1999-153945 19990924
 DT Patent
 LA English
 OS 2000-687537 [67]
 CR N-PSDB: AAB6896
 DESC Mouse laminin 2 mature alpha-2 chain.

L7 ANSWER 26 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAB19795 Protein DGENE
 TI Purified laminin 2 protein, useful for research and therapeutic purposes including peripheral nerve regeneration, treatment of degenerative muscle disorders, angiogenesis regulation, and ex vivo cell therapy -
 IN Yurchenco P
 PA (UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
 PI ***WO 2000066730 A2 20001109 305p***
 WO 2000-US11378 20000428
 PRAI US 1999-131720 19990430
 US 1999-139198 19990615
 US 1999-143289 19990712
 US 1999-155945 19990924
 DT Patent
 LA English
 OS 2000-687537 [67]
 CR N-PSDB: AAB6895
 DESC Mouse laminin 2 alpha-2 chain.

L7 ANSWER 27 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAB19794 Protein DGENE
 TI Purified laminin 2 protein, useful for research and therapeutic purposes including peripheral nerve regeneration, treatment of degenerative muscle disorders, angiogenesis regulation, and ex vivo cell therapy -
 IN Yurchenco P
 PA (UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
 PI ***WO 2000066730 A2 20001109 305p***
 WO 2000-US11378 20000428
 PRAI US 1999-131720 19990430
 US 1999-139198 19990615
 US 1999-143289 19990712
 US 1999-155945 19990924
 DT Patent
 LA English
 OS 2000-687537 [67]
 CR N-PSDB: AAB6894
 DESC Human laminin 2 mature alpha-2 chain.

L7 ANSWER 28 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAB19793 Protein DGENE
 TI Purified laminin 2 protein, useful for research and therapeutic purposes including peripheral nerve regeneration, treatment of degenerative muscle disorders, angiogenesis regulation, and ex vivo cell therapy -
 IN Yurchenco P
 PA (UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
 PI ***WO 2000066730 A2 20001109 305p***
 WO 2000-US11378 20000428

FRAI US 1999-131720 19990430
 US 1999-139198 19990615
 US 1999-143289 19990712
 US 1999-155945 19990924
 DT Patent
 LA English
 OS 2000-687537 (67)
 CR N-PSDB: AAA8893
 DESC Human laminin 2 alpha-2 chain.
 L7 ANSWER 29 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAB19792 Protein DGENE
 TI Purified laminin 2 protein, useful for research and therapeutic purposes including peripheral nerve regeneration, treatment of degenerative muscle disorders, angiogenesis regulation, and ex vivo cell therapy -
 IN Yurchenco P
 PA (UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
 PI ***WO 2000066730 A2 20001109 305p***
 FRAI WO 2000-US11378 20000428
 US 1999-131720 19990430
 US 1999-139198 19990615
 US 1999-143289 19990712
 US 1999-155945 19990924
 DT Patent
 LA English
 OS 2000-687537 (67)
 CR N-PSDB: AAA8892
 DESC Human laminin 2 mature alpha-2 chain.
 L7 ANSWER 30 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAB19791 Protein DGENE
 TI Purified laminin 2 protein, useful for research and therapeutic purposes including peripheral nerve regeneration, treatment of degenerative muscle disorders, angiogenesis regulation, and ex vivo cell therapy -
 IN Yurchenco P
 PA (UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
 PI ***WO 2000066730 A2 20001109 305p***
 FRAI WO 2000-US11378 20000428
 US 1999-131720 19990430
 US 1999-139198 19990615
 US 1999-143289 19990712
 US 1999-155945 19990924
 DT Patent
 LA English
 OS 2000-687537 (67)
 CR N-PSDB: AAA8891
 DESC Human laminin 2 alpha-2 chain.
 L7 ANSWER 31 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAB19790 Protein DGENE
 TI Purified laminin 2 protein, useful for promoting tissue repair and promoting nerve growth
 IN Brunken W; Burgess R E; Champilaud M; Koch M; Olson P
 PA (GEHO) GEN HOSPITAL CORP.
 PI ***WO 9919348 A1 19990422 86p***
 FRAI WO 1998-US21391 19981008
 US 1997-61609 19971010

DT Patent
 LA English
 OS 1999-126542 (27)
 CR N-PSDB: AAX9768
 DESC Human laminin alpha 2 subunit.
 L7 ANSWER 32 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAB18244 Protein DGENE
 TI New nucleic acid expressed at high level in prostatic tumor tissue and encoded polypeptides, useful for treating cancer and screening for therapeutic agents -
 IN Specht T; Hinemann B; Schmitt A; Piliarsky C; Dahl E; Rosenthal A
 PA (MERA-N) METAGEN GES GENOMFORSCHUNG MBH.
 PI ***DE 19811193 A1 19990916 166p***
 FRAI DE 1998-1011193 19980310
 DE 1998-19811193 19980310
 DT Patent
 LA German
 OS 1999-519628 (44)
 CR N-PSDB: AAZ33446
 DESC Human prostate cancer-associated protein 30.
 L7 ANSWER 33 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAB17130 Protein DGENE
 TI New merosin fragments, corresp. DNA and antibodies - for diagnosing tumour malignancy, promoting or inhibiting neurite growth and promoting cell attachment.
 IN Engvall E; Leivo I
 PA (LUOL-N) LA JOLLA CANCER RES FOUND.
 PI ***WO 9508628 A2 19950330 65p***
 FRAI WO 1994-US10730 19940921
 US 1993-123077 19930922
 DT Patent
 LA English
 OS 1995-139597 (18)
 CR N-PSDB: AAG6480 and AAT17419
 DESC Merosin major subunit.
 L7 ANSWER 34 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAB82244 Protein DGENE
 TI Production of fibrinogen in transgenic mammals - by introducing DNA segments into the germ line of a non-human mammal and collecting milk from female progeny.
 IN Dalrymple M A; Foster D C; Garner I; Prunkard D E
 PA (PHAR-N) PHARM PROTEINS LTD. (ZIMO)
 PI ***WO 9523868 A1 19950908 99p***
 FRAI WO 1995-US2648 19950301
 US 1994-206176 19940303
 DT Patent
 LA English
 OS 1995-320382 (41)
 CR N-PSDB: AAT03853
 DESC Human fibrinogen A-alpha chain protein.
 L7 ANSWER 35 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAB60020 Protein DGENE

```

T1  New hybrid proteins for use in tissue sealing and wound healing -
    comprising a tissue-binding domain from a protein covalently linked to a
    crosslinking domain of another protein
IN  Iranl M H
PA  (ZYMO)      ZYMOGENETICS INC.
PI  **WO 9416085 A2 19940721      87p***
AI  WO 1993-US12687      19931230
PRAI US 1992-998271      19921230
DT  Patent
LA  English
OS  1994-249231 (30)
CR  N-PDB: AAQ70008
DESC Fibrinectin.

L7  ANSWER 36 OF 36 DEGENE COPYRIGHT 2004 The Thomson Corp on STN
AN  AAS56269 peptide DEGENE
T1  Synthetic peptide(s) and antibodies against fragment E - derived from
    plasmin-cleaved fibrinogen useful for therapy of disturbances in the
    fibrinolytic system
IN  Kraus M; Stueber W
PA  (BEHM)      BEHRINGER AG.
PI  ***DE 4242736 AI 19940623      33p***
AI  DE 1992-4242736      19921217
PRAI DE 1992-4242736      19921217
DT  Patent
LA  German
OS  1994-209452 (26)
DESC Peptide corresponding to C-terminal fragment of cleaved fibrinogen.

```

=> help display
The DISPLAY command is used to view various types of saved and current-session information. To use this command, enter DISPLAY and the name of the item to be displayed. The system will display the item online. Highlighting characters may be suppressed by adding the NOHIGHLIGHT (NOH) option on the command line.

For information on the predefined formats available for the display of records in this file, enter HELP FORMAT at an arrow prompt (=>). For information on the display of records using individual fields or groups of fields, enter HELP FIELDS. For information on how to create a user-defined display format, enter HELP SET FORMAT. For information on how to change the default display format for this file, enter HELP SET DFORMAT. To see the current default display format for this file, enter DISPLAY SET DFORMAT.

For more information about the DISPLAY command, enter one of the following HELP commands at an arrow prompt.

```

=> HELP DISPLAY ACC ----- To see the record for a specific
                             Accession Number in a file

=> HELP DISPLAY ARCHIVE --- To grant permission to store STN records
                             for the purposes of electronic access
                             by a specified number of users within
                             your worldwide organization

```

```

=> HELP DISPLAY BROWSE ---- To browse through an answer set without
                             rekeying the DISPLAY command before each
                             answer number

=> HELP DISPLAY CLUSTER --- To see user-defined and system-defined
                             file clusters

=> HELP DISPLAY COST ----- To see the approximate cost of a session

=> HELP DISPLAY CURRENCY -- To see the patent currency status of
                             certain files

=> HELP DISPLAY EXPAND ---- To see the E-number list from an EXPAND
                             or SELECT command

=> HELP DISPLAY FIELD ----- To see the user-defined search fields

=> HELP DISPLAY FORMAT ---- To see the user-defined display formats

=> HELP DISPLAY FROM ----- To see records from specific files when
                             the I-number contains records from
                             multiple files

=> HELP DISPLAY HISTORY --- To see the commands used in this session

=> HELP DISPLAY I# ----- To see answers from a search

=> HELP DISPLAY PFAM ----- To see selective records from specified
                             patent families in an FSORT I-number

=> HELP DISPLAY PRINT ----- To see the status of offline prints
                             requested in this session

=> HELP DISPLAY QUERY ----- To see the definition of a query

=> HELP DISPLAY REDISTRIBUTE -- To grant permission to redistribute
                             within your worldwide organization a
                             specified number of printed or electronic
                             copies of STN records

=> HELP DISPLAY SAVED ----- To list saved items for this loginid

=> HELP DISPLAY SCAN ----- To scan through an answer set in random
                             order with a predefined display format

=> HELP DISPLAY SELECT ---- To see the E-number list from a SELECT or
                             EXPAND command

=> HELP DISPLAY SET ----- To see the SET parameters currently
                             active, changed, or set permanently

=> HELP DISPLAY TERM ----- To see the terms extracted using
                             SmartSELECT

=> HELP DISPLAY TOLERANCE - To see the tolerance in effect for
                             numeric fields available in the current

```

file

=> HELP DISPLAY TSHORT ----- To sort the entries in a display that uses a table format

=> HELP DISPLAY UNIT ----- To see the units in effect for numeric fields available in the current file

=> help display format
To see a list of user-defined display formats for this loginid, enter "DISPLAY FORMAT" at an arrow prompt (=>). This will display for each user-defined format: its name, its definition, and all files for which it is the current default format. To display the information for selected formats, enter "DISPLAY FORMAT" followed by a list of user-defined format names.

Examples:

=> DISPLAY FORMAT
(Lists all user-defined formats for this loginid.)

=> DISPLAY FORMAT .ABS .BASIC
(Lists the values associated with user-defined formats .ABS and .BASIC.)

=> d his

(FILE 'HOME' ENTERED AT 15:27:24 ON 07 OCT 2004)

FILE 'DGENE' ENTERED AT 15:28:00 ON 07 OCT 2004

RUN GETSEQ C(PROST) (ANDQIGLMPSTWV) (ES) (PDENOSTY) (WILMNSTV) (

L1 RUN STATEMENT CREATED

L2 334 DUP REM L1 (0 DUPLICATES REMOVED)

L3 334 S L2

L4 334 S L2 NOT "WESCOTT CHARLES R"/IN

L5 334 S L2

L6 300 S L2 NOT E4

L7 36 S L6 AND PY <=2001

=> d 17.1-36 seqn3 bib

'SQN3' IS NOT A VALID FORMAT FOR FILE 'DGENE'

The following are valid formats:

ABS ----- An, Abstract
ALL ----- An, Title, Abstract, Inventor(s), Patent Assignee(s),
Patent Information, Keywords, Organism, Sequence Information
IALL ----- Same as ALL, Indented
BIB ----- An, Title, Abstract, Inventor(s), Patent Assignee(s),
Patent Information, Application Information, Priority Information,
Document Type, Language, Other Source
IBIB ----- Same as BIB, Indented Format
SQIDE ----- An, Sequence Information, Feature Table
SQIDE3 ----- An, Sequence Information, Feature Table
TRIAL ----- An, Molecule Type, Title, Description, Keywords
FAM ----- Patent Family

AN Accession Number
TI Document Title
IN Inventor(s)
PA Patent Assignee(s)
PI Patent Information
AI Application Information
PRAI Priority Information
PSL Patent Sequence Location
DED Data Entry Date
DT Document Type
LA Language
OS Other Source
DESC Description
KW Keywords
ORGN Organism
AB Abstract
AA Amino Acid
NA Nucleic Acid
SOL Sequence Length
SEQ Sequence
SEQ3 Sequence with 3 Letter Codes
FEAT Feature Table
MTY Molecule Type

To display a particular field or fields, enter the display field codes. For a list of display field codes enter 'HELP DFIELDS' at an arrow prompt (=>). Examples of formats include: 'TI', 'AN, TI, KW', 'HI, SEQ', 'PA, ORGN'. The order of the terms in the formats is not important, but information will be displayed in the same order as the format specification. The same formats may be used with the DISPLAY AN command to display the record for a specified accession number.

ENTER DISPLAY FORMAT (BIB): seq 3 bib

'3' IS NOT A VALID FORMAT FOR FILE 'DGENE'

The following are valid formats:

ABS ----- An, Abstract
ALL ----- An, Title, Abstract, Inventor(s), Patent Assignee(s),
Patent Information, Keywords, Organism, Sequence Information
IALL ----- Same as ALL, Indented
BIB ----- An, Title, Abstract, Inventor(s), Patent Assignee(s),
Patent Information, Application Information, Priority Information,
Document Type, Language, Other Source
IBIB ----- Same as BIB, Indented Format
SQIDE ----- An, Sequence Information, Feature Table
SQIDE3 ----- An, Sequence Information, Feature Table
TRIAL ----- An, Molecule Type, Title, Description, Keywords
FAM ----- Patent Family
AN Accession Number
TI Document Title
IN Inventor(s)
PA Patent Assignee(s)
PI Patent Information
AI Application Information
PRAI Priority Information

PSL Patent Sequence Location
DED Data Entry Date
DT Document Type
LA Language
OS Other Source
DESC Description
KW Keywords
ORGN Organism
AB Abstract
AA Amino Acid
NA Nucleic Acid
SOL Sequence Length
SEQ3 Sequence with 3 Letter Codes
FEAT Feature Table
MTY Molecule Type

To display a particular field or fields, enter the display field codes. For a list of display field codes enter 'HELP DFIELDS' at an arrow prompt (=>). Examples of formats include: 'RT', 'AN,RT,KW', 'RT,SEQ','PA,ORGN'. The order of the terms in the formats is not important, but information will be displayed in the same order as the format specification. The same formats may be used with the DISPLAY AN command to display the record for a specified accession number.
ENTER DISPLAY FORMAT (RIB):lib sqide3

++L7 ANSWER 1 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABB7066 Protein DGENE
TI Novel human polypeptides and polynucleotides useful for diagnosing, preventing and treating cardiovascular disease, neurodegenerative, hyperproliferative disorders and autoimmune disorders -
IN Shinkens R A; Leach M D
PA (CURA-N) CURAGEN CORP.
PI ***WO 2001092523 A2 20011206 999p***
WO 2001-US10836 20010529
US 2000-206132P 20000530
PRAI US 2000-228716P 20000829

DT Patent
LA English
OS 2002-106308 [14]
CR N-PSDB: ABB22818
DESC Human ORF protein sequence SEQ ID NO:14114.
AN ABB7066 Protein DGENE
AA 3 A; 3 R; 1 N; 2 D; 0 B; 5 C; 0 Q; 3 E; 0 Z; 3 G; 1 H; 4 I; 9
L7 0 K; 1 M; 4 F; 4 P; 7 S; 2 T; 2 W; 3 Y; 1 V; 1 Others
SOL 59
SEQ3 1 Met-Tyr-Cys-Glu-Ala-Asp-Gly-Ile-Ser-Leu-
11 Leu-Cys-Pro-Leu-Pro-Phe-Cys-Pro-Tyr-Glu-
21 Thr-Tip-Ser-Phe-Ser-Leu-Leu-Ala-Asp-Phe-
31 Cys-Leu-Arg-Gly-Ser-Phe-Tyr-Ile-Phe-Thr-
41 Ser-Ile-Tip-Kxx-Aan-Gly-Ala-Ser-Leu-Leu-
51 Leu-His-Ile-Cys-Val-Arg-Glu-Arg-Ser
HITS AT: 17-24

L7 ANSWER 2 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABB89477 Protein DGENE
TI Novel 1405 isolated polypeptides, useful for diagnosis, treatment and prevention of neural, immune system, muscular, reproductive, gastrointestinal, pulmonary, cardiovascular, renal and proliferative disorders -
IN Birse C E; Rosen C A
PA (HOPA-N) HOPAN GENOME SCI INC.
PI ***WO 2001090304 A2 20011129 999p***
WO 2001-US16450 20010518
PRAI US 2000-205515P 20000519
DT Patent
LA English
OS 2002-122018 [16]
CR N-PSDB: ABB89886
DESC Human polypeptide SEQ ID NO 1853.
AN ABB89477 Protein DGENE
AA 6 A; 4 R; 7 N; 3 D; 0 B; 9 C; 4 Q; 7 E; 0 Z; 9 G; 3 H; 4 I; 14 L; 2 K; 4 M; 4 F; 10 P; 9 S; 6 T; 3 W; 3 Y; 4 V; 3 Others
SOL 118
SEQ3 1 Met-Ala-Glu-Met-Asn-His-Val-Cys-Pro-
11 Val-Glu-Asn-Tip-Ser-Tyr-Asn-Glu-Ser-Cys-
21 Pro-Pro-Asp-Pro-Ala-Glu-Gln-Gly-Gly-Pro-
31 Lys-Thr-Cys-Cys-Thr-Leu-Asp-Asp-Xxx-Pro-
41 Leu-Ile-Ser-Lys-Cys-Gly-Ser-Tyr-Pro-Pro-
51 Glu-Ser-Cys-Leu-Phe-Ser-Leu-Ile-Gly-Asn-
61 Met-Gly-Ala-Phe-Met-Glu-Ala-Leu-Ile-Cys-
71 Leu-Leu-Arg-Tyr-Gly-Gln-Leu-Leu-Gln-
81 Ser-Arg-His-Ser-Tip-Val-Asn-Thr-Thr-Xxx-
91 Leu-Ile-Thr-Gly-Cys-Thr-Asn-Ala-Ala-Gly-
101 Leu-Leu-Xxx-Val-Gly-Asn-Phe-Gln-Pro-Arg-
111 Phe-Arg-Tip-Ser-Leu-Leu-Cys-Pro

HITS AT: 9-16
L7 ANSWER 3 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAO14005 Protein DGENE
TI Novel isolated nucleic acid molecule which encodes a fibrinogen E polypeptide which is useful for treating cancer, diabetic retinopathy, obesity, hepatitis, pneumonia, glomerulonephritis, asthma and thyroiditis
IN Lewis C; Staton C
PA (VUSH-N) UNIV SHEFFIELD.
PI ***WO 2001086129 A1 20011122 41p***
WO 2001-GB2079 20010514
AI GB 2000-11464 20000513
PRAI GB 2000-14370 20000614
GB 2000-27396 20001109
DT Patent
LA English
OS 2002-062380 [08]
CR N-PSDB: AAK98254
DESC Human fibrinogen E-fragment alpha-chain amino acids 1-78.
AN AAO14005 protein DGENE
AA 3 A; 5 R; 5 N; 8 D; 0 B; 4 C; 3 Q; 6 E; 0 Z; 8 G; 1 H; 2 I; 4

L; 6 K; 1 M; 4 F; 3 P; 6 S; 1 T; 2 W; 2 Y; 4 V; 0 Others

SEQ3

1 Ala-Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-
11 Glu-Gly-Gly-Gly-Val-Arg-Gly-Pro-Arg-Val-
21 Val-Glu-Arg-His-Gln-Ser-Ala-Cys-Lys-Asp-
31 Ser-Asp-Tip-Pro-Phe-Cys-Ser-Asp-Glu-Asp-
41 Tip-Asn-Tyr-Lys-Cys-Pro-Ser-Gly-Cys-Arg-
51 Met-Lys-Gly-Leu-Ile-Asp-Glu-Val-Asn-Gln-
61 Asp-Phe-Thr-Asn-Arg-Ile-Asn-Lys-Leu-Lys-
71 Asn-Ser-Leu-Phe-Glu-Tyr-Gln-Lys

HITS AT: 36-43

IN ANSWER 4 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABB70490 Protein DGENE
TI New isolated nucleic acid detection reagent for detecting 1000 or more
genes from Drosophila and for elucidating cell signalling and cell-cell
interactions -

IN Venter J C; Adams M; Li P W D; Myers E W
PA (PEKE) PE CORP NY.
PI ***WO 2001071042 A2 20010927 21p***
AI WO 2001-US9231 20010323
PRAI US 2000-191637P 20000323
US 2000-614150 20000711

DT Patent
LA English
OS 2001-656860 [75]
CR N-PDB: ABL14593
DESC Drosophila melanogaster polypeptide SEQ ID NO 38262.
AN ABB70490 Protein DGENE
AA 17 A; 11 R; 12 N; 8 D; 0 B; 3 C; 9 Q; 7 E; 0 Z; 18 G; 7 H; 9 I;
20 L; 14 K; 8 M; 14 F; 15 P; 15 S; 12 T; 7 W; 12 Y; 11 V; 0 Others

SEQ3

1 Met-Arg-Ala-Gln-Lys-His-Lys-Pro-His-Trp-
11 Phe-Phe-Asn-Glu-Thr-Leu-Pro-Val-Gln-Tyr-
21 Ala-Tyr-Val-Gly-Gly-Ala-Val-Asn-Leu-Ser-
31 Cys-Asp-Ala-Met-Gly-Glu-Pro-Pro-Pro-Ser-
41 Phe-Thr-Trp-Leu-His-Asn-Asn-Lys-Gly-Ile-
51 Val-Gly-Phe-Asn-His-Arg-Ile-Phe-Val-Ala-
61 Asp-Tyr-Gly-Ala-Thr-Leu-Gln-Leu-Met-
71 Lys-Asn-Ala-Ser-Gln-Phe-Gly-Asp-Tyr-Lys-
81 Cys-Lys-Val-Ala-Asn-Pro-Leu-Gly-Met-Leu-
91 Glu-Arg-Val-Ile-Lys-Leu-Arg-Pro-Gly-Pro-
101 Lys-Pro-Leu-Gly-Pro-Arg-Arg-Phe-Glu-Leu-
111 Lys-Lys-Leu-Tyr-Trp-Asn-Gly-Phe-Glu-Leu-
121 Asp-Ile-Gln-Thr-Pro-Arg-Met-Ser-Asn-Val-
131 Ser-Asp-Glu-Met-Gln-Ile-Tyr-Gly-Tyr-Arg-
141 Val-Ala-Tyr-Met-Ser-Asp-Thr-Glu-Phe-Lys-
151 Phe-Ser-Ala-Gly-Asn-Trp-Ser-Tyr-Ala-Lys-
161 Gln-Arg-Asp-Phe-Ser-Phe-His-Gly-Gly-Lys-
171 His-Phe-Ile-Ile-Pro-His-Leu-Glu-Tyr-Asn-
181 Thr-Thr-Tyr-Leu-Met-Arg-Ala-Ala-Ser-Asp-
191 Asn-Leu-Ala-Gly-Leu-Ser-Asp-Tip-Ser-Pro-
201 Val-Lys-Val-Phe-Thr-Thr-Ala-Ala-Gly-Cys-

211 Ser-Tip-Ser-Pro-Tip-Leu-Tyr-Pro-Ser-Tyr-
221 Gly-Leu-Ile-Leu-Ala-Leu-Ile-Tip-Thr

HITS AT: 210-217

IN ANSWER 5 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABB59448 Protein DGENE
TI New isolated nucleic acid detection reagent for detecting 1000 or more
genes from Drosophila and for elucidating cell signalling and cell-cell
interactions -

IN Venter J C; Adams M; Li P W D; Myers E W
PA (PEKE) PE CORP NY.
PI ***WO 2001071042 A2 20010927 21p***
AI WO 2001-US9231 20010323
PRAI US 2000-191637P 20000323
US 2000-614150 20000711

DT Patent
LA English
OS 2001-656860 [75]
CR N-PDB: ABL03591
DESC Drosophila melanogaster polypeptide SEQ ID NO 5136.
AN ABB59448 Protein DGENE
AA 24 A; 26 R; 23 N; 21 D; 0 B; 7 C; 13 Q; 16 E; 0 Z; 23 G; 11 H; 28 I;
57 L; 21 K; 10 M; 31 F; 22 P; 25 S; 24 T; 13 W; 15 Y; 28 V; 0 Others

SEQ3

1 Met-Leu-Asn-Thr-Phe-Ser-Ser-Val-Arg-Gln-
11 Tyr-Leu-Lys-Phe-Asp-Leu-Thr-Arg-Val-Val-
21 Ile-Asp-Asn-Ile-Val-Phe-Lys-Leu-His-Tyr-
31 Arg-Tip-Thr-Phe-Val-Ile-Leu-Leu-Val-Ala-
41 Thr-Leu-Leu-Ile-Thr-Ser-Arg-Gln-Tyr-Ile-
51 Gly-Glu-His-Ile-Gln-Cys-Leu-Ser-Asp-Gly-
61 Val-Val-Ser-Pro-Val-Ile-Asn-Thr-Phe-Cys-
71 Phe-Phe-Thr-Pro-Thr-Phe-Thr-Val-Val-Arg-
81 Asp-Gln-Asn-Gln-Thr-Ala-Tyr-Arg-Pro-Gly-
91 Ser-Glu-Pro-Pro-Gly-Ile-Gly-Ala-Phe-Asp-
101 Pro-Glu-Lys-Asp-Thr-Ile-Lys-Arg-His-Ala-
111 Tyr-Tyr-Gln-Tip-Val-Pro-Phe-Val-Leu-His-
121 Phe-Gln-Ala-Leu-Cys-Phe-Tyr-Ile-Pro-His-
131 Ala-Leu-Tip-Lys-Ser-Tip-Glu-Gly-Gly-Arg-
141 Ile-Lys-Ala-Leu-Val-Phe-Gly-Leu-Arg-Met-
151 Val-Gly-Leu-Thr-Arg-Tyr-Leu-Lys-Asn-Asp-
161 Ser-Leu-Arg-Ile-Gly-Lys-Leu-Asn-Ile-Pro-
171 Ser-Met-Ala-Glu-Ala-Glu-Glu-Arg-Val-Lys-
181 Asp-Ile-Arg-Arg-Thr-Met-Ile-Asp-Arg-Met-
191 Arg-Leu-Asn-Gln-Ser-Tip-Gly-Ala-His-Leu-
201 Val-Phe-Ala-Glu-Val-Leu-Asn-Leu-Ile-Asn-
211 Leu-Leu-Leu-Gln-Ile-Thr-Tip-Thr-Asn-Arg-
221 Phe-Leu-Gly-Gly-Gln-Phe-Leu-Thr-Leu-Gly-
231 Pro-His-Ala-Leu-Lys-Asn-Arg-Tip-Ser-Asp-
241 Glu-Leu-Ser-Val-Leu-Asp-Leu-Val-Phe-Pro-
251 Lys-Ile-Thr-Lys-Cys-Lys-Phe-His-Lys-She-
261 Gly-Asp-Ser-Gly-Ser-Ile-Gln-Met-His-Ser-
271 Ala-Leu-Cys-Val-Met-Ala-Leu-Asn-Ile-Met-
281 Asn-Glu-Lys-Ile-Tyr-Ile-Ile-Leu-Tip-Phe-
291 Tip-Tyr-Ala-Phe-Leu-Leu-Ile-Val-Thr-Thr-

L7 ANSWER 6 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABG20414 Protein DGENE
T1 New isolated polynucleotide and encoded polypeptides, useful in
diagnostics, forensics, gene mapping, identification of mutations
responsible for genetic disorders or other traits and to assess
biodiversity -
IN Dramac R T; Liu C; Tang Y T
PA (HYSEQ) HYSEQ INC 103p***
PI ***MO 2001075067 A2 20011011
P1 WO 2001-058631 20010330
AI US 2000-540217 200000331
PBAI US 2000-649167 20000823

HTS AT: 343-350
301 Leu-Gly-Leu-Leu-Tip-Arg-Ile-Leu-Thr-Leu-
311 Cys-Phe-Tyr-Arg-Asn-Val-Thr-Phe-Thr-Arg-
321 Trp-Ser-Leu-Tyr-Trp-Ala-Lys-Pro-Gly-Gln-
331 Leu-Asp-Glu-Asn-Glu-Leu-Leu-Ala-Val-Ile-
341 Asp-Lys-Cys-Asn-Phe-Ser-Asn-Tip-Met-Phe-
351 Leu-Phe-Phe-Leu-Arg-Ser-Asn-Leu-Ser-Glu-
361 Phe-Leu-Phe-Lys-Lys-Val-Ile-Tyr-His-Leu-
371 Ala-Ser-Glu-Phe-Pro-Asn-Pro-Glu-His-Asp-
381 Asn-Asp-Val-Asn-Ala-Tyr-Arg-Glu-Ala-Pro-
391 Pro-Thr-Pro-Ala-Lys-Asn-Arg-Tyr-Pro-Glu-
401 Leu-Ser-Gly-Leu-Asp-Thr-Ile-Asp-Ser-Pro-
411 Leu-Leu-His-Leu-Arg-Arg-Asn-Gly-Ser-Pro-
421 Ser-Ala-Gly-Gly-Ala-Gln-Gly-Pro-Ser-Thr-
431 Ser-Asp-Met-Ala-Lys-Leu-Pro-Val

1 Ser-Asp-Ser-Ser-Gly-Ser-Arg-Glu-Val-Asp-
11 Pro-Val-Ala-Ala-Thr-Thr-Met-Pro-Gly-Ala-
21 Ala-Gly-Val-Leu-Leu-Leu-Leu-Leu-Ser-
31 Gly-Gly-Leu-Gly-Gly-Val-Gln-Ala-Gln-Arg-
41 Pro-Gln-Gln-Gln-Arg-Gln-Ser-Gln-Ala-His-
51 Gln-Gln-Arg-Gly-Leu-Phe-Pro-Ala-Val-Leu-
61 Asn-Leu-Ala-Ser-Asn-Ala-Leu-Ile-Thr-Thr-
71 Asn-Ala-Thr-Cys-Gly-Glu-Lys-Gly-Pro-Glu-
81 Met-Tyr-Cys-Lys-Leu-Val-Glu-His-Val-Pro-
91 Gly-Gln-Pro-Val-Arg-Asn-Pro-Gln-Cys-Arg-
101 Ile-Cys-Asn-Gln-Asn-Ser-Ser-Asn-Pro-Asn-
111 Gln-Arg-His-Pro-Ile-Thr-Asn-Ala-Ile-Asp-
121 Gly-Lys-Asn-Thr-Tip-Trp-Gln-Ser-Pro-Ser-
131 Ile-Lys-Asn-Gly-Ile-Glu-Tyr-His-Tyr-Val-
141 Thr-Ile-Thr-Leu-Asp-Leu-Gln-Gln-Val-Phe-
151 Gln-Ile-Ala-Tyr-Val-Ile-Val-Lys-Ala-Ala-
161 Asn-Ser-Pro-Arg-Pro-Gly-Asn-Tip-Ile-Leu-
171 Glu-Arg-Ser-Leu-Asp-Val-Glu-Tyr-Lys-

181 Ala-Tip-Gln-Xxx-His-Ala-Val-Thr-Asp-Thr-
191 Glu-Ala-Leu-Thr-Pro-Xxx-Pro-Asn-Xxx-Ser-
201 Pro-Glu-Leu-Gly-His-Arg-Gln-Asn-Ala-Gln-
211 Asp-Xxx-Glu-Val-Ile-Cys-Thr-Ser-Phe-Tyr-
221 Ser-Lys-Ile-His-Pro-Leu-Glu-Asn-Gly-Glu-
231 Ile-His-Ile-Ser-Leu-Ile-Asn-Gly-Arg-Pro-
241 Ser-Ala-Asp-Asp-Pro-Ser-Pro-Glu-Leu-Leu-
251 Glu-Phe-Thr-Ser-Ala-Arg-Tyr-Ile-Arg-Leu-
261 Arg-Phe-Gln-Arg-Ile-Arg-Thr-Leu-Asn-Ala-
271 Asp-Leu-Met-Met-Phe-Ala-His-Lys-Asp-Pro-
281 Arg-Glu-Ile-Asp-Pro-Ile-Val-Thr-Arg-Arg-
291 Tyr-Tyr-Tyr-Ser-Val-Lys-Asp-Ile-Ser-Val-
301 Gly-Gly-Met-Cys-Ile-Cys-Tyr-Gly-His-Ala-
311 Arg-Ala-Cys-Pro-Leu-Asp-Pro-Ala-Thr-Asn-
321 Lys-Ser-Arg-Cys-Glu-Cys-Glu-His-Asn-Thr-
331 Cys-Gly-Asp-Ser-Cys-Asp-Gln-Cys-Cys-Pro-
341 Gly-Phe-His-Gln-Lys-Pro-Tip-Arg-Ala-Gly-
351 Thr-Phe-Leu-Thr-Lys-Thr-Glu-Cys-Glu-Ala-
361 Cys-Asn-Cys-His-Gly-Lys-Ala-Glu-Glu-Cys-
371 Tyr-Tyr-Asp-Glu-Asn-Val-Ala-Arg-Arg-Asn-
381 Leu-Ser-Leu-Asn-Ile-Arg-Gly-Lys-Tyr-Ile-
391 Gly-Gly-Gly-Val-Cys-Ile-Asn-Cys-Thr-Gln-
401 Asn-Thr-Ala-Gly-Ile-Asn-Cys-Glu-Thr-Cys-
411 Thr-Asp-Gly-Phe-Phe-Arg-Pro-Lys-Gly-Val-
421 Ser-Pro-Asn-Tyr-Pro-Arg-Pro-Cys-Gln-Pro-
431 Cys-His-Cys-Asp-Pro-Ile-Gly-Ser-Leu-Asn-
441 Glu-Val-Cys-Val-Lys-Asp-Glu-Lys-His-Ala-
451 Arg-Arg-Gly-Leu-Ala-Pro-Gly-Ser-Cys-His-
461 Cys-Lys-Thr-Gly-Phe-Gly-Gly-Val-Ser-Cys-
471 Asp-Arg-Cys-Ala-Arg-Gly-Tyr-Thr-Gly-Tyr-
481 Pro-Asp-Cys-Lys-Ala-Cys-Asn-Cys-Ser-Gly-
491 Leu-Gly-Ser-Lys-Asn-Glu-Asp-Pro-Cys-Phe-
501 Gly-Pro-Cys-Ile-Cys-Lys-Glu-Asn-Val-Glu-
511 Gly-Gly-Asp-Cys-Ser-Arg-Cys-Lys-Ser-Gly-
521 Phe-Phe-Asn-Leu-Gln-Glu-Asp-Asn-Tip-Lys-
531 Gly-Cys-Asp-Glu-Cys-Phe-Cys-Ser-Gly-Val-
541 Ser-Asn-Arg-Cys-Gln-Ser-Ser-Tyr-Tip-Thr-

551 Tyr-Gly-Lys-Ile-Gln-Asp-Met-Ser-Gly-Tip-
561 Tyr-Leu-Thr-Asp-Leu-Pro-Gly-Arg-Ile-Arg-
571 Val-Ala-Pro-Gln-Gln-Asp-Asp-Leu-Asp-Ser-
581 Pro-Gln-Gln-Ile-Ser-Ile-Ser-Asn-Ala-Glu-
591 Ala-Arg-Gln-Ala-Leu-Pro-His-Ser-Tyr-Tyr-
601 Trp-Ser-Ala-Pro-Ala-Pro-Tyr-Leu-Gly-Asn-
611 Lys-Leu-Pro-Ala-Val-Gly-Gly-Gln-Leu-Thr-
621 Phe-Thr-Ile-Ser-Tyr-Asp-Leu-Glu-Glu-
631 Glu-Glu-Asp-Thr-Glu-Arg-Val-Leu-Gln-Leu-
641 Met-Ile-Ile-Leu-Glu-Gly-Asn-Asp-Leu-Ser-
651 Ile-Ser-Thr-Ala-Gln-Asp-Glu-Val-Tyr-Leu-
661 His-Pro-Ser-Glu-Glu-His-Thr-Asn-Val-Leu-
671 Leu-Leu-Lys-Glu-Glu-Ser-Phe-Thr-Ile-His-
681 Gly-Thr-His-Phe-Pro-Val-Arg-Arg-Lys-Arg-
691 Phe-Met-Thr-Val-Leu-Ala-Asn-Leu-Lys-Arg-
701 Val-Leu-Leu-Gln-Ile-Thr-Tyr-Ser-Phe-Gly-
711 Met-Asp-Ala-Ile-Phe-Arg-Leu-Ser-Ser-Val-
721 Asn-Leu-Glu-Ser-Ala-Val-Ser-Tyr-Pro-Thr-

731 Asp-Gly-Ser-Ile-Ala-Ala-Ala-Val-Glu-Val-
741 Cys-Gln-Cys-Pro-Pro-Gly-Tyr-Thr-Gly-Ser-
751 Ser-Cys-Glu-Ser-Cys-Trip-Pro-Arg-His-Arg-
761 Arg-Val-Asn-Gly-Thr-Ile-Phe-Gly-Gly-Ile-
771 Cys-Glu-Pro-Cys-Gln-Cys-Phe-Gly-His-Ala-
781 Glu-Ser-Cys-Asp-Asp-Val-Thr-Gly-Glu-Cys-
791 Leu-Asn-Cys-Lys-Asp-His-Thr-Gly-Gly-Pro-
801 Tyr-Cys-Asp-Lys-Cys-Leu-Pro-Gly-Phe-Tyr-
811 Gly-Glu-Pro-Thr-Lys-Gly-Thr-Ser-Glu-Asp-
821 Cys-Gln-Pro-Cys-Ala-Cys-Pro-Leu-Asn-Ile-
831 Pro-Ser-Asn-Asn-Phe-Ser-Pro-Thr-Cys-His-
841 Leu-Asp-Arg-Ser-Leu-Gly-Leu-Ile-Cys-Asp-
851 Gly-Cys-Pro-Val-Gly-Tyr-Thr-Gly-Pro-Arg-
861 Cys-Glu-Arg-Cys-Ala-Glu-Gly-Tyr-Phe-Gly-
871 Gln-Pro-Ser-Val-Pro-Gly-Gly-Ser-Cys-Gln-
881 Pro-Cys-Gln-Cys-Asn-Asp-Asn-Leu-Asp-Phe-
891 Ser-Ile-Pro-Gly-Ser-Cys-Asp-Ser-Leu-Ser-
901 Gly-Ser-Cys-Leu-Ile-Cys-Lys-Pro-Gly-Thr-
911 Thr-Gly-Arg-Tyr-Cys-Glu-Leu-Cys-Ala-Asp-
921 Gly-Tyr-Phe-Gly-Asp-Ala-Val-Asp-Ala-Lys-
931 Asn-Cys-Gln-Pro-Cys-Arg-Cys-Asn-Ala-Gly-
941 Gly-Ser-Phe-Ser-Glu-Val-Cys-His-Ser-Gln-
951 Thr-Gly-Gln-Cys-Glu-Cys-Arg-Ala-Asn-Val-
961 Gln-Gly-Gln-Arg-Cys-Asp-Lys-Cys-Lys-Ala-
971 Gly-Thr-Phe-Gly-Leu-Gln-Ser-Ala-Arg-Gly-
981 Cys-Val-Pro-Cys-Asn-Cys-Asn-Ser-Phe-Gly-
991 Ser-Lys-Ser-Phe-Asp-Cys-Glu-Glu-Ser-Gly-
1001 Gln-Cys-Trip-Cys-Gln-Pro-Gly-Val-Thr-Gly-
1011 Lys-Lys-Cys-Asp-Arg-Cys-Ala-His-Gly-Tyr-
1021 Phe-Asn-Phe-Gln-Glu-Gly-Gly-Cys-Thr-Ala-
1031 Cys-Glu-Cys-Ser-His-Leu-Gly-Asn-Asn-Cys-
1041 Asp-Pro-Lys-Thr-Gly-Arg-Cys-Ile-Cys-Pro-
1051 Pro-Asn-Thr-Ile-Gly-Glu-Lys-Cys-Ser-Lys-
1061 Cys-Ala-Pro-Asn-Thr-Trip-Gly-His-Ser-Ile-
1071 Thr-Thr-Gly-Cys-Lys-Ala-Cys-Asn-Cys-Ser-
1081 Thr-Val-Gly-Ser-Leu-Asp-Phe-Gln-Cys-Asn-
1091 Val-Asn-Thr-Gly-Gln-Cys-Asn-Cys-His-Pro-
1101 Lys-Phe-Ser-Gly-Ala-Lys-Cys-Thr-Glu-Cys-
1111 Ser-Arg-Gly-His-Trip-Asn-Tyr-Pro-Arg-Cys-
1121 Asn-Leu-Cys-Asp-Cys-Phe-Leu-Pro-Gly-Thr-
1131 Asp-Ala-Thr-Thr-Cys-Asp-Ser-Gly-Thr-Lys-
1141 Lys-Cys-Ser-Cys-Ser-Asp-Gln-Thr-Gly-Gln-
1151 Cys-Thr-Cys-Lys-Val-Asn-Val-Glu-Gly-Ile-
1161 His-Cys-Asp-Arg-Cys-Arg-Pro-Gly-Lys-Phe-
1171 Gly-Leu-Asp-Ala-Lys-Asn-Pro-Leu-Gly-Cys-
1181 Ser-Ser-Cys-Tyr-Cys-Phe-Gly-Thr-Thr-Thr-
1191 Gln-Cys-Ser-Glu-Ala-Lys-Gly-Leu-Ile-Arg-
1201 Thr-Trip-Val-Thr-Leu-Lys-Ala-Glu-Gln-Thr-
1211 Ile-Leu-Pro-Leu-Val-Asp-Glu-Ala-Leu-Gln-
1221 His-Thr-Thr-Thr-Lys-Gly-Ile-Val-Phe-Gln-
1231 His-Pro-Glu-Ile-Val-Ala-His-Met-Asp-Leu-
1241 Met-Arg-Glu-Asp-Leu-His-Leu-Glu-Pro-Phe-
1251 Tyr-Trip-Lys-Leu-Pro-Glu-Gln-Phe-Glu-Lys-
1261 Lys-Lys-Leu-Met-Ala-Tyr-Gly-Lys-Leu-
1271 Lys-Tyr-Ala-Ile-Tyr-Phe-Glu-Ala-Arg-Glu-
1281 Glu-Thr-Gly-Phe-Ser-Thr-Tyr-Ile-Pro-Gln-
1291 Val-Ile-Ile-Arg-Gly-Gly-Thr-Pro-Thr-His-

1301 Ala-Arg-Ile-Ile-Val-Arg-His-Met-Ala-Ala-
1311 Pro-Leu-Ile-Gly-Gln-Leu-Thr-Arg-His-Glu-
1321 Ile-Glu-Met-Thr-Glu-Lys-Glu-Trip-Lys-Tyr-
1331 Tyr-Gly-Asp-Asp-Pro-Arg-Val-His-Arg-Thr-
1341 Val-Thr-Arg-Glu-Asp-Phe-Leu-Asp-Ile-Leu-
1351 Tyr-Asp-Ile-His-Tyr-Ile-Leu-Ile-Lys-Ala-
1361 Thr-Tyr-Gly-Asn-Phe-Met-Arg-Gln-Ser-Arg-
1371 Ile-Ser-Glu-Ile-Ser-Met-Glu-Val-Ala-Glu-
1381 Gln-Gly-Arg-Gly-Thr-Thr-Met-Thr-Pro-Phe-
1391 Ala-Asp-Leu-Ile-Glu-Lys-Cys-Asp-Cys-Pro-
1401 Leu-Gly-Tyr-Ser-Gly-Leu-Ser-Cys-Glu-Ala-
1411 Cys-Leu-Pro-Gly-Phe-Tyr-Arg-Leu-Arg-Ser-
1421 Gln-Pro-Gly-Gly-Arg-Thr-Pro-Gly-Pro-Thr-
1431 Leu-Gly-Thr-Cys-Val-Pro-Cys-Gln-Cys-Asn-
1441 Gly-His-Ser-Ser-Leu-Cys-Asp-Pro-Glu-Thr-
1451 Ser-Ile-Cys-Gln-Asn-Cys-Gln-His-His-Thr-
1461 Ala-Gly-Asp-Phe-Cys-Glu-Arg-Cys-Ala-Leu-
1471 Gly-Tyr-Tyr-Gly-Ile-Val-Lys-Gly-Leu-Pro-
1481 Asn-Asp-Cys-Gln-Gln-Cys-Ala-Cys-Pro-Leu-
1491 Ile-Ser-Ser-Ser-Asn-Asn-Phe-Ser-Pro-Ser-
1501 Cys-Val-Ala-Glu-Gly-Leu-Asp-Asp-Tyr-Arg-
1511 Cys-Thr-Ala-Cys-Pro-Arg-Gly-Tyr-Glu-Gly-
1521 Gln-Tyr-Cys-Glu-Arg-Cys-Ala-Pro-Gly-Tyr-
1531 Thr-Gly-Ser-Pro-Gly-Asn-Pro-Gly-Gly-Ser-
1541 Cys-Gln-Glu-Cys-Glu-Cys-Asp-Pro-Tyr-Gly-
1551 Ser-Leu-Pro-Val-Pro-Cys-Asp-Pro-Val-Thr-
1561 Gly-Phe-Cys-Thr-Cys-Arg-Pro-Gly-Ala-Thr-
1571 Gly-Arg-Lys-Cys-Asp-Gly-Cys-Lys-His-Trip-
1581 His-Ala-Arg-Glu-Gly-Trip-Glu-Cys-Val-Phe-
1591 Cys-Gly-Asp-Glu-Cys-Thr-Gly-Leu-Leu-Leu-
1601 Gly-Asp-Leu-Ala-Arg-Leu-Glu-Gln-Met-Val-
1611 Met-Ser-Ile-Asn-Leu-Thr-Gly-Pro-Leu-Pro-
1621 Ala-Pro-Tyr-Lys-Met-Leu-Tyr-Gly-Leu-Glu-
1631 Asn-Met-Thr-Gln-Glu-Leu-Lys-His-Leu-Leu-
1641 Ser-Pro-Gln-Arg-Ala-Pro-Glu-Arg-Leu-Ile-
1651 Gln-Leu-Ala-Glu-Gly-Asn-Leu-Asn-Thr-Leu-
1661 Val-Thr-Glu-Met-Asn-Glu-Leu-Leu-Thr-Arg-
1671 Ala-Thr-Lys-Val-Thr-Ala-Asp-Gly-Glu-Gln-
1681 Thr-Gly-Gln-Asp-Ala-Glu-Arg-Thr-Asn-Thr-
1691 Arg-Ala-Lys-Ser-Leu-Gly-Glu-Phe-Ile-Lys-
1701 Glu-Leu-Ala-Arg-Asp-Ala-Glu-Ala-Val-Asn-
1711 Gly-Lys-Ala-Ile-Lys-Leu-Asn-Glu-Thr-Leu-
1721 Gly-Thr-Arg-Asp-Glu-Ala-Phe-Glu-Arg-Asn-
1731 Leu-Glu-Gly-Leu-Gln-Lys-Glu-Ile-Asp-Gln-
1741 Met-Ile-Lys-Glu-Leu-Arg-Arg-Lys-Asn-Leu-
1751 Glu-Thr-Gln-Lys-Glu-Ile-Ala-Glu-Asp-Glu-
1761 Leu-Val-Ala-Ala-Glu-Ala-Leu-Leu-Lys-Lys-
1771 Val-Lys-Lys-Leu-Phe-Gly-Glu-Ser-Arg-Gly-
1781 Glu-Asn-Glu-Glu-Met-Glu-Lys-Asp-Leu-Arg-
1791 Gly-Lys-Leu-Ala-Asp-Tyr-Lys-Asn-Lys-Val-
1801 Asp-Asp-Ala-Trip-Asp-Leu-Leu-Arg-Glu-Ala-
1811 Thr-Asp-Lys-Ile-Arg-Glu-Leu-Asn-Arg-Leu-
1821 Phe-Ala-Val-Asn-Gln-Lys-Asn-Met-Thr-Ala-
1831 Leu-Glu-Lys-Lys-Lys-Glu-Ala-Val-Glu-Ser-
1841 Gly-Lys-Arg-Gln-Ile-Glu-Asn-Thr-Leu-Lys-
1851 Glu-Gly-Asn-Asp-Ile-Leu-Asp-Glu-Ala-Asn-
1861 Arg-Leu-Ala-Asp-Glu-Ile-Asn-Ser-Ile-Ile-

1871 Asp-Tyr-Val-Glu-Asp-Ile-Gln-Thr-Lys-Leu-
1881 Pro-Pro-Phe-Ser-Glu-Glu-Leu-Asn-Asp-Lys-
1891 Ile-Asp-Asp-Leu-Ser-Gln-Glu-Ile-Lys-Asp-
1901 Arg-Lys-Leu-Ala-Glu-Lys-Glu-Val-Ser-Gln-Ala-
1911 Glu-Ser-His-Ala-Ala-Gln-Leu-Asn-Asp-Ser-
1921 Ser-Ala-Val-Leu-Asp-Gly-Ile-Leu-Asp-Glu-
1931 Ala-Lys-Asn-Ile-Ser-Phe-Asn-Ala-Thr-Ala-
1941 Ala-Phe-Lys-Ala-Tyr-Ser-Asn-Ile-Lys-Asp-
1951 Tyr-Ile-Asp-Glu-Ala-Glu-Lys-Val-Ala-Lys-
1961 Glu-Ala-Lys-Asp-Leu-Ala-His-Glu-Ala-Thr-
1971 Lys-Leu-Ala-Thr-Gly-Pro-Arg-Gly-Leu-Leu-
1981 Lys-Glu-Asp-Ala-Lys-Gly-Cys-Leu-Gln-Lys-
1991 Ser-Phe-Arg-Ile-Leu-Asn-Glu-Ala-Lys-Lys-
2001 Leu-Ala-Asn-Asp-Val-Lys-Glu-Asn-Glu-Asp-
2011 His-Leu-Asn-Gly-Leu-Lys-Thr-Arg-Ile-Glu-
2021 Asn-Ala-Asp-Ala-Arg-Asn-Gly-Asp-Leu-Leu-
2031 Arg-Thr-Leu-Asn-Asp-Thr-Leu-Gly-Lys-Leu-
2041 Ser-Ala-Ile-Pro-Asn-Asp-Thr-Ala-Ala-Lys-
2051 Leu-Gln-Ala-Val-Lys-Asp-Lys-Ala-Arg-Gln-
2061 Ala-Asn-Asp-Thr-Ala-Lys-Asp-Val-Leu-Ala-
2071 Gln-Ile-Thr-Glu-Leu-His-Gln-Asn-Leu-Asp-
2081 Gly-Leu-Lys-Lys-Asn-Tyr-Asn-Lys-Leu-Ala-
2091 Asp-Ser-Val-Ala-Lys-Thr-Asn-Ala-Val-Val-
2101 Lys-Asp-Pro-Ser-Lys-Asn-Lys-Ile-Ile-Ala-
2111 Asp-Ala-Asp-Ala-Thr-Val-Lys-Asn-Leu-Glu-
2121 Gln-Glu-Ala-Asp-Arg-Leu-Ile-Asp-Lys-Leu-
2131 Lys-Pro-Ile-Lys-Glu-Leu-Glu-Asn-Leu-
2141 Lys-Lys-Asn-Ile-Ser-Glu-Ile-Lys-Glu-Leu-
2151 Ile-Asn-Gln-Ala-Arg-Lys-Gln-Ala-Asn-Ser-
2161 Ile-Lys-Val-Ser-Val-Ser-Ser-Gly-Gly-Asp-
2171 Cys-Ile-Arg-Thr-Tyr-Lys-Pro-Glu-Ile-Lys-
2181 Lys-Gly-Ser-Tyr-Asn-Asn-Ile-Val-Val-Asn-
2191 Val-Lys-Thr-Ala-Val-Ala-Asp-Asn-Leu-Leu-
2201 Phe-Tyr-Leu-Gly-Ser-Ala-Lys-Phe-Ile-Asp-
2211 Phe-Leu-Ala-Ile-Glu-Met-Arg-Lys-Gly-Lys-
2221 Val-Ser-Phe-Leu-Tyr-Asp-Val-Gly-Ser-Gly-
2231 Val-Gly-Arg-Val-Glu-Tyr-Pro-Asp-Leu-Thr-
2241 Ile-Asp-Asp-Ser-Tyr-Tyr-Tyr-Arg-Ile-Ile-
2251 Ala-Ser-Arg-Thr-Gly-Arg-Asn-Gly-Thr-Ile-
2261 Ser-Val-Arg-Ala-Leu-Asp-Gly-Pro-Lys-Ala-
2271 Ser-Ile-Val-Pro-Ser-Thr-His-His-Ser-Thr-
2281 Ser-Pro-Pro-Gly-Tyr-Thr-Ile-Leu-Asp-Val-
2291 Asp-Ala-Asn-Ala-Met-Leu-Phe-Val-Gly-Gly-
2301 Leu-Thr-Gly-Lys-Leu-Lys-Lys-Ala-Asp-Ala-
2311 Val-Arg-Val-Ile-Thr-Phe-Thr-Gly-Cys-Met-
2321 Gly-Glu-Thr-Tyr-Phe-Asp-Asn-Lys-Pro-Ile-
2331 Gly-Leu-Tyr-Asn-Phe-Arg-Glu-Lys-Glu-Ile-
2341 Asp-Cys-Lys-Gly-Cys-Thr-Val-Ser-Pro-Gln-
2351 Val-Glu-Asp-Ser-Glu-Gly-Thr-Ile-Gln-Phe-
2361 Asp-Gly-Glu-Gly-Tyr-Ala-Ile-Gly-Gln-Ala-
2371 Arg-Pro-Ile-Arg-Tyr-Pro-Asn-Ile-Ser-
2381 Thr-Val-Met-Phe-Lys-Phe-Arg-Thr-Phe-Ser-
2391 Ser-Ser-Ala-Leu-Leu-Met-Tyr-Leu-Ala-Thr-
2401 Arg-Asp-Leu-Arg-Asp-Phe-Met-Ser-Val-Glu-
2411 Leu-Thr-Asp-Gly-His-Ile-Lys-Val-Ser-Tyr-
2421 Asp-Leu-Gly-Ser-Gly-Met-Ala-Ser-Val-Val-
2431 Ser-Asn-Gln-Asn-His-Asn-Asp-Gly-Lys-Tyr-

2441 Lys-Ser-Phe-Thr-Leu-Ser-Arg-Ile-Gln-Lys-
2451 Gln-Ala-Asn-Ile-Ser-Ile-Val-Asp-Ile-Asp-
2461 Thr-Asn-Gln-Glu-Glu-Asn-Ile-Ala-Thr-Ser-
HITS AT: 544-551

L7 ANSWER 7 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABG02222 Protein DGENE

TI New isolated polynucleotide and encoded polypeptides, useful in
diagnostics, forensics, gene mapping, identification of mutations
responsible for genetic disorders or other traits and to assess
biodiversity -

IN Dmanac R T; Liu C; Tang Y T
PA (HSP-N) HYSEQ INC. 103p***
PI ***WO 2001075067 A2 20011011
AI WO 2001-US8631 20010330
PRAI US 2000-3540217 20000331
US 2000-649167 20000823

DT Patent
LA English
OS 2001-639362 (73)
CR N-SPDS: AAS80015

DESC Novel human diagnostic protein #15619.
AN ABG15828 Protein DGENE
AA 21 A; 6 R; 4 N; 10 D; 0 B; 3 C; 6 Q; 7 E; 0 Z; 14 G; 6 H; 12 I;
15 L; 3 K; 4 M; 5 F; 5 P; 18 S; 6 T; 2 W; 5 Y; 12 V; 0 Others
164

SEQ3

1 Ile-Arg-Ala-Gln-Asn-Gly-Ser-Pro-Tyr-Leu-
11 Ser-Phe-Leu-Val-Asp-Ser-Val-Cys-Val-Leu-
21 Lys-Ala-Cys-Val-Asp-Ala-Val-Met-Arg-Ala-
31 Gly-Ile-Cys-Ser-Val-Ser-Tyr-Tyr-Gln-Tyr-
41 Gln-Ser-Gly-Val-Gly-Ala-Asn-Ser-Ser-Ala-
51 Leu-Ser-Gly-Phe-Ser-Gln-Gly-Ala-Ile-Met-
61 Met-Leu-Glu-Ser-Ile-Lys-Ala-Glu-Pro-Gly-
71 Leu-Ala-Ser-Arg-Val-Ile-Ala-Phe-Asn-Gly-
81 Arg-Tyr-Ser-Ser-Leu-Pro-Glu-Thr-Ala-Ser-
91 Thr-Ala-Thr-Thr-Ile-His-Leu-Ile-His-Gly-
101 Gly-Glu-Asp-Pro-Val-Ile-Asp-Leu-Ala-His-
111 Ala-Val-Ala-Ala-Gln-Glu-Ala-Leu-Ile-Ser-
121 Ala-Gly-Ala-Asp-Val-Thr-Leu-Asp-Ile-Val-
131 Glu-Asp-Leu-Gly-His-Ala-Ile-Asp-Asn-Arg-
141 Ser-Met-Gln-Phe-Ala-Leu-Asp-His-Leu-Arg-
151 Tyr-Thr-Ile-Pro-Lys-His-Tyr-Phe-Asp-Glu-
161 Ala-Leu-Ser-Gly

HITS AT: 33-40

L7 ANSWER 8 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABG02222 Protein DGENE

TI New isolated polynucleotide and encoded polypeptides, useful in
diagnostics, forensics, gene mapping, identification of mutations
responsible for genetic disorders or other traits and to assess
biodiversity -

IN Dmanac R T; Liu C; Tang Y T
PA (HSP-N) HYSEQ INC. 103p***
PI ***WO 2001075067 A2 20011011
AI WO 2001-US8631 20010330

PRAI US 2000-540217 20000331
US 2000-649167 20000623

DT Patent
LA English
OS 2001-639362 [73]
CR N-PSDB: AAS66409
DESC Novel human diagnostic protein #2213.

AN AAG62222 Protein DGENE
AA 21 A; 12 R; 12 N; 10 D; 0 B; 6 C; 13 Q; 16 E; 0 Z; 10 G; 14 H; 8 I;
34 L; 10 K; 4 M; 6 F; 21 P; 29 S; 13 T; 5 W; 9 Y; 20 V; 0 Others

SOL 273

SEQ3
1 Met-Asp-Arg-Tyr-Gln-Glu-His-Thr-Ser-Arg-
11 Ala-Leu-Thr-Gln-Lys-Ala-Gly-Ser-Gln-Asp-
21 Tyr-Glu-Ala-Val-Ala-Ser-Pro-Pro-Ala-Ala-
31 Leu-Val-His-Leu-Cys-His-Glu-Ala-Val-Ser-
41 His-His-Leu-Gln-Cys-Ser-Asp-Glu-Thr-Tyr-
51 Val-Phe-Leu-Leu-His-Pro-Leu-Leu-Ile-Glu-
61 Trp-Gln-Asn-Thr-Lys-Pro-Ser-Cys-Ile-
71 Thr-Gln-Leu-Ala-Leu-Gln-Ser-Pro-Ser-Pro-
81 Phe-Gly-Phe-Ser-Val-Ile-Leu-Phe-Asp-Glu-
91 Gln-Asn-Asn-Asp-Leu-Lys-Glu-Leu-Ala-His-
101 Leu-Ala-Ser-Leu-Pro-Phe-Val-Ile-Tyr-Val-
111 Met-Asn-Lys-Arg-Ser-Asp-Ser-Lys-Lys-Val-
121 Ser-Leu-His-Leu-Tyr-Gln-Ser-Asn-Gln-Ser-
131 Gly-Leu-Tyr-Leu-Ser-His-Ala-Leu-Ser-His-
141 Val-Cys-Leu-Thr-Glu-Thr-Lys-Tyr-Ser-Cys-
151 Gly-Thr-Asn-Met-Val-Val-Gly-Arg-Val-
161 Ser-Pro-Gln-Pro-His-Pro-His-Ser-Ile-Asp-
171 Lys-Arg-Gln-Lys-Ser-Gly-Arg-Glu-Val-Tyr-
181 Arg-Glu-Met-Asn-Lys-Ser-Asn-Asn-Tyr-Ile-
191 Glu-Arg-Arg-Val-Leu-Phe-Ser-Leu-Thr-Leu-
201 Leu-Val-Thr-Pro-Ser-Ser-Arg-Pro-Leu-Asn-
211 Pro-Leu-Leu-Leu-Thr-His-Ile-Gly-Ser-Tyr-
221 Leu-Thr-Ala-Pro-Ser-Pro-Ile-Asn-His-Pro-
231 Arg-Ala-Glu-Glu-Cys-Gly-Leu-Thr-Ala-Ala-
241 Asp-Tyr-Gln-Ala-Ala-Pro-Pro-Val-Ala-Leu-
251 Val-Arg-Asp-Pro-Leu-Gly-Glu-Ala-Ser-Tyr-
261 Ala-Pro-Glu-Ser-Gly-Ala-Asp-Val-Glu-Asn-
271 Leu-Tyr-Val

HITS AT: 45-52

L7 ANSWER 9 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAG65891 protein DGENE
TI Isolated polypeptides, which may be peptide hormones, which are identified by high throughput genome-based biology which identifies genes and gene products as therapeutic targets for treatment of diseases such as diabetes and cancer

IN Agarwal P; Murdoch P R; Rizvi S K; Smith R F; Xiang Z; Kabanick K S; Lai Y
PA (SMK) SMITHKLINE BEECHAM CORP.
PI ***WO 2001072961 A2 20011004 99P***
AI WO 2001-US9226 20010322
PRAI US 2000-192158P 20000324
US 2000-192668P 20000328

DT US 2000-200166P 20000427
Patent
LA English
OS 2001-639223 [73]
CR N-PSDB: AAI67181
DESC Amino acid sequence of GSK gene Id 74552.

AN AAG65891 protein DGENE
AA 15 A; 5 R; 15 N; 11 D; 0 B; 9 C; 7 Q; 10 E; 0 Z; 9 G; 7 H; 22 I;
23 L; 13 K; 7 M; 6 F; 16 P; 17 S; 13 T; 4 W; 14 Y; 20 V; 0 Others

SOL 243

SEQ3
1 Met-Thr-Glu-Lys-Ser-Tyr-Asn-Phe-Leu-Ser-
11 Met-Leu-Leu-Phe-Pro-Val-Ala-Leu-Ala-Phe-
21 Asn-Pro-Asp-Tyr-Thr-Val-Ser-Ser-Thr-Pro-
31 Pro-Tyr-Leu-Val-Tyr-Leu-Lys-Ser-Asp-Tyr-
41 Leu-Pro-Cys-Ala-Gly-Val-Leu-Ile-His-Pro-
51 Leu-Tyr-Val-Ile-Thr-Ala-Ala-His-Cys-Asn-
61 Leu-Pro-Lys-Leu-Arg-Val-Ile-Leu-Gly-Val-
71 Thr-Ile-Pro-Ala-Asp-Ser-Asn-Glu-Lys-His-
81 Leu-Gln-Val-Ile-Gly-Tyr-Glu-Lys-Met-Ile-
91 His-His-Pro-His-Phe-Ser-Val-Thr-Ser-Ile-
101 Asp-His-Asp-Ile-Met-Leu-Ile-Lys-Leu-Lys-
111 Thr-Glu-Ala-Glu-Leu-Asn-Asp-Tyr-Val-Lys-
121 Leu-Ala-Asn-Leu-Pro-Tyr-Gln-Thr-Ile-Ser-
131 Glu-Asn-Thr-Met-Cys-Ser-Val-Ser-Thr-Tyr-
141 Ser-Tyr-Asn-Val-Cys-Asp-Ile-Tyr-Lys-Glu-
151 Pro-Asp-Ser-Leu-Gln-Thr-Val-Asn-Ile-Ser-
161 Val-Ile-Ser-Lys-Pro-Gln-Cys-Arg-Asp-Ala-
171 Tyr-Lys-Thr-Tyr-Asn-Ile-Thr-Glu-Asn-Met-
181 Leu-Cys-Val-Gly-Ile-Val-Pro-Gly-Arg-Arg-
191 Gln-Pro-Cys-Lys-Glu-Val-Ser-Ala-Ala-Pro-
201 Ala-Ile-Cys-Asn-Gly-Met-Leu-Gln-Gly-Ile-
211 Leu-Ser-Phe-Ala-Asp-Gly-Cys-Val-Leu-Arg-
221 Ala-Asp-Val-Gly-Ile-Tyr-Ala-Lys-Ile-Phe-
231 Tyr-Tyr-Ile-Pro-Tyr-Ile-Glu-Asn-Val-Ile-
241 Gln-Asn-Asn

HITS AT: 135-142

L7 ANSWER 10 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAG65890 protein DGENE
TI Isolated polypeptides, which may be peptide hormones, which are identified by high throughput genome-based biology which identifies genes and gene products as therapeutic targets for treatment of diseases such as diabetes and cancer

IN Agarwal P; Murdoch P R; Rizvi S K; Smith R F; Xiang Z; Kabanick K S; Lai Y
PA (SMK) SMITHKLINE BEECHAM CORP.
PI ***WO 2001072961 A2 20011004 99P***
AI WO 2001-US9226 20010322
PRAI US 2000-192158P 20000324
US 2000-192668P 20000328
US 2000-200166P 20000427

DT Patent
LA English
OS 2001-639223 [73]

CR N-PSDB: AAI67180
DESC Amino acid sequence of GSK gene Id 74552.
AN AAG55890 protein DGENE
AA 16 A; 5 R; 15 N; 11 D; 0 B; 9 C; 7 Q; 9 E; 0 Z; 9 G; 7 H; 23 I;
25 L; 13 K; 6 M; 5 F; 15 P; 15 S; 13 T; 4 W; 14 Y; 20 V; 0 Others
SQL 241
SEQ3
1 Met-Lys-Phe-Ile-Leu-Leu-Tyr-Ala-Leu-Leu-
11 Asn-Leu-Thr-Val-Ala-Leu-Ala-Phe-Asn-Pro-
21 Asp-Tyr-Thr-Val-Ser-Ser-Thr-Pro-Pro-Tyr-
31 Leu-Val-Tyr-Leu-Lys-Ser-Asp-Tyr-Leu-Pro-
41 Cys-Ala-Gly-Val-Leu-Ile-His-Pro-Leu-Tyr-
51 Val-Ile-Thr-Ala-Ala-His-Cys-Asn-Leu-Pro-
61 Lys-Leu-Arg-Val-Ile-Leu-Gly-Val-Thr-Ile-
71 Pro-Ala-Asp-Ser-Asn-Glu-Lys-His-Leu-Glu-
81 Val-Ile-Gly-Tyr-Glu-Lys-Met-Ile-His-His-
91 Pro-His-Phe-Ser-Val-Thr-Ser-Ile-Asp-His-
101 Asp-Ile-Met-Leu-Ile-Lys-Leu-Lys-Thr-Glu-
111 Ala-Glu-Leu-Asn-Asp-Tyr-Val-Lys-Leu-Ala-
121 Asn-Leu-Pro-Tyr-Gln-Thr-Ile-Ser-Glu-Asn-
131 Thr-Met-Cys-Ser-Val-Ser-Thr-Tyr-Ser-Tyr-
141 Asn-Val-Cys-Asp-Ile-Tyr-Lys-Glu-Pro-Asp-
151 Ser-Leu-Gln-Thr-Val-Asn-Ile-Ser-Val-Ile-
161 Ser-Lys-Pro-Gln-Cys-Arg-Asp-Ala-Tyr-Lys-
171 Thr-Tyr-Asn-Ile-Thr-Glu-Asn-Met-Leu-Cys-
181 Val-Gly-Ile-Val-Pro-Gly-Arg-Arg-Gln-Pro-
191 Cys-Lys-Glu-Val-Ser-Ala-Ala-Pro-Ala-Ile-
201 Cys-Asn-Gly-Met-Leu-Gln-Gly-Ile-Leu-Ser-
211 Phe-Ala-Asp-Gly-Cys-Val-Leu-Arg-Ala-Asp-
221 Val-Gly-Ile-Tyr-Ala-Lys-Ile-Phe-Tyr-Tyr-
231 Ile-Pro-Tyr-Ile-Glu-Asn-Val-Ile-Gln-Asn-
241 Asn
HITS AT: 133-140

LN ANSWER 11 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STM
AN AAB47569 Protein DGENE
TI New polypeptide for treating gastrointestinal, cardiovascular and
autoimmune disorders, comprises novel human proteases (PRTS) and
polynucleotides -
IN Yue H; Lu D A M; Policky J L; Deleage A M; Tribouley C M; Khan F A;
Au-Young J; Bandman O; Lai P; Borowsky M L; Gendel A R; Hillman U L; Tang
Y T; Burford N; Baughn M R; Nguyen D B; Yao W G; Walia N K; He A; Hafalia
A; Lu Y; Patterson C
PA (INCY-N) INCYTE GENOMICS INC.
PI ***WO 2001/071004 A2 20010927 129p***
AI WO 2001-US8641 20010316
PRAI US 2000-190708P 20000317
US 2000-193182P 20000330
US 2000-197086P 20000414
US 2000-199022P 20000420
US 2000-200227P 20000428
DT Patent
LA English
OS 2001-611509 (701)
CR N-PSDB: AAB43522
DESC Protease PRTS-11.

AN AAB47569 Protein DGENE
AA 16 A; 5 R; 15 N; 12 D; 0 B; 9 C; 7 Q; 9 E; 0 Z; 10 G; 7 H; 24 I;
27 L; 13 K; 6 M; 6 F; 15 P; 18 S; 14 T; 4 W; 13 Y; 20 V; 0 Others
SQL 250
SEQ3
1 Met-Lys-Phe-Ile-Leu-Leu-Tyr-Ala-Leu-Leu-
11 Asn-Leu-Thr-Val-Ala-Leu-Ala-Phe-Asn-Pro-
21 Asp-Tyr-Thr-Val-Ser-Ser-Thr-Pro-Pro-Tyr-
31 Leu-Val-Tyr-Leu-Lys-Ser-Asp-Tyr-Leu-Pro-
41 Cys-Ala-Gly-Val-Leu-Ile-His-Pro-Leu-Tyr-
51 Val-Ile-Thr-Ala-Ala-His-Cys-Asp-Leu-Tyr-
61 Lys-Leu-Arg-Val-Ile-Leu-Gly-Val-Thr-Ile-
71 Pro-Ala-Asp-Ser-Asn-Glu-Lys-His-Leu-Gln-
81 Val-Ile-Gly-Tyr-Glu-Lys-Met-Ile-His-His-
91 Pro-His-Phe-Ser-Val-Thr-Ser-Ile-Asp-His-
101 Asp-Ile-Met-Leu-Ile-Lys-Leu-Lys-Thr-Glu-
111 Ala-Glu-Leu-Asn-Asp-Tyr-Val-Lys-Leu-Ala-
121 Asn-Leu-Pro-Tyr-Gln-Thr-Ile-Ser-Glu-Asn-
131 Thr-Met-Cys-Ser-Val-Ser-Thr-Tyr-Ser-Tyr-
141 Asn-Val-Cys-Asp-Ile-Gly-Ser-Leu-Thr-Ser-
151 Ile-Phe-Ser-Leu-Asp-Lys-Glu-Pro-Asp-Ser-
161 Leu-Gln-Thr-Val-Asn-Ile-Ser-Val-Ile-Ser-
171 Lys-Pro-Gln-Cys-Arg-Asp-Ala-Tyr-Lys-Thr-
181 Tyr-Asn-Ile-Thr-Glu-Asn-Met-Leu-Cys-Val-
191 Gly-Ile-Val-Pro-Gly-Arg-Arg-Gln-Pro-Cys-
201 Lys-Glu-Val-Ser-Ala-Ala-Pro-Ala-Ile-Cys-
211 Asn-Gly-Met-Leu-Gln-Gly-Ile-Leu-Ser-Phe-
221 Ala-Asp-Gly-Cys-Val-Leu-Arg-Ala-Asp-Val-
231 Gly-Ile-Tyr-Ala-Lys-Ile-Phe-Tyr-Tyr-Ile-
241 Pro-Tyr-Ile-Glu-Asn-Val-Ile-Gln-Asn-Asn
HITS AT: 133-140

FEATURE TABLE:
Key Location/Qualifier
Peptide 1..20 |label| potential signal peptide
Modified-site|11| |label| potential glycosylation site
Active-site|35..77| |label| serine protease active site
Domain 41..54 |label| type I fibronectin domain
Domain 41..243 |label| trypsin domain
Domain 41..583 |label| trypsin domain
Active-site 52..57 |label| trypsin active site motif
Modified-site|96| |label| potential phosphorylation site
Modified-site|109| |label| potential phosphorylation site
Modified-site|116| |label| potential phosphorylation site
Modified-site|126| |label| potential phosphorylation site
Modified-site|165| |label| potential glycosylation site
Modified-site|182| |label| potential glycosylation site
Domain 202..243|label| trypsin domain
Modified-site|219| |label| potential phosphorylation site

L7 ANSWER 12 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STM
AN AAO1054 Protein DGENE

TI Isolated nucleic acids and polypeptides, useful for preventing diagnosing and treating e.g. leukaemia, inflammation and immune disorders - Tang Y T, Liu C, Drenth R T (HSE-N) HYSEQ INC. 999p***

PA **WO 2001064835 A2 20010907

PI WO 2001-US4927 20010226

AI US 2000-515126 20000228

PRAI US 2000-577409 20000518

DT Patent

LA English

OS 2001-514638 [56]

CR N-PSDB: AA190985

DESC Human polypeptide SEQ ID NO 24946.

AN AA011054 Protein DGENE

AA 6 A; 6 R; 2 N; 3 D; 0 B; 4 C; 4 Q; 4 E; 0 Z; 11 G; 7 H; 3 I; 16 L; 3 K; 1 M; 6 F; 7 P; 12 S; 10 T; 4 W; 2 Y; 9 V; 1 Others

SOL 121

SEQ3

1 Leu-Val-Glu-Met-Gly-Phe-Leu-Arg-Val-Arg-11 Gln-Asn-Gly-Leu-Tyr-Leu-Leu-Thr-Ser-Xxx-21 Ser-Ala-Arg-Leu-Gly-Leu-Ser-Lys-Cys-Tip-31 Asp-Tyr-Arg-Arg-Glu-Pro-Pro-Cys-Pro-Ala-41 Ser-Asp-Tip-Val-Phe-Ile-Leu-Thr-Ser-Pro-51 Leu-Ile-His-Ala-Leu-Asp-Gly-Lys-Glu-His-61 Thr-His-Thr-His-Thr-His-Thr-His-His-71 Thr-Gly-Leu-Gly-Ile-Cys-Gln-Ser-Ser-Leu-81 Gly-Lys-Gln-Ser-Gly-Gly-Tip-Gly-Tip-Leu-91 Ser-Ala-Asn-Arg-Gly-Gln-Phe-Ser-Pro-Phe-101 Ala-Val-Cys-Leu-Val-Val-Ser-Phe-Leu-Pro-111 Gln-Val-Pro-Val-Thr-Ser-Ala-Leu-Phe-121 Thr

HITS AT: 38-45

L7 ANSWER 13 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN

TI Isolated, secretory and transmembrane PRO polypeptide used to detect other PRO polypeptides, link bioactive molecules to cells expressing PRO polypeptides, and detect the presence of mammalian tumours e.g. lung, breast, prostate, cervical - Baker K P; Beresini M; DeForge L; Desnoyers L; Filvaroff E; Gao W; Gerritsen M B; Goddard A; Godowski P J; Gurney A L; Sharwood S; Smith V; Stewart T A; Tamas D; Watanabe C K; Wood W I; Zhang Z (GENI) GENENTECH INC. 813p***

PA **WO 2001040466 A2 20010607

PI WO 2000-US32676 20001201

PRAI WO 1999-US28301 19991201

WO 1999-US28634 19991201

WO 1999-US28551 19991202

WO 1999-US28564 19991202

WO 1999-US28565 19991202

US 1999-170262 19991209

WO 1999-US30095 19991216

WO 1999-US30911 19991220

WO 1999-US30999 19991220

WO 1999-US31243 19991230

WO 2000-US277 20000106

WO 2000-US376 20000106

WO 2000-US3565 20000211

WO 2000-US4341 20000218

WO 2000-US4342 20000218

WO 2000-US4414 20000222

WO 2000-US4914 20000224

WO 2000-US5004 20000224

WO 2000-US5601 20000301

WO 2000-US7377 20000320

WO 2000-US7532 20000321

WO 2000-US8439 20000330

WO 2000-US13705 20000517

WO 2000-US14042 20000522

WO 2000-US14941 20000530

WO 2000-US13264 20000602

WO 2000-US30873 20001110

DT Patent

LA English

OS 2001-408281 [43]

CR N-PSDB: AAS21367

DESC Human PRO6030 Polypeptide sequence.

AN AAU12295 Protein DGENE

AA 16 A; 5 R; 15 N; 11 D; 0 B; 9 C; 7 Q; 9 E; 0 Z; 9 G; 7 H; 23 I; 25 L; 13 K; 6 M; 5 F; 15 P; 15 S; 13 T; 4 W; 14 Y; 20 V; 0 Others

SOL 241

SEQ3

1 Met-Lys-Phe-Ile-Leu-Leu-Tip-Ala-Leu-Leu-11 Asn-Leu-Thr-Val-Ala-Leu-Ala-Phe-Asn-Pro-21 Asp-Tyr-Thr-Val-Ser-Ser-Thr-Pro-Tyr-Tip-31 Leu-Val-Tyr-Leu-Lys-Ser-Asp-Tyr-Leu-Pro-41 Cys-Ala-Gly-Val-Leu-Ile-His-Pro-Leu-Tip-51 Val-Ile-Thr-Ala-Ala-His-Cys-Asn-Leu-Pro-61 Lys-Leu-Arg-Val-Ile-Leu-Gly-Val-Thr-Ile-71 Pro-Ala-Asp-Ser-Asn-Glu-Lys-His-Leu-Gln-81 Val-Ile-Gly-Tyr-Glu-Lys-Met-Ile-His-His-91 Pro-His-Phe-Ser-Val-Thr-Ser-Ile-Asp-His-101 Asp-Ile-Met-Leu-Ile-Lys-Leu-Lys-Thr-Glu-111 Ala-Glu-Leu-Asn-Asp-Tyr-Val-Lys-Leu-Ala-121 Asn-Leu-Pro-Tyr-Gln-Thr-Ile-Ser-Glu-Asn-131 Thr-Met-Cys-Ser-Val-Ser-Thr-Tip-Ser-Tyr-141 Asn-Val-Cys-Asp-Ile-Tyr-Lys-Glu-Pro-Asp-151 Ser-Leu-Gln-Thr-Val-Asn-Ile-Ser-Val-Ile-161 Ser-Lys-Pro-Gln-Cys-Arg-Asp-Ala-Tyr-Lys-171 Thr-Tyr-Asn-Ile-Thr-Glu-Asn-Met-Leu-Cys-181 Val-Gly-Ile-Val-Pro-Gly-Arg-Arg-Gln-Pro-191 Cys-Lys-Glu-Val-Ser-Ala-Ala-Pro-Ala-Ile-201 Cys-Asn-Gly-Met-Leu-Gln-Gly-Ile-Leu-Ser-211 Phe-Ala-Asp-Gly-Cys-Val-Leu-Arg-Ala-Asp-221 Val-Gly-Ile-Tyr-Ala-Lys-Ile-Phe-Tyr-Tyr-231 Ile-Pro-Tip-Ile-Glu-Asn-Val-Ile-Gln-Asn-241 Asn

HITS AT: 133-140

L7 ANSWER 14 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN

AN AA00334 Protein DGENE

71 Novel membrane bound protein, Zs1g60 isolated from pituitary gland, and anti-Zs1g60 antibodies which are useful for identifying or isolating cells of pituitary gland and to detect size and morphology of the gland -
 IN Presnell S R ZYMOGENETICS INC. 89p***
 PA (Zymo) ***WO 2001023567 A1 20010405
 PI WO 2000-US26664 20000928
 AI US 1999-156367 19990928
 PRAI Patent
 DT English
 LA 2001-266161 [27]
 OS Human membrane-bound protein-60 alternative mature extracellular portion.
 DESC AAE00334 Protein DGENE
 AN 17 A; 4 R; 7 N; 5 D; 0 B; 10 C; 5 Q; 5 E; 0 Z; 13 G; 6 H; 5 I;
 AA 20 L; 2 K; 4 M; 5 F; 10 P; 10 S; 8 T; 3 W; 7 Y; 14 V; 0 Others
 SQL 160
 SEQ3 1 Ile-Tyr-Thr-Val-Tyr-Ala-Met-Ala-Val-Met-
 11 Asn-His-His-Val-Cys-Pro-Val-Glu-Asn-Tyr-
 21 Ser-Tyr-Asn-Glu-Ser-Cys-Pro-Pro-Asp-Pro-
 31 Ala-Glu-Gln-Gly-Gly-Pro-Lys-Thr-Cys-Cys-
 41 Thr-Leu-Asp-Asp-Val-Pro-Leu-Ile-Ser-Lys-
 51 Cys-Gly-Ser-Tyr-Pro-Pro-Glu-Ser-Cys-Leu-
 61 Phe-Ser-Leu-Ile-Gly-Asn-Met-Gly-Ala-Phe-
 71 Met-Val-Ala-Leu-Ile-Cys-Leu-Leu-Arg-Tyr-
 81 Gly-Gln-Leu-Leu-Gln-Ser-Arg-His-Ser-
 91 Tyr-Val-Asn-Thr-Thr-Ala-Leu-Ile-Thr-Gly-
 101 Cys-Thr-Asn-Ala-Ala-Gly-Leu-Leu-Val-Val-
 111 Gly-Asp-Phe-Gln-Val-Asp-His-Ala-Arg-Ser-
 121 Leu-His-Tyr-Val-Gly-Ala-Gly-Val-Ala-Phe-
 131 Pro-Ala-Gly-Leu-Leu-Phe-Val-Cys-Leu-His-
 141 Cys-Ala-Leu-Ser-Tyr-Gln-Gly-Ala-Thr-Ala-
 151 Pro-Leu-Asp-Leu-Leu-Ala-Val-Ala-Tyr-Leu-Arg
 HITS AT: 15-22
 L7 ANSWER 15 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAE00333 Protein DGENE
 TI Novel membrane bound protein, Zs1g60 isolated from pituitary gland, and anti-Zs1g60 antibodies which are useful for identifying or isolating cells of pituitary gland and to detect size and morphology of the gland -
 IN Presnell S R
 PA (Zymo) ZYMOGENETICS INC. 89p***
 PI WO 2000-US26664 20000928
 AI US 1999-156367 19990928
 PRAI Patent
 DT English
 LA 2001-266161 [27]
 OS Human membrane-bound protein-60 (Zs1g60) mature extracellular portion.
 DESC AAE00333 Protein DGENE
 AN 17 A; 4 R; 7 N; 5 D; 0 B; 10 C; 5 Q; 5 E; 0 Z; 14 G; 6 H; 6 I;
 AA 20 L; 2 K; 4 M; 5 F; 10 P; 10 S; 9 T; 3 W; 7 Y; 14 V; 0 Others
 SQL 163
 SEQ3 1 Ile-Thr-Gly-Ile-Tyr-Thr-Val-Tyr-Ala-Met-

11 Ala-Val-Met-Asn-His-His-Val-Cys-Pro-Val-
 21 Glu-Asn-Tyr-Ser-Tyr-Asn-Glu-Ser-Cys-Pro-
 31 Pro-Asp-Pro-Ala-Glu-Gln-Gly-Pro-Lys-
 41 Thr-Cys-Cys-Thr-Leu-Asp-Asp-Val-Pro-Leu-
 51 Ile-Ser-Lys-Cys-Gly-Ser-Tyr-Pro-Glu-
 61 Ser-Cys-Leu-Phe-Ser-Leu-Ile-Gly-Asn-Met-
 71 Gly-Ala-Phe-Met-Val-Ala-Leu-Ile-Cys-Leu-
 81 Leu-Arg-Tyr-Gly-Gln-Leu-Leu-Glu-Gln-Ser-
 91 Arg-His-Ser-Tyr-Val-Asn-Thr-Thr-Ala-Leu-
 101 Ile-Thr-Gly-Cys-Thr-Asn-Ala-Ala-Gly-Leu-
 111 Leu-Val-Val-Gly-Asn-Phe-Gln-Val-Asp-His-
 121 Ala-Arg-Ser-Leu-His-Tyr-Val-Gly-Ala-Gly-
 131 Val-Ala-Phe-Pro-Ala-Gly-Leu-Leu-Phe-Val-
 141 Cys-Leu-His-Cys-Ala-Leu-Ser-Tyr-Gln-Gly-
 151 Ala-Thr-Ala-Pro-Leu-Asp-Leu-Ala-Val-Ala-
 161 Tyr-Leu-Arg
 HITS AT: 18-25
 L7 ANSWER 16 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAE00332 Protein DGENE
 TI Novel membrane bound protein, Zs1g60 isolated from pituitary gland, and anti-Zs1g60 antibodies which are useful for identifying or isolating cells of pituitary gland and to detect size and morphology of the gland -
 IN Presnell S R ZYMOGENETICS INC. 89p***
 PA (Zymo) ***WO 2001023567 A1 20010405
 PI WO 2000-US26664 20000928
 AI US 1999-156367 19990928
 PRAI Patent
 DT English
 LA 2001-266161 [27]
 OS Human membrane-bound protein-60 alternative mature protein sequence.
 DESC AAE00332 Protein DGENE
 AN 27 A; 5 R; 8 N; 7 D; 0 B; 14 C; 8 Q; 9 E; 0 Z; 13 G; 9 H; 12 I;
 AA 30 L; 3 K; 5 M; 11 F; 13 P; 24 S; 13 T; 4 W; 9 Y; 23 V; 0 Others
 SQL 253
 SEQ3 1 Ile-Tyr-Thr-Val-Tyr-Ala-Met-Ala-Val-Met-
 11 Asn-His-His-Val-Cys-Pro-Val-Glu-Asn-Tyr-
 21 Ser-Tyr-Asn-Glu-Ser-Cys-Pro-Pro-Asp-Pro-
 31 Ala-Glu-Gln-Gly-Gly-Pro-Lys-Thr-Cys-Cys-
 41 Thr-Leu-Asp-Asp-Val-Pro-Leu-Ile-Ser-Lys-
 51 Cys-Gly-Ser-Tyr-Pro-Pro-Glu-Ser-Cys-Leu-
 61 Phe-Ser-Leu-Ile-Gly-Asn-Met-Gly-Ala-Phe-
 71 Met-Val-Ala-Leu-Ile-Cys-Leu-Leu-Arg-Tyr-
 81 Gly-Gln-Leu-Leu-Gln-Ser-Arg-His-Ser-
 91 Tyr-Val-Asn-Thr-Thr-Ala-Leu-Ile-Thr-Gly-
 101 Cys-Thr-Asn-Ala-Ala-Gly-Leu-Leu-Val-Val-
 111 Gly-Asn-Phe-Gln-Val-Asp-His-Ala-Arg-Ser-
 121 Leu-His-Tyr-Val-Gly-Ala-Gly-Val-Ala-Phe-
 131 Pro-Ala-Gly-Leu-Leu-Phe-Val-Cys-Leu-His-
 141 Cys-Ala-Leu-Ser-Tyr-Gln-Gly-Ala-Thr-Ala-
 151 Pro-Leu-Asp-Leu-Leu-Ala-Val-Ala-Tyr-Leu-Arg-

161 Ser-Val-Leu-Ala-Val-Ile-Ala-Phe-Ile-Thr-
171 Leu-Val-Leu-Ser-Gly-Val-Phe-Phe-Val-His-
181 Glu-Ser-Ser-Gln-Leu-Gln-His-Gly-Ala-Ala-
191 Leu-Cys-Ser-Glu-Tyr-Val-Cys-Val-Ile-Asp-Ile-
201 Leu-Ile-Phe-Tyr-Gly-Thr-Phe-Ser-Tyr-Glu-
211 Phe-Gly-Ala-Val-Ser-Ser-Asp-Thr-Leu-Val-
221 Ala-Ala-Leu-Gln-Leu-Pro-Pro-Gly-Arg-Ala-
231 Cys-Lys-Ser-Ser-Gly-Ser-Ser-Thr-Ser-
241 Thr-His-Leu-Asn-Cys-Ala-Pro-Glu-Ser-Ile-
251 Ala-Met-Ile

HITS AT: 15-22

L7 ANSWER 17 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAED00330 Protein DGENE
TI Novel membrane bound protein, Zsig60 isolated from pituitary gland, and
anti-Zsig60 antibodies which are useful for identifying or isolating
cells of pituitary gland and to detect size and morphology of the gland -

IN Presnell S R

PA (ZYMO) ZYMOGENETICS INC.

PI ***WO 2001023567 A1 20010405

AI WO 2000-US26664 20000928

PRAT US 1999-156367 19990928

DT Patent

LA English

OS 2001-266161 (27)

DESC Human membrane-bound protein-60 (Zsig60) mature protein sequence.

AN AAED00331 Protein DGENE

AA 27 A; 5 R; 8 N; 7 D; 0 B; 14 C; 8 Q; 9 E; 0 Z; 20 G; 9 H; 13 I;
30 L; 3 K; 5 M; 11 F; 13 P; 24 S; 14 T; 4 W; 9 Y; 23 V; 0 Others

SOL 256

SEQ3

1 Ile-Thr-Gly-Ile-Tyr-Thr-Val-Tyr-Ala-Met-
11 Ala-Val-Met-Asn-His-His-Val-Cys-Pro-Val-
21 Glu-Asn-Tyr-Ser-Tyr-Asn-Glu-Ser-Cys-Pro-
31 Pro-Asp-Pro-Ala-Glu-Gln-Gly-Gly-Pro-Lys-
41 Thr-Cys-Cys-Thr-Leu-Asp-Asp-Val-Pro-Leu-
51 Ile-Ser-Lys-Cys-Gly-Ser-Tyr-Pro-Pro-Glu-
61 Ser-Cys-Leu-Phe-Ser-Leu-Ile-Gly-Asn-Met-
71 Gly-Ala-Phe-Met-Val-Ala-Leu-Ile-Cys-Leu-
81 Leu-Arg-Tyr-Gly-Gln-Leu-Leu-Gln-Ser-
91 Arg-His-Ser-Tyr-Val-Asp-Thr-Thr-Ala-Leu-
101 Ile-Thr-Gly-Cys-Thr-Asn-Ala-Ala-Gly-Leu-
111 Leu-Val-Val-Gly-Asn-Phe-Gln-Val-Asp-His-
121 Ala-Arg-Ser-Leu-His-Tyr-Val-Gly-Ala-Gly-
131 Val-Ala-Phe-Pro-Ala-Gly-Leu-Leu-Phe-Val-
141 Cys-Leu-His-Cys-Ala-Leu-Ser-Tyr-Gln-Gly-
151 Ala-Thr-Ala-Pro-Leu-Asp-Leu-Ala-Val-Ala-
161 Tyr-Leu-Arg-Ser-Val-Leu-Ala-Val-Ile-Ala-
171 Phe-Ile-Thr-Leu-Val-Leu-Ser-Gly-Val-Phe-
181 Phe-Val-His-Glu-Ser-Ser-Gln-Leu-Gln-His-
191 Gly-Ala-Ala-Leu-Cys-Glu-Tyr-Val-Cys-Val-
201 Ile-Asp-Ile-Leu-Ile-Phe-Tyr-Gly-Thr-Phe-
211 Ser-Tyr-Glu-Phe-Gly-Ala-Val-Ser-Ser-Asp-
221 Thr-Leu-Val-Ala-Ala-Leu-Gln-Leu-Pro-Pro-
231 Gly-Arg-Ala-Cys-Lys-Ser-Ser-Gly-Ser-Ser-

241 Ser-Thr-Ser-Thr-His-Leu-Asn-Cys-Ala-Pro-
251 Glu-Ser-Ile-Ala-Met-Ile

HITS AT: 18-25

L7 ANSWER 18 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAED00330 Protein DGENE
TI Novel membrane bound protein, Zsig60 isolated from pituitary gland, and
anti-Zsig60 antibodies which are useful for identifying or isolating
cells of pituitary gland and to detect size and morphology of the gland -

IN Presnell S R

PA (ZYMO) ZYMOGENETICS INC.

PI ***WO 2001023567 A1 20010405

AI WO 2000-US26664 20000928

PRAT US 1999-156367 19990928

DT Patent

LA English

OS 2001-266161 (27)

DESC Human membrane-bound protein-60 (Zsig60).

AN AAED00330 Protein DGENE

AA 29 A; 5 R; 8 N; 7 D; 0 B; 14 C; 8 Q; 9 E; 0 Z; 20 G; 9 H; 14 I;
33 L; 3 K; 6 M; 12 F; 14 P; 27 S; 15 T; 5 W; 9 Y; 24 V; 0 Others

SOL 271

SEQ3

1 Met-Thr-Ala-Tyr-Ile-Leu-Leu-Pro-Val-Ser-
11 Leu-Ser-Ala-Phe-Ser-Ile-Thr-Gly-Ile-Tyr-
21 Thr-Val-Tyr-Ala-Met-Ala-Val-Met-Asn-His-
31 His-Val-Cys-Pro-Val-Glu-Asn-Tyr-Ser-Tyr-
41 Asn-Glu-Ser-Cys-Pro-Pro-Asp-Pro-Ala-Glu-
51 Gln-Gly-Gly-Pro-Lys-Thr-Cys-Cys-Thr-Leu-
61 Asp-Asp-Val-Pro-Leu-Ile-Ser-Lys-Cys-Gly-
71 Ser-Tyr-Pro-Pro-Glu-Ser-Cys-Leu-Phe-Ser-
81 Leu-Ile-Gly-Asn-Met-Gly-Ala-Phe-Met-Val-
91 Ala-Leu-Ile-Cys-Leu-Leu-Arg-Tyr-Gly-Gln-
101 Leu-Leu-Glu-Gln-Ser-Arg-His-Ser-Tyr-Val-
111 Asn-Thr-Thr-Ala-Leu-Ile-Thr-Gly-Cys-Thr-
121 Asn-Ala-Ala-Gly-Leu-Leu-Val-Val-Gly-Asn-
131 Phe-Gln-Val-Asp-His-Ala-Arg-Ser-Leu-His-
141 Tyr-Val-Gly-Ala-Gly-Val-Ala-Phe-Pro-Ala-
151 Gly-Leu-Leu-Phe-Val-Cys-Leu-His-Cys-Ala-
161 Leu-Ser-Tyr-Gln-Gly-Ala-Thr-Ala-Pro-Leu-
171 Asp-Leu-Ala-Val-Ala-Tyr-Leu-Arg-Ser-Val-
181 Leu-Ala-Val-Ile-Ala-Phe-Ile-Thr-Leu-Val-
191 Leu-Ser-Gly-Val-Phe-Phe-Val-His-Glu-Ser-
201 Ser-Gln-Leu-Gln-His-Gly-Ala-Ala-Leu-Cys-
211 Glu-Tyr-Val-Cys-Val-Ile-Asp-Ile-Leu-Ile-
221 Phe-Tyr-Gly-Thr-Phe-Ser-Tyr-Gly-Phe-Gly-
231 Ala-Val-Ser-Ser-Asp-Thr-Leu-Val-Ala-Lys-
241 Leu-Gln-Leu-Pro-Pro-Gly-Arg-Ala-Cys-Lys-
251 Ser-Ser-Gly-Ser-Ser-Thr-Ser-Thr-His-
261 Leu-Asn-Cys-Ala-Pro-Glu-Ser-Ile-Ala-Met-
271 Ile

HITS AT: 33-40

```

FEATURE TABLE:
Key      Location|Qualifier|
=====|=====|
Peptide  11..15      |label|
Protein  16..271     |label|
Peptide  11..18      |label|
Protein  19..271     |label|
Region   116..178   |label|
Region   119..178   |label|
Region   139..56    |label|
Region   139..76    |label|
Region   139..108   |label|
Region   1179..1971 |label|
Region   1198..2711 |label|
Region   |              |Intracellular_or_cytoplasmic_region|

L7  ANSWER 19 OF 36  DGENE  COPYRIGHT 2004 The Thomson Corp on STN
AN  AAY64866 Protein  DGENE
TI  Novel secreted protein 5' expressed sequence tag sequences used in
    diagnostic, forensic, gene therapy, and chromosome mapping procedures
IN  Dumas Milne Edwards J; Duclet A; Giordano J
PA  (GSET)  GENSET.
PI  **WO 9953051  A2 19991021  837p***
P1  WO 1999-18712  19990409
PRAI US 1998-57719  19980409
PRAI US 1998-69047  19980408

DT  Patent
LA  English
OS  2000-038446 [03]
CR  N-PSTB: AA242480
DESC Human 5' EST related polypeptide SEQ ID NO:1027.
AN  AAY64866 Protein  DGENE
AA  3 A; 6 R; 2 N; 0 D; 4 G; 1 Q; 3 E; 0 Z; 3 G; 3 H; 1 I;
    12 L; 1 K; 2 M; 2 F; 5 P; 10 S; 6 T; 2 W; 1 Y; 7 V; 0 others
SOL 74
SEQ3
1 Met-Ala-Ala-Ser-Val-Leu-Asn-Thr-Val-Leu-
11 Arg-Arg-Leu-Pro-Met-Leu-Ser-Leu-Phe-Arg-
21 Gly-Ser-His-Arg-Val-Gln-Val-Thr-Leu-Arg-
31 Lys-Thr-Phe-Cys-Thr-Thr-Ser-Ser-Tip-Leu-
41 Tyr-Leu-Leu-Glu-Val-Val-Ala-Pro-Leu-Ser-
51 Gly-Ile-His-Glu-Tip-Arg-Pro-Ser-His-Val-
61 Cys-Leu-Ser-Cys-Leu-Gly-Ser-Thr-Ser-Cys-
71 Asn-Pro-Pro-Glu
HITS AT: 34-41

L7  ANSWER 20 OF 36  DGENE  COPYRIGHT 2004 The Thomson Corp on STN
AN  AAY94930 Protein  DGENE
TI  New polynucleotides encoding secreted proteins, which may have e.g.
    nutritional, chemokine, immune stimulating or suppressing, hematopoiesis
    regulating, tissue growth, activin/inhibin antiinflammatory or tumor
    inhibition activity -
    Jacobs K; McCoy J M; LaVallie E R; Collins-Racie L A; Evans C; Merberg D;
    Treacy M; Agostino M J; Steininger R J; Spaulding V; Wong G; Clark H F;
    Fochtel K
PA  (GENY)  GENETICS INST INC.
PI  ***WO 2000093552 A1 20000224  641p***
P1  WO 1999-US18298  19990813
PRAI US 1998-96622  19980814
PRAI US 1998-96622  19980817
PRAI US 1998-96622  19980904
PRAI US 1998-96622  19981023
PRAI US 1999-115234  19990106
PRAI US 1999-115234  19990106
PRAI US 1999-115234  19990106
PRAI US 1999-120575  19990218
PRAI US 1999-120575  19990218
PRAI US 1999-132020  19990430
PRAI US 1999-96622  19990811

DT  Patent
LA  English
OS  2000-205979 [18]
DESC Human secreted protein clone qai36.1 protein sequence SEQ ID NO:66.
AN  AAY94930 Protein  DGENE
AA  31 A; 19 R; 10 N; 7 D; 0 B; 21 C; 16 Q; 13 E; 0 Z; 36 G; 15 H; 13 I;
    48 L; 7 K; 10 M; 16 F; 54 P; 49 S; 21 T; 17 W; 7 Y; 27 V; 0 others
SOL 437
SEQ3
1 Met-Val-Arg-Arg-Arg-Gly-Ala-Pro-Gly-
11 Arg-Pro-Gly-Gln-Leu-Met-Val-Val-Ala-Glu-
21 Thr-Ser-Gln-Gly-Ser-Tip-Ser-Ala-Pro-His-
31 Phe-Pro-Ile-Tyr-Leu-Leu-Ser-Ser-Pro-Pro-
41 Thr-Pro-Pro-Pro-Tip-Leu-Leu-Ser-Ser-Leu-
51 Met-Thr-Ala-Tip-Ile-Leu-Leu-Pro-Val-Ser-
61 Leu-Ser-Ala-Phe-Ser-Ile-Thr-Gly-Ile-Tip-
71 Thr-Val-Tyr-Ala-Met-Ala-Val-Met-Asn-His-
81 His-Val-Cys-Pro-Val-Glu-Asn-Tip-Ser-Tyr-
91 Asn-Glu-Ser-Cys-Pro-Pro-Asp-Pro-Ala-Glu-
101 Gln-Gly-Gly-Pro-Lys-Thr-Cys-Cys-Thr-Leu-
111 Asp-Asp-Val-Pro-Leu-Ile-Ser-Lys-Cys-Gly-
121 Ser-Tyr-Pro-Pro-Glu-Ser-Cys-Leu-Phe-Ser-
131 Leu-Ile-Gly-Asn-Met-Gly-Ala-Phe-Met-Val-
141 Ala-Leu-Ile-Cys-Leu-Leu-Arg-Tyr-Gly-Gln-
151 Leu-Leu-Glu-Gln-Ser-Arg-His-Ser-Tip-Val-
161 Asn-Thr-Thr-Ala-Leu-Ile-Thr-Gly-Cys-Thr-
171 Asn-Ala-Ala-Gly-Leu-Leu-Val-Val-Gly-Asn-
181 Phe-Gln-Val-Asp-His-Ala-Arg-Ser-Leu-His-
191 Tyr-Val-Gly-Ala-Gly-Val-Ala-Phe-Pro-Ala-
201 Gly-Leu-Leu-Phe-Val-Cys-Leu-His-Cys-Leu-
211 Ser-Pro-Thr-Lys-Gly-Pro-Pro-Pro-Arg-Tip-
221 Thr-Tip-Leu-Tip-Pro-Ile-Cys-Glu-Val-Cys-
231 Tip-Leu-Ser-Ser-Pro-Leu-Ser-Pro-Tip-Ser-
241 Ser-Val-Glu-Ser-Ser-Leu-Ser-Met-Arg-Val-
251 Leu-Ser-Cys-Asn-Met-Gly-Gln-Pro-Cys-Val-
261 Ser-Gly-Cys-Val-Ser-Ser-Ile-Ser-Ser-Phe-
271 Ser-Met-Ala-Pro-Ser-Ala-Thr-Ser-Leu-Gly-
281 Gln-Ser-Pro-Gln-Thr-His-Tip-Tip-Leu-His-
291 Cys-Ser-Leu-Pro-Leu-Ala-Gly-Pro-Ala-Ser-
301 Pro-Pro-Gly-Ala-Ala-Ala-Leu-His-Pro-Pro-
311 Gln-Leu-Cys-Pro-Arg-Glu-His-Arg-Tyr-Asp-

```

HITS AT: 63-90

L7 ANSWER 21 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN

AN AA82891 Protein DGENE

T1 New fragments of human fibrinogen, useful for treating conditions

IN associated with fibrinogen metabolism -

PA Greeninger G; Appligate D; Stoike-steben L

PI (NY&L-N) NEW YORK BLOOD CENT INC.

PRAT **WO 200009562 A1 20000224 66p**

DT US 1998-0518412 19980812

LA Patent

OS English

CR 2000-205983 [18]

DESC N-PSDB: AA293039

AN AA82891 Protein DGENE

SQL Alpha2 subunit of human fibrinogen.

847

36 A; 53 R; 45 N; 50 D; 0 B; 12 C; 30 Q; 64 E; 0 Z; 96 G; 19 H; 25 I;

47 L; 43 K; 13 M; 28 F; 41 P; 103S; 57 T; 18 W; 24 Y; 41 V; 0 Others

1 Ala-Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-

11 Glu-Gly-Gly-Gly-Val-Arg-Arg-Pro-Arg-Val-

21 Val-Glu-Arg-His-Gln-Ser-Ala-Cys-Lys-Asp-

31 Ser-Asp-Tip-Pro-Phe-Cys-Ser-Asp-Glu-Asp-

41 Tip-Asn-Tyr-Lys-Cys-Pro-Ser-Gly-Cys-Arg-

51 Met-Lys-Gly-Leu-Ile-Asp-Glu-Val-Asn-Gln-

61 Asp-Phe-Thr-Asn-Arg-Ile-Asn-Lys-Leu-Lys-

71 Asn-Ser-Leu-Phe-Glu-Tyr-Gln-Lys-Asn-Asn-

81 Lys-Asp-Ser-His-Ser-Leu-Thr-Thr-Asn-Ile-

91 Met-Glu-Ile-Leu-Arg-Gly-Asp-Phe-Ser-Ser-

101 Ala-Asn-Asn-Arg-Asp-Asn-Thr-Tyr-Asn-Arg-

111 Val-Ser-Glu-Asp-Leu-Arg-Ser-Arg-Ile-Glu-

121 Val-Leu-Lys-Arg-Lys-Val-Ile-Glu-Lys-Val-

131 Gln-His-Ile-Gln-Leu-Leu-Gln-Lys-Asn-Val-

141 Arg-Ala-Gln-Leu-Val-Asp-Met-Lys-Arg-Leu-

151 Glu-Val-Asp-Ile-Asp-Ile-Lys-Ile-Arg-Ser-

161 Cys-Arg-Gly-Ser-Cys-Ser-Arg-Ala-Leu-Ala-

171 Arg-Glu-Val-Asp-Leu-Lys-Asp-Tyr-Glu-Asp-

181 Gln-Gln-Lys-Gln-Leu-Glu-Val-Ile-Ala-

191 Lys-Asp-Leu-Leu-Pro-Ser-Arg-Arg-Arg-Gln-

201 His-Leu-Pro-Leu-Ile-Lys-Met-Lys-Pro-Val-

211 Pro-Asp-Leu-Val-Pro-Gly-Asn-Phe-Lys-Ser-

221 Gln-Leu-Gln-Lys-Val-Pro-Pro-Glu-Tip-Lys-

231 Ala-Leu-Thr-Asp-Met-Pro-Gln-Met-Arg-Met-

241 Lys-Leu-Glu-Arg-Pro-Gly-Gly-Asn-Glu-Ile-

251 Thr-Arg-Gly-Gly-Ser-Thr-Ser-Tyr-Gly-Thr-

261 Gly-Ser-Glu-Thr-Glu-Ser-Pro-Arg-Asn-Pro-

271 Ser-Ser-Ala-Gly-Ser-Tip-Asn-Ser-Gly-Ser-

281 Ser-Gly-Pro-Gly-Ser-Thr-Gly-Asn-Arg-Asp-

291 Pro-Gly-Ser-Ser-Gly-Thr-Gly-Gly-Thr-Ala-

301 Thr-Tip-Lys-Pro-Gly-Ser-Ser-Gly-Pro-Gly-

311 Ser-Thr-Gly-Ser-Tip-Asn-Ser-Gly-Ser-Ser-

321 Gly-Thr-Gly-Ser-Thr-Gly-Asn-Gln-Asn-Pro-

331 Gly-Ser-Pro-Arg-Pro-Gly-Ser-Thr-Gly-Thr-

341 Tip-Asn-Pro-Gly-Ser-Ser-Glu-Arg-Gly-Ser-

351 Ala-Gly-His-Thr-Thr-Ser-Glu-Ser-Ser-Val-

361 Ser-Gly-Ser-Thr-Gly-Gln-Tip-His-Ser-Glu-

371 Ser-Gly-Ser-Phe-Arg-Pro-Asp-Ser-Pro-Gly-

381 Ser-Gly-Asn-Ala-Arg-Pro-Asn-Asn-Pro-Asp-

391 Tip-Gly-Thr-Phe-Glu-Glu-Val-Ser-Gly-Asn-

401 Val-Ser-Pro-Gly-Thr-Arg-Arg-Glu-Tyr-His-

411 Thr-Glu-Lys-Leu-Val-Thr-Ser-Lys-Gly-Asp-

421 Lys-Glu-Leu-Arg-Thr-Gly-Lys-Glu-Lys-Val-

431 Thr-Ser-Gly-Ser-Thr-Thr-Thr-Thr-Arg-Arg-

441 Ser-Cys-Ser-Lys-Thr-Val-Thr-Lys-Thr-Val-

451 Ile-Gly-Pro-Asp-Gly-His-Lys-Glu-Val-Thr-

461 Lys-Glu-Val-Val-Thr-Ser-Glu-Asp-Gly-Ser-

471 Asp-Cys-Pro-Glu-Ala-Met-Asp-Leu-Gly-Thr-

481 Leu-Ser-Gly-Ile-Gly-Thr-Leu-Asp-Gly-Phe-

491 Arg-His-Arg-His-Pro-Asp-Glu-Ile-Ala-Phe-

501 Phe-Asp-Thr-Ala-Ser-Thr-Gly-Lys-Thr-Phe-

511 Pro-Gly-Phe-Phe-Ser-Pro-Met-Leu-Gly-Glu-

521 Phe-Val-Ser-Glu-Thr-Glu-Ser-Arg-Gly-Glu-

531 Glu-Ser-Gly-Ile-Phe-Thr-Asn-Thr-Lys-Glu-

541 Ser-Ser-Ser-His-His-Pro-Gly-Ile-Ala-Glu-

551 Phe-Pro-Ser-Arg-Gly-Lys-Ser-Ser-Ser-Tyr-

561 Ser-Lys-Gln-Phe-Thr-Ser-Ser-Thr-Ser-Tyr-

571 Asn-Arg-Gly-Asp-Ser-Thr-Phe-Glu-Ser-Lys-

581 Ser-Tyr-Lys-Met-Ala-Asp-Glu-Ala-Gly-Ser-

591 Glu-Ala-Asp-His-Glu-Gly-Thr-His-Ser-Thr-

601 Lys-Arg-Gly-His-Ala-Lys-Ser-Arg-Pro-Val-

611 Arg-Asp-Cys-Asp-Asp-Val-Leu-Gln-Thr-His-

621 Pro-Ser-Gly-Thr-Gln-Ser-Gly-Ile-Phe-Asn-

631 Ile-Lys-Leu-Pro-Gly-Ser-Ser-Lys-Ile-Phe-

641 Ser-Val-Tyr-Cys-Asp-Gln-Gln-Thr-Ser-Leu-

651 Gly-Gly-Tip-Leu-Leu-Ile-Gln-Gln-Arg-Met-

661 Asp-Gly-Ser-Leu-Asn-Phe-Asn-Arg-Thr-Tip-

671 Gln-Asp-Tyr-Lys-Arg-Gly-Phe-Gly-Ser-Leu-

681 Asn-Asp-Gly-Gly-Glu-Gly-Phe-Thr-Tip-Leu-

691 Gly-Asn-Asp-Tyr-Leu-His-Leu-Thr-Gln-

701 Arg-Gly-Ser-Val-Leu-Arg-Val-Glu-Leu-Glu-

711 Asp-Tip-Ala-Gly-Asn-Glu-Ala-Tyr-Ala-Glu-

721 Tyr-His-Phe-Arg-Val-Gly-Ser-Glu-Ala-Glu-

731 Gly-Tyr-Ala-Leu-Glu-Val-Ser-Ser-Tyr-Glu-

741 Gly-Thr-Ala-Leu-Gly-Asp-Ala-Leu-Ile-Glu-Gly-

751 Ser-Val-Glu-Glu-Gly-Ala-Glu-Tyr-Thr-Ser-

761 His-Asn-Asn-Met-Gln-Phe-Ser-Thr-Phe-Asp-

771 Arg-Asp-Ala-Asp-Gln-Tip-Glu-Glu-Asn-Cys-

781 Ala-Glu-Val-Tyr-Gly-Gly-Gly-Tip-Tip-Tyr-

791 Asn-Asn-Cys-Gln-Ala-Ala-Asn-Leu-Asp-Gly-
801 Ile-Tyr-Tyr-Pro-Gly-Gly-Ser-Tyr-Asp-Pro-
811 Arg-Asn-Asn-Ser-Pro-Tyr-Glu-Ile-Glu-Asn-
821 Gly-Val-Val-Tip-Val-Ser-Phe-Arg-Gly-Ala-
831 Asp-Tyr-Ser-Leu-Arg-Ala-Val-Arg-Met-Lys-
841 Ile-Arg-Pro-Leu-Val-Thr-Gln

HITS AT: 36-43

L7 ANSWER 22 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAB38373 Protein DGENE
TI New nucleic acid molecules encoding 62 human secreted proteins for
diagnosing, preventing, treating or ameliorating medical conditions and
used as food additives or preservatives -
Ruben S M; Nt J; Komatsoulis G A; Rosen C A; Soppet D R; Shi Y; Lafleur D
W; Olsen H S; Ebner R; Florence K A; Moore P A; Birse C E; Young P E
PA (HMA-N) HUMAN GENE SCI INC. 716p***
PI ***WO 2000061623 A1 20001019
AI WO 2000-US8979 20000406
PRAI US 1999-128693 19990409
US 1999-130991 19990426
DT Patent
LA English
OS 2000-647418 (62)
DESC Human secreted protein encoded by gene 53 clone HFABG18.
AN AAB38373 Protein DGENE
AA 10 A; 1 R; 3 N; 4 D; 0 B; 4 C; 1 Q; 4 E; 0 Z; 6 G; 2 H; 4 I; 9
L; 1 K; 3 M; 1 F; 11 P; 7 S; 5 T; 3 W; 2 Y; 6 V; 1 Others
SQL 88
SEQ3

1 Met-Thr-Ala-Tip-Ile-Leu-Leu-Pro-Val-Ser-
11 Leu-Ser-Ala-Phe-Ser-Ile-Thr-Gly-Ile-Tip-
21 Thr-Val-Tyr-Ala-Met-Ala-Val-Met-Asn-His-
31 His-Val-Cys-Pro-Val-Glu-Asn-Tip-Ser-Tyr-
41 Asn-Glu-Ser-Cys-Pro-Pro-Asp-Pro-Ala-Glu-
51 Gln-Gly-Gly-Pro-Lys-Thr-Cys-Cys-Thr-Leu-
61 Asp-Asp-Val-Pro-Leu-Ile-Ser-Gly-Pro-Asp-
71 Leu-Pro-Pro-Ala-Leu-Arg-Ala-Ala-Pro-Gly-
81 Ala-Glu-Ser-Ala-Leu-Leu-Gly-Xxx

HITS AT: 33-40

L7 ANSWER 23 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAB18985 Protein DGENE
TI New human transmembrane proteins are used to treat a disease or condition
associated with decreased expression of functional HTPF e.g. Tourette's
disorder, angina and leukaemia -
Yue H; Lal P; Tang Y T; Hillman J L; Reddy R; Bandman O; Baughn M R; Lu D
A M; Azimzal Y; Yang J
PA (INCY-N) INCYTE PHARM INC. 130p***
PI ***WO 2000056891 A2 20000928
AI WO 2000-US7817 20000322
PRAI US 1999-128537 19990322
US 1999-139565 19990616
DT Patent
LA English
OS 2000-579485 (54)
CR N-PSDB: AAB96496

DESC Amino acid sequence of a human transmembrane protein.
AN AAB18985 Protein DGENE
AA 29 A; 5 R; 8 N; 7 D; 0 B; 14 C; 8 Q; 9 E; 0 Z; 20 G; 9 H; 14 I;
32 L; 3 K; 6 M; 12 F; 14 P; 27 S; 16 T; 5 W; 9 Y; 24 V; 0 Others
SQL 271
SEQ3

1 Met-Thr-Ala-Tip-Ile-Leu-Leu-Pro-Val-Ser-
11 Leu-Ser-Ala-Phe-Ser-Ile-Thr-Gly-Ile-Tip-
21 Thr-Val-Tyr-Ala-Met-Ala-Val-Met-Asn-His-
31 His-Val-Cys-Pro-Val-Glu-Asn-Tip-Ser-Tyr-
41 Asn-Glu-Ser-Cys-Pro-Pro-Asp-Pro-Ala-Glu-
51 Gln-Gly-Gly-Pro-Lys-Thr-Cys-Cys-Thr-Leu-
61 Asp-Asp-Val-Pro-Leu-Ile-Ser-Lys-Cys-Gly-
71 Ser-Tyr-Pro-Pro-Glu-Ser-Cys-Leu-Phe-Ser-
81 Leu-Ile-Gly-Asn-Met-Gly-Ala-Phe-Met-Val-
91 Ala-Leu-Ile-Cys-Leu-Leu-Arg-Tyr-Gly-Gln-
101 Leu-Leu-Glu-Gln-Ser-Arg-His-Ser-Tip-Val-
111 Asn-Thr-Thr-Ala-Leu-Ile-Thr-Gly-Cys-Thr-
121 Asn-Ala-Ala-Gly-Leu-Leu-Val-Val-Gly-Asn-
131 Phe-Gln-Val-Asp-His-Ala-Arg-Ser-Leu-His-
141 Tyr-Val-Gly-Ala-Gly-Val-Ala-Phe-Pro-Ala-
151 Gly-Leu-Leu-Phe-Val-Cys-Leu-His-Cys-Ala-
161 Leu-Ser-Tyr-Gln-Gly-Ala-Thr-Ala-Pro-Leu-
171 Asp-Leu-Ala-Val-Ala-Tyr-Leu-Arg-Ser-Val-
181 Leu-Ala-Val-Ile-Ala-Phe-Ile-Thr-Leu-Val-
191 Leu-Ser-Gly-Val-Phe-Phe-Val-His-Glu-Ser-
201 Ser-Gln-Leu-Gln-His-Gly-Ala-Ala-Leu-Cys-
211 Glu-Tip-Val-Cys-Val-Ile-Asp-Ile-Leu-Ile-
221 Phe-Tyr-Gly-Thr-Phe-Ser-Tyr-Glu-Phe-Gly-
231 Ala-Val-Ser-Ser-Asp-Thr-Leu-Val-Ala-Ala-
241 Leu-Gln-Pro-Thr-Pro-Gly-Arg-Ala-Cys-Lys-
251 Ser-Ser-Gly-Ser-Ser-Ser-Thr-Ser-Thr-His-
261 Leu-Asn-Cys-Ala-Pro-Glu-Ser-Ile-Ala-Met-
271 Ile

HITS AT: 33-40

FEATURE TABLE:
Key | Location | Qualifier |
=====|=====|=====|
Peptide |1..21 | |note | "signal peptide"
Modified-site |37 | |note | "potential glycosylation site"
Modified-site |39 | |note | "potential phosphorylation site"
Modified-site |41 | |note | "potential glycosylation site"
Modified-site |39 | |note | "potential phosphorylation site"
Modified-site |111 | |note | "potential glycosylation site"

L7 ANSWER 24 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAB54155 Protein DGENE
TI New nucleic acid that is a pancreatic cancer antigen for preventing,
treating, or ameliorating a medical condition, particularly pancreatic
cancer, or for use in assays for diagnosing a pathological condition -

IN Rosen C A; Ruben S M
PA (HMAN-N) HUMAN GENOME SCI INC.
PI ***WO 2000053320 A1 20000921 999p***
AI WO 2000-055989 20000308
PRAI US 1999-124270 19990312
DT Patent
LA English
OS 2000-579444 [54]
CR N-SSDS: AAC98900
DESC Human pancreatic cancer antigen protein sequence SEQ ID NO:587.
AN AAB54135 Protein DGENE
AA 13 A; 27 R; 20 N; 22 D; 0 B; 7 C; 15 Q; 26 E; 0 Z; 22 G; 4 H; 14 I;
34 L; 27 K; 9 M; 7 F; 22 P; 29 S; 14 T; 15 W; 6 Y; 21 V; 6 Others
SOL 360
SEQ3

1 Leu-Asn-Pro-Gly-Arg-Pro-Ala-Arg-Pro-Val-
11 Leu-Leu-Arg-Ser-Xxx-Ala-Pro-Pro-Leu-Glu-
21 Lys-Met-Phe-Ser-Met-Arg-Ile-Val-Cys-Leu-
31 Val-Leu-Ser-Val-Val-Gly-Thr-Ala-Trp-Thr-
41 Ala-Asp-Ser-Gly-Gly-Val-Arg-Phe-Leu-Ala-
51 Glu-Gly-Gly-Gly-Val-Arg-Gly-Pro-Arg-Val-
61 Val-Glu-Arg-His-Gln-Ser-Ala-Cys-Lys-Asp-
71 Ser-Asp-Trp-Pro-Phe-Cys-Ser-Asp-Glu-Asp-
81 Trp-Asn-Tyr-Lys-Cys-Pro-Ser-Gly-Cys-Arg-
91 Met-Lys-Gly-Leu-Ile-Asp-Glu-Val-Asn-Gln-
101 Asp-Phe-Thr-Asn-Arg-Ile-Asn-Lys-Leu-Lys-
111 Asn-Ser-Leu-Phe-Glu-Tyr-Gln-Lys-Asn-Asn-
121 Lys-Asp-Ser-His-Ser-Leu-Thr-Thr-Asn-Ile-
131 Met-Glu-Ile-Leu-Arg-Gly-Asp-Phe-Ser-Ser-
141 Ala-Asn-Asn-Arg-Asp-Asn-Thr-Tyr-Asn-Arg-
151 Val-Ser-Glu-Asp-Leu-Arg-Ser-Arg-Ile-Glu-
161 Val-Leu-Lys-Arg-Lys-Val-Ile-Glu-Lys-Val-
171 Gln-His-Ile-Gln-Leu-Leu-Gln-Lys-Asn-Val-
181 Arg-Ala-Gln-Leu-Val-Asp-Met-Lys-Arg-Leu-
191 Glu-Val-Asp-Ile-Asp-Ile-Lys-Ile-Arg-Ser-
201 Cys-Arg-Gly-Ser-Cys-Ser-Arg-Ala-Leu-Ala-
211 Arg-Glu-Val-Asp-Leu-Lys-Asp-Tyr-Glu-Asp-
221 Gln-Gln-Lys-Gln-Leu-Glu-Gln-Val-Ile-Ala-
231 Lys-Asp-Leu-Leu-Pro-Ser-Arg-Asp-Arg-Gln-
241 His-Leu-Pro-Leu-Ile-Lys-Met-Lys-Pro-Val-
251 Pro-Asp-Leu-Val-Pro-Gly-Asn-Phe-Lys-Ser-
261 Gln-Leu-Gln-Lys-Val-Pro-Pro-Glu-Trp-Lys-
271 Ala-Leu-Thr-Asp-Met-Pro-Gln-Met-Arg-Met-
281 Glu-Leu-Glu-Arg-Pro-Gly-Gly-Asn-Glu-Ile-
291 Thr-Arg-Gly-Gly-Ser-Thr-Ser-Tyr-Glu-Thr-
301 Gly-Ser-Glu-Thr-Glu-Ser-Pro-Arg-Asn-Pro-
311 Ser-Ser-Ala-Gly-Xxx-Trp-Asn-Ser-Gly-Ser-
321 Ser-Gly-Thr-Trp-Xxx-Xxx-Xxx-Asn-Leu-Glu-
331 Thr-Trp-Glu-Leu-Trp-Thr-Trp-Lys-Xxx-Trp-
341 Lys-Leu-Glu-Leu-Trp-Glu-Leu-Trp-Asn-Trp-
351 Lys-Tyr-Trp-Lys-Pro-Lys-Pro-Trp-Glu-Pro
HITS AT: 76-83

L7 ANSWER 25 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on SIN
AN AAB19796 Protein DGENE

TI Purified laminin 2 protein, useful for research and therapeutic purposes
including peripheral nerve regeneration, treatment of degenerative muscle
disorders, angiogenesis regulation, and ex vivo cell therapy -
Yurchenco P
IN (UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PA ***WO 2000066730 A2 20001109 305p***
PI WO 2000-US11378 20000428
AI US 1999-131720 19990430
PRAI US 1999-139198 19990615
US 1999-143289 19990712
US 1999-155945 19990924
DT Patent
LA English
OS 2000-687537 [67]
CR N-PSDB: AAB8896
DESC Mouse laminin 2 mature alpha-2 chain.
AN AAB19796 Protein DGENE
AA 183A; 163R; 161D; 0 B; 161C; 123Q; 206E; 0 Z; 255G; 65 H; 166I;
242L; 171K; 43 M; 101F; 175P; 207S; 187T; 27 W; 99 Y; 165V; 0 Others
SOL 3084
SEQ3

1 Gln-Arg-Arg-Gln-Ser-Gln-Ala-His-Gln-Gln-
11 Arg-Gly-Leu-Phe-Pro-Ala-Val-Leu-Asn-Leu-
21 Ala-Ser-Asn-Ala-Leu-Ile-Thr-Thr-Asn-Ala-
31 Thr-Cys-Gly-Glu-Lys-Gly-Pro-Glu-Met-Tyr-
41 Cys-Lys-Leu-Val-Glu-His-Val-Pro-Gly-Gln-
51 Pro-Val-Arg-Asn-Pro-Gln-Cys-Arg-Ile-Cys-
61 Asn-Gln-Asn-Ser-Ser-Asn-Pro-Tyr-Gln-Arg-
71 His-Pro-Ile-Thr-Asn-Ala-Ile-Asp-Gly-Lys-
81 Asn-Thr-Trp-Trp-Gln-Ser-Pro-Ser-Ile-Lys-
91 Asn-Gly-Val-Glu-Tyr-His-Tyr-Val-Thr-Ile-
101 Thr-Leu-Asp-Leu-Gln-Gln-Val-Phe-Gln-Ile-
111 Ala-Tyr-Val-Ile-Val-Lys-Ala-Ala-Asn-Ser-
121 Pro-Arg-Pro-Gly-Asn-Trp-Ile-Leu-Asp-Arg-
131 Ser-Leu-Asp-Asp-Val-Glu-Tyr-Lys-Pro-Trp-
141 Gln-Tyr-His-Ala-Val-Thr-Asp-Thr-Glu-Cys-
151 Leu-Thr-Leu-Tyr-Asn-Ile-Tyr-Pro-Arg-Thr-
161 Gly-Pro-Pro-Ser-Tyr-Ala-Lys-Asp-Asp-Glu-
171 Val-Ile-Cys-Thr-Ser-Phe-Tyr-Ser-Lys-Ile-
181 His-Pro-Leu-Glu-Asn-Gly-Glu-Ile-His-Ile-
191 Ser-Leu-Ile-Asn-Gly-Arg-Pro-Ser-Ala-Asp-
201 Asp-Pro-Ser-Pro-Glu-Leu-Leu-Glu-Phe-Thr-
211 Ser-Ala-Arg-Tyr-Ile-Arg-Leu-Leu-Arg-Phe-Gln-
221 Arg-Ile-Arg-Thr-Leu-Asn-Ala-Asp-Leu-Met-
231 Met-Phe-Ala-His-Lys-Asp-Pro-Arg-Glu-Ile-
241 Asp-Pro-Ile-Val-Thr-Arg-Arg-Tyr-Tyr-Tyr-
251 Ser-Val-Lys-Asp-Ile-Ser-Val-Gly-Gly-Met-
261 Cys-Ile-Cys-Tyr-Gly-His-Ala-Arg-Ala-Cys-
271 Pro-Leu-Asp-Pro-Ala-Thr-Asn-Lys-Ser-Arg-
281 Cys-Glu-Cys-Glu-His-Asn-Thr-Cys-Ser-Glu-
291 Ser-Cys-Asp-Arg-Cys-Pro-Gly-Phe-Ile-
301 Gln-Lys-Pro-Trp-Arg-Ala-Gly-Thr-Phe-Leu-
311 Thr-Lys-Ser-Glu-Cys-Glu-Ala-Cys-Asn-Cys-
321 His-Gly-Lys-Ala-Glu-Glu-Cys-Tyr-Tyr-Asp-
331 Glu-Thr-Val-Ala-Ser-Arg-Asn-Leu-Ser-Leu-
341 Asn-Ile-His-Gly-Lys-Tyr-Ile-Gly-Gly-Gly-
351 Val-Cys-Ile-Asn-Cys-Thr-His-Asn-Thr-Ala-

361 Gly-Ile-Asn-Cys-Glu-Thr-Cys-Val-Asp-Gly-
371 Phe-Phe-Arg-Pro-Lys-Gly-Val-Ser-Pro-Asn-
381 Tyr-Pro-Arg-Pro-Cys-Gln-Pro-Cys-His-Cys-
391 Asp-Pro-Thr-Gly-Ser-Leu-Ser-Glu-Val-Cys-
401 Val-Lys-Asp-Glu-Lys-Tyr-Ala-Gln-Arg-Gly-
411 Leu-Lys-Pro-Gly-Ser-Cys-His-Cys-Lys-Thr-
421 Gly-Phe-Gly-Val-Asn-Cys-Asp-Arg-Cys-
431 Val-Arg-Gly-Tyr-His-Gly-Tyr-Pro-Asp-Cys-
441 Gln-Pro-Cys-Asn-Cys-Ser-Gly-Leu-Gly-Ser-
451 Thr-Asn-Glu-Asp-Pro-Cys-Val-Gly-Pro-Cys-
461 Ser-Cys-Lys-Glu-Asn-Val-Glu-Gly-Glu-Asp-
471 Cys-Ser-Arg-Cys-Lys-Ser-Gly-Phe-Phe-Asn-
481 Leu-Gln-Glu-Asp-Asn-Gln-Lys-Gly-Cys-Glu-
491 Glu-Cys-Phe-Cys-Ser-Gly-Val-Ser-Asn-Arg-
501 Cys-Gln-Ser-Ser-Tyr-Trp-Thr-Tyr-Gly-Asn-
511 Ile-Gln-Asp-Met-Arg-Gly-Trp-Tyr-Leu-Thr-
521 Asp-Leu-Ser-Gly-Arg-Ile-Arg-Met-Ala-Pro-
531 Gln-Leu-Asp-Asn-Pro-Asp-Ser-Pro-Gln-Gln-
541 Ile-Ser-Ile-Ser-Asn-Ser-Glu-Ala-Arg-Lys-
551 Ser-Leu-Leu-Asp-Gly-Tyr-Tyr-Trp-Ser-Ala-
561 Pro-Pro-Pro-Tyr-Leu-Gly-Asn-Arg-Leu-Pro-
571 Ala-Val-Gly-Gly-Gln-Ileu-Ser-Phe-Thr-Ile-
581 Ser-Tyr-Asp-Leu-Leu-Gln-Glu-Glu-Asp-Asp-
591 Thr-Glu-Lys-Leu-Leu-Gln-Leu-Met-Ile-Ile-
601 Phe-Glu-Gly-Asn-Asp-Leu-Arg-Ile-Ser-Thr-
611 Ala-Tyr-Lys-Glu-Val-Tyr-Leu-Glu-Pro-Ser-
621 Glu-Glu-His-Val-Glu-Glu-Val-Ser-Leu-Lys-
631 Glu-Glu-Ala-Phe-Thr-Ile-His-Gly-Thr-Asn-
641 Leu-Pro-Val-Thr-Arg-Lys-Asp-Phe-Met-Ile-
651 Val-Leu-Thr-Asn-Leu-Gly-Glu-Ile-Leu-Ile-
661 Gln-Ile-Thr-Tyr-Asn-Leu-Gly-Met-Asp-Ala-
671 Ile-Phe-Arg-Leu-Ser-Ser-Val-Asn-Leu-Glu-
681 Ser-Pro-Val-Pro-Tyr-Pro-Thr-Asp-Arg-Arg-
691 Ile-Ala-Thr-Asp-Val-Glu-Val-Cys-Gln-Cys-
701 Pro-Pro-Gly-Tyr-Ser-Gly-Ser-Ser-Cys-Glu-
711 Thr-Cys-Trp-Pro-Arg-His-Arg-Arg-Val-Asn-
721 Gly-Thr-Ile-Phe-Gly-Gly-Ile-Cys-Glu-Pro-
731 Cys-Gln-Cys-Phe-Ala-His-Ala-Glu-Ala-Cys-
741 Asp-Asp-Ile-Thr-Gly-Glu-Cys-Leu-Asn-Cys-
751 Lys-Asp-His-Thr-Gly-Gly-Pro-Tyr-Cys-Asn-
761 Glu-Cys-Leu-Pro-Gly-Phe-Tyr-Gly-Asp-Pro-
771 Thr-Arg-Gly-Ser-Pro-Glu-Asp-Cys-Gln-Pro-
781 Cys-Ala-Cys-Pro-Leu-Asn-Ile-Pro-Ser-Asn-
791 Asn-Phe-Ser-Pro-Thr-Cys-His-Leu-Asp-Arg-
801 Ser-Leu-Gly-Leu-Ile-Cys-Asp-Glu-Cys-Pro-
811 Ile-Gly-Tyr-Thr-Gly-Pro-Arg-Cys-Glu-Arg-
821 Cys-Ala-Glu-Gly-Tyr-Phe-Gly-Gln-Pro-Ser-
831 Val-Pro-Gly-Gly-Ser-Cys-Gln-Pro-Cys-Gln-
841 Cys-Asn-Asp-Asn-Leu-Asp-Tyr-Ser-Ile-Pro-
851 Gly-Ser-Cys-Asp-Ser-Leu-Ser-Gly-Ser-Cys-
861 Leu-Ile-Cys-Lys-Pro-Gly-Thr-Thr-Gly-Arg-
871 Tyr-Cys-Glu-Leu-Cys-Ala-Asp-Gly-Tyr-Phe-
881 Gly-Asp-Ala-Val-Asn-Thr-Lys-Asn-Cys-Gln-
891 Pro-Cys-Arg-Cys-Asp-Ile-Asn-Gly-Ser-Phe-
901 Ser-Glu-Asp-Cys-His-Thr-Arg-Thr-Gly-Gln-
911 Cys-Glu-Cys-Arg-Pro-Asn-Val-Gln-Gly-Arg-

921 His-Cys-Asp-Glu-Glu-Cys-Lys-Pro-Glu-Thr-Phe-
931 Gly-Leu-Gln-Leu-Gly-Arg-Gly-Cys-Leu-Pro-
941 Cys-Asn-Cys-Asn-Ser-Phe-Gly-Ser-Lys-Ser-
951 Phe-Asp-Cys-Glu-Ala-Ser-Gly-Gln-Cys-Trp-
961 Cys-Gln-Pro-Gly-Val-Ala-Gly-Lys-Cys-
971 Asp-Arg-Cys-Ala-His-Gly-Tyr-Phe-Asn-Phe-
981 Gln-Glu-Gly-Gly-Cys-Ile-Ala-Cys-Asp-Cys-
991 Ser-His-Leu-Gly-Asn-Asn-Cys-Asp-Pro-Lys-
1001 Thr-Gly-Gln-Cys-Ile-Cys-Pro-Pro-Asn-Thr-
1011 Thr-Gly-Glu-Lys-Cys-Ser-Glu-Cys-Leu-Pro-
1021 Asn-Thr-Trp-Gly-His-Ser-Ile-Val-Thr-Gly-
1031 Cys-Lys-Val-Cys-Asn-Cys-Ser-Thr-Val-Gly-
1041 Ser-Leu-Ala-Ser-Gln-Cys-Asn-Val-Asn-Thr-
1051 Gly-Gln-Cys-Ser-Cys-His-Pro-Lys-Phe-Ser-
1061 Gly-Met-Lys-Cys-Ser-Glu-Cys-Ser-Arg-Gly-
1071 His-Trp-Asn-Tyr-Pro-Leu-Cys-Thr-Leu-Cys-
1081 Asp-Cys-Phe-Leu-Pro-Gly-Thr-Asp-Ala-Thr-
1091 Thr-Cys-Asp-Leu-Glu-Thr-Arg-Lys-Cys-Ser-
1101 Cys-Ser-Asp-Gln-Thr-Gly-Gln-Cys-Ser-Cys-
1111 Lys-Val-Asn-Val-Glu-Gly-Val-His-Cys-Asp-
1121 Arg-Cys-Arg-Pro-Gly-Lys-Phe-Gly-Leu-Asp-
1131 Ala-Lys-Asn-Pro-Leu-Gly-Cys-Ser-Ser-Cys-
1141 Tyr-Cys-Phe-Gly-Val-Thr-Ser-Gln-Cys-Ser-
1151 Glu-Ala-Lys-Gly-Leu-Ile-Arg-Thr-Trp-Val-
1161 Thr-Leu-Ser-Asp-Glu-Gln-Thr-Ile-Leu-Pro-
1171 Leu-Val-Asp-Glu-Ala-Leu-Gln-His-Thr-Thr-
1181 Thr-Lys-Gly-Ile-Ala-Phe-Gln-Lys-Pro-Glu-
1191 Ile-Val-Ala-Lys-Met-Asp-Glu-Val-Arg-Gln-
1201 Glu-Leu-His-Leu-Glu-Pro-Phe-Tyr-Trp-Lys-
1211 Leu-Pro-Gln-Gln-Phe-Glu-Gly-Lys-Leu-
1221 Met-Ala-Tyr-Gly-Gly-Lys-Leu-Lys-Tyr-Ala-
1231 Ile-Tyr-Phe-Glu-Ala-Arg-Asp-Glu-Thr-Gly-
1241 Phe-Ala-Thr-Tyr-Lys-Pro-Gln-Val-Ile-Ile-
1251 Arg-Gly-Gly-Thr-Pro-Thr-His-Ala-Arg-Ile-
1261 Ile-Thr-Arg-His-Met-Ala-Ala-Pro-Leu-Ile-
1271 Gly-Gln-Leu-Thr-Arg-His-Glu-Ile-Glu-Met-
1281 Thr-Glu-Lys-Glu-Trp-Lys-Tyr-Tyr-Gly-Asp-
1291 Asp-Pro-Arg-Ile-Ser-Arg-Thr-Val-Thr-Arg-
1301 Glu-Asp-Phe-Leu-Asp-Ile-Leu-Tyr-Asp-Ile-
1311 His-Tyr-Ile-Leu-Ile-Lys-Ala-Thr-Tyr-Gly-
1321 Asn-Val-Val-Arg-Gln-Ser-Arg-Ile-Ser-Glu-
1331 Ile-Ser-Met-Glu-Val-Ala-Glu-Pro-Gly-His-
1341 Val-Leu-Ala-Gly-Ser-Pro-Pro-Ala-His-Leu-
1351 Ile-Glu-Arg-Cys-Asp-Cys-Pro-Pro-Gly-Tyr-
1361 Ser-Gly-Leu-Ser-Cys-Glu-Thr-Cys-Ala-Pro-
1371 Gly-Phe-Tyr-Arg-Leu-Arg-Ser-Glu-Pro-Gly-
1381 Gly-Arg-Thr-Pro-Gly-Pro-Thr-Leu-Gly-Thr-
1391 Cys-Val-Pro-Cys-Gln-Cys-Asn-Gly-His-Ser-
1401 Ser-Gln-Cys-Asp-Pro-Glu-Thr-Ser-Val-Cys-
1411 Gln-Asn-Cys-Gln-His-His-Thr-Ala-Gly-Asp-
1421 Phe-Cys-Glu-Arg-Cys-Ala-Leu-Gly-Tyr-Tyr-
1431 Gly-Ile-Val-Arg-Gly-Leu-Pro-Asn-Asp-Cys-
1441 Gln-Pro-Cys-Ala-Cys-Pro-Leu-Ile-Ser-Pro-
1451 Ser-Asn-Asn-Phe-Ser-Pro-Ser-Cys-Val-Leu-
1461 Glu-Gly-Leu-Glu-Asp-Tyr-Arg-Cys-Thr-Ala-
1471 Cys-Pro-Arg-Gly-Tyr-Glu-Gly-Gln-Tyr-Cys-
1481 Glu-Arg-Cys-Ala-Pro-Gly-Tyr-Thr-Gly-Ser-

1491 Pro-Ser-Ser-Pro-Gly-Gly-Ser-Cys-Gln-Glu-
1501 Cys-Glu-Cys-Asp-Pro-Tyr-Gly-Ser-Leu-Pro-
1511 Val-Pro-Cys-Arg-Arg-Val-Thr-Gly-Leu-Cys-
1521 Thr-Cys-Arg-Pro-Gly-Ala-Thr-Gly-Arg-Lys-
1531 Cys-Asp-Gly-Cys-Glu-His-Trp-His-Ala-Arg-
1541 Glu-Gly-Ala-Glu-Cys-Val-Phe-Cys-Gly-Asp-
1551 Glu-Cys-Thr-Gly-Leu-Leu-Leu-Gly-Asp-Leu-
1561 Ala-Arg-Leu-Glu-Gln-Met-Thr-Met-Asn-Ile-
1571 Asn-Leu-Thr-Gly-Pro-Leu-Pro-Ala-Pro-Tyr-
1581 Lys-Ile-Leu-Tyr-Gly-Leu-Glu-Asn-Thr-Thr-
1591 Gln-Glu-Leu-Lys-His-Leu-Leu-Ser-Pro-Gln-
1601 Arg-Ala-Pro-Glu-Arg-Leu-Ile-Gln-Leu-Ala-
1611 Glu-Gly-Asn-Val-Asn-Thr-Leu-Val-Met-Glu-
1621 Thr-Asn-Glu-Leu-Leu-Thr-Arg-Ala-Thr-Lys-
1631 Val-Thr-Ala-Asp-Gly-Glu-Gln-Thr-Gly-Gln-
1641 Asp-Ala-Glu-Arg-Thr-Asn-Ser-Arg-Ala-Glu-
1651 Ser-Leu-Glu-Glu-Phe-Ile-Lys-Gly-Leu-Val-
1661 Gln-Asp-Ala-Glu-Ala-Ile-Asn-Glu-Lys-Ala-
1671 Val-Lys-Leu-Asn-Glu-Thr-Leu-Gly-Asn-Gln-
1681 Asp-Lys-Thr-Ala-Arg-Asn-Leu-Glu-Glu-
1691 Leu-Gln-Lys-Glu-Ile-Asp-Arg-Met-Leu-Lys-
1701 Glu-Leu-Arg-Ser-Lys-Asp-Leu-Gln-Thr-Gln-
1711 Lys-Glu-Val-Ala-Glu-Asp-Glu-Leu-Val-Ala-
1721 Ala-Glu-Gly-Leu-Leu-Lys-Arg-Val-Asn-Lys-
1731 Leu-Phe-Gly-Glu-Pro-Arg-Ala-Gln-Asn-Lys-
1741 Asp-Met-Glu-Lys-Asp-Leu-Gln-Gln-Lys-Leu-
1751 Ala-Glu-Tyr-Lys-Asn-Lys-Leu-Asp-Ala-
1761 Trp-Asp-Leu-Leu-Arg-Glu-Ala-Thr-Asp-Lys-
1771 Thr-Arg-Asp-Ala-Asn-Arg-Leu-Ser-Ala-Ala-
1781 Asn-Gln-Lys-Asn-Met-Thr-Ile-Leu-Glu-Thr-
1791 Lys-Lys-Glu-Ala-Ile-Glu-Gly-Ser-Lys-Arg-
1801 Gln-Ile-Glu-Asn-Thr-Leu-Lys-Glu-Gly-Asn-
1811 Asp-Ile-Leu-Asp-Glu-Ala-Asn-Gln-Leu-Leu-
1821 Gly-Glu-Ile-Asn-Ser-Val-Ile-Asp-Tyr-Val-
1831 Asp-Asp-Ile-Lys-Thr-Lys-Leu-Pro-Met-
1841 Ser-Glu-Glu-Leu-Ser-Asp-Lys-Ile-Asp-Asp-
1851 Leu-Ala-Gln-Glu-Ile-Lys-Asp-Arg-Arg-Leu-
1861 Ala-Glu-Lys-Val-Phe-Gln-Ala-Glu-Ser-His-
1871 Ala-Ala-Gln-Leu-Asn-Asp-Ser-Ser-Ala-Val-
1881 Leu-Asp-Gly-Ile-Leu-Asp-Glu-Ala-Lys-Asn-
1891 Ile-Ser-Phe-Asn-Ala-Thr-Ala-Phe-Arg-
1901 Ala-Tyr-Ser-Asn-Ile-Lys-Asp-Tyr-Ile-Asp-
1911 Glu-Ala-Glu-Lys-Val-Ala-Arg-Glu-Ala-Lys-
1921 Glu-Leu-Ala-Gln-Gly-Ala-Thr-Lys-Leu-Ala-
1931 Thr-Ser-Pro-Gln-Gly-Leu-Leu-Lys-Glu-Asp-
1941 Ala-Lys-Gly-Ser-Leu-Gln-Lys-Ser-Phe-Arg-
1951 Ile-Leu-Asn-Glu-Ala-Lys-Leu-Ala-Asn-
1961 Asp-Val-Lys-Gly-Asn-His-Asn-Asp-Leu-Asn-
1971 Asp-Leu-Lys-Thr-Arg-Leu-Glu-Thr-Ala-Asp-
1981 Leu-Arg-Asn-Ser-Gly-Leu-Leu-Gly-Ala-Leu-
1991 Asn-Asp-Thr-Met-Asp-Lys-Leu-Ser-Ala-Ile-
2001 Thr-Asn-Asp-Thr-Ala-Ala-Lys-Leu-Gln-Ala-
2011 Val-Lys-Glu-Lys-Ala-Arg-Lys-Leu-Asn-Asp-
2021 Thr-Ala-Lys-Ala-Val-Leu-Ala-Gln-Val-Lys-
2031 Asp-Leu-His-Gln-Asn-Leu-Asp-Gly-Leu-Lys-
2041 Gln-Asn-Tyr-Asn-Lys-Leu-Ala-Asp-Ser-Val-
2051 Ala-Lys-Thr-Asn-Ala-Val-Val-Lys-Asp-Pro-

2061 Ser-Lys-Asn-Lys-Ile-Ile-Ala-Asp-Ala-Gly-
2071 Thr-Ser-Val-Arg-Asn-Leu-Glu-Gln-Glu-Ala-
2081 Asp-Arg-Leu-Ile-Asp-Lys-Leu-Lys-Pro-Ile-
2091 Lys-Glu-Leu-Glu-Asp-Asn-Leu-Lys-Asn-
2101 Ile-Ser-Glu-Ile-Lys-Glu-Leu-Ile-Asn-Gln-
2111 Ala-Arg-Lys-Gln-Ala-Asn-Ser-Ile-Lys-Val-
2121 Ser-Val-Ser-Ser-Gly-Gly-Asp-Cys-Val-Arg-
2131 Thr-Tyr-Arg-Pro-Glu-Ile-Lys-Lys-Gly-Ser-
2141 Tyr-Asn-Asn-Ile-Val-Val-His-Val-Lys-Thr-
2151 Ala-Val-Ala-Asp-Asn-Leu-Leu-Phe-Tyr-Leu-
2161 Gly-Ser-Ala-Lys-Phe-Ile-Asp-Phe-Leu-Ala-
2171 Ile-Glu-Met-Arg-Lys-Gly-Lys-Val-Ser-Phe-
2181 Leu-Trp-Ile-Val-Gly-Ser-Gly-Val-Gly-Arg-
2191 Val-Gly-Phe-Pro-Asp-Leu-Thr-Ile-Asp-Asp-
2201 Ser-Tyr-Trp-Tyr-Arg-Ile-Glu-Ala-Ser-Arg-
2211 Thr-Gly-Arg-Asn-Gly-Ser-Ile-Ser-Val-Arg-
2221 Ala-Leu-Asp-Gly-Pro-Lys-Ala-Ser-Met-Val-
2231 Pro-Ser-Thr-Tyr-His-Ser-Val-Ser-Pro-Pro-
2241 Gly-Tyr-Thr-Ile-Leu-Asp-Val-Asp-Ala-Asn-
2251 Ala-Met-Leu-Phe-Val-Gly-Glu-Leu-Thr-Gly-
2261 Lys-Ile-Lys-Lys-Ala-Asp-Ala-Val-Arg-Val-
2271 Ile-Thr-Phe-Thr-Gly-Cys-Met-Gly-Glu-Thr-
2281 Tyr-Phe-Asp-Asn-Lys-Pro-Ile-Gly-Leu-Trp-
2291 Asn-Phe-Arg-Glu-Lys-Glu-Gly-Asp-Cys-Lys-
2301 Gly-Cys-Thr-Val-Ser-Pro-Gln-Val-Glu-Asp-
2311 Ser-Glu-Gly-Thr-Ile-Gln-Phe-Asp-Gly-Glu-
2321 Gly-Tyr-Ala-Leu-Val-Ser-Arg-Pro-Ile-Arg-
2331 Trp-Tyr-Pro-Asn-Ile-Ser-Thr-Val-Met-Phe-
2341 Lys-Phe-Arg-Thr-Phe-Ser-Ser-Ser-Ala-Leu-
2351 Leu-Met-Tyr-Leu-Ala-Thr-Arg-Asp-Leu-Lys-
2361 Asp-Phe-Met-Ser-Val-Glu-Leu-Ser-Asp-Gly-
2371 His-Val-Lys-Val-Ser-Tyr-Asp-Leu-Gly-Ser-
2381 Gly-Met-Thr-Ser-Val-Val-Ser-Asn-Gln-Asn-
2391 His-Asn-Asp-Gly-Lys-Trp-Lys-Ala-Phe-Thr-
2401 Leu-Ser-Arg-Ile-Gln-Lys-Gln-Ala-Asn-Ile-
2411 Ser-Ile-Val-Asp-Ile-Asp-Ser-Asn-Gln-Glu-
2421 Glu-Asn-Val-Ala-Thr-Ser-Ser-Ser-Gly-Asn-
2431 Asn-Phe-Gly-Leu-Asp-Leu-Lys-Ala-Asp-Asp-
2441 Lys-Ile-Tyr-Phe-Gly-Gly-Leu-Pro-Thr-Leu-
2451 Arg-Asn-Leu-Ser-Met-Lys-Ala-Arg-Pro-Glu-
2461 Val-Asn-Val-Lys-Lys-Tyr-Ser-Gly-Cys-Leu-
2471 Lys-Asp-Ile-Glu-Ile-Ser-Arg-Thr-Pro-Tyr-

HITS AT: 501-508

L7 ANSWER 26 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAB19795 Protein DGENE
TI Purified laminin 2 protein, useful for research and therapeutic purposes
including peripheral nerve regeneration, treatment of degenerative muscle
disorders, angiogenesis regulation, and ex vivo cell therapy -
Yurchenco P
IN (UNNE-N) UNIT NEW JERSEY MEDICINE & DENTISTRY.
PA *****NO 200006730 A2 20001109 305p***
PI WO 2000-US11378 20000428
AI US 1999-131720 19990430
PRAI US 1999-139198 19990613
US 1999-143289 19990712
US 1999-145345 19990924

DI Patent
LA English
OS 2000-687537 (67)
CR N-PSDB: AAA88895
DESC Mouse laminin 2 alpha-2 chain.
AN AA19795 Protein DQENF
AA 186A; 163R; 164N; 181D; 0 B; 161C; 124Q; 207E; 0 Z; 258G; 65 H; 167I;
245L; 171K; 44 M; 101F; 176P; 208S; 190T; 27 W; 99 Y; 165V; 0 Others
SQL
SEQ3
3106

1 Met-Pro-Ala-Ala-Thr-Ala-Gly-Ile-Leu-Leu-
11 Leu-Leu-Leu-Leu-Gly-Thr-Leu-Glu-Gly-Ser-
21 Gln-Thr-Gln-Arg-Arg-Gln-Ser-Gln-Ala-His-
31 Gln-Gln-Arg-Gly-Leu-Phe-Pro-Ala-Val-Leu-
41 Asn-Leu-Ala-Ser-Asn-Ala-Leu-Ile-Thr-Thr-
51 Asn-Ala-Thr-Cys-Gly-Glu-Lys-Gly-Pro-Glu-
61 Met-Tyr-Cys-Lys-Leu-Val-Glu-His-Val-Pro-
71 Gly-Gln-Pro-Val-Arg-Asn-Pro-Gln-Cys-Arg-
81 Ile-Cys-Asn-Gln-Asn-Ser-Ser-Asn-Pro-Tyr-
91 Gln-Arg-His-Pro-Ile-Thr-Asn-Ala-Ile-Asp-
101 Gly-Lys-Asn-Thr-Tyr-Gln-Ser-Pro-Ser-
111 Ile-Lys-Asn-Gly-Val-Glu-Tyr-His-Tyr-Val-
121 Thr-Ile-Thr-Leu-Asp-Leu-Gln-Gln-Val-Phe-
131 Gln-Ile-Ala-Tyr-Val-Ile-Val-Lys-Ala-Ala-
141 Asn-Ser-Pro-Arg-Pro-Gly-Asn-Tyr-Ile-Leu-
151 Glu-Arg-Ser-Leu-Asp-Asp-Val-Glu-Tyr-Lys-
161 Pro-Tyr-Gln-Tyr-His-Ala-Val-Thr-Asp-Thr-
171 Glu-Cys-Leu-Thr-Leu-Tyr-Asn-Ile-Tyr-Pro-
181 Arg-Thr-Gly-Pro-Pro-Ser-Tyr-Ala-Lys-Asp-
191 Asp-Glu-Val-Ile-Cys-Thr-Ser-Phe-Tyr-Ser-
201 Lys-Ile-His-Pro-Leu-Glu-Asn-Gly-Glu-Ile-
211 His-Ile-Ser-Leu-Ile-Asn-Gly-Arg-Pro-Ser-
221 Ala-Asp-Asp-Pro-Ser-Pro-Glu-Leu-Leu-Glu-
231 Phe-Thr-Ser-Ala-Arg-Tyr-Ile-Arg-Leu-Arg-
241 Phe-Gln-Arg-Ile-Arg-Thr-Leu-Asn-Ala-Asp-
251 Leu-Met-Met-Phe-Ala-His-Lys-Asp-Pro-Arg-
261 Glu-Ile-Asp-Pro-Ile-Val-Thr-Arg-Arg-Tyr-
271 Tyr-Tyr-Ser-Val-Lys-Asp-Ile-Ser-Val-Gly-
281 Gly-Met-Cys-Ile-Cys-Tyr-Gly-His-Ala-Arg-
291 Ala-Cys-Pro-Leu-Asp-Pro-Ala-Thr-Asn-Lys-
301 Ser-Arg-Cys-Glu-Cys-Glu-His-Asn-Thr-Cys-
311 Gly-Glu-Ser-Cys-Asp-Arg-Cys-Cys-Pro-Gly-
321 Phe-His-Gln-Lys-Pro-Tyr-Arg-Ala-Gly-Thr-
331 Phe-Leu-Thr-Lys-Ser-Glu-Cys-Glu-Ala-Cys-
341 Asn-Cys-His-Gly-Lys-Ala-Glu-Glu-Cys-Tyr-
351 Tyr-Asp-Glu-Thr-Val-Ala-Ser-Arg-Asn-Leu-
361 Ser-Leu-Asn-Ile-His-Gly-Lys-Tyr-Ile-Gly-
371 Gly-Gly-Val-Cys-Ile-Asn-Cys-Thr-His-Asn-
381 Thr-Ala-Gly-Ile-Asn-Cys-Glu-Thr-Cys-Val-
391 Asp-Gly-Phe-Phe-Arg-Pro-Lys-Gly-Val-Ser-
401 Pro-Asn-Tyr-Pro-Arg-Pro-Cys-Gln-Pro-Cys-
411 His-Cys-Asp-Pro-Thr-Gly-Ser-Leu-Ser-Glu-
421 Val-Cys-Val-Lys-Asp-Glu-Lys-Tyr-Ala-Gln-
431 Arg-Gly-Leu-Lys-Pro-Gly-Ser-Cys-His-Cys-
441 Lys-Thr-Gly-Phe-Gly-Gly-Val-Asn-Cys-Asp-
451 Arg-Cys-Val-Arg-Gly-Tyr-His-Gly-Tyr-Pro-
461 Asp-Cys-Gln-Pro-Cys-Asn-Cys-Ser-Gly-Leu-

471 Gly-Ser-Thr-Asn-Glu-Asp-Pro-Cys-Val-Gly-
481 Pro-Cys-Ser-Cys-Lys-Glu-Asn-Val-Glu-Gly-
491 Glu-Asp-Cys-Ser-Arg-Cys-Lys-Ser-Gly-Phe-
501 Phe-Asn-Leu-Gln-Glu-Asp-Asn-Gln-Lys-Gly-
511 Cys-Glu-Glu-Cys-Phe-Cys-Ser-Gly-Val-Ser-
521 Asn-Arg-Cys-Gln-Ser-Ser-Tyr-Tyr-Thr-Tyr-
531 Gly-Asn-Ile-Gln-Asp-Met-Arg-Gly-Tyr-Tyr-
541 Leu-Thr-Asp-Leu-Ser-Gly-Arg-Ile-Arg-Met-
551 Ala-Pro-Gln-Leu-Asp-Asn-Pro-Asp-Ser-Pro-
561 Gln-Gln-Ile-Ser-Ile-Ser-Asn-Ser-Gln-Ala-
571 Arg-Lys-Ser-Leu-Leu-Asp-Gly-Tyr-Tyr-Tyr-
581 Ser-Ala-Pro-Pro-Tyr-Leu-Gly-Asn-Arg-
591 Leu-Pro-Ala-Val-Gly-Gly-Gln-Leu-Ser-Phe-
601 Thr-Ile-Ser-Tyr-Asp-Leu-Glu-Glu-Glu-
611 Asp-Asp-Thr-Glu-Lys-Leu-Leu-Gln-Leu-Met-
621 Ile-Ile-Phe-Glu-Gly-Asn-Asp-Leu-Arg-Ile-
631 Ser-Thr-Ala-Tyr-Lys-Glu-Val-Tyr-Leu-Glu-
641 Pro-Ser-Glu-Glu-His-Val-Glu-Glu-Val-Ser-
651 Leu-Lys-Glu-Glu-Ala-Phe-Thr-Ile-His-Gly-
661 Thr-Asn-Leu-Pro-Val-Thr-Arg-Lys-Asp-Phe-
671 Met-Ile-Val-Leu-Thr-Asn-Leu-Gly-Glu-Ile-
681 Leu-Ile-Gln-Ile-Thr-Tyr-Asn-Leu-Gly-Met-
691 Asp-Ala-Ile-Phe-Arg-Leu-Ser-Ser-Val-Asn-
701 Leu-Glu-Ser-Pro-Val-Pro-Tyr-Pro-Thr-Asp-
711 Arg-Arg-Ile-Ala-Thr-Asp-Val-Glu-Val-Cys-
721 Gln-Cys-Pro-Pro-Gly-Tyr-Ser-Gly-Ser-Ser-
731 Cys-Glu-Thr-Cys-Tyr-Pro-Arg-His-Arg-Arg-
741 Val-Asn-Gly-Thr-Ile-Phe-Gly-Gly-Ile-Glu-
751 Glu-Pro-Cys-Gln-Cys-Phe-Ala-His-Ala-Glu-
761 Ala-Cys-Asp-Asp-Ile-Thr-Gly-Glu-Cys-Leu-
771 Asn-Cys-Lys-Asp-His-Thr-Gly-Gly-Pro-Tyr-
781 Cys-Asn-Glu-Cys-Leu-Pro-Gly-Phe-Tyr-Gly-
791 Asp-Pro-Thr-Arg-Gly-Ser-Pro-Glu-Asp-Cys-
801 Gln-Pro-Cys-Ala-Cys-Pro-Leu-Asn-Ile-Pro-
811 Ser-Asn-Asn-Phe-Ser-Pro-Thr-Cys-Leu-
821 Asp-Arg-Ser-Leu-Gly-Leu-Ile-Cys-Asp-Glu-
831 Cys-Pro-Ile-Gly-Tyr-Thr-Gly-Pro-Arg-Cys-
841 Glu-Arg-Cys-Ala-Glu-Gly-Tyr-Phe-Gly-Gln-
851 Pro-Ser-Val-Pro-Gly-Gly-Ser-Gln-Pro-
861 Cys-Gln-Cys-Asn-Asp-Asn-Leu-Asp-Tyr-Ser-
871 Ile-Pro-Gly-Ser-Cys-Asp-Ser-Leu-Ser-Gly-
881 Ser-Cys-Leu-Ile-Cys-Lys-Pro-Gly-Thr-Thr-
891 Gly-Arg-Tyr-Cys-Glu-Leu-Cys-Ala-Asp-Gly-
901 Tyr-Phe-Gly-Asp-Ala-Val-Asn-Thr-Lys-Asn-
911 Cys-Gln-Pro-Cys-Arg-Cys-Asp-Ile-Asn-Gly-
921 Ser-Phe-Ser-Glu-Asp-Cys-His-Thr-Arg-Thr-
931 Gly-Gln-Cys-Glu-Cys-Arg-Pro-Asn-Val-Gln-
941 Gly-Arg-His-Cys-Asp-Glu-Cys-Lys-Pro-Glu-
951 Thr-Phe-Gly-Leu-Gln-Leu-Gly-Arg-Gly-Cys-
961 Leu-Pro-Cys-Asn-Cys-Asn-Ser-Phe-Gly-Ser-
971 Lys-Ser-Phe-Asp-Cys-Glu-Ala-Ser-Gly-Gln-
981 Cys-Tyr-Cys-Gln-Pro-Gly-Val-Ala-Gly-Lys-
991 Lys-Cys-Asp-Arg-Cys-Ala-His-Gly-Tyr-Phe-
1001 Asn-Phe-Gln-Glu-Gly-Gly-Asn-Asn-Cys-Asp-
1011 Asp-Cys-Ser-His-Leu-Gly-Asn-Asn-Cys-Asp-
1021 Pro-Lys-Thr-Gly-Gln-Cys-Ile-Cys-Pro-Pro-

1031 Asn-Thr-Thr-Gly-Glu-Lys-Cys-Ser-Glu-Cys-
1041 Leu-Pro-Asn-Thr-Tyr-Gly-His-Ser-Ile-Val-
1051 Thr-Gly-Cys-Lys-Val-Cys-Asn-Cys-Ser-Thr-
1061 Val-Gly-Ser-Leu-Ala-Ser-Gln-Cys-Asn-Val-
1071 Asn-Thr-Gly-Gln-Cys-Ser-Cys-His-Pro-Lys-
1081 Phe-Ser-Gly-Met-Lys-Cys-Ser-Glu-Cys-Ser-
1091 Arg-Gly-His-Tyr-Asn-Tyr-Pro-Leu-Cys-Thr-
1101 Leu-Cys-Asp-Cys-Phe-Leu-Pro-Gly-Thr-Asp-
1111 Ala-Thr-Thr-Cys-Asp-Leu-Glu-Thr-Arg-Lys-
1121 Cys-Ser-Cys-Ser-Asp-Gln-Thr-Gly-Gln-Cys-
1131 Ser-Cys-Lys-Val-Asn-Val-Glu-Gly-Val-His-
1141 Cys-Asp-Arg-Cys-Arg-Pro-Gly-Lys-Phe-Gly-
1151 Leu-Asp-Ala-Lys-Asn-Pro-Leu-Gly-Cys-Ser-
1161 Ser-Cys-Tyr-Cys-Phe-Gly-Val-Thr-Ser-Gln-
1171 Cys-Ser-Glu-Ala-Lys-Gly-Leu-Ile-Arg-Thr-
1181 Trp-Val-Thr-Leu-Ser-Asp-Glu-Gln-Thr-Ile-
1191 Leu-Pro-Leu-Val-Asp-Glu-Ala-Leu-Gln-His-
1201 Thr-Thr-Thr-Lys-Gly-Ile-Ala-Phe-Gln-Lys-
1211 Pro-Glu-Ile-Val-Ala-Lys-Met-Asp-Glu-Val-
1221 Arg-Gln-Glu-Leu-His-Leu-Glu-Pro-Phe-Tyr-
1231 Trp-Lys-Leu-Pro-Gln-Gln-Phe-Glu-Gly-Lys-
1241 Lys-Leu-Met-Ala-Tyr-Gly-Gly-Lys-Leu-Lys-
1251 Tyr-Ala-Ile-Tyr-Phe-Glu-Ala-Arg-Asp-Glu-
1261 Thr-Gly-Phe-Ala-Thr-Tyr-Lys-Pro-Gln-Val-
1271 Ile-Ile-Arg-Gly-Gly-Thr-Pro-Thr-His-Ala-
1281 Arg-Ile-Ile-Thr-Arg-His-Met-Ala-Ala-Pro-
1291 Leu-Ile-Gly-Gln-Leu-Thr-Arg-His-Glu-Ile-
1301 Glu-Met-Thr-Glu-Lys-Glu-Tyr-Lys-Tyr-Tyr-
1311 Gly-Asp-Asp-Pro-Arg-Ile-Ser-Arg-Thr-Val-
1321 Thr-Arg-Glu-Asp-Phe-Leu-Asp-Ile-Leu-Tyr-
1331 Asp-Ile-His-Tyr-Ile-Leu-Ile-Lys-Ala-Thr-
1341 Tyr-Gly-Asn-Val-Val-Arg-Gln-Ser-Ala-Ile-
1351 Ser-Glu-Ile-Ser-Met-Glu-Val-Ala-Glu-Pro-
1361 Gly-His-Val-Leu-Ala-Gly-Ser-Pro-Pro-Ala-
1371 His-Leu-Ile-Glu-Arg-Cys-Asp-Cys-Pro-Pro-
1381 Gly-Tyr-Ser-Gly-Leu-Ser-Cys-Glu-Thr-Cys-
1391 Ala-Pro-Gly-Phe-Tyr-Arg-Leu-Arg-Ser-Glu-
1401 Pro-Gly-Gly-Arg-Thr-Pro-Gly-Pro-Thr-Leu-
1411 Gly-Thr-Cys-Val-Pro-Cys-Gln-Cys-Asn-Gly-
1421 His-Ser-Ser-Gln-Cys-Asp-Pro-Glu-Thr-Ser-
1431 Val-Cys-Gln-Asn-Cys-Gln-His-His-Thr-Ala-
1441 Gly-Asp-Phe-Cys-Glu-Arg-Cys-Ala-Leu-Gly-
1451 Tyr-Tyr-Gly-Ile-Val-Arg-Gly-Leu-Pro-Asn-
1461 Asp-Cys-Gln-Pro-Cys-Ala-Cys-Pro-Leu-Ile-
1471 Ser-Pro-Ser-Asn-Asn-Phe-Ser-Pro-Ser-Cys-
1481 Val-Leu-Glu-Gly-Leu-Glu-Asp-Tyr-Arg-Cys-
1491 Thr-Ala-Cys-Pro-Arg-Gly-Tyr-Gly-Tyr-Thr-
1501 Tyr-Cys-Glu-Arg-Cys-Ala-Pro-Gly-Tyr-Thr-
1511 Gly-Ser-Pro-Ser-Ser-Pro-Gly-Gly-Ser-Cys-
1521 Gln-Glu-Cys-Glu-Cys-Asp-Pro-Tyr-Gly-Ser-
1531 Leu-Pro-Val-Pro-Cys-Asp-Arg-Val-Thr-Gly-
1541 Leu-Cys-Thr-Cys-Arg-Pro-Gly-Ala-Thr-Gly-
1551 Arg-Lys-Cys-Asp-Gly-Cys-Glu-His-Tyr-His-
1561 Ala-Arg-Glu-Gly-Ala-Glu-Cys-Val-Phe-Cys-
1571 Gly-Asp-Glu-Cys-Thr-Gly-Leu-Leu-Gly-
1581 Asp-Leu-Ala-Arg-Leu-Glu-Gln-Met-Thr-Met-
1591 Asn-Ile-Asn-Leu-Thr-Gly-Pro-Leu-Pro-Ala-

1601 Pro-Tyr-Lys-Ile-Leu-Tyr-Gly-Leu-Glu-Asn-
1611 Thr-Thr-Gln-Glu-Leu-Lys-His-Leu-Leu-Ser-
1621 Pro-Gln-Arg-Ala-Pro-Glu-Arg-Leu-Ile-Gln-
1631 Leu-Glu-Thr-Asn-Glu-Leu-Leu-Thr-Arg-Ala-
1641 Met-Glu-Thr-Asn-Glu-Leu-Leu-Thr-Arg-Ala-
1651 Thr-Lys-Val-Thr-Ala-Arg-Thr-Glu-Gln-Thr-
1661 Gly-Gln-Asp-Ala-Glu-Arg-Thr-Asn-Ser-Arg-
1671 Ala-Glu-Ser-Leu-Glu-Glu-Phe-Ile-Lys-Gly-
1681 Leu-Val-Gln-Asp-Ala-Glu-Ala-Ile-Asn-Glu-
1691 Lys-Ala-Val-Lys-Leu-Asn-Glu-Thr-Leu-Gly-
1701 Asn-Gln-Asp-Lys-Thr-Ala-Glu-Arg-Asn-Leu-
1711 Glu-Glu-Leu-Gln-Lys-Glu-Ile-Asp-Arg-Met-
1721 Leu-Lys-Glu-Leu-Arg-Ser-Lys-Asp-Leu-Gln-
1731 Thr-Gln-Lys-Glu-Val-Ala-Glu-Asp-Glu-Leu-
1741 Val-Ala-Ala-Glu-Gly-Leu-Leu-Lys-Arg-Val-
1751 Asn-Lys-Leu-Phe-Gly-Glu-Pro-Arg-Ala-Gln-
1761 Asn-Glu-Asp-Met-Glu-Lys-Asp-Leu-Gln-Gln-
1771 Lys-Leu-Ala-Glu-Tyr-Lys-Asn-Lys-Leu-Asp-
1781 Asp-Ala-Trp-Asp-Leu-Leu-Arg-Glu-Ala-Thr-
1791 Asp-Lys-Thr-Arg-Asp-Ala-Asn-Arg-Leu-Ser-
1801 Ala-Ala-Asn-Gln-Lys-Asn-Met-Thr-Ile-Leu-
1811 Glu-Thr-Lys-Lys-Glu-Ala-Ile-Glu-Gly-Ser-
1821 Lys-Arg-Gln-Ile-Glu-Asn-Thr-Leu-Lys-Glu-
1831 Gly-Asn-Asp-Ile-Leu-Asp-Glu-Ala-Asn-Gln-
1841 Leu-Leu-Gly-Glu-Ile-Asn-Ser-Val-Ile-Asp-
1851 Tyr-Val-Asp-Asp-Ile-Lys-Thr-Lys-Leu-Pro-
1861 Pro-Met-Ser-Glu-Glu-Leu-Ser-Asp-Lys-Ile-
1871 Asp-Asp-Leu-Ala-Gln-Glu-Ile-Lys-Asp-Arg-
1881 Arg-Leu-Ala-Glu-Lys-Val-Phe-Glu-Ala-Glu-
1891 Ser-His-Ala-Ala-Gln-Leu-Asn-Asp-Ser-Ser-
1901 Lys-Val-Leu-Asp-Gly-Ile-Leu-Asp-Glu-Ala-
1911 Lys-Asn-Ile-Ser-Phe-Asn-Ala-Thr-Ala-Ala-
1921 Phe-Arg-Ala-Tyr-Ser-Asn-Ile-Lys-Asp-Tyr-
1931 Ile-Asp-Glu-Ala-Glu-Lys-Val-Ala-Arg-Glu-
1941 Ala-Lys-Glu-Leu-Ala-Gln-Gly-Ala-Thr-Lys-
1951 Leu-Ala-Thr-Ser-Pro-Gln-Gly-Leu-Leu-Lys-
1961 Glu-Asp-Ala-Lys-Gly-Ser-Leu-Gln-Lys-Ser-
1971 Phe-Arg-Ile-Leu-Asn-Glu-Ala-Lys-Lys-Leu-
1981 Ala-Asn-Asp-Val-Lys-Gly-Asn-His-Asn-Asp-
1991 Leu-Asn-Asp-Leu-Lys-Thr-Arg-Leu-Glu-Thr-
2001 Ala-Asp-Leu-Arg-Asn-Ser-Gly-Leu-Leu-Gly-
2011 Ala-Leu-Asn-Asp-Thr-Met-Asp-Lys-Leu-Ser-
2021 Ala-Ile-Thr-Asn-Asp-Thr-Ala-Ala-Lys-Leu-
2031 Gln-Ala-Val-Lys-Glu-Lys-Ala-Arg-Glu-Ala-
2041 Asn-Asp-Thr-Ala-Lys-Ala-Val-Leu-Ala-Gln-
2051 Val-Lys-Asp-Leu-His-Gln-Asn-Leu-Asp-Gly-
2061 Leu-Lys-Gln-Asn-Tyr-Asn-Lys-Leu-Ala-Asp-
2071 Ser-Val-Ala-Lys-Thr-Asn-Ala-Val-Val-Lys-
2081 Asp-Pro-Ser-Lys-Asn-Lys-Ile-Ile-Ala-Asp-
2091 Ala-Gly-Thr-Ser-Val-Arg-Asn-Leu-Glu-Gln-
2101 Glu-Ala-Asp-Arg-Leu-Ile-Asp-Lys-Leu-Lys-
2111 Pro-Ile-Lys-Glu-Leu-Glu-Asp-Asn-Leu-Lys-
2121 Lys-Asn-Ile-Ser-Glu-Ile-Lys-Glu-Leu-Ile-
2131 Asn-Gln-Ala-Arg-Lys-Gln-Ala-Asn-Ser-Ile-
2141 Lys-Val-Ser-Val-Ser-Ser-Gly-Gly-Asp-Cys-
2151 Val-Arg-Thr-Tyr-Arg-Pro-Glu-Ile-Lys-Lys-
2161 Gly-Ser-Tyr-Asn-Asn-Ile-Val-Val-His-Val-

2171 Lys-Thr-Ala-Val-Ala-Asp-Asn-Leu-Phe-
 2181 Tyr-Leu-Gly-Ser-Ala-Lys-Phe-Ile-Asp-Phe-
 2191 Leu-Ala-Ile-Glu-Met-Arg-Lys-Gly-Lys-Val-
 2201 Ser-Phe-Leu-Tyr-Ile-Val-Gly-Ser-Gly-Val-
 2211 Gly-Arg-Val-Gly-Phe-Pro-Asp-Leu-Thr-Ile-
 2221 Asp-Asp-Ser-Tyr-Tyr-Arg-Asn-Gly-Ser-Ile-Ser-
 2231 Ser-Arg-Thr-Gly-Arg-Asn-Gly-Ser-Ile-Ser-
 2241 Val-Arg-Ala-Leu-Asp-Gly-Pro-Lys-Ala-Ser-
 2251 Met-Val-Pro-Ser-Thr-Tyr-His-Ser-Val-Asp-
 2261 Pro-Pro-Gly-Tyr-Thr-Ile-Leu-Asp-Val-Asp-
 2271 Ala-Asn-Ala-Met-Leu-Phe-Val-Gly-Gly-Leu-
 2281 Thr-Gly-Lys-Ile-Lys-Lys-Ala-Asp-Ala-Val-
 2291 Arg-Val-Ile-Thr-Phe-Thr-Gly-Cys-Met-Gly-
 2301 Glu-Thr-Tyr-Phe-Asp-Asn-Lys-Pro-Ile-Gly-
 2311 Leu-Tyr-Asn-Phe-Arg-Glu-Lys-Glu-Gly-Asp-
 2321 Cys-Lys-Gly-Cys-Thr-Val-Ser-Pro-Glu-Val-
 2331 Glu-Asp-Ser-Glu-Gly-Thr-Ile-Gln-Phe-Asp-
 2341 Gly-Glu-Gly-Tyr-Ala-Leu-Val-Ser-Arg-Pro-
 2351 Ile-Arg-Tyr-Tyr-Pro-Asn-Ile-Ser-Thr-Val-
 2361 Met-Phe-Lys-Phe-Arg-Thr-Phe-Ser-Ser-Ser-
 2371 Ala-Leu-Leu-Met-Tyr-Leu-Ala-Thr-Arg-Asp-
 2381 Leu-Lys-Asp-Phe-Met-Ser-Val-Glu-Leu-Ser-
 2391 Asp-Gly-His-Val-Lys-Val-Ser-Tyr-Asp-Leu-
 2401 Gly-Ser-Gly-Met-Thr-Ser-Val-Val-Ser-Asn-
 2411 Gln-Asn-His-Asn-Asp-Gly-Lys-Tyr-Gln-Ala-
 2421 Phe-Thr-Leu-Ser-Arg-Ile-Gln-Lys-Gln-Ala-
 2431 Asn-Ile-Ser-Ile-Val-Asp-Ile-Asp-Ser-Asn-
 2441 Gln-Glu-Glu-Asn-Val-Ala-Thr-Ser-Ser-Ser-
 2451 Gly-Asn-Asn-Phe-Gly-Leu-Asp-Leu-Lys-Ala-
 2461 Asp-Asp-Lys-Ile-Tyr-Phe-Gly-Gly-Leu-Pro-
 2471 Thr-Leu-Arg-Asn-Leu-Ser-Met-Lys-Ala-Arg-
 HITS RT: 523-530

FEATURE TABLE:
 Key | Location | Qualifier |
 =====
 Peptide | 11..22 | label | Signal peptide
 Protein | 123..3106 | label | Mature Protein

L7 ANSWER 27 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AAB19794 Protein DGENE
 TI Purified laminin 2 protein, useful for research and therapeutic purposes
 including peripheral nerve regeneration, treatment of degenerative muscle
 disorders, angiogenesis regulation, and ex vivo cell therapy -
 Yurchenco P
 IN Yurchenco P UNIV NEW JERSEY MEDICINE & DENTISTRY.
 PA (UNNE-N) **WO 200006730 A2 20001109 305p**
 P1 WO 2000-0511378 20000428
 AI US 1999-131720 19990430
 PRAI US 1999-139198 19990615
 US 1999-143289 19990712
 US 1999-155945 19990924
 DT Patent
 LA English

OS 2000-667537 [67]
 CR N-PSDB: AAB19794
 DESC Human laminin 2 mature alpha-2 chain.
 AN AAB19794 Protein DGENE
 AA 202A: 159R; 162N; 163D; 0 B; 162C; 1180; 202E; 0 Z; 255G; 71 H; 166I;
 239L; 184K; 45 W; 103F; 172P; 193S; 193T; 29 W; 96 Y; 154V; 0 Others
 SEQ
 SEQ3
 3088

1 Gln-Arg-Pro-Gln-Gln-Arg-Gln-Ser-Gln-
 11 Ala-His-Gln-Gln-Arg-Gly-Leu-Phe-Pro-Ala-
 21 Val-Leu-Asn-Leu-Ala-Ser-Asn-Ala-Leu-Ile-
 31 Thr-Thr-Asn-Ala-Thr-Cys-Gly-Glu-Lys-Gly-
 41 Pro-Glu-Met-Tyr-Cys-Lys-Leu-Val-Glu-His-
 51 Val-Pro-Gly-Gln-Pro-Val-Arg-Asn-Pro-Gln-
 61 Cys-Arg-Ile-Cys-Asn-Gln-Asn-Ser-Ser-Asn-
 71 Pro-Asn-Gln-Arg-His-Pro-Ile-Thr-Asn-Ala-
 81 Ile-Asp-Gly-Lys-Asn-Thr-Tyr-Tyr-Gln-Ser-
 91 Pro-Ser-Ile-Lys-Asn-Gly-Ile-Glu-Tyr-His-
 101 Tyr-Val-Thr-Ile-Thr-Leu-Asp-Leu-Gln-Gln-
 111 Val-Phe-Gln-Ile-Ala-Tyr-Val-Ile-Val-Lys-
 121 Ala-Ala-Asn-Ser-Pro-Arg-Pro-Gly-Asn-Tyr-
 131 Ile-Leu-Glu-Arg-Ser-Leu-Asp-Asp-Val-Glu-
 141 Tyr-Lys-Pro-Tyr-Gln-Tyr-His-Ala-Val-Thr-
 151 Asp-Thr-Glu-Cys-Leu-Thr-Leu-Tyr-Asn-Ile-
 161 Tyr-Pro-Arg-Thr-Gly-Pro-Pro-Ser-Tyr-Ala-
 171 Lys-Asp-Asp-Glu-Val-Ile-Cys-Thr-Ser-Phe-
 181 Tyr-Ser-Lys-Ile-His-Pro-Leu-Glu-Asn-Gly-
 191 Glu-Ile-His-Ile-Ser-Leu-Ile-Asn-Gly-Arg-
 201 Pro-Ser-Ala-Asp-Asp-Pro-Ser-Pro-Glu-Leu-
 211 Leu-Glu-Phe-Thr-Ser-Ala-Arg-Tyr-Ile-Arg-
 221 Leu-Arg-Phe-Gln-Arg-Ile-Arg-Thr-Leu-Asp-
 231 Ala-Asp-Leu-Met-Met-Phe-Ala-His-Lys-Asp-
 241 Pro-Arg-Glu-Ile-Asp-Pro-Ile-Val-Thr-Arg-
 251 Arg-Tyr-Tyr-Ser-Val-Lys-Asp-Ile-Ser-
 261 Val-Gly-Gly-Met-Cys-Ile-Cys-Tyr-Gly-His-
 271 Ala-Arg-Ala-Cys-Pro-Leu-Asp-Pro-Ala-Thr-
 281 Asn-Lys-Ser-Arg-Cys-Glu-Cys-Glu-His-Asn-
 291 Thr-Cys-Gly-Asp-Ser-Cys-Asp-Gln-Cys-Cys-
 301 Pro-Gly-Phe-His-Gln-Lys-Pro-Tyr-Arg-Ala-
 311 Gly-Thr-Phe-Leu-Thr-Lys-Thr-Glu-Cys-Glu-
 321 Ala-Cys-Asn-Cys-His-Gly-Lys-Ala-Glu-Glu-
 331 Cys-Tyr-Tyr-Asp-Glu-Asn-Val-Ala-Arg-Arg-
 341 Asn-Leu-Ser-Leu-Asn-Ile-Arg-Gly-Lys-Tyr-
 351 Ile-Gly-Gly-Gly-Val-Cys-Ile-Asn-Cys-Thr-
 361 Gln-Asn-Thr-Ala-Gly-Ile-Asn-Cys-Glu-Thr-
 371 Cys-Thr-Asp-Gly-Phe-Arg-Pro-Lys-Gly-
 381 Val-Ser-Pro-Asn-Tyr-Pro-Arg-Pro-Cys-Gln-
 391 Pro-Cys-His-Cys-Asp-Pro-Ile-Gly-Ser-Leu-
 401 Asn-Glu-Val-Cys-Val-Lys-Asp-Glu-Lys-His-
 411 Ala-Arg-Arg-Gly-Leu-Ala-Pro-Gly-Ser-Cys-
 421 His-Cys-Lys-Thr-Gly-Phe-Gly-Gly-Val-Ser-
 431 Cys-Asp-Arg-Cys-Ala-Arg-Gly-Tyr-Thr-Gly-
 441 Tyr-Pro-Asp-Cys-Lys-Ala-Cys-Asn-Cys-Ser-
 451 Gly-Leu-Gly-Ser-Lys-Asn-Glu-Asp-Pro-Cys-
 461 Phe-Gly-Pro-Cys-Ile-Cys-Lys-Glu-Asn-Val-
 471 Glu-Gly-Gly-Asp-Cys-Ser-Arg-Cys-Lys-Ser-
 481 Gly-Phe-Phe-Asn-Leu-Gln-Glu-Asp-Asn-Tyr-

491 Lys-Gly-Cys-Asp-Glu-Cys-Phe-Cys-Ser-Gly-
501 Val-Ser-Asn-Arg-Cys-Gln-Ser-Ser-Tyr-Trp-
511 Thr-Tyr-Gly-Lys-Ile-Gln-Asp-Met-Ser-Gly-
521 Trp-Tyr-Leu-Thr-Asp-Leu-Pro-Gly-Arg-Ile-
531 Arg-Val-Ala-Pro-Gln-Gln-Asp-Asp-Leu-Asp-
541 Ser-Pro-Gln-Gln-Ile-Ser-Ile-Ser-Asn-Ala-
551 Glu-Ala-Arg-Gln-Ala-Leu-Pro-His-Ser-Tyr-
561 Tyr-Trp-Ser-Ala-Pro-Ala-Pro-Tyr-Leu-Gly-
571 Asn-Lys-Leu-Pro-Ala-Val-Gly-Gly-Gln-Leu-
581 Thr-Phe-Thr-Ile-Ser-Tyr-Asp-Leu-Glu-Glu-
591 Glu-Glu-Glu-Asp-Thr-Glu-Arg-Val-Leu-Gln-
601 Leu-Met-Ile-Ile-Leu-Glu-Gly-Asn-Asp-Leu-
611 Ser-Ile-Ser-Thr-Ala-Gln-Asp-Glu-Val-Tyr-
621 Leu-His-Pro-Ser-Glu-Glu-His-Thr-Asn-Val-
631 Leu-Leu-Leu-Lys-Glu-Glu-Ser-Phe-Thr-Ile-
641 His-Gly-Thr-His-Phe-Pro-Val-Arg-Arg-Lys-
651 Glu-Phe-Met-Thr-Val-Leu-Ala-Asn-Leu-Lys-
661 Arg-Val-Leu-Leu-Gln-Ile-Thr-Tyr-Ser-Phe-
671 Gly-Met-Asp-Ala-Ile-Phe-Arg-Leu-Ser-Ser-
681 Val-Asn-Leu-Glu-Ser-Ala-Val-Ser-Tyr-Pro-
691 Thr-Asp-Gly-Ser-Ile-Ala-Ala-Ala-Val-Glu-
701 Val-Cys-Gln-Cys-Pro-Pro-Gly-Tyr-Thr-Gly-
711 Ser-Ser-Cys-Glu-Ser-Cys-Trp-Pro-Arg-His-
721 Arg-Arg-Val-Asn-Gly-Thr-Ile-Phe-Gly-His-
731 Ile-Cys-Glu-Pro-Cys-Gln-Cys-Phe-Gly-His-
741 Ala-Glu-Ser-Cys-Asp-Asp-Val-Thr-Gly-Glu-
751 Cys-Leu-Asn-Cys-Lys-Asp-His-Thr-Gly-Gly-
761 Pro-Tyr-Cys-Asp-Lys-Cys-Leu-Pro-Gly-Phe-
771 Tyr-Gly-Glu-Pro-Thr-Lys-Gly-Thr-Ser-Glu-
781 Asp-Cys-Gln-Pro-Cys-Ala-Cys-Pro-Leu-Asn-
791 Ile-Pro-Ser-Asn-Asn-Phe-Ser-Pro-Thr-Cys-
801 His-Leu-Asp-Arg-Ser-Leu-Gly-Leu-Ile-Cys-
811 Asp-Gly-Cys-Pro-Val-Gly-Tyr-Thr-Gly-Pro-
821 Arg-Cys-Glu-Arg-Cys-Ala-Glu-Gly-Tyr-Phe-
831 Gly-Gln-Pro-Ser-Val-Pro-Gly-Gly-Ser-Cys-
841 Gln-Pro-Cys-Gln-Cys-Asn-Asp-Asn-Leu-Asp-
851 Phe-Ser-Ile-Pro-Gly-Ser-Cys-Asp-Ser-Leu-
861 Ser-Gly-Ser-Cys-Leu-Ile-Cys-Lys-Pro-Gly-
871 Thr-Thr-Gly-Arg-Tyr-Cys-Glu-Leu-Cys-Ala-
881 Asp-Gly-Tyr-Phe-Gly-Asp-Ala-Val-Asp-Ala-
891 Lys-Asn-Cys-Gln-Pro-Cys-Arg-Cys-Asn-Ala-
901 Gly-Gly-Ser-Phe-Ser-Glu-Val-Cys-His-Ser-
911 Gln-Thr-Gly-Gln-Cys-Glu-Cys-Arg-His-Asn-
921 Val-Gln-Gly-Gln-Arg-Cys-Asp-Lys-Cys-Lys-
931 Ala-Gly-Thr-Phe-Gly-Leu-Gln-Ser-Ala-Arg-
941 Gly-Cys-Val-Pro-Cys-Asn-Cys-Asn-Ser-Phe-
951 Gly-Ser-Lys-Ser-Phe-Asp-Cys-Glu-Glu-Ser-
961 Gly-Gln-Cys-Trp-Cys-Gln-Pro-Gly-Val-Thr-
971 Gly-Lys-Lys-Cys-Asp-Arg-Cys-Ala-His-Gly-
981 Tyr-Phe-Asn-Phe-Gln-Glu-Gly-Gly-Cys-Thr-
991 Ala-Cys-Glu-Cys-Ser-His-Leu-Gly-Asn-Asn-
1001 Cys-Asp-Pro-Lys-Thr-Gly-Arg-Cys-Ile-Cys-
1011 Pro-Pro-Asn-Thr-Ile-Gly-Glu-Lys-Cys-Ser-
1021 Lys-Cys-Ala-Pro-Asn-Thr-Trp-Gly-His-Ser-
1031 Ile-Thr-Thr-Gly-Cys-Lys-Ala-Cys-Asn-Cys-

1041 Ser-Thr-Val-Gly-Ser-Leu-Asp-Phe-Gln-Cys-
1051 Asn-Val-Asn-Thr-Gly-Gln-Cys-Asn-Cys-His-
1061 Pro-Lys-Phe-Ser-Gly-Ala-Lys-Cys-Thr-Glu-
1071 Cys-Ser-Arg-Gly-His-Trp-Asn-Tyr-Pro-Arg-
1081 Cys-Asn-Leu-Cys-Asp-Cys-Phe-Leu-Pro-Gly-
1091 Thr-Asp-Ala-Thr-Thr-Cys-Asp-Ser-Glu-Thr-
1101 Lys-Cys-Cys-Ser-Cys-Ser-Asp-Gln-Thr-Gly-
1111 Gln-Cys-Thr-Cys-Lys-Val-Asn-Val-Glu-Gly-
1121 Ile-His-Cys-Asp-Arg-Cys-Arg-Pro-Gly-Lys-
1131 Phe-Gly-Leu-Asp-Ala-Lys-Asn-Pro-Leu-Gly-
1141 Cys-Ser-Ser-Cys-Tyr-Cys-Phe-Gly-Thr-Thr-
1151 Thr-Gln-Cys-Ser-Glu-Ala-Lys-Gly-Leu-Ile-
1161 Arg-Thr-Trp-Val-Thr-Leu-Lys-Ala-Glu-Gln-
1171 Thr-Ile-Leu-Pro-Leu-Val-Asp-Glu-Ala-Leu-
1181 Gln-His-Thr-Thr-Thr-Lys-Gly-Ile-Val-Phe-
1191 Gln-His-Pro-Glu-Ile-Val-Ala-His-Met-Asp-
1201 Leu-Met-Arg-Glu-Asp-Leu-His-Leu-Glu-Pro-
1211 Phe-Tyr-Trp-Lys-Leu-Pro-Gln-Gln-Phe-Glu-
1221 Gly-Lys-Lys-Leu-Met-Ala-Tyr-Gly-Gly-Lys-
1231 Leu-Lys-Tyr-Ala-Ile-Tyr-Phe-Glu-Ala-Arg-
1241 Glu-Glu-Thr-Gly-Phe-Ser-Thr-Tyr-Asn-Pro-
1251 Gln-Val-Ile-Ile-Arg-Gly-Gly-Thr-Pro-Thr-
1261 His-Ala-Arg-Ile-Ile-Val-Arg-His-Met-Ala-
1271 Ala-Pro-Leu-Ile-Gly-Gln-Leu-Thr-Arg-His-
1281 Glu-Ile-Glu-Met-Thr-Glu-Lys-Glu-Trp-Lys-
1291 Tyr-Tyr-Gly-Asp-Asp-Pro-Arg-Val-His-Arg-
1301 Thr-Val-Thr-Arg-Glu-Asp-Phe-Leu-Asp-Ile-
1311 Leu-Tyr-Asp-Ile-His-Tyr-Ile-Leu-Ile-Lys-
1321 Ala-Thr-Tyr-Gly-Asn-Phe-Met-Arg-Gln-Ser-
1331 Arg-Ile-Ser-Glu-Ile-Ser-Met-Glu-Val-Ala-
1341 Gln-Gln-Gly-Arg-Gly-Thr-Thr-Met-Thr-Pro-
1351 Pro-Ala-Asp-Leu-Ile-Glu-Lys-Cys-Asp-Cys-
1361 Pro-Leu-Gly-Tyr-Ser-Gly-Leu-Ser-Cys-Glu-
1371 Ala-Cys-Leu-Pro-Gly-Phe-Tyr-Arg-Leu-Arg-
1381 Ser-Gln-Pro-Gly-Gly-Arg-Thr-Pro-Gly-Pro-
1391 Thr-Leu-Gly-Thr-Cys-Val-Pro-Cys-Gln-Cys-
1401 Asn-Gly-His-Ser-Ser-Leu-Cys-Asp-Pro-Glu-
1411 Thr-Ser-Ile-Cys-Gln-Asn-Cys-Gln-His-His-
1421 Thr-Ala-Gly-Asp-Phe-Cys-Glu-Arg-Cys-Ala-
1431 Leu-Gly-Tyr-Tyr-Gly-Ile-Val-Lys-Gly-Leu-
1441 Pro-Asn-Asp-Cys-Gln-Gln-Cys-Ala-Cys-Pro-
1451 Leu-Ile-Ser-Ser-Ser-Asn-Asn-Phe-Ser-Pro-
1461 Ser-Cys-Val-Ala-Glu-Gly-Leu-Asp-Asp-Tyr-
1471 Arg-Cys-Thr-Ala-Cys-Pro-Arg-Gly-Tyr-Glu-
1481 Gly-Gln-Tyr-Cys-Glu-Arg-Cys-Ala-Pro-Gly-
1491 Tyr-Thr-Gly-Ser-Pro-Gly-Asn-Pro-Gly-Gly-
1501 Ser-Cys-Gln-Glu-Cys-Glu-Cys-Asp-Pro-Tyr-
1511 Gly-Ser-Leu-Pro-Val-Pro-Cys-Asp-Pro-Val-
1521 Thr-Gly-Phe-Cys-Thr-Cys-Arg-Pro-Gly-Ala-
1531 Thr-Gly-Arg-Lys-Cys-Asp-Gly-Cys-Lys-His-
1541 Trp-His-Ala-Arg-Glu-Gly-Trp-Glu-Cys-Val-
1551 Phe-Cys-Ala-Arg-Glu-Cys-Thr-Gly-Leu-Leu-
1561 Leu-Gly-Asp-Leu-Ala-Arg-Leu-Glu-Gln-Met-
1571 Val-Met-Ser-Ile-Asn-Leu-Thr-Gly-Pro-Leu-
1581 Pro-Ala-Pro-Tyr-Lys-Met-Leu-Tyr-Gly-Leu-
1591 Glu-Asn-Met-Thr-Gln-Glu-Leu-Lys-His-Leu-
1601 Leu-Ser-Pro-Gln-Arg-Ala-Pro-Glu-Arg-Leu-

1611 Ile-Gln-Leu-Ala-Glu-Gly-Asn-Leu-Asn-Thr-
1621 Leu-Val-Thr-Glu-Met-Asn-Glu-Leu-Leu-Thr-
1631 Arg-Ala-Thr-Lys-Val-Thr-Ala-Asp-Gly-Glu-
1641 Gln-Thr-Gly-Gln-Asp-Ala-Glu-Arg-Thr-Asn-
1651 Thr-Arg-Ala-Lys-Ser-Leu-Gly-Gln-Phe-Ile-
1661 Lys-Glu-Leu-Ala-Arg-Asp-Ala-Glu-Ala-Val-
1671 Asn-Glu-Lys-Ala-Ile-Lys-Leu-Asn-Glu-Thr-
1681 Leu-Gly-Thr-Arg-Asp-Glu-Ala-Phe-Glu-Arg-
1691 Asn-Leu-Gly-Gly-Leu-Gln-Lys-Glu-Ile-Asp-
1701 Gln-Met-Ile-Lys-Gln-Arg-Arg-Lys-Asn-
1711 Leu-Glu-Thr-Gln-Lys-Glu-Ile-Ala-Glu-Asp-
1721 Glu-Leu-Val-Ala-Ala-Glu-Ala-Leu-Leu-Lys-
1731 Lys-Val-Lys-Lys-Leu-Phe-Gly-Glu-Ser-Arg-
1741 Gly-Glu-Asn-Glu-Glu-Met-Glu-Lys-Asp-Leu-
1751 Arg-Glu-Lys-Leu-Ala-Asp-Tyr-Lys-Asn-Lys-
1761 Val-Asp-Asp-Ala-Tip-Asp-Leu-Leu-Arg-Glu-
1771 Ala-Thr-Asp-Lys-Ile-Arg-Glu-Ala-Asn-Arg-
1781 Leu-Phe-Ala-Val-Asn-Gln-Lys-Asn-Met-Thr-
1791 Ala-Leu-Glu-Lys-Lys-Glu-Ala-Val-Glu-
1801 Ser-Gly-Lys-Arg-Gln-Ile-Glu-Asn-Thr-Leu-
1811 Lys-Glu-Gly-Asn-Asp-Ile-Leu-Asp-Glu-Ala-
1821 Asn-Arg-Leu-Ala-Asp-Glu-Ile-Asn-Ser-Ile-
1831 Ile-Asp-Tyr-Val-Glu-Asp-Ile-Gln-Thr-Lys-
1841 Leu-Pro-Met-Ser-Glu-Glu-Leu-Asn-Asp-
1851 Lys-Ile-Asp-Asp-Leu-Ser-Gln-Glu-Ile-Lys-
1861 Asp-Arg-Lys-Leu-Ala-Glu-Lys-Val-Ser-Gln-
1871 Ala-Glu-Ser-His-Ala-Ala-Gln-Leu-Asn-Asp-
1881 Ser-Ser-Ala-Val-Leu-Asp-Gly-Ile-Leu-Asp-
1891 Glu-Ala-Lys-Asn-Ile-Ser-Phe-Asn-Ala-Thr-
1901 Ala-Ala-Phe-Lys-Ala-Tyr-Ser-Asn-Ile-Lys-
1911 Asp-Tyr-Ile-Asp-Glu-Ala-Glu-Lys-Val-Ala-
1921 Lys-Glu-Ala-Lys-Asp-Leu-Ala-His-Glu-Ala-
1931 Thr-Lys-Leu-Ala-Thr-Gly-Pro-Arg-Gly-Leu-
1941 Leu-Lys-Glu-Asp-Ala-Lys-Gly-Cys-Leu-Gln-
1951 Lys-Ser-Phe-Arg-Ile-Leu-Asn-Glu-Ala-Lys-
1961 Lys-Leu-Ala-Asn-Asp-Val-Lys-Glu-Asn-Glu-
1971 Asp-His-Leu-Asn-Gly-Leu-Lys-Thr-Arg-Ile-
1981 Glu-Asn-Ala-Asp-Ala-Arg-Asn-Gly-Asp-Leu-
1991 Leu-Arg-Thr-Leu-Asn-Asp-Thr-Leu-Gly-Lys-
2001 Leu-Ser-Ala-Ile-Pro-Asn-Asp-Thr-Ala-Ala-
2011 Lys-Leu-Gln-Ala-Val-Lys-Asp-Lys-Ala-Arg-
2021 Gln-Ala-Asn-Asp-Thr-Ala-Lys-Asp-Val-Leu-
2031 Ala-Gln-Ile-Thr-Glu-Leu-His-Gln-Asn-Leu-
2041 Asp-Gly-Leu-Lys-Lys-Asn-Tyr-Asn-Lys-Leu-
2051 Ala-Asp-Ser-Val-Ala-Lys-Thr-Asn-Ala-Val-
2061 Val-Lys-Asp-Pro-Ser-Lys-Asn-Lys-Ile-Ile-
2071 Ala-Asp-Ala-Asp-Ala-Thr-Val-Lys-Asn-Leu-
2081 Glu-Gln-Glu-Ala-Asp-Arg-Leu-Ile-Asp-Lys-
2091 Leu-Lys-Pro-Ile-Lys-Glu-Leu-Glu-Asp-Asn-
2101 Leu-Lys-Lys-Asn-Ile-Ser-Glu-Ile-Lys-Glu-
2111 Leu-Ile-Asn-Gln-Ala-Arg-Lys-Gln-Ala-Asn-
2121 Ser-Ile-Lys-Val-Ser-Val-Ser-Ser-Gly-Gly-
2131 Asp-Cys-Ile-Arg-Thr-Tyr-Lys-Pro-Glu-Ile-
2141 Lys-Lys-Gly-Ser-Tyr-Asn-Asn-Ile-Val-Val-
2151 Asn-Val-Lys-Thr-Ala-Val-Ala-Asp-Asn-Leu-
2161 Leu-Phe-Tyr-Leu-Gly-Ser-Ala-Lys-Phe-Ile-
2171 Asp-Phe-Leu-Ala-Ile-Glu-Met-Arg-Lys-Gly-

2181 Lys-Val-Ser-Phe-Leu-Tip-Asp-Val-Gly-Ser-
2191 Gly-Val-Gly-Arg-Val-Glu-Tyr-Pro-Asp-Leu-
2201 Thr-Ile-Asp-Asp-Ser-Tyr-Tip-Tyr-Arg-Ile-
2211 Val-Ala-Ser-Arg-Thr-Gly-Arg-Asn-Gly-Thr-
2221 Ile-Ser-Val-Arg-Ala-Leu-Asp-Gly-Pro-Lys-
2231 Ala-Ser-Ile-Val-Pro-Ser-Thr-His-Ser-
2241 Thr-Ser-Pro-Gly-Tyr-Thr-Ile-Leu-Asp-
2251 Val-Asp-Ala-Asn-Ala-Met-Leu-Phe-Val-Gly-
2261 Gly-Leu-Thr-Gly-Lys-Leu-Lys-Lys-Ala-Asp-
2271 Ala-Val-Arg-Val-Ile-Thr-Phe-Thr-Gly-Cys-
2281 Met-Gly-Glu-Thr-Tyr-Phe-Asp-Asn-Lys-Pro-
2291 Ile-Gly-Leu-Tip-Asn-Phe-Arg-Glu-Lys-Glu-
2301 Gly-Asp-Cys-Lys-Gly-Cys-Thr-Val-Ser-Pro-
2311 Gln-Val-Glu-Asp-Ser-Glu-Gly-Thr-Ile-Gln-
2321 Phe-Asp-Gly-Gly-Tyr-Ala-Leu-Val-Ser-
2331 Arg-Pro-Ile-Arg-Tip-Tyr-Pro-Asn-Ile-Ser-
2341 Thr-Val-Met-Phe-Lys-Phe-Arg-Thr-Phe-Ser-
2351 Ser-Ser-Ala-Leu-Leu-Met-Tyr-Leu-Ala-Thr-
2361 Arg-Asp-Leu-Arg-Asp-Phe-Met-Ser-Val-Glu-
2371 Leu-Thr-Asp-Gly-His-Ile-Lys-Val-Ser-Tyr-
2381 Asp-Leu-Gly-Ser-Gly-Met-Ala-Ser-Val-Val-
2391 Ser-Asn-Gln-Asn-His-Asn-Asp-Gly-Lys-Tip-
2401 Lys-Ser-Phe-Thr-Leu-Ser-Arg-Ile-Gln-Lys-
2411 Gln-Ala-Asn-Ile-Ser-Ile-Val-Asp-Ile-Asp-
2421 Thr-Asn-Gln-Glu-Glu-Asn-Ile-Ala-Thr-Ser-
2431 Ser-Ser-Gly-Asn-Asn-Phe-Gly-Leu-Asp-Leu-
2441 Lys-Ala-Asp-Asp-Lys-Ile-Tyr-Phe-Gly-Gly-
2451 Leu-Pro-Thr-Leu-Arg-Asn-Leu-Ser-Met-Lys-
2461 Ala-Arg-Pro-Glu-Val-Asn-Leu-Lys-Lys-Tyr-
HITS At: 505-512

L7 ANSWER 28 OF 36 GENE COPYRIGHT 2004 The Thomson Corp on STN
AN ABB19793 Protein DGENE
TI Including laminin 2 protein, useful for research and therapeutic purposes
IN including peripheral nerve regeneration, treatment of degenerative muscle
PA disorders, angiogenesis regulation, and ex vivo cell therapy -
PI Yurchenco P
PR1 (VYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
US 2000-06730 A2 20001109 305P***
US 1999-131720 20000428
US 1999-139198 19990615
US 1999-143289 19990712
US 1999-155945 19990924

DT Patent
LA English
OS 2000-687537 [67]
CR N-PSDB: AAB8893
DESC Human laminin 2 alpha-2 chain.
AN ABB19793 Protein DGENE
AA 205A; 159K; 163D; 0 B; 162C; 119Q; 202E; 0 Z; 261G; 71 H; 166I;
246L; 184K; 46 M; 103F; 173P; 194S; 193T; 29 W; 96 Y; 156V; 0 Others
SOL 3110
SEQ3 1 Met-Pro-Gly-Ala-Ala-Gly-Val-Leu-Leu-Leu-
11 Leu-Leu-Leu-Ser-Gly-Gly-Leu-Gly-Gly-Val-
21 Gln-Ala-Gln-Arg-Pro-Gln-Gln-Gln-Arg-Gln-

31 Ser-Gln-Ala-His-Gln-Gln-Arg-Gly-Leu-Phe-
41 Pro-Ala-Val-Leu-Asn-Leu-Ala-Ser-Asn-Ala-
51 Leu-Ile-Thr-Thr-Asn-Ala-Thr-Cys-Gly-Glu-
61 Lys-Gly-Pro-Glu-Met-Tyr-Cys-Lys-Leu-Val-
71 Gln-His-Val-Pro-Gly-Gln-Pro-Val-Arg-Asn-
81 Pro-Gln-Cys-Arg-Ile-Cys-Asn-Gln-Asn-Ser-
91 Ser-Asn-Pro-Asn-Gln-Arg-His-Pro-Ile-Thr-
101 Asn-Ala-Ile-Asp-Gly-Lys-Asn-Thr-Tip-Tip-
111 Gln-Ser-Pro-Ser-Ile-Lys-Asn-Gly-Ile-Glu-
121 Tyr-His-Tyr-Val-Thr-Ile-Thr-Leu-Asp-Leu-
131 Gln-Gln-Val-Phe-Gln-Ile-Ala-Tyr-Val-Ile-
141 Val-Lys-Ala-Ala-Asn-Ser-Pro-Arg-Pro-Gly-
151 Asn-Tip-Ile-Leu-Glu-Arg-Ser-Leu-Asp-Asp-
161 Val-Glu-Tyr-Lys-Pro-Tip-Gln-Tyr-His-Ala-
171 Val-Thr-Asp-Thr-Glu-Cys-Leu-Thr-Leu-Tyr-
181 Asn-Ile-Tyr-Pro-Arg-Thr-Gly-Pro-Pro-Ser-
191 Tyr-Ala-Lys-Asp-Asp-Glu-Val-Ile-Cys-Thr-
201 Ser-Phe-Tyr-Ser-Lys-Ile-His-Pro-Leu-Glu-
211 Asn-Gly-Glu-Ile-His-Ile-Ser-Leu-Ile-Asn-
221 Gly-Arg-Pro-Ser-Ala-Asp-Asp-Pro-Ser-Pro-
231 Glu-Leu-Leu-Glu-Phe-Thr-Ser-Ala-Arg-Tyr-
241 Ile-Arg-Leu-Arg-Phe-Gln-Arg-Ile-Arg-Thr-
251 Leu-Asn-Ala-Asp-Leu-Met-Met-Phe-Ala-His-
261 Lys-Asp-Pro-Arg-Glu-Ile-Asp-Pro-Ile-Val-
271 Thr-Arg-Arg-Tyr-Tyr-Tyr-Ser-Val-Lys-Asp-
281 Ile-Ser-Val-Gly-Gly-Met-Cys-Ile-Cys-Tyr-
291 Gly-His-Ala-Arg-Ala-Cys-Pro-Leu-Asp-Pro-
301 Ala-Thr-Asn-Lys-Ser-Arg-Cys-Glu-Cys-Glu-
311 His-Asn-Thr-Cys-Gly-Asp-Ser-Cys-Asp-Gln-
321 Cys-Cys-Pro-Gly-Phe-His-Gln-Lys-Pro-Tip-
331 Arg-Ala-Gly-Thr-Phe-Leu-Thr-Lys-Thr-Glu-
341 Cys-Glu-Ala-Cys-Asn-Cys-His-Gly-Lys-Ala-
351 Glu-Glu-Cys-Tyr-Tyr-Asp-Glu-Asn-Val-Ala-
361 Arg-Arg-Asn-Leu-Ser-Leu-Asn-Ile-Arg-Gly-
371 Lys-Tyr-Ile-Gly-Gly-Gly-Val-Cys-Ile-Asn-
381 Cys-Thr-Gln-Asn-Thr-Ala-Gly-Ile-Asn-Cys-
391 Glu-Thr-Cys-Thr-Asp-Gly-Phe-Phe-Arg-Pro-
401 Lys-Gly-Val-Ser-Pro-Asn-Tyr-Pro-Arg-Pro-
411 Cys-Gln-Pro-Cys-His-Cys-Asp-Pro-Ile-Gly-
421 Ser-Leu-Asn-Glu-Val-Cys-Val-Lys-Asp-Glu-
431 Lys-His-Ala-Arg-Arg-Gly-Leu-Ala-Pro-Gly-
441 Ser-Cys-His-Cys-Lys-Thr-Gly-Phe-Gly-Gly-
451 Val-Ser-Cys-Asp-Arg-Cys-Ala-Arg-Gly-Tyr-
461 Thr-Gly-Tyr-Pro-Asp-Cys-Lys-Ala-Cys-Asn-
471 Cys-Ser-Gly-Leu-Gly-Ser-Lys-Asn-Glu-Asp-
481 Pro-Cys-Phe-Gly-Pro-Cys-Ile-Cys-Lys-Glu-
491 Asn-Val-Glu-Gly-Gly-Asp-Cys-Ser-Arg-Cys-
501 Lys-Ser-Gly-Phe-Phe-Asn-Leu-Gln-Glu-Asp-
511 Asn-Tip-Lys-Gly-Cys-Asp-Glu-Cys-Phe-Cys-
521 Ser-Gly-Val-Ser-Asn-Arg-Cys-Gln-Ser-Ser-
531 Tyr-Tip-Thr-Tyr-Gly-Lys-Ile-Gln-Asp-Met-

541 Ser-Gly-Tyr-Tyr-Leu-Thr-Asp-Leu-Pro-Gly-
551 Arg-Ile-Arg-Val-Ala-Pro-Gln-Gln-Asp-Asp-
561 Leu-Asp-Ser-Pro-Gln-Gln-Ile-Ser-Ile-Ser-
571 Asn-Ala-Glu-Ala-Arg-Gln-Ala-Leu-Pro-His-
581 Ser-Tyr-Tyr-Tip-Ser-Ala-Pro-Ala-Pro-Tyr-
591 Leu-Gly-Asn-Lys-Leu-Pro-Ala-Val-Gly-Gly-
601 Gln-Leu-Thr-Phe-Thr-Ile-Ser-Tyr-Asp-Leu-
611 Glu-Glu-Glu-Glu-Glu-Asp-Thr-Glu-Arg-Val-
621 Leu-Gln-Leu-Met-Ile-Ile-Leu-Glu-Gly-Asn-
631 Asp-Leu-Ser-Ile-Ser-Thr-Ala-Gln-Asp-Glu-
641 Val-Tyr-Leu-His-Pro-Ser-Glu-Glu-His-Thr-
651 Asn-Val-Leu-Leu-Lys-Glu-Glu-Ser-Phe-
661 Thr-Ile-His-Gly-Thr-His-Phe-Pro-Val-Arg-
671 Arg-Lys-Gly-Phe-Met-Thr-Val-Leu-Ala-Asn-
681 Leu-Lys-Arg-Val-Leu-Leu-Gln-Ile-Thr-Tyr-
691 Ser-Phe-Gly-Met-Asp-Ala-Ile-Phe-Arg-Leu-
701 Ser-Ser-Val-Asn-Leu-Glu-Ser-Ala-Val-Ser-
711 Tyr-Pro-Thr-Asp-Gly-Ser-Ile-Ala-Ala-Ala-
721 Val-Glu-Val-Cys-Gln-Cys-Pro-Pro-Gly-Tyr-
731 Thr-Gly-Ser-Ser-Cys-Glu-Ser-Cys-Tip-Pro-
741 Arg-His-Arg-Arg-Val-Asn-Gly-Thr-Ile-Phe-
751 Gly-Gly-Ile-Cys-Glu-Pro-Cys-Gln-Cys-Phe-
761 Gly-His-Ala-Glu-Ser-Cys-Asp-Asp-Val-Thr-
771 Gly-Glu-Cys-Leu-Asn-Cys-Lys-Asp-His-Thr-
781 Gly-Gly-Pro-Tyr-Cys-Asp-Lys-Cys-Leu-Pro-
791 Gly-Phe-Tyr-Gly-Glu-Pro-Thr-Lys-Gly-Thr-
801 Ser-Glu-Asp-Cys-Gln-Pro-Cys-Ala-Cys-Pro-
811 Leu-Asn-Ile-Pro-Ser-Asn-Asn-Phe-Ser-Pro-
821 Thr-Cys-His-Leu-Asp-Arg-Ser-Leu-Gly-Leu-
831 Ile-Cys-Asp-Gly-Cys-Pro-Val-Gly-Tyr-Thr-
841 Gly-Pro-Arg-Cys-Glu-Arg-Cys-Ala-Glu-Gly-
851 Tyr-Phe-Gly-Gln-Pro-Ser-Val-Pro-Gly-Gly-
861 Ser-Cys-Gln-Pro-Cys-Gln-Cys-Asn-Asp-Asn-
871 Leu-Asp-Phe-Ser-Ile-Pro-Gly-Ser-Cys-Asp-
881 Ser-Leu-Ser-Gly-Ser-Cys-Leu-Ile-Cys-Lys-
891 Pro-Gly-Thr-Thr-Gly-Arg-Tyr-Cys-Glu-Leu-
901 Cys-Ala-Asp-Gly-Tyr-Phe-Gly-Asp-Ala-Val-
911 Asp-Ala-Lys-Asn-Cys-Gln-Pro-Cys-Arg-Cys-
921 Asn-Ala-Gly-Gly-Ser-Phe-Ser-Glu-Val-Cys-
931 His-Ser-Gln-Thr-Gly-Gln-Cys-Glu-Cys-Arg-
941 Ala-Asn-Val-Gln-Gly-Gln-Arg-Cys-Asp-Lys-
951 Cys-Lys-Ala-Gly-Thr-Phe-Gly-Leu-Gln-Ser-
961 Ala-Arg-Gly-Cys-Val-Pro-Cys-Asn-Cys-Asn-
971 Ser-Phe-Gly-Ser-Lys-Ser-Phe-Asp-Cys-Glu-
981 Glu-Ser-Gly-Gln-Cys-Tip-Cys-Gln-Pro-Gly-
991 Val-Thr-Gly-Lys-Lys-Cys-Asp-Arg-Cys-Ala-
1001 His-Gly-Tyr-Phe-Asn-Phe-Gln-Glu-Gly-Gly-
1011 Cys-Thr-Ala-Cys-Glu-Cys-Ser-His-Leu-Gly-
1021 Asn-Asn-Cys-Asp-Pro-Lys-Thr-Gly-Arg-Cys-
1031 Ile-Cys-Pro-Pro-Asn-Thr-Ile-Gly-Glu-Lys-
1041 Cys-Ser-Lys-Cys-Ala-Pro-Asn-Thr-Tip-Gly-
1051 His-Ser-Ile-Thr-Thr-Gly-Cys-Lys-Ala-Cys-
1061 Asn-Cys-Ser-Thr-Val-Gly-Ser-Leu-Asp-Phe-
1071 Gln-Cys-Asn-Val-Asn-Thr-Gly-Gln-Cys-Asn-
1081 Cys-His-Pro-Lys-Phe-Ser-Gly-Ala-Lys-Cys-
1091 Thr-Glu-Cys-Ser-Arg-Gly-His-Tip-Asn-Tyr-
1101 Pro-Arg-Cys-Asn-Leu-Cys-Asp-Cys-Phe-Leu-
1111 Pro-Gly-Thr-Asp-Ala-Thr-Thr-Cys-Asp-Ser-
1121 Glu-Thr-Lys-Lys-Cys-Ser-Cys-Ser-Asp-Gln-
1131 Thr-Gly-Gln-Cys-Thr-Cys-Lys-Val-Asn-Val-
1141 Glu-Gly-Ile-His-Cys-Asp-Arg-Cys-Arg-Pro-

1151 Gly-Lys-Phe-Gly-Leu-Asp-Ala-Lys-Asn-Pro-
1161 Leu-Gly-Cys-Ser-Cys-Tyr-Cys-Phe-Gly-
1171 Thr-Thr-Thr-Gln-Cys-Ser-Glu-Ala-Lys-Gly-
1181 Leu-Ile-Arg-Thr-Tyr-Val-Thr-Leu-Lys-Ala-
1191 Glu-Gln-Thr-Ile-Leu-Pro-Leu-Val-Asp-Glu-
1201 Ala-Leu-Gln-His-Thr-Thr-Lys-Gly-Ile-
1211 Val-Phe-Gln-His-Pro-Glu-Ile-Val-Ala-His-
1221 Met-Asp-Leu-Met-Arg-Glu-Asp-Leu-His-Leu-
1231 Glu-Pro-Phe-Tyr-Trp-Lys-Leu-Pro-Glu-Gln-
1241 Phe-Glu-Gly-Lys-Lys-Leu-Met-Ala-Tyr-Gly-
1251 Gly-Lys-Leu-Lys-Tyr-Ala-Ile-Tyr-Phe-Glu-
1261 Ala-Arg-Glu-Glu-Thr-Gly-Phe-Ser-Thr-Tyr-
1271 Asn-Pro-Gln-Val-Ile-Ile-Arg-Gly-Gly-Thr-
1281 Pro-Thr-His-Ala-Arg-Ile-Ile-Val-Arg-His-
1291 Met-Ala-Ala-Pro-Leu-Ile-Gly-Glu-Leu-Thr-
1301 Arg-His-Glu-Ile-Glu-Met-Thr-Glu-Lys-Glu-
1311 Trp-Lys-Tyr-Tyr-Gly-Asp-Pro-Arg-Val-
1321 His-Arg-Thr-Val-Thr-Arg-Glu-Asp-Phe-Leu-
1331 Asp-Ile-Leu-Tyr-Asp-Ile-His-Tyr-Ile-Leu-
1341 Ile-Lys-Ala-Thr-Tyr-Gly-Asn-Phe-Met-Arg-
1351 Gln-Ser-Arg-Ile-Ser-Glu-Ile-Ser-Met-Glu-
1361 Val-Ala-Glu-Gln-Gly-Arg-Arg-Thr-Met-
1371 Thr-Pro-Pro-Ala-Asp-Leu-Ile-Glu-Lys-Cys-
1381 Asp-Cys-Pro-Leu-Gly-Tyr-Ser-Gly-Leu-Ser-
1391 Cys-Glu-Ala-Cys-Leu-Pro-Gly-Phe-Tyr-Arg-
1401 Leu-Arg-Ser-Gln-Pro-Gly-Gly-Arg-Thr-Pro-
1411 Gly-Pro-Thr-Leu-Gly-Thr-Cys-Val-Pro-Cys-
1421 Gln-Cys-Asn-Gly-His-Ser-Ser-Leu-Cys-Asp-
1431 Pro-Glu-Thr-Ser-Ile-Cys-Gln-Asn-Cys-Gln-
1441 His-His-Thr-Ala-Gly-Asp-Phe-Cys-Glu-Arg-
1451 Cys-Ala-Leu-Gly-Tyr-Tyr-Gly-Ile-Val-Lys-
1461 Gly-Leu-Pro-Asn-Asp-Cys-Gln-Gln-Cys-Ala-
1471 Cys-Pro-Leu-Ile-Ser-Ser-Ser-Asn-Asn-Phe-
1481 Ser-Pro-Ser-Cys-Val-Ala-Glu-Gly-Leu-Asp-
1491 Asp-Tyr-Arg-Cys-Thr-Ala-Cys-Pro-Arg-Gly-
1501 Tyr-Glu-Gly-Gln-Tyr-Cys-Glu-Arg-Cys-Ala-
1511 Pro-Gly-Tyr-Thr-Gly-Ser-Pro-Gly-Asn-Pro-
1521 Gly-Gly-Ser-Cys-Gln-Glu-Cys-Glu-Cys-Asp-
1531 Pro-Tyr-Gly-Ser-Leu-Pro-Val-Pro-Cys-Asp-
1541 Pro-Val-Thr-Gly-Phe-Cys-Thr-Cys-Arg-Pro-
1551 Gly-Ala-Thr-Gly-Arg-Lys-Cys-Asp-Gly-Cys-
1561 Lys-His-Tip-His-Ala-Arg-Glu-Gly-Trp-Glu-
1571 Cys-Val-Phe-Cys-Gly-Asp-Glu-Cys-Thr-Gly-
1581 Leu-Leu-Leu-Gly-Asp-Leu-Ala-Arg-Leu-Glu-
1591 Gln-Met-Val-Met-Ser-Ile-Asn-Leu-Thr-Gly-
1601 Pro-Leu-Pro-Ala-Pro-Tyr-Lys-Met-Leu-Tyr-
1611 Gly-Leu-Glu-Asn-Met-Thr-Gln-Glu-Leu-Lys-
1621 His-Leu-Leu-Ser-Pro-Gln-Arg-Ala-Pro-Glu-
1631 Arg-Leu-Ile-Gln-Leu-Ala-Glu-Gly-Asn-Leu-
1641 Asn-Thr-Leu-Val-Thr-Glu-Met-Asn-Gly-Leu-
1651 Leu-Thr-Arg-Ala-Thr-Lys-Val-Thr-Ala-Asp-
1661 Gly-Glu-Gln-Thr-Gly-Gln-Asp-Ala-Glu-Arg-
1671 Thr-Asn-Thr-Arg-Ala-Lys-Ser-Leu-Gly-Glu-
1681 Phe-Ile-Lys-Glu-Leu-Ala-Arg-Asp-Ala-Glu-
1691 Ala-Val-Asn-Glu-Lys-Ala-Ile-Leu-Leu-Asn-
1701 Glu-Thr-Leu-Gly-Thr-Arg-Asp-Glu-Ala-Phe-
1711 Glu-Arg-Asn-Leu-Glu-Gly-Leu-Gln-Lys-Glu-

1721 Ile-Asp-Gln-Met-Ile-Lys-Glu-Leu-Arg-Arg-
1731 Lys-Asn-Leu-Glu-Thr-Gln-Lys-Glu-Ile-Ala-
1741 Glu-Asp-Glu-Leu-Val-Ala-Ala-Glu-Ala-Leu-
1751 Leu-Lys-Lys-Val-Lys-Lys-Leu-Phe-Gly-Glu-
1761 Ser-Arg-Gly-Glu-Asn-Glu-Glu-Met-Glu-Lys-
1771 Asp-Leu-Arg-Glu-Lys-Leu-Ala-Asp-Tyr-Lys-
1781 Asn-Lys-Val-Asp-Asp-Ala-Tip-Asp-Leu-Leu-
1791 Arg-Glu-Ala-Thr-Asp-Lys-Ile-Arg-Glu-Ala-
1801 Asn-Arg-Leu-Phe-Ala-Val-Asn-Gln-Lys-Asn-
1811 Met-Thr-Ala-Leu-Glu-Lys-Lys-Lys-Glu-Ala-
1821 Val-Glu-Ser-Gly-Lys-Arg-Gln-Ile-Glu-Asp-
1831 Thr-Leu-Lys-Glu-Gly-Asn-Asp-Ile-Leu-Asp-
1841 Glu-Ala-Asn-Arg-Leu-Ala-Asp-Glu-Ile-Asn-
1851 Ser-Ile-Ile-Asp-Tyr-Val-Glu-Asp-Ile-Gln-
1861 Thr-Lys-Leu-Pro-Pro-Met-Ser-Glu-Glu-Leu-
1871 Asn-Asp-Lys-Ile-Asp-Asp-Leu-Ser-Gln-Glu-
1881 Ile-Lys-Asp-Arg-Lys-Leu-Ala-Glu-Lys-Val-
1891 Ser-Gln-Ala-Glu-Ser-His-Ala-Ala-Gln-Leu-
1901 Asn-Asp-Ser-Ser-Ala-Val-Leu-Asp-Gly-Ile-
1911 Leu-Asp-Glu-Ala-Lys-Asn-Ile-Ser-Phe-Asn-
1921 Ala-Thr-Ala-Ala-Phe-Lys-Ala-Tyr-Ser-Asn-
1931 Ile-Lys-Asp-Tyr-Ile-Asp-Glu-Ala-Glu-Lys-
1941 Val-Ala-Thr-Glu-Ala-Lys-Asp-Leu-Ala-His-
1951 Glu-Ala-Thr-Lys-Leu-Ala-Thr-Gly-Pro-Arg-
1961 Gly-Leu-Leu-Lys-Glu-Asp-Ala-Lys-Gly-Cys-
1971 Leu-Gln-Lys-Ser-Phe-Arg-Ile-Leu-Asn-Glu-
1981 Ala-Lys-Lys-Leu-Ala-Asn-Asp-Val-Lys-Glu-
1991 Asn-Gly-Asp-His-Leu-Asn-Gly-Leu-Lys-Thr-
2001 Arg-Ile-Glu-Asn-Ala-Asp-Ala-Arg-Asn-Gly-
2011 Asp-Leu-Leu-Arg-Thr-Leu-Asn-Asp-Thr-Leu-
2021 Gly-Lys-Leu-Ser-Ala-Ile-Pro-Asp-Asp-Thr-
2031 Ala-Ala-Lys-Leu-Gln-Ala-Val-Lys-Asp-Lys-
2041 Ala-Arg-Gln-Ala-Asn-Asp-Thr-Ala-Lys-Asp-
2051 Val-Leu-Arg-Gln-Ile-Thr-Glu-Leu-His-Gln-
2061 Asn-Leu-Asp-Gly-Leu-Lys-Lys-Asn-Tyr-Asn-
2071 Lys-Leu-Ala-Asp-Ser-Val-Ala-Lys-Thr-Asn-
2081 Ala-Val-Val-Lys-Asp-Pro-Ser-Lys-Asn-Lys-
2091 Ile-Ile-Ala-Asp-Ala-Asp-Ala-Thr-Val-Lys-
2101 Asn-Leu-Glu-Gln-Glu-Ala-Asp-Arg-Leu-Ile-
2111 Asp-Lys-Leu-Lys-Pro-Ile-Lys-Glu-Leu-Glu-
2121 Asp-Asn-Leu-Lys-Lys-Asn-Ile-Ser-Glu-Ile-
2131 Lys-Glu-Leu-Ile-Asn-Gln-Ala-Arg-Lys-Gln-
2141 Ala-Asn-Ser-Ile-Lys-Val-Ser-Val-Ser-Ser-
2151 Gly-Gly-Asp-Cys-Ile-Arg-Thr-Tyr-Lys-Pro-
2161 Glu-Ile-Lys-Lys-Gly-Ser-Tyr-Asn-Asn-Ile-
2171 Val-Val-Asn-Val-Lys-Thr-Ala-Val-Ala-Asp-
2181 Asn-Leu-Leu-Phe-Tyr-Leu-Gly-Ser-Ala-Lys-
2191 Phe-Ile-Asp-Phe-Leu-Ala-Ile-Glu-Met-Arg-
2201 Lys-Ile-Lys-Phe-Leu-Ala-Ile-Glu-Met-Arg-
2211 Gly-Ser-Gly-Val-Ser-Phe-Leu-Trp-Asp-Val-
2221 Asp-Leu-Thr-Ile-Asp-Asp-Ser-Tyr-Trp-Pro-
2231 Arg-Ile-Val-Ala-Ser-Arg-Thr-Gly-Arg-Asn-
2241 Gly-Thr-Ile-Ser-Val-Arg-Ala-Leu-Asp-Asn-
2251 Pro-Lys-Ala-Ser-Ile-Val-Pro-Ser-Thr-His-
2261 His-Ser-Thr-Ser-Pro-Pro-Gly-Tyr-Thr-Ile-
2271 Leu-Asp-Val-Asp-Ala-Asn-Ala-Met-Leu-Phe-
2281 Val-Gly-Gly-Leu-Thr-Gly-Lys-Leu-Lys-Lys-

2291 Ala-Asp-Ala-Val-Arg-Val-Ile-Thr-Phe-Thr-
2301 Gly-Cys-Met-Gly-Glu-Thr-Tyr-Phe-Asp-Asn-
2311 Lys-Pro-Ile-Gly-Leu-Thr-Asn-Phe-Arg-Glu-
2321 Lys-Gly-Gly-Asp-Cys-Lys-Gly-Cys-Thr-Val-
2331 Ser-Pro-Gln-Val-Glu-Asp-Ser-Glu-Gly-Thr-
2341 Ile-Gln-Phe-Asp-Gly-Glu-Gly-Tyr-Ala-Leu-
2351 Val-Ser-Arg-Pro-Ile-Arg-Tyr-Pro-Asn-
2361 Ile-Ser-Thr-Val-Met-Phe-Lys-Phe-Arg-Thr-
2371 Phe-Ser-Ser-Ser-Ala-Leu-Leu-Met-Tyr-Leu-
2381 Ala-Thr-Arg-Asp-Leu-Arg-Phe-Met-Ser-
2391 Val-Glu-Leu-Thr-Asp-Gly-His-Ile-Lys-Val-
2401 Ser-Tyr-Asp-Leu-Gly-Ser-Gly-Met-Ala-Ser-
2411 Val-Val-Ser-Asn-Gln-Asn-His-Asn-Asp-Gly-
2421 Lys-Tyr-Lys-Ser-Phe-Thr-Leu-Ser-Arg-Ile-
2431 Gln-Lys-Gln-Ala-Asn-Ile-Ser-Ile-Val-Asp-
2441 Ile-Asp-Thr-Asn-Gln-Glu-Asn-Ile-Ala-
2451 Thr-Ser-Ser-Ser-Gly-Asn-Phe-Gly-Leu-
2461 Asp-Leu-Lys-Ala-Asp-Asp-Lys-Ile-Tyr-Phe-
HITS AT: 527-534

FEATURE TABLE:

Key	Location	Qualifier
Peptide	1..22	Signal peptide
Protein	23..3110	Mature protein

L7 ANSWER 29 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAB19792 Protein DGENE
TI Purified laminin 2 protein, useful for research and therapeutic purposes
including peripheral nerve regeneration, treatment of degenerative muscle
disorders, angiogenesis regulation, and ex vivo cell therapy -

IN Yurchenco P UNIV NEW JERSEY MEDICINE & DENTISTRY.
PA (JURNE-N) ***NO 2000066730 A2 20001109 303p***

AI WO 2000-0511378 20000428
FRA1 US 1999-131720 19990430
US 1999-139198 19990615
US 1999-143289 19990712
US 1999-155945 19990924

DI Patent
English

LA English
OS 2000-687937 1671
CR N-PSDB: AAB8892

DESC Human laminin 2 mature alpha-2 chain.

AN AAB19792 Protein DGENE
AA 2003: 157R; 162N; 163D; 0 B; 162C; 118G; 204E; 0 Z; 256G; 70 H; 165I;
240J; 166K; 45 N; 104F; 171P; 192S; 193T; 27 W; 96 Y; 155V; 0 Others

SGL
SEQ3

1 Gln-Arg-Pro-Gln-Gln-Gln-Arg-Gln-Ser-Gln-
11 Ala-His-Gln-Gln-Arg-Gly-Leu-Phe-Pro-Ala-
21 Val-Leu-Asn-Leu-Ala-Ser-Asn-Ala-Leu-Ile-
31 Thr-Thr-Asn-Ala-Thr-Cys-Gly-Glu-Lys-Gly-
41 Pro-Glu-Met-Tyr-Cys-Lys-Leu-Val-Glu-His-

51 Val-Pro-Gly-Gln-Pro-Val-Arg-Asn-Pro-Gln-
61 Cys-Arg-Ile-Cys-Asn-Gln-Asn-Ser-Ser-Asn-
71 Pro-Asn-Gln-Arg-His-Pro-Ile-Thr-Asn-Ala-
81 Ile-Asp-Gly-Lys-Asn-Thr-Tyr-Tyr-Gln-Ser-
91 Pro-Ser-Ile-Lys-Asn-Gly-Ile-Glu-Tyr-His-
101 Tyr-Val-Thr-Ile-Thr-Leu-Asp-Leu-Gln-Gln-
111 Val-Phe-Gln-Ile-Ala-Tyr-Val-Ile-Lys-
121 Ala-Ala-Asn-Ser-Pro-Arg-Pro-Gly-Asn-Tyr-
131 Ile-Leu-Glu-Arg-Ser-Leu-Asp-Asp-Val-Glu-
141 Tyr-Lys-Pro-Tyr-Gln-Tyr-His-Ala-Val-Thr-
151 Asp-Thr-Glu-Cys-Leu-Thr-Leu-Tyr-Asn-Ile-
161 Tyr-Pro-Arg-Thr-Gly-Pro-Pro-Ser-Tyr-Ala-
171 Lys-Asp-Arg-Glu-Val-Ile-Cys-Thr-Ser-Phe-
181 Tyr-Ser-Lys-Ile-His-Pro-Leu-Glu-Asn-Gly-
191 Glu-Ile-His-Ile-Ser-Leu-Ile-Asp-Gly-Arg-
201 Pro-Ser-Ala-Asp-Asp-Pro-Ser-Pro-Glu-Leu-
211 Leu-Glu-Phe-Thr-Ser-Ala-Arg-Tyr-Ile-Arg-
221 Leu-Arg-Phe-Gln-Arg-Ile-Arg-Thr-Leu-Asn-
231 Ala-Asp-Leu-Met-Met-Phe-Ala-His-Lys-Asp-
241 Pro-Arg-Glu-Ile-Asp-Pro-Ile-Val-Thr-Arg-
251 Arg-Tyr-Tyr-Ser-Val-Lys-Asp-Ile-Ser-
261 Val-Gly-Gly-Met-Cys-Ile-Cys-Tyr-Gly-His-
271 Ala-Arg-Ala-Cys-Pro-Leu-Asp-Pro-Ala-Thr-
281 Asn-Lys-Ser-Arg-Cys-Glu-Cys-Glu-His-Asn-
291 Thr-Cys-Gly-Asp-Ser-Cys-Asp-Gln-Cys-Cys-
301 Pro-Gly-Phe-His-Gln-Lys-Pro-Tyr-Arg-Ala-
311 Gly-Thr-Phe-Leu-Thr-Lys-Thr-Glu-Cys-Glu-
321 Ala-Cys-Asn-Cys-His-Gly-Lys-Ala-Glu-Glu-
331 Cys-Tyr-Tyr-Asp-Glu-Asn-Val-Ala-Arg-Arg-
341 Asn-Leu-Ser-Leu-Asn-Ile-Arg-Gly-Lys-Tyr-
351 Ile-Gly-Gly-Gly-Val-Cys-Ile-Asn-Cys-Thr-
361 Gln-Asn-Thr-Ala-Gly-Ile-Asn-Cys-Glu-Thr-
371 Cys-Thr-Asp-Gly-Phe-Phe-Arg-Pro-Lys-Gly-
381 Val-Ser-Pro-Asn-Tyr-Pro-Arg-Pro-Cys-Gln-
391 Pro-Cys-His-Cys-Asp-Pro-Ile-Gly-Ser-Leu-
401 Asn-Glu-Val-Cys-Val-Lys-Asp-Glu-Lys-His-
411 Ala-Arg-Arg-Gly-Leu-Ala-Pro-Gly-Ser-Cys-
421 His-Cys-Lys-Thr-Gly-Phe-Gly-Tyr-Thr-Gly-
431 Cys-Asp-Arg-Cys-Ala-Arg-Gly-Tyr-Thr-Gly-
441 Tyr-Pro-Asp-Cys-Lys-Ala-Cys-Asn-Cys-Ser-
451 Gly-Leu-Gly-Ser-Lys-Asn-Glu-Asp-Pro-Cys-
461 Phe-Gly-Pro-Cys-Ile-Cys-Lys-Glu-Asn-Val-
471 Glu-Gly-Gly-Asp-Cys-Ser-Arg-Cys-Lys-Ser-
481 Gly-Phe-Phe-Asn-Leu-Gln-Glu-Asp-Asn-Tyr-
491 Lys-Gly-Cys-Asp-Glu-Cys-Phe-Cys-Ser-Gly-
501 Val-Ser-Asn-Arg-Cys-Gln-Ser-Ser-Tyr-Tyr-
511 Thr-Tyr-Gly-Lys-Ile-Gln-Asp-Met-Ser-Gly-

601 Leu-Met-Ile-Ile-Leu-Glu-Gly-Asn-Asp-Leu-
611 Ser-Ile-Ser-Thr-Ala-Gln-Asp-Glu-Val-Tyr-
621 Leu-His-Pro-Ser-Glu-Glu-His-Thr-Asn-Val-
631 Leu-Leu-Leu-Lys-Glu-Glu-Ser-Phe-Thr-Ile-
641 His-Gly-Thr-His-Phe-Pro-Val-Arg-Arg-Lys-
651 Glu-Phe-Met-Thr-Val-Leu-Ala-Asn-Leu-Lys-
661 Arg-Val-Leu-Leu-Gln-Ile-Thr-Tyr-Ser-Phe-
671 Gly-Met-Asp-Ala-Ile-Phe-Arg-Leu-Ser-Ser-
681 Val-Asn-Leu-Glu-Ser-Ala-Val-Ser-Tyr-Pro-
691 Thr-Asp-Gly-Ser-Ile-Ala-Ala-Ala-Val-Glu-
701 Val-Cys-Gln-Cys-Pro-Pro-Gly-Tyr-Thr-Gly-
711 Ser-Ser-Cys-Glu-Ser-Cys-Tyr-Pro-Arg-His-
721 Arg-Arg-Val-Asn-Gly-Thr-Ile-Phe-Gly-Gly-
731 Ile-Cys-Glu-Pro-Cys-Gln-Cys-Phe-Gly-His-
741 Ala-Glu-Ser-Cys-Asp-Asp-Val-Thr-Gly-Glu-
751 Cys-Leu-Asn-Cys-Lys-Asp-His-Thr-Gly-Gly-
761 Pro-Tyr-Cys-Asp-Lys-Cys-Leu-Pro-Gly-Phe-
771 Tyr-Gly-Glu-Pro-Thr-Lys-Gly-Thr-Ser-Glu-
781 Asp-Cys-Gln-Pro-Cys-Ala-Cys-Pro-Leu-Asn-
791 Ile-Pro-Ser-Asn-Asn-Phe-Ser-Pro-Thr-Cys-
801 His-Leu-Asp-Arg-Ser-Leu-Gly-Leu-Ile-Cys-
811 Asp-Gly-Cys-Pro-Val-Gly-Tyr-Thr-Gly-Pro-
821 Arg-Cys-Glu-Arg-Cys-Ala-Glu-Gly-Tyr-Phe-
831 Gly-Gln-Pro-Ser-Val-Pro-Gly-Gly-Ser-Cys-
841 Gln-Pro-Cys-Gln-Cys-Asn-Asp-Asn-Leu-Asp-
851 Phe-Ser-Ile-Pro-Gly-Ser-Cys-Asp-Ser-Leu-
861 Ser-Gly-Ser-Cys-Leu-Ile-Cys-Lys-Pro-Gly-
871 Thr-Thr-Gly-Arg-Tyr-Cys-Glu-Leu-Cys-Ala-
881 Asp-Gly-Tyr-Phe-Gly-Asp-Ala-Val-Asp-Ala-
891 Lys-Asn-Cys-Gln-Pro-Cys-Arg-Cys-Asn-Ala-
901 Gly-Gly-Ser-Phe-Ser-Glu-Val-Cys-His-Ser-
911 Gln-Thr-Gly-Gln-Cys-Glu-Cys-Arg-Ala-Asn-
921 Val-Gln-Gly-Gln-Arg-Cys-Asp-Lys-Cys-Lys-
931 Ala-Gly-Thr-Phe-Gly-Leu-Gln-Ser-Ala-Arg-
941 Gly-Cys-Val-Pro-Cys-Asn-Cys-Asn-Ser-Phe-
951 Gly-Ser-Lys-Ser-Phe-Asp-Cys-Glu-Glu-Ser-
961 Gly-Gln-Cys-Tyr-Cys-Gln-Pro-Gly-Val-Thr-
971 Gly-Lys-Lys-Cys-Asp-Arg-Cys-Ala-His-Gly-
981 Tyr-Phe-Asn-Phe-Gln-Glu-Gly-Gly-Cys-Thr-
991 Ala-Cys-Glu-Cys-Ser-His-Leu-Gly-Asn-Asn-
1001 Cys-Asp-Pro-Lys-Thr-Gly-Arg-Cys-Ile-Cys-
1011 Pro-Pro-Asn-Thr-Ile-Gly-Glu-Lys-Cys-Ser-
1021 Lys-Cys-Ala-Pro-Asn-Thr-Tyr-Gly-His-Ser-
1031 Ile-Thr-Thr-Gly-Cys-Lys-Ala-Cys-Asn-Cys-
1041 Ser-Thr-Val-Gly-Ser-Leu-Asp-Phe-Gln-Cys-
1051 Asn-Val-Asn-Thr-Gly-Gln-Cys-Asn-Cys-His-
1061 Pro-Lys-Phe-Ser-Gly-Ala-Lys-Cys-Thr-Glu-
1071 Cys-Ser-Arg-Gly-His-Tyr-Asn-Tyr-Pro-Arg-
1081 Cys-Asn-Leu-Cys-Asp-Cys-Phe-Leu-Pro-Gly-
1091 Thr-Asp-Ala-Thr-Thr-Cys-Asp-Ser-Glu-Thr-
1101 Lys-Lys-Cys-Ser-Cys-Ser-Asp-Gln-Thr-Gly-
1111 Gln-Cys-Thr-Cys-Lys-Val-Asn-Val-Glu-Gly-
1121 Ile-His-Cys-Asp-Arg-Cys-Arg-Pro-Gly-Lys-
1131 Phe-Gly-Leu-Asp-Ala-Lys-Asn-Pro-Leu-Gly-
1141 Cys-Ser-Ser-Cys-Tyr-Cys-Phe-Gly-Thr-Thr-
1151 Thr-Gln-Cys-Ser-Glu-Ala-Lys-Gly-Leu-Ile-
1161 Arg-Thr-Tyr-Val-Thr-Leu-Lys-Ala-Glu-Gln-

1171 Thr-Ile-Leu-Pro-Leu-Val-Asp-Glu-Ala-Leu-
1181 Gln-His-Thr-Thr-Thr-Lys-Gly-Ile-Val-Phe-
1191 Gln-His-Pro-Glu-Ile-Val-Ala-His-Met-Asp-
1201 Leu-Met-Arg-Glu-Asp-Leu-His-Leu-Glu-Pro-
1211 Phe-Tyr-Tyr-Lys-Leu-Pro-Glu-Glu-Phe-Gly-
1221 Gly-Lys-Lys-Leu-Met-Ala-Tyr-Gly-Gly-Lys-
1231 Leu-Lys-Tyr-Ala-Ile-Tyr-Phe-Glu-Ala-Arg-
1241 Glu-Glu-Thr-Gly-Phe-Ser-Thr-Tyr-Asn-Pro-
1251 Gln-Val-Ile-Ile-Arg-Gly-Thr-Thr-Pro-Thr-
1261 His-Ala-Arg-Ile-Ile-Val-Arg-His-Met-Ala-
1271 Ala-Pro-Leu-Ile-Ile-Gln-Leu-Thr-Arg-His-
1281 Glu-Ile-Glu-Met-Thr-Glu-Lys-Glu-Tyr-Lys-
1291 Tyr-Tyr-Gly-Met-Asp-Pro-Arg-Val-His-Arg-
1301 Thr-Val-Thr-Arg-Glu-Asp-Phe-Leu-Asp-Ile-
1311 Leu-Tyr-Asp-Ile-His-Tyr-Ile-Leu-Ile-Lys-
1321 Ala-Thr-Tyr-Gly-Asn-Phe-Met-Arg-Gln-Ser-
1331 Arg-Ile-Ser-Glu-Ile-Ser-Met-Glu-Val-Ala-
1341 Glu-Gln-Gly-Arg-Gly-Thr-Thr-Met-Thr-Pro-
1351 Pro-Ala-Asp-Leu-Ile-Glu-Lys-Cys-Asp-Cys-
1361 Pro-Leu-Gly-Tyr-Ser-Gly-Leu-Ser-Cys-Glu-
1371 Ala-Cys-Leu-Pro-Gly-Phe-Tyr-Arg-Leu-Arg-
1381 Ser-Gln-Pro-Gly-Gly-Arg-Thr-Pro-Gly-Pro-
1391 Thr-Leu-Gly-Thr-Cys-Val-Pro-Cys-Gln-Cys-
1401 Asn-Gly-His-Ser-Ser-Leu-Cys-Asp-Pro-Glu-
1411 Thr-Ser-Ile-Cys-Gln-Asn-Cys-Gln-His-His-
1421 Thr-Ala-Gly-Asp-Phe-Cys-Glu-Arg-Cys-Ala-
1431 Leu-Gly-Tyr-Tyr-Gly-Ile-Val-Lys-Gly-Leu-
1441 Pro-Asn-Asp-Cys-Gln-Gln-Cys-Ala-Cys-Pro-
1451 Leu-Ile-Ser-Ser-Asn-Asn-Phe-Ser-Pro-
1461 Ser-Cys-Val-Ala-Glu-Gly-Leu-Asp-Asp-Tyr-
1471 Arg-Cys-Thr-Ala-Cys-Pro-Arg-Gly-Tyr-Glu-
1481 Gly-Gln-Tyr-Cys-Glu-Arg-Cys-Ala-Pro-Gly-
1491 Tyr-Thr-Gly-Ser-Pro-Gly-Asn-Pro-Gly-Gly-
1501 Ser-Cys-Gln-Glu-Cys-Glu-Cys-Asp-Pro-Tyr-
1511 Gly-Ser-Leu-Pro-Val-Pro-Cys-Asp-Pro-Val-
1521 Thr-Gly-Phe-Cys-Thr-Cys-Arg-Pro-Gly-Ala-
1531 Thr-Gly-Arg-Lys-Cys-Asp-Gly-Cys-Lys-His-
1541 Tyr-His-Ala-Arg-Glu-Gly-Tyr-Glu-Cys-Val-
1551 Phe-Cys-Gly-Asp-Glu-Cys-Thr-Gly-Leu-Leu-
1561 Leu-Gly-Asp-Leu-Ala-Arg-Leu-Glu-Met-
1571 Val-Met-Ser-Ile-Asn-Leu-Thr-Gly-Pro-Leu-
1581 Pro-Ala-Pro-Tyr-Lys-Met-Leu-Tyr-Gly-Leu-
1591 Glu-Asn-Met-Thr-Gln-Glu-Leu-Lys-His-Leu-
1601 Leu-Ser-Pro-Gln-Arg-Ala-Pro-Glu-Arg-Leu-
1611 Ile-Gln-Leu-Ala-Glu-Gly-Asn-Leu-Asn-Thr-
1621 Leu-Val-Thr-Glu-Met-Asn-Glu-Leu-Leu-Thr-
1631 Arg-Ala-Thr-Lys-Val-Thr-Ala-Asp-Gly-Glu-
1641 Gln-Thr-Gly-Gln-Asp-Ala-Glu-Arg-Thr-Asn-
1651 Thr-Arg-Ala-Lys-Ser-Leu-Gly-Glu-Phe-Ile-
1661 Lys-Glu-Leu-Ala-Arg-Asp-Ala-Glu-Ala-Val-
1671 Asn-Glu-Lys-Ala-Ile-Lys-Leu-Asn-Glu-Thr-
1681 Leu-Gly-Thr-Arg-Asp-Glu-Ala-Phe-Glu-Arg-
1691 Asn-Leu-Gly-Gly-Leu-Gln-Lys-Glu-Ile-Asp-
1701 Gln-Met-Ile-Lys-Glu-Leu-Arg-Arg-Lys-Asn-
1711 Leu-Glu-Thr-Gln-Lys-Glu-Ile-Ala-Glu-Asp-
1721 Glu-Leu-Val-Ala-Ala-Glu-Ala-Leu-Leu-Lys-
1731 Lys-Val-Lys-Lys-Leu-Phe-Gly-Glu-Ser-Arg-

1741 Gly-Glu-Asn-Glu-Glu-Met-Glu-Lys-Asp-Leu-
1751 Arg-Glu-Lys-Leu-Ala-Asp-Tyr-Asn-Lys-
1761 Val-Asp-Asp-Ala-Tyr-Asp-Leu-Leu-Arg-Glu-
1771 Ala-Thr-Asp-Lys-Ile-Arg-Glu-Ala-Asn-Arg-
1781 Leu-Phe-Ala-Val-Asn-Gln-Lys-Asn-Met-Thr-
1791 Ala-Leu-Glu-Lys-Lys-Lys-Glu-Ala-Val-Glu-
1801 Ser-Gly-Lys-Arg-Gln-Ile-Glu-Asn-Thr-Leu-
1811 Lys-Glu-Gly-Asn-Asp-Ile-Leu-Asp-Glu-Ala-
1821 Asn-Arg-Leu-Ala-Asp-Glu-Ile-Asn-Ser-Ile-
1831 Ile-Asp-Tyr-Val-Glu-Asp-Ile-Gln-Thr-Lys-
1841 Leu-Pro-Pro-Met-Ser-Glu-Glu-Leu-Asn-Asp-
1851 Lys-Ile-Asp-Asp-Leu-Ser-Gln-Glu-Ile-Lys-
1861 Asp-Arg-Lys-Leu-Ala-Glu-Lys-Val-Ser-Gln-
1871 Ala-Glu-Ser-His-Ala-Ala-Gln-Leu-Asn-Asp-
1881 Ser-Ser-Ala-Val-Leu-Asp-Gly-Ile-Leu-Asp-
1891 Glu-Ala-Lys-Asn-Ile-Ser-Phe-Asn-Ala-Thr-
1901 Ala-Ala-Phe-Lys-Ala-Tyr-Ser-Asn-Ile-Lys-
1911 Asp-Tyr-Ile-Asp-Glu-Ala-Glu-Lys-Val-Ala-
1921 Lys-Glu-Ala-Lys-Asp-Leu-Ala-His-Glu-Ala-
1931 Thr-Lys-Leu-Ala-Thr-Gly-Pro-Arg-Gly-Leu-
1941 Leu-Lys-Glu-Asp-Ala-Lys-Gly-Cys-Leu-Gln-
1951 Lys-Ser-Phe-Arg-Ile-Leu-Asn-Glu-Ala-Lys-
1961 Lys-Leu-Ala-Asn-Asp-Val-Lys-Glu-Asn-Glu-
1971 Asp-His-Leu-Asn-Asp-Gly-Leu-Thr-Arg-Ile-
1981 Glu-Asn-Ala-Asp-Ala-Arg-Asn-Gly-Asp-Leu-
1991 Leu-Arg-Thr-Leu-Asn-Asp-Thr-Leu-Gly-Lys-
2001 Leu-Ser-Ala-Ile-Pro-Asp-Asp-Thr-Ala-Ala-
2011 Lys-Leu-Gln-Ala-Val-Lys-Asp-Lys-Ala-Arg-
2021 Gln-Ala-Asn-Asp-Thr-Ala-Lys-Asp-Val-Leu-
2031 Ala-Gln-Ile-Thr-Glu-Leu-His-Gln-Asn-Leu-
2041 Asp-Gly-Leu-Lys-Lys-Asn-Tyr-Asn-Lys-Leu-
2051 Ala-Asp-Ser-Val-Ala-Lys-Thr-Asn-Ala-Val-
2061 Val-Lys-Asp-Pro-Ser-Lys-Asn-Lys-Ile-Ile-
2071 Ala-Asp-Ala-Asp-Ala-Thr-Val-Lys-Asn-Leu-
2081 Glu-Gln-Glu-Ala-Asp-Arg-Leu-Ile-Asp-Lys-
2091 Leu-Lys-Pro-Ile-Lys-Glu-Leu-Glu-Asp-Asn-
2101 Leu-Lys-Lys-Asn-Ile-Ser-Glu-Ile-Lys-Glu-
2111 Leu-Ile-Asn-Gln-Ala-Arg-Lys-Gln-Ala-Asn-
2121 Ser-Ile-Lys-Val-Ser-Val-Ser-Ser-Gly-Gly-
2131 Asp-Cys-Ile-Arg-Thr-Tyr-Lys-Pro-Glu-Ile-
2141 Lys-Lys-Gly-Ser-Tyr-Asn-Asn-Ile-Val-Val-
2151 Asn-Val-Lys-Thr-Ala-Val-Ala-Asp-Asn-Leu-
2161 Leu-Phe-Tyr-Leu-Gly-Ser-Ala-Lys-Phe-Ile-
2171 Asp-Phe-Leu-Ala-Ile-Glu-Met-Arg-Lys-Gly-
2181 Lys-Val-Ser-Phe-Leu-Tip-Asp-Val-Gly-Ser-
2191 Gly-Val-Gly-Arg-Val-Glu-Tyr-Pro-Asp-Leu-
2201 Thr-Ile-Asp-Asp-Ser-Tyr-Tip-Tyr-Arg-Ile-
2211 Val-Ala-Ser-Arg-Thr-Gly-Arg-Asn-Gly-Thr-
2221 Ile-Ser-Val-Arg-Ala-Leu-Asp-Gly-Pro-Lys-
2231 Ala-Ser-Ile-Val-Pro-Ser-Thr-His-His-Ser-
2241 Thr-Ser-Pro-Pro-Gly-Tyr-Thr-Ile-Leu-Asp-
2251 Val-Asp-Ala-Asn-Ala-Met-Leu-Phe-Val-Gly-
2261 Gly-Leu-Thr-Gly-Lys-Leu-Lys-Phe-Ala-Asp-
2271 Ala-Val-Arg-Val-Ile-Thr-Phe-Thr-Gly-Cys-
2281 Met-Gly-Glu-Thr-Tyr-Phe-Asp-Glu-Lys-Pro-
2291 Ile-Gly-Leu-Tip-Asn-Phe-Arg-Glu-Lys-Glu-
2301 Gly-Asp-Cys-Lys-Gly-Cys-Thr-Val-Ser-Pro-

2311 Gln-Val-Glu-Asp-Ser-Glu-Gly-Thr-Ile-Gln-
2321 Phe-Asp-Gly-Glu-Gly-Tyr-Ala-Leu-Val-Ser-
2331 Arg-Pro-Ile-Arg-Tip-Tyr-Pro-Asn-Ile-Ser-
2341 Thr-Val-Met-Phe-Lys-Phe-Arg-Thr-Phe-Ser-
2351 Ser-Ser-Ala-Leu-Leu-Met-Tyr-Leu-Ala-Thr-
2361 Arg-Asp-Leu-Arg-Asp-Phe-Met-Ser-Val-Glu-
2371 Leu-Thr-Asp-Gly-His-Ile-Lys-Val-Ser-Tyr-
2381 Asp-Leu-Gly-Ser-Gly-Met-Ala-Ser-Val-Val-
2391 Ser-Asn-Gln-Asn-His-Asn-Asp-Gly-Lys-Tip-
2401 Lys-Ser-Phe-Thr-Leu-Ser-Arg-Ile-Gln-Lys-
2411 Gln-Ala-Asn-Ile-Ser-Ile-Val-Asp-Ile-Ser-
2421 Thr-Asn-Gln-Glu-Asn-Ile-Ala-Thr-Ser-
2431 Ser-Ser-Gly-Asn-Asn-Phe-Gly-Leu-Asp-Leu-
2441 Lys-Ala-Asp-Asp-Lys-Ile-Tyr-Phe-Gly-Gly-
2451 Leu-Pro-Thr-Leu-Arg-Asn-Leu-Ser-Met-Lys-
2461 Ala-Arg-Pro-Glu-Val-Asn-Leu-Lys-Lys-Tyr-
HITS AT: 505-512

L7 ANSWER 30 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STM
AN AAB19791 Protein DGENE
TI Purified laminin 2 protein, useful for research and therapeutic purposes
including peripheral nerve regeneration, treatment of degenerative muscle
dysorders, angiogenesis regulation, and ex vivo cell therapy -
Yurchenco P
IN (UYNE-N) UNIV NEW JERSEY MEDICINE & DENTISTRY.
PA ***NO 2000066730 A2 20001109
PI WO 2000-US11378 20000428 305p***
AI US 1999-131720 19990430
PRAI US 1999-139198 19990615
US 1999-143289 19990712
US 1999-155945 19990924

DI Patent
LA English
OS 2000-667537 (67)
CR N-PSDB: AAB68891
DESC Human laminin 2 alpha-2 chain.
AN AAB19791 Protein DGENE
AA 206A; 157R; 162N; 183D; 0 B; 162C; 119Q; 204E; 0 Z; 262G; 70 H; 165I;
246L; 186K; 46 M; 104F; 172P; 193S; 193T; 27 W; 96 Y; 157V; 0 Others
SOL 310

1 Met-Pro-Gly-Ala-Ala-Gly-Val-Leu-Leu-Leu-
11 Leu-Leu-Leu-Ser-Gly-Gly-Leu-Gly-Gly-Val-
21 Gln-Ala-Gln-Arg-Pro-Gln-Gln-Gln-Arg-Gln-
31 Ser-Gln-Ala-His-Gln-Gln-Arg-Gly-Leu-Phe-
41 Pro-Ala-Val-Leu-Asn-Leu-Ala-Ser-Asn-Ala-
51 Leu-Ile-Thr-Thr-Asn-Ala-Thr-Cys-Gly-Glu-
61 Lys-Gly-Pro-Glu-Met-Tyr-Cys-Lys-Leu-Val-
71 Glu-His-Val-Pro-Gly-Gln-Pro-Val-Arg-Asn-
81 Pro-Gln-Cys-Arg-Ile-Cys-Asn-Gln-Asn-Ser-
91 Ser-Asn-Pro-Asn-Gln-Arg-His-Pro-Ile-Thr-
101 Asn-Ala-Ile-Asp-Gly-Lys-Asn-Thr-Tip-Tip-
111 Gln-Ser-Pro-Ser-Ile-Lys-Asn-Gly-Ile-Glu-
121 Tyr-His-Tyr-Val-Thr-Ile-Thr-Leu-Asp-Leu-
131 Gln-Gln-Val-Phe-Gln-Ile-Ala-Tyr-Val-Ile-
141 Val-Lys-Ala-Ala-Asn-Ser-Pro-Arg-Pro-Gly-
151 Asn-Tip-Ile-Leu-Glu-Arg-Ser-Leu-Asp-Asp-

161 Val-Glu-Tyr-Lys-Pro-Trp-Gln-Tyr-His-Ala-
171 Val-Thr-Asp-Thr-Glu-Cys-Leu-Thr-Leu-Tyr-
181 Asn-Ile-Tyr-Pro-Arg-Thr-Gly-Pro-Pro-Ser-
191 Tyr-Ala-Lys-Asp-Asp-Glu-Val-Ile-Cys-Thr-
201 Ser-Phe-Tyr-Ser-Lys-Ile-His-Pro-Leu-Glu-
211 Asn-Gly-Glu-Ile-His-Ile-Ser-Leu-Ile-Asn-
221 Gly-Arg-Pro-Ser-Ala-Asp-Asp-Pro-Ser-Pro-
231 Glu-Leu-Leu-Glu-Phe-Thr-Ser-Ala-Arg-Tyr-
241 Ile-Arg-Leu-Arg-Phe-Gln-Arg-Ile-Arg-Thr-
251 Leu-Asn-Ala-Asp-Leu-Met-Met-Phe-Ala-His-
261 Lys-Asp-Pro-Arg-Glu-Ile-Asp-Pro-Ile-Val-
271 Thr-Arg-Arg-Tyr-Tyr-Ser-Val-Lys-Asp-
281 Ile-Ser-Val-Gly-Gly-Met-Cys-Ile-Cys-Tyr-
291 Gly-His-Ala-Arg-Ala-Cys-Pro-Leu-Asp-Pro-
301 Ala-Thr-Asn-Lys-Ser-Arg-Cys-Glu-Cys-Glu-
311 His-Asn-Thr-Cys-Gly-Asp-Ser-Cys-Asp-Gln-
321 Cys-Cys-Pro-Gly-Phe-His-Gln-Lys-Pro-Trp-
331 Arg-Ala-Gly-Thr-Phe-Leu-Thr-Lys-Thr-Glu-
341 Cys-Glu-Ala-Cys-Asn-Cys-His-Gly-Lys-Ala-
351 Glu-Glu-Cys-Tyr-Tyr-Asp-Glu-Asn-Val-Ala-
361 Arg-Arg-Asn-Leu-Ser-Leu-Asn-Ile-Arg-Gly-
371 Lys-Tyr-Ile-Gly-Gly-Gly-Val-Cys-Ile-Asn-
381 Cys-Thr-Gln-Asn-Thr-Ala-Gly-Ile-Asn-Cys-
391 Glu-Thr-Cys-Thr-Asp-Gly-Phe-Phe-Arg-Pro-
401 Lys-Gly-Val-Ser-Pro-Asn-Tyr-Pro-Arg-Pro-
411 Cys-Gln-Pro-Cys-His-Cys-Asp-Pro-Ile-Gly-
421 Ser-Leu-Asn-Glu-Val-Cys-Val-Lys-Asp-Glu-
431 Lys-His-Ala-Arg-Arg-Gly-Leu-Ala-Pro-Gly-
441 Ser-Cys-His-Cys-Lys-Thr-Gly-Phe-Gly-Gly-
451 Val-Ser-Cys-Asp-Arg-Cys-Ala-Arg-Gly-Tyr-
461 Thr-Gly-Tyr-Pro-Asp-Cys-Lys-Ala-Cys-Asn-
471 Cys-Ser-Gly-Leu-Gly-Ser-Lys-Asn-Glu-Asp-
481 Pro-Cys-Phe-Gly-Pro-Cys-Ile-Cys-Lys-Glu-
491 Asn-Val-Glu-Gly-Gly-Asp-Cys-Ser-Arg-Cys-
501 Lys-Ser-Gly-Phe-Phe-Asn-Leu-Gln-Glu-Asp-
511 Asn-Trp-Lys-Gly-Cys-Asp-Glu-Cys-Phe-Cys-
521 Ser-Gly-Val-Ser-Asn-Arg-Cys-Gln-Ser-Ser-
531 Tyr-Trp-Thr-Tyr-Gly-Lys-Ile-Gln-Asp-Met-
541 Ser-Gly-Tyr-Tyr-Leu-Thr-Asp-Leu-Pro-Gly-
551 Arg-Ile-Arg-Val-Ala-Pro-Gln-Gln-Asp-Asp-
561 Leu-Asp-Ser-Pro-Gln-Gln-Ile-Ser-Ile-Ser-
571 Asn-Ala-Glu-Ala-Arg-Gln-Ala-Leu-Pro-His-
581 Ser-Tyr-Tyr-Trp-Ser-Ala-Pro-Ala-Pro-Tyr-
591 Leu-Gly-Asn-Lys-Leu-Pro-Ala-Val-Gly-Gly-
601 Gln-Leu-Thr-Phe-Thr-Ile-Ser-Tyr-Asp-Leu-
611 Glu-Glu-Glu-Glu-Asp-Thr-Glu-Arg-Val-
621 Leu-Gln-Leu-Met-Ile-Ile-Leu-Glu-Gly-Asn-
631 Asp-Leu-Ser-Ile-Ser-Thr-Ala-Gln-Asp-Glu-
641 Val-Tyr-Leu-His-Pro-Ser-Glu-Glu-His-Thr-
651 Asn-Val-Leu-Leu-Leu-Lys-Glu-Glu-Ser-Phe-
661 Thr-Ile-His-Gly-Thr-His-Phe-Pro-Val-Arg-
671 Arg-Lys-Glu-Phe-Met-Thr-Val-Leu-Ala-Asn-
681 Leu-Lys-Arg-Val-Leu-Leu-Gln-Ile-Thr-Tyr-
691 Ser-Phe-Gly-Met-Asp-Ala-Ile-Phe-Arg-Leu-
701 Ser-Ser-Val-Asn-Leu-Glu-Ser-Ala-Val-Ser-

711 Tyr-Pro-Thr-Asp-Gly-Ser-Ile-Ala-Ala-Ala-
721 Val-Glu-Val-Cys-Gln-Cys-Pro-Pro-Gly-Tyr-
731 Thr-Gly-Ser-Ser-Cys-Glu-Ser-Cys-Trp-Pro-
741 Arg-His-Arg-Arg-Val-Asn-Gly-Thr-Ile-Phe-
751 Gly-Gly-Ile-Cys-Glu-Pro-Cys-Gln-Cys-Phe-
761 Gly-His-Ala-Glu-Ser-Cys-Asp-Asp-Val-Thr-
771 Gly-Glu-Cys-Leu-Asn-Cys-Lys-Asp-His-Thr-
781 Gly-Gly-Pro-Tyr-Cys-Asp-Lys-Cys-Leu-Pro-
791 Gly-Phe-Tyr-Gly-Glu-Pro-Thr-Lys-Gly-Thr-
801 Ser-Glu-Asp-Cys-Gln-Pro-Cys-Ala-Cys-Pro-
811 Leu-Asn-Ile-Pro-Ser-Asn-Asn-Phe-Ser-Pro-
821 Thr-Cys-His-Leu-Asp-Arg-Ser-Leu-Gly-Leu-
831 Ile-Cys-Asp-Gly-Cys-Pro-Val-Gly-Tyr-Thr-
841 Gly-Pro-Arg-Cys-Glu-Arg-Cys-Ala-Glu-Gly-
851 Tyr-Phe-Gly-Gln-Pro-Ser-Val-Pro-Gly-Gly-
861 Ser-Cys-Gln-Pro-Cys-Gln-Cys-Asn-Asp-Asp-
871 Leu-Asp-Phe-Ser-Ile-Pro-Gly-Ser-Cys-Asp-
881 Ser-Leu-Ser-Gly-Ser-Cys-Leu-Ile-Cys-Lys-
891 Pro-Gly-Thr-Thr-Gly-Arg-Tyr-Cys-Glu-Leu-
901 Cys-Ala-Asp-Gly-Tyr-Phe-Gly-Asp-Ala-Val-
911 Asp-Ala-Lys-Asn-Cys-Gln-Pro-Cys-Arg-Cys-
921 Asn-Ala-Gly-Gly-Ser-Phe-Ser-Glu-Val-Cys-
931 His-Ser-Gln-Thr-Gly-Gln-Cys-Glu-Cys-Arg-
941 Ala-Asn-Val-Gln-Gly-Gln-Arg-Cys-Asp-Lys-
951 Cys-Lys-Ala-Gly-Thr-Phe-Gly-Leu-Gln-Ser-
961 Ala-Arg-Gly-Cys-Val-Pro-Cys-Asn-Cys-Asn-
971 Ser-Phe-Gly-Ser-Lys-Ser-Phe-Asp-Cys-Glu-
981 Glu-Ser-Gly-Gln-Cys-Trp-Cys-Gln-Pro-Gly-
991 Val-Thr-Gly-Lys-Lys-Cys-Asp-Arg-Cys-Ala-
1001 His-Gly-Tyr-Phe-Asn-Phe-Gln-Glu-Gly-Gly-
1011 Cys-Thr-Ala-Cys-Glu-Cys-Ser-His-Leu-Gly-
1021 Asn-Asn-Cys-Asp-Pro-Lys-Thr-Gly-Arg-Cys-
1031 Ile-Cys-Pro-Pro-Asn-Thr-Ile-Gly-Glu-Lys-
1041 Cys-Ser-Lys-Cys-Ala-Pro-Asn-Thr-Trp-Gly-
1051 His-Ser-Ile-Thr-Thr-Gly-Cys-Lys-Ala-Cys-
1061 Asn-Cys-Ser-Thr-Val-Gly-Ser-Leu-Asp-Phe-
1071 Gln-Cys-Asp-Val-Asn-Thr-Gly-Gln-Cys-Asn-
1081 Cys-His-Pro-Lys-Phe-Ser-Gly-Ala-Lys-Cys-
1091 Thr-Glu-Cys-Ser-Arg-Gly-His-Trp-Asn-Tyr-
1101 Pro-Arg-Cys-Asn-Leu-Cys-Asp-Cys-Phe-Leu-
1111 Gly-Thr-Lys-Lys-Cys-Ser-Cys-Ser-Asp-Gln-
1121 Thr-Gly-Gln-Cys-Thr-Cys-Lys-Val-Asn-Val-
1131 Glu-Gly-Ile-His-Cys-Asp-Arg-Cys-Arg-Pro-
1141 Gly-Lys-Phe-Gly-Leu-Asp-Ala-Lys-Asn-Pro-
1151 Leu-Gly-Cys-Ser-Ser-Cys-Tyr-Cys-Phe-Gly-
1161 Thr-Thr-Thr-Gln-Cys-Ser-Glu-Ala-Lys-Gly-
1171 Leu-Ile-Arg-Thr-Trp-Val-Thr-Leu-Lys-Ala-
1181 Glu-Gln-Thr-Ile-Leu-Pro-Leu-Val-Asp-Glu-
1191 Ala-Leu-Gln-His-Thr-Thr-Lys-Gly-Ile-
1201 Val-Phe-Gln-His-Pro-Glu-Ile-Val-Ala-His-
1211 Met-Asp-Leu-Met-Arg-Glu-Asp-Leu-His-Leu-
1221 Glu-Pro-Phe-Tyr-Trp-Lys-Leu-Pro-Glu-Gln-
1231 Phe-Glu-Gly-Lys-Lys-Leu-Met-Ala-Tyr-Gly-
1241 Gly-Lys-Leu-Lys-Tyr-Ala-Ile-Tyr-Phe-Gly-
1251 Ala-Arg-Glu-Glu-Thr-Gly-Phe-Ser-Thr-Tyr-
1261 Asn-Pro-Gln-Val-Ile-Ile-Arg-Gly-Gly-Thr-
1271

1281 Pro-Thr-His-Ala-Arg-Ile-Ile-Val-Arg-His-
1291 Met-Ala-Ala-Pro-Leu-Ile-Gly-Gln-Leu-Thr-
1301 Arg-His-Glu-Ile-Glu-Met-Thr-Glu-Lys-Glu-
1311 Trp-Lys-Tyr-Tyr-Gly-Asp-Asp-Pro-Arg-Val-
1321 His-Arg-Thr-Val-Thr-Arg-Glu-Asp-Phe-Leu-
1331 Asp-Ile-Leu-Tyr-Asp-Ile-His-Tyr-Ile-Leu-
1341 Ile-Lys-Ala-Thr-Tyr-Gly-Asn-Phe-Met-Arg-
1351 Gln-Ser-Arg-Ile-Ser-Glu-Ile-Ser-Met-Glu-
1361 Val-Ala-Glu-Gln-Gly-Arg-Gly-Thr-Met-
1371 Thr-Pro-Pro-Ala-Asp-Leu-Ile-Glu-Lys-Cys-
1381 Asp-Cys-Pro-Leu-Gly-Tyr-Ser-Gly-Leu-Ser-
1391 Cys-Glu-Ala-Cys-Leu-Pro-Gly-Phe-Tyr-Arg-
1401 Leu-Arg-Ser-Gln-Pro-Gly-Gly-Arg-Thr-Pro-
1411 Gly-Pro-Thr-Leu-Gly-Thr-Cys-Val-Pro-Cys-
1421 Gln-Cys-Asn-Gly-His-Ser-Ser-Leu-Cys-Gln-
1431 Pro-Glu-Thr-Ser-Ile-Cys-Gln-Asn-Cys-Gln-
1441 His-His-Thr-Ala-Gly-Asp-Phe-Cys-Glu-Arg-
1451 Cys-Ala-Leu-Gly-Tyr-Tyr-Gly-Ile-Val-Lys-
1461 Gly-Leu-Pro-Asn-Asp-Cys-Gln-Gln-Cys-Ala-
1471 Cys-Pro-Leu-Ile-Ser-Ser-Ser-Asn-Asn-Phe-
1481 Ser-Pro-Ser-Cys-Val-Ala-Glu-Gly-Leu-Asp-
1491 Asp-Tyr-Arg-Cys-Thr-Ala-Cys-Pro-Arg-Gly-
1501 Tyr-Glu-Gly-Gln-Tyr-Cys-Glu-Arg-Cys-Ala-
1511 Pro-Gly-Tyr-Thr-Gly-Ser-Pro-Gly-Asn-Pro-
1521 Gly-Gly-Ser-Cys-Gln-Glu-Cys-Glu-Cys-Asp-
1531 Pro-Tyr-Gly-Ser-Leu-Pro-Val-Pro-Cys-Asp-
1541 Pro-Val-Thr-Gly-Phe-Cys-Thr-Cys-Arg-Pro-
1551 Gly-Ala-Thr-Gly-Arg-Lys-Cys-Asp-Gly-Cys-
1561 Lys-His-Trp-His-Ala-Arg-Glu-Gly-Trp-Glu-
1571 Cys-Val-Phe-Cys-Gly-Asp-Glu-Cys-Thr-Gly-
1581 Leu-Leu-Leu-Gly-Asp-Leu-Ala-Arg-Leu-Glu-
1591 Gln-Met-Val-Met-Ser-Ile-Asn-Leu-Thr-Gly-
1601 Pro-Leu-Pro-Ala-Pro-Tyr-Lys-Met-Leu-Tyr-
1611 Gly-Leu-Glu-Asn-Met-Thr-Gln-Glu-Leu-Lys-
1621 His-Leu-Ile-Gln-Leu-Ala-Glu-Ala-Pro-Glu-
1631 Arg-Leu-Ile-Gln-Leu-Ala-Glu-Gly-Asn-Leu-
1641 Asn-Thr-Leu-Val-Thr-Glu-Met-Asn-Glu-Leu-
1651 Leu-Thr-Arg-Ala-Thr-Lys-Val-Thr-Ala-Asp-
1661 Gly-Glu-Gln-Thr-Gly-Gln-Asp-Ala-Glu-Arg-
1671 Thr-Asn-Thr-Arg-Ala-Lys-Ser-Leu-Gly-Glu-
1681 Phe-Ile-Lys-Glu-Leu-Ala-Arg-Asp-Ala-Glu-
1691 Ala-Val-Asn-Glu-Lys-Ala-Ile-Lys-Leu-Asn-
1701 Gln-Thr-Leu-Gly-Thr-Arg-Asp-Glu-Ala-Phe-
1711 Glu-Arg-Asn-Leu-Glu-Gly-Leu-Gln-Lys-Glu-
1721 Ile-Asp-Gln-Met-Ile-Lys-Glu-Leu-Arg-Arg-
1731 Lys-Asn-Leu-Glu-Thr-Gln-Lys-Glu-Ile-Ala-
1741 Glu-Asp-Glu-Leu-Val-Ala-Ala-Glu-Ala-Leu-
1751 Leu-Lys-Lys-Val-Lys-Lys-Leu-Phe-Gly-Glu-
1761 Ser-Arg-Gly-Glu-Asn-Glu-Glu-Met-Glu-Lys-
1771 Asp-Leu-Arg-Glu-Lys-Leu-Ala-Asp-Tyr-Lys-
1781 Asn-Lys-Val-Asp-Asp-Ala-Trp-Asp-Leu-Leu-
1791 Arg-Glu-Ala-Thr-Asp-Lys-Ile-Arg-Glu-Ala-
1801 Asn-Arg-Leu-Phe-Ala-Val-Asn-Gln-Lys-Asn-
1811 Met-Thr-Ala-Leu-Glu-Lys-Lys-Lys-Glu-Ala-
1821 Val-Glu-Ser-Gly-Lys-Arg-Gln-Ile-Glu-Asn-
1831 Thr-Leu-Lys-Glu-Gly-Asn-Asp-Ile-Leu-Asp-
1841 Glu-Ala-Asn-Arg-Leu-Ala-Asp-Glu-Ile-Asn-

1851 Ser-Ile-Ile-Asp-Tyr-Val-Glu-Asp-Ile-Gln-
1861 Thr-Lys-Leu-Pro-Pro-Met-Ser-Glu-Glu-Leu-
1871 Asn-Asp-Lys-Ile-Asp-Asp-Leu-Ser-Gln-Glu-
1881 Ile-Lys-Asp-Arg-Lys-Leu-Ala-Glu-Lys-Val-
1891 Ser-Gln-Ala-Glu-Ser-His-Ala-Ala-Gln-Leu-
1901 Asn-Asp-Ser-Ser-Ala-Val-Leu-Asp-Gly-Ile-
1911 Leu-Asp-Glu-Ala-Lys-Asn-Ile-Ser-Phe-Asn-
1921 Ala-Thr-Ala-Ala-Phe-Lys-Ala-Tyr-Ser-Asn-
1931 Ile-Lys-Asp-Tyr-Ile-Asp-Glu-Ala-Glu-Lys-
1941 Val-Ala-Lys-Glu-Ala-Lys-Asp-Leu-Ala-His-
1951 Glu-Ala-Thr-Lys-Leu-Ala-Thr-Gly-Pro-Arg-
1961 Gly-Leu-Leu-Lys-Glu-Asp-Ala-Lys-Gly-Cys-
1971 Leu-Gln-Lys-Ser-Phe-Arg-Ile-Leu-Asn-Glu-
1981 Ala-Lys-Lys-Leu-Ala-Asn-Asp-Val-Lys-Glu-
1991 Asn-Glu-Asp-His-Leu-Asn-Gly-Leu-Lys-Thr-
2001 Arg-Ile-Glu-Asn-Ala-Asp-Ala-Arg-Asn-Gly-
2011 Asp-Leu-Leu-Arg-Thr-Leu-Asn-Asp-Thr-Leu-
2021 Gly-Lys-Leu-Ser-Ala-Ile-Pro-Asn-Asp-Thr-
2031 Ala-Ala-Lys-Leu-Gln-Ala-Val-Lys-Asp-Lys-
2041 Ala-Arg-Gln-Ala-Asn-Asp-Thr-Ala-Lys-Asp-
2051 Val-Leu-Ala-Gln-Ile-Thr-Glu-Leu-His-Gln-
2061 Asn-Leu-Asp-Gly-Leu-Lys-Lys-Asn-Tyr-Asn-
2071 Lys-Leu-Ala-Asp-Ser-Val-Ala-Lys-Thr-Asn-
2081 Ala-Val-Val-Lys-Asp-Pro-Ser-Lys-Asn-Lys-
2091 Ile-Ile-Ala-Asp-Ala-Asp-Ala-Thr-Val-Lys-
2101 Asn-Leu-Glu-Gln-Glu-Ala-Asp-Arg-Leu-Ile-
2111 Asp-Lys-Leu-Lys-Pro-Ile-Lys-Glu-Leu-Glu-
2121 Asp-Asn-Leu-Lys-Lys-Asn-Ile-Ser-Glu-Ile-
2131 Lys-Glu-Leu-Ile-Asn-Gln-Ala-Arg-Lys-Gln-
2141 Ala-Asn-Ser-Ile-Lys-Val-Ser-Val-Ser-Ser-
2151 Gly-Gly-Asp-Cys-Ile-Arg-Thr-Tyr-Lys-Pro-
2161 Glu-Ile-Lys-Lys-Gly-Ser-Tyr-Asn-Asn-Ile-
2171 Val-Val-Asn-Val-Lys-Thr-Ala-Val-Ala-Asp-
2181 Asn-Leu-Leu-Phe-Tyr-Leu-Gly-Ser-Ala-Lys-
2191 Phe-Ile-Asp-Phe-Leu-Ala-Ile-Glu-Met-Arg-
2201 Lys-Gly-Lys-Val-Ser-Phe-Leu-Trp-Asp-Val-
2211 Gly-Ser-Gly-Val-Gly-Arg-Val-Glu-Tyr-Pro-
2221 Asp-Leu-Thr-Ile-Asp-Asp-Ser-Tyr-Trp-Tyr-
2231 Arg-Ile-Val-Ala-Ser-Arg-Thr-Gly-Arg-Asn-
2241 Gly-Thr-Ile-Ser-Glu-Arg-Ala-Leu-Asp-Gly-
2251 Pro-Lys-Ala-Ser-Ile-Val-Pro-Ser-Thr-His-
2261 His-Ser-Thr-Ser-Pro-Pro-Gly-Tyr-Thr-Ile-
2271 Leu-Asp-Val-Asp-Ala-Asn-Ala-Met-Leu-Phe-
2281 Val-Gly-Gly-Leu-Thr-Gly-Lys-Leu-Lys-Lys-
2291 Ala-Asp-Ala-Val-Arg-Val-Ile-Thr-Phe-Thr-
2301 Gly-Cys-Met-Gly-Glu-Thr-Tyr-Phe-Asp-Asn-
2311 Lys-Pro-Ile-Gly-Leu-Trp-Asn-Phe-Arg-Glu-
2321 Lys-Glu-Gly-Asp-Cys-Lys-Gly-Cys-Thr-Val-
2331 Ser-Pro-Gln-Val-Glu-Asp-Ser-Glu-Gly-Thr-
2341 Ile-Gln-Phe-Asp-Gly-Glu-Gly-Tyr-Ala-Leu-
2351 Val-Ser-Arg-Pro-Ile-Arg-Trp-Tyr-Pro-Asn-
2361 Ile-Ser-Thr-Val-Met-Phe-Lys-Phe-Arg-Thr-
2371 Phe-Ser-Ser-Ser-Ala-Leu-Leu-Met-Tyr-Leu-
2381 Ala-Thr-Arg-Asp-Leu-Arg-Asp-Phe-Met-Ser-
2391 Val-Glu-Leu-Thr-Asp-Gly-His-Ile-Lys-Val-
2401 Ser-Tyr-Asp-Leu-Gly-Ser-Gly-Met-Ala-Ser-
2411 Val-Val-Ser-Asn-Gln-Asn-His-Asn-Asp-Gly-

2421 Lys-Tyr-Lys-Ser-Phe-Thr-Leu-Ser-Arg-Ile-
2431 Gln-Lys-Gln-Ala-Asn-Ile-Ser-Ile-Val-Asp-
2441 Ile-Asp-Thr-Asn-Gln-Glu-Ala-Asn-Ile-Ala-
2451 Thr-Ser-Ser-Gly-Asn-Asn-Phe-Gly-Leu-
2461 Asp-Leu-Lys-Ala-Asp-Asp-Lys-Ile-Tyr-Phe-
HITS AT: 527-534

FEATURE TABLE:

Key	Location Qualifier
Peptide	11..22 label signal_peptide

L7 ANSWER 31 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAY15460 Protein 12 useful for promoting tissue repair and promoting
T1 Purified laminin 12 useful for promoting tissue repair and promoting
IN nerve growth
PA Brunken W; Burgeson R E; Champliand M; Koch M; Olson P
PI (GCHO) GEN HOSPITAL CORP.
PI **WO 9919348 A1 19990422 86p***
AI WO 1998-US21391 19981008
PRAI US 1997-61609 19971010
DT Patent
LA English
OS 1999-326542 (27)
CR N-PSDB: AAX59768
DESC Human laminin alpha 2 subunit.
AN AAY15460 Protein DGENE
AA 205A; 159R; 162N; 183D; 0 B; 162C; 119Q; 202E; 0 Z; 261G; 71 H; 166I;
246I; 184R; 46 W; 103E; 173P; 194S; 193I; 29 W; 96 Y; 156V; 0 Others
SQL
SEQ3
3110

1 Met-Pro-Gly-Ala-Ala-Gly-Val-Leu-Leu-Leu-
11 Leu-Leu-Leu-Ser-Gly-Gly-Leu-Gly-Gly-Val-
21 Gln-Ala-Gln-Arg-Pro-Gln-Gln-Arg-Gln-
31 Ser-Gln-Ala-His-Gln-Gln-Arg-Gly-Leu-Phe-
41 Pro-Ala-Val-Leu-Asn-Leu-Ala-Ser-Asn-Ala-
51 Leu-Ile-Thr-Thr-Asn-Ala-Thr-Cys-Gly-Glu-
61 Lys-Gly-Pro-Glu-Met-Tyr-Cys-Lys-Leu-Val-
71 Gln-His-Val-Pro-Gly-Gln-Pro-Val-Arg-Asn-
81 Pro-Gln-Cys-Arg-Ile-Cys-Asn-Gln-Asn-Ser-
91 Ser-Asn-Pro-Asn-Gln-Arg-His-Pro-Ile-Thr-
101 Asn-Ala-Ile-Asp-Gly-Lys-Asn-Thr-Tyr-Tyr-
111 Gln-Ser-Pro-Ser-Ile-Lys-Asn-Gly-Ile-Glu-
121 Tyr-His-Tyr-Val-Thr-Ile-Thr-Leu-Asp-Leu-
131 Gln-Gln-Val-Phe-Gln-Ile-Ala-Tyr-Val-Ile-
141 Val-Lys-Ala-Ala-Asn-Ser-Pro-Arg-Pro-Gly-
151 Asn-Tyr-Ile-Leu-Glu-Arg-Ser-Leu-Asp-Asp-
161 Val-Glu-Tyr-Lys-Pro-Tyr-Gln-Tyr-His-Ala-
171 Val-Thr-Asp-Thr-Glu-Cys-Leu-Thr-Leu-Tyr-
181 Asn-Ile-Tyr-Pro-Arg-Thr-Gly-Pro-Pro-Ser-
191 Tyr-Ala-Lys-Asp-Asp-Glu-Val-Ile-Cys-Thr-
201 Ser-Phe-Tyr-Ser-Lys-Ile-His-Pro-Leu-Glu-
211 Asn-Gly-Glu-Ile-His-Ile-Ser-Leu-Ile-Asn-
221 Gly-Arg-Pro-Ser-Ala-Asp-Asp-Pro-Ser-Pro-

231 Glu-Leu-Leu-Glu-Phe-Thr-Ser-Ala-Arg-Tyr-
241 Ile-Arg-Leu-Arg-Phe-Gln-Arg-Ile-Arg-Thr-
251 Leu-Asn-Ala-Asp-Leu-Met-Met-Phe-Ala-His-
261 Lys-Asp-Pro-Arg-Glu-Ile-Asp-Pro-Ile-Val-
271 Thr-Arg-Arg-Tyr-Tyr-Ser-Val-Lys-Asp-
281 Ile-Ser-Val-Gly-Met-Cys-Ile-Cys-Tyr-
291 Gly-His-Ala-Arg-Ala-Cys-Pro-Leu-Asp-Pro-
301 Ala-Thr-Asn-Lys-Ser-Arg-Cys-Glu-Cys-Glu-
311 His-Asn-Thr-Cys-Gly-Asp-Ser-Cys-Asp-Gln-
321 Cys-Cys-Pro-Gly-Phe-His-Gln-Lys-Pro-Tyr-
331 Arg-Ala-Gly-Thr-Phe-Leu-Thr-Lys-Thr-Glu-
341 Cys-Glu-Ala-Cys-Asn-Cys-His-Gly-Lys-Ala-
351 Glu-Glu-Cys-Tyr-Tyr-Asp-Glu-Asn-Val-Ala-
361 Arg-Arg-Asn-Leu-Ser-Leu-Asn-Ile-Arg-Gly-
371 Lys-Tyr-Ile-Gly-Gly-Val-Cys-Ile-Asn-
381 Cys-Thr-Gln-Asn-Thr-Ala-Gly-Ile-Asn-Cys-
391 Glu-Thr-Cys-Thr-Asp-Gly-Phe-Phe-Arg-Pro-
401 Lys-Gly-Val-Ser-Pro-Asn-Tyr-Pro-Arg-Pro-
411 Cys-Gln-Pro-Cys-His-Cys-Asp-Pro-Ile-Gly-
421 Ser-Leu-Asn-Glu-Val-Cys-Val-Lys-Asp-Glu-
431 Lys-His-Ala-Arg-Arg-Gly-Leu-Ala-Pro-Gly-
441 Ser-Cys-His-Cys-Lys-Thr-Gly-Phe-Gly-Tyr-
451 Val-Ser-Cys-Asp-Arg-Cys-Ala-Arg-Gly-Tyr-
461 Thr-Gly-Tyr-Pro-Asp-Cys-Lys-Ala-Cys-Asn-
471 Cys-Ser-Gly-Leu-Gly-Ser-Lys-Asn-Glu-Asp-
481 Pro-Cys-Phe-Gly-Pro-Cys-Ile-Cys-Lys-Glu-
491 Asn-Val-Glu-Gly-Gly-Asp-Cys-Ser-Arg-Cys-
501 Lys-Ser-Gly-Phe-Phe-Asn-Leu-Gln-Glu-Asp-
511 Asn-Thr-Lys-Gly-Cys-Asp-Glu-Cys-Phe-Cys-
521 Ser-Gly-Val-Ser-Asn-Arg-Cys-Gln-Ser-Ser-

531 Tyr-Tyr-Thr-Tyr-Gly-Lys-Ile-Gln-Asp-Met-
541 Ser-Gly-Tyr-Tyr-Leu-Thr-Asp-Leu-Pro-Gly-
551 Arg-Ile-Arg-Val-Ala-Pro-Gln-Gln-Asp-Asp-
561 Leu-Asp-Ser-Pro-Gln-Gln-Ile-Ser-Ile-Ser-
571 Asn-Ala-Glu-Ala-Arg-Gln-Ala-Leu-Pro-His-
581 Ser-Tyr-Tyr-Tyr-Ser-Ala-Pro-Ala-Pro-Tyr-
591 Leu-Gly-Asn-Lys-Leu-Pro-Ala-Val-Gly-Gly-
601 Gln-Leu-Thr-Phe-Thr-Ile-Ser-Tyr-Asp-Leu-
611 Glu-Gln-Glu-Glu-Glu-Asp-Thr-Glu-Arg-Val-
621 Leu-Leu-Leu-Met-Ile-Ile-Leu-Glu-Gly-Asn-
631 Asp-Leu-Ser-Ile-Ser-Thr-Ala-Gln-Asp-Glu-
641 Val-Tyr-Leu-His-Pro-Ser-Glu-Glu-His-Thr-
651 Asn-Val-Leu-Leu-Leu-Lys-Glu-Glu-Ser-Phe-
661 Thr-Ile-His-Gly-Thr-His-Phe-Pro-Val-Arg-
671 Arg-Lys-Glu-Phe-Met-Thr-Val-Leu-Ala-Asn-
681 Leu-Lys-Arg-Val-Leu-Leu-Gln-Ile-Thr-Tyr-
691 Ser-Phe-Gly-Met-Asp-Ala-Ile-Phe-Arg-Leu-
701 Ser-Ser-Val-Asn-Leu-Glu-Ser-Ala-Val-Ser-
711 Tyr-Pro-Thr-Asp-Gly-Ser-Ile-Ala-Ala-Ala-
721 Val-Glu-Val-Cys-Gln-Cys-Pro-Pro-Gly-Tyr-
731 Thr-Gly-Ser-Ser-Cys-Glu-Ser-Cys-Tyr-Pro-
741 Arg-His-Arg-Arg-Val-Asn-Gly-Thr-Ile-Phe-
751 Gly-Gly-Ile-Cys-Glu-Pro-Cys-Gln-Cys-Phe-
761 Gly-His-Ala-Glu-Ser-Cys-Asp-Asp-Val-Thr-
771 Gly-Glu-Cys-Leu-Asn-Cys-Lys-Asp-His-Thr-

781 Gly-Gly-Pro-Tyr-Cys-Asp-Lys-Cys-Leu-Pro
791 Gly-Phe-Tyr-Gly-Glu-Pro-Thr-Lys-Gly-Thr
801 Ser-Glu-Asp-Cys-Gln-Pro-Cys-Ala-Cys-Pro
811 Leu-Asn-Ile-Pro-Ser-Asn-Asn-Phe-Ser-Pro
821 Thr-Cys-His-Leu-Asp-Arg-Ser-Leu-Gly-Leu
831 Ile-Cys-Asp-Gly-Cys-Pro-Val-Gly-Tyr-Thr
841 Gly-Pro-Arg-Cys-Glu-Arg-Cys-Ala-Glu-Gly
851 Tyr-Phe-Gln-Gln-Pro-Ser-Val-Pro-Gly-Gly
861 Ser-Cys-Gln-Pro-Cys-Gln-Cys-Asn-Asp-Asn
871 Leu-Asp-Phe-Ser-Ile-Pro-Gly-Ser-Cys-Asp
881 Ser-Leu-Ser-Gly-Ser-Cys-Leu-Ile-Cys-Lys
891 Pro-Gly-Thr-Thr-Gly-Arg-Tyr-Cys-Glu-Leu
901 Cys-Ala-Asp-Gly-Tyr-Phe-Gly-Asp-Ala-Val
911 Asp-Ala-Lys-Asn-Cys-Gln-Pro-Cys-Arg-Cys
921 Asn-Ala-Gly-Gly-Ser-Phe-Ser-Glu-Val-Cys
931 His-Ser-Gln-Thr-Gly-Gln-Cys-Glu-Cys-Arg
941 Ala-Asn-Val-Gln-Gly-Thr-Phe-Gly-Leu-Ser
951 Cys-Lys-Ala-Gly-Thr-Phe-Gly-Leu-Ser
961 Ala-Arg-Gly-Cys-Val-Pro-Cys-Asn-Cys-Asn
971 Ser-Phe-Gly-Ser-Lys-Ser-Phe-Asp-Cys-Glu
981 Glu-Ser-Gly-Gln-Cys-Trp-Cys-Gln-Pro-Gly
991 Val-Thr-Gly-Lys-Lys-Cys-Asp-Arg-Cys-Ala
1001 His-Gly-Tyr-Phe-Asn-Phe-Gln-Glu-Gly-Gly
1011 Cys-Thr-Ala-Cys-Glu-Cys-Ser-His-Leu-Gly
1021 Asn-Asn-Cys-Asp-Pro-Lys-Thr-Gly-Arg-Cys
1031 Ile-Cys-Pro-Pro-Asn-Thr-Ile-Gly-Glu-Lys
1041 Cys-Ser-Lys-Cys-Ala-Pro-Asn-Thr-Trp-Gly
1051 His-Ser-Ile-Thr-Thr-Gly-Cys-Lys-Ala-Cys
1061 Asn-Cys-Ser-Thr-Val-Gly-Ser-Leu-Asp-Phe
1071 Gln-Cys-Asn-Val-Asn-Thr-Gly-Gln-Cys-Asn
1081 Cys-His-Pro-Lys-Phe-Ser-Gly-Ala-Lys-Cys
1091 Thr-Glu-Cys-Ser-Arg-Gly-His-Trp-Asn-Tyr
1101 Pro-Arg-Cys-Asn-Leu-Cys-Asp-Cys-Phe-Leu
1111 Pro-Gly-Thr-Asp-Ala-Thr-Cys-Asp-Ser
1121 Glu-Thr-Lys-Lys-Cys-Ser-Cys-Ser-Asp-Gln
1131 Thr-Gly-Gln-Cys-Thr-Cys-Lys-Val-Asn-Val
1141 Glu-Gly-Ile-His-Cys-Asp-Arg-Cys-Arg-Pro
1151 Gly-Lys-Phe-Gly-Leu-Asp-Ala-Lys-Asn-Pro
1161 Leu-Gly-Cys-Ser-Ser-Cys-Tyr-Cys-Phe-Gly
1171 Thr-Thr-Thr-Gln-Cys-Ser-Glu-Ala-Lys-Gly
1181 Leu-Ile-Arg-Thr-Trp-Val-Thr-Leu-Lys-Ala
1191 Glu-Gln-Thr-Ile-Leu-Pro-Leu-Val-Asp-Glu
1201 Ala-Phe-Gln-His-Thr-Thr-Thr-Lys-Gly-Ile
1211 Val-Phe-Gln-His-Pro-Glu-Ile-Val-Ala-His
1221 Met-Asp-Leu-Met-Arg-Glu-Asp-Leu-His-Leu
1231 Glu-Pro-Phe-Tyr-Trp-Lys-Leu-Pro-Glu-Gln
1241 Phe-Glu-Gly-Lys-Lys-Leu-Met-Ala-Tyr-Gly
1251 Gly-Lys-Leu-Lys-Tyr-Ala-Ile-Tyr-Phe-Glu
1261 Ala-Arg-Glu-Glu-Thr-Gly-Phe-Ser-Thr-Tyr
1271 Asn-Pro-Gln-Val-Ile-Ile-Arg-Gly-Gly-Thr
1281 Pro-Thr-His-Ala-Arg-Ile-Ile-Val-Arg-His
1291 Met-Ala-Ala-Pro-Leu-Ile-Gly-Gln-Leu-Thr
1301 Arg-His-Glu-Ile-Glu-Met-Thr-Glu-Lys-Glu
1311 Trp-Lys-Tyr-Tyr-Gly-Asp-Asp-Pro-Arg-Val
1321 His-Arg-Thr-Val-Thr-Arg-Glu-Asp-Phe-Leu
1331 Asp-Ile-Leu-Tyr-Asp-Ile-His-Tyr-Ile-Leu
1341 Ile-Lys-Ala-Thr-Tyr-Gly-Asn-Phe-Met-Arg

1351 Gln-Ser-Arg-Ile-Ser-Glu-Ile-Ser-Met-Glu
1361 Val-Ala-Glu-Gln-Gly-Arg-Gly-Thr-Thr-Met
1371 Thr-Pro-Pro-Ala-Asp-Leu-Ile-Glu-Lys-Cys
1381 Asp-Cys-Pro-Leu-Gly-Tyr-Ser-Gly-Leu-Ser
1391 Cys-Glu-Ala-Cys-Leu-Pro-Gly-Phe-Tyr-Arg
1401 Leu-Arg-Ser-Gln-Pro-Gly-Arg-Thr-Pro
1411 Gly-Pro-Thr-Leu-Gly-Thr-Cys-Val-Pro-Cys
1421 Gln-Cys-Asn-Gly-His-Ser-Ser-Leu-Cys-Asp
1431 Pro-Glu-Thr-Ser-Ile-Cys-Gln-Asn-Cys-Gln
1441 His-His-Thr-Ala-Gly-Asp-Phe-Cys-Glu-Arg
1451 Cys-Ala-Leu-Gly-Tyr-Tyr-Gly-Ile-Val-Lys
1461 Gly-Leu-Pro-Asn-Asp-Cys-Gln-Gln-Cys-Ala
1471 Cys-Pro-Leu-Ile-Ser-Ser-Ser-Asn-Phe
1481 Ser-Pro-Ser-Cys-Val-Ala-Glu-Gly-Leu-Asp
1491 Asp-Tyr-Arg-Cys-Thr-Ala-Cys-Pro-Arg-Gly
1501 Tyr-Glu-Gly-Gln-Tyr-Cys-Glu-Arg-Cys-Ala
1511 Pro-Gly-Tyr-Thr-Gly-Ser-Pro-Gly-Asn-Pro
1521 Gly-Gly-Ser-Cys-Gln-Glu-Cys-Glu-Cys-Asp
1531 Pro-Tyr-Gly-Ser-Leu-Pro-Val-Pro-Cys-Asp
1541 Pro-Val-Thr-Gly-Phe-Cys-Thr-Cys-Arg-Pro
1551 Gly-Ala-Thr-Gly-Arg-Lys-Cys-Asp-Gly-Cys
1561 Lys-His-Trp-His-Ala-Arg-Glu-Gly-Trp-Glu
1571 Cys-Val-Phe-Cys-Gly-Asp-Glu-Cys-Thr-Glu
1581 Leu-Leu-Leu-Gly-Asp-Leu-Ala-Arg-Leu-Glu
1591 Gln-Met-Val-Met-Ser-Ile-Asn-Leu-Thr-Gly
1601 Pro-Leu-Pro-Ala-Pro-Tyr-Lys-Met-Leu-Tyr
1611 Gly-Leu-Glu-Asn-Met-Thr-Gln-Glu-Leu-Lys
1621 His-Leu-Leu-Ser-Pro-Gln-Arg-Ala-Pro-Glu
1631 Arg-Leu-Ile-Gln-Leu-Ala-Glu-Gly-Asn-Leu
1641 Leu-Thr-Leu-Val-Thr-Glu-Met-Asn-Glu-Leu
1651 Leu-Thr-Arg-Ala-Thr-Lys-Val-Thr-Ala-Asp
1661 Gly-Glu-Gln-Thr-Gly-Gln-Asp-Ala-Glu-Arg
1671 Thr-Asn-Thr-Arg-Ala-Lys-Ser-Leu-Gly-Glu
1681 Phe-Ile-Lys-Glu-Leu-Ala-Arg-Asp-Ala-Glu
1691 Ala-Val-Asn-Glu-Lys-Ala-Ile-Lys-Leu-Asn
1701 Glu-Thr-Leu-Gly-Thr-Arg-Asp-Glu-Ala-Phe
1711 Ile-Arg-Asn-Leu-Glu-Gly-Leu-Gln-Lys-Glu
1721 Ile-Asp-Gln-Met-Ile-Lys-Glu-Leu-Arg-Arg
1731 Lys-Asn-Leu-Glu-Thr-Gln-Lys-Glu-Ile-Ala
1741 Glu-Asp-Glu-Leu-Val-Ala-Ala-Glu-Ala-Leu
1751 Leu-Lys-Lys-Val-Lys-Lys-Leu-Phe-Gly-Glu
1761 Ser-Arg-Gly-Glu-Asn-Glu-Glu-Met-Glu-Lys
1771 Asp-Leu-Arg-Glu-Lys-Leu-Ala-Asp-Tyr-Lys
1781 Asn-Lys-Val-Asp-Asp-Ala-Trp-Asp-Leu-Leu
1791 Arg-Glu-Ala-Thr-Asp-Lys-Ile-Arg-Glu-Ala
1801 Asn-Arg-Leu-Phe-Ala-Val-Asn-Gln-Lys-Asn
1811 Met-Thr-Ala-Leu-Glu-Lys-Lys-Glu-Ala
1821 Val-Glu-Ser-Gly-Lys-Arg-Gln-Ile-Glu-Asn
1831 Thr-Leu-Lys-Glu-Gly-Asn-Asp-Ile-Leu-Asp
1841 Glu-Ala-Asn-Arg-Leu-Ala-Asp-Glu-Ile-Asn
1851 Ser-Ile-Ile-Arg-Tyr-Val-Glu-Asp-Ile-Gln
1861 Thr-Lys-Leu-Pro-Pro-Met-Ser-Glu-Glu-Leu
1871 Asn-Asp-Lys-Ile-Asp-Asp-Leu-Ser-Gln-Glu
1881 Ile-Lys-Asp-Arg-Lys-Leu-Ala-Glu-Lys-Val
1891 Ser-Gln-Ala-Glu-Ser-His-Ala-Ala-Gln-Leu
1901 Asn-Asp-Ser-Ser-Ala-Val-Leu-Asp-Gly-Ile
1911 Leu-Asp-Glu-Ala-Lys-Asn-Ile-Ser-Phe-Asn

1921 Ala-Thr-Ala-Ala-Phe-Lys-Ala-Tyr-Ser-Asn-
 1931 Ile-Lys-Asp-Tyr-Ile-Asp-Glu-Ala-Glu-Lys-
 1941 Val-Ala-Lys-Glu-Ala-Lys-Asp-Leu-Ala-His-
 1951 Glu-Ala-Thr-Lys-Leu-Ala-Thr-Gly-Pro-Arg-
 1961 Gly-Leu-Leu-Lys-Glu-Asp-Ala-Lys-Gly-Cys-
 1971 Leu-Gln-Lys-Ser-Phe-Arg-Ile-Leu-Asn-Glu-
 1981 Ala-Lys-Lys-Leu-Ala-Asn-Asp-Val-Lys-Glu-
 1991 Asn-Glu-Asp-His-Leu-Asn-Gly-Leu-Lys-Thr-
 2001 Arg-Ile-Glu-Asn-Ala-Asp-Ala-Arg-Asn-Gly-
 2011 Asp-Leu-Leu-Arg-Thr-Leu-Asn-Asp-Thr-Leu-
 2021 Gly-Lys-Leu-Ser-Ala-Ile-Pro-Asn-Asp-Thr-
 2031 Ala-Ala-Lys-Leu-Gln-Ala-Val-Lys-Asp-Lys-
 2041 Ala-Arg-Gln-Ala-Asn-Asp-Thr-Ala-Lys-Asp-
 2051 Val-Leu-Ala-Gln-Ile-Thr-Glu-Leu-His-Gln-
 2061 Asn-Leu-Asp-Gly-Leu-Lys-Lys-Asn-Tyr-Asn-
 2071 Lys-Leu-Ala-Asp-Ser-Val-Ala-Lys-Thr-Asn-
 2081 Ala-Val-Val-Lys-Asp-Pro-Ser-Lys-Asn-Lys-
 2091 Ile-Ile-Ala-Asp-Ala-Asp-Ala-Thr-Val-Lys-
 2101 Asn-Leu-Glu-Gln-Glu-Ala-Asp-Arg-Leu-Ile-
 2111 Asp-Lys-Leu-Lys-Pro-Ile-Lys-Glu-Leu-Glu-
 2121 Asp-Asn-Leu-Lys-Lys-Asn-Ile-Ser-Glu-Ile-
 2131 Lys-Glu-Leu-Ile-Asn-Gln-Ala-Arg-Lys-Gln-
 2141 Ala-Asn-Ser-Ile-Lys-Val-Ser-Val-Ser-Ser-
 2151 Gly-Gly-Asp-Cys-Ile-Arg-Thr-Tyr-Lys-Pro-
 2161 Glu-Ile-Lys-Lys-Gly-Ser-Tyr-Asn-Asn-Ile-
 2171 Val-Val-Asn-Val-Lys-Thr-Ala-Val-Ala-Asp-
 2181 Asn-Leu-Leu-Phe-Tyr-Leu-Gly-Ser-Ala-Lys-
 2191 Phe-Ile-Asp-Phe-Leu-Ala-Ile-Glu-Met-Arg-
 2201 Lys-Gly-Lys-Val-Ser-Phe-Leu-Tyr-Asp-Val-
 2211 Gly-Ser-Gly-Val-Gly-Arg-Val-Glu-Tyr-Pro-
 2221 Asp-Leu-Thr-Ile-Asp-Asp-Ser-Tyr-Trp-Tyr-
 2231 Arg-Ile-Val-Ala-Ser-Arg-Thr-Gly-Arg-Asn-
 2241 Gly-Thr-Ile-Ser-Val-Arg-Ala-Leu-Asp-Gly-
 2251 Pro-Lys-Ala-Ser-Ile-Val-Pro-Ser-Thr-His-
 2261 His-Ser-Thr-Ser-Pro-Pro-Gly-Tyr-Thr-Ile-
 2271 Leu-Asp-Val-Asp-Ala-Asn-Ala-Met-Leu-Phe-
 2281 Val-Gly-Gly-Leu-Thr-Gly-Lys-Leu-Lys-Lys-
 2291 Ala-Asp-Ala-Val-Arg-Val-Ile-Thr-Phe-Thr-
 2301 Gly-Cys-Met-Gly-Glu-Thr-Tyr-Phe-Asp-Asn-
 2311 Lys-Pro-Ile-Gly-Leu-Tyr-Asn-Phe-Arg-Glu-
 2321 Lys-Glu-Gly-Asp-Cys-Lys-Gly-Cys-Thr-Val-
 2331 Ser-Pro-Gln-Val-Glu-Asp-Ser-Glu-Gly-Thr-
 2341 Ile-Gln-Phe-Asp-Gly-Gly-Tyr-Ala-Leu-
 2351 Val-Ser-Arg-Pro-Ile-Arg-Trp-Tyr-Pro-Asn-
 2361 Ile-Ser-Thr-Val-Met-Phe-Lys-Phe-Arg-Thr-
 2371 Phe-Ser-Ser-Ser-Ala-Leu-Leu-Met-Tyr-Leu-
 2381 Ala-Thr-Arg-Asp-Leu-Arg-His-Ile-Lys-Val-
 2391 Val-Glu-Leu-Thr-Asp-Gly-His-Ile-Lys-Val-
 2401 Ser-Tyr-Asp-Leu-Gly-Ser-Gly-Met-Ala-Ser-
 2411 Val-Val-Ser-Asn-Gln-Asn-His-Asn-Asp-Gly-
 2421 Lys-Trp-Lys-Ser-Phe-Thr-Leu-Ser-Arg-Ile-
 2431 Gln-Lys-Gln-Ala-Asn-Ile-Ser-Ile-Val-Asp-
 2441 Ile-Asp-Thr-Asn-Gln-Glu-Glu-Asn-Ile-Ala-
 2451 Thr-Ser-Ser-Ser-Gly-Asn-Asn-Phe-Gly-Leu-
 2461 Asp-Leu-Lys-Ala-Asp-Asp-Lys-Ile-Tyr-Phe-

HITS AT: 527-534

L7 ANSWER 32 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AA148244 Protein DGENE
 TI New nucleic acid expressed at high level in prostatic tumor tissue and
 encoded polypeptides, useful for treating cancer and screening for
 therapeutic agents -
 IN Specht T; Hinemann B; Schmitt A; Pilsarsky C; Dahl E; Rosenthal A
 PA (MENA-1) METAGEN GRS GENOMFORSCHUNG MBH. 166p***
 PI ****DE 19811193 AI 19900916
 AI DE 1998-1011193 19980310
 DE 1998-19811193 19980310
 DT Patent
 LA German
 OS 1999-519628 [44]
 CR N-PSDB: AA233466
 DESC Human prostate cancer-associated protein 30.
 AN AA148244 Protein DGENE
 AA 29 A; 5 R; 8 N; 7 D; 0 B; 15 C; 10 Q; 9 E; 0 Z; 21 G; 11 H; 14 I;
 40 L; 6 K; 5 M; 12 F; 27 P; 28 S; 17 T; 7 W; 8 Y; 25 V; 0 Others
 SOL 304
 SEQ3
 1 Trp-Leu-Cys-Glu-Lys-His-Leu-Lys-Val-Ala-
 11 Gly-Pro-Pro-Pro-Leu-Pro-His-Leu-Pro-Leu-
 21 Val-Leu-Pro-Pro-Thr-Pro-Pro-Pro-Pro-Trp-
 31 Leu-Pro-Ser-Leu-Met-Thr-Ala-Trp-Ile-Leu-
 41 Leu-Pro-Val-Ser-Leu-Ser-Ala-Phe-Ser-Ile-
 51 Thr-Gly-Ile-Trp-Thr-Val-Gln-Pro-Lys-Ala-
 61 Val-Met-Asn-His-His-Val-Cys-Pro-Val-Glu-
 71 Asn-Trp-Ser-Tyr-Asn-Glu-Ser-Cys-Pro-Pro-
 81 Asp-Pro-Ala-Glu-Gln-Gly-Pro-Lys-Thr-
 91 Cys-Cys-Thr-Leu-Asp-Asp-Val-Pro-Leu-Ile-
 101 Ser-Lys-Cys-Gly-Ser-Tyr-Pro-Pro-Glu-Ser-
 111 Cys-Leu-Phe-Ser-Leu-Ile-Gly-Asn-Met-Gly-
 121 Ala-Phe-Met-Val-Ala-Leu-Ile-Cys-Leu-Leu-
 131 Arg-Tyr-Gly-Gln-Leu-Leu-Glu-Gln-Ser-Arg-
 141 His-Ser-Trp-Val-Asn-Thr-Thr-Ala-Leu-Ile-
 151 Thr-Gly-Cys-Thr-Asn-Ala-Asp-His-Ala-Arg-
 161 Val-Gly-Asn-Phe-Gln-Val-Asp-His-Ala-Arg-
 171 Ser-Leu-His-Tyr-Val-Gly-Ala-Gly-Val-Ala-
 181 Phe-Pro-Ala-Gly-Leu-Leu-Phe-Val-Cys-Leu-
 191 His-Cys-Ala-Leu-Ser-Tyr-Gln-Gly-Ala-Thr-
 201 Ala-Pro-Leu-Asp-Leu-Ala-Val-Ala-Tyr-Leu-
 211 Arg-Ser-Val-Leu-Ala-Val-Ile-Ala-Phe-Ile-
 221 Thr-Leu-Val-Leu-Ser-Gly-Val-Phe-Phe-Val-
 231 His-Glu-Ser-Ser-Gln-Leu-Gln-His-Gly-Ala-
 241 Ala-Leu-Cys-Glu-Trp-Val-Cys-Val-Ile-Asp-
 251 Ile-Leu-Ile-Phe-Tyr-Gly-Thr-Phe-Ser-Tyr-
 261 Glu-Phe-Gly-Ala-Val-Ser-Ser-Asp-Thr-Leu-
 271 Val-Ala-Ala-Leu-Gln-Pro-Thr-Pro-Gly-Arg-
 281 Ala-Cys-Lys-Ser-Ser-Gly-Ser-Ser-Ser-Thr-
 291 Ser-Thr-His-Leu-Asn-Cys-Ala-Pro-Glu-Ser-
 301 Ile-Ala-Met-Ile

HITS AT: 67-74

L7 ANSWER 33 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
 AN AA171730 Protein DGENE

71 New neovasin fragments, corresp. DNA and antibodies - for diagnosing
 tumour malignancy, promoting or inhibiting neurite growth and promoting
 cell attachment.
 IN Engvall E; Leivo I
 PA (L902-N) LA JOLLA CANCER RES FOUND. 65p***
 PI ***WO 9508628 A2 19950330
 AI WO 1994-US10730 19940921
 PRAI US 1993-125077 19930922
 DT Patent
 LA English
 OS 1985-133597 (181)
 CR N-PSDB: AA086480 and AA117419
 DESC Neovasin major subunit.
 AN AA071730 Protein DEGENE
 AA 205A; 159R; 162N; 183D; 0 B; 162C; 119Q; 202E; 0 Z; 261G; 71 H; 166I;
 246L; 184K; 46 M; 103F; 173P; 194S; 193T; 29 W; 96 Y; 156V; 0 Others
 SQL
 SEQ3 3110

1 Met-Pro-Gly-Ala-Ala-Gly-Val-Leu-Leu-Leu-
 11 Leu-Leu-Leu-Ser-Gly-Gly-Leu-Gly-Gly-Val-
 21 Gln-Ala-Gln-Arg-Pro-Gln-Gln-Arg-Gln-
 31 Ser-Gln-Ala-His-Gln-Gln-Arg-Gly-Leu-Phe-
 41 Pro-Ala-Val-Leu-Asn-Leu-Ala-Ser-Asn-Ala-
 51 Leu-Ile-Thr-Thr-Asn-Ala-Thr-Cys-Gly-Glu-
 61 Lys-Gly-Pro-Glu-Met-Tyr-Cys-Lys-Leu-Val-
 71 Glu-His-Val-Pro-Gly-Gln-Pro-Val-Arg-Asn-
 81 Pro-Gln-Cys-Arg-Ile-Cys-Asn-Gln-Asn-Ser-
 91 Ser-Asn-Pro-Asn-Gln-Arg-His-Pro-Ile-Thr-
 101 Asn-Ala-Ile-Asp-Gly-Lys-Asn-Thr-Tip-Tip-
 111 Gln-Ser-Pro-Ser-Ile-Lys-Asn-Gly-Ile-Glu-
 121 Tyr-His-Tyr-Thr-Ile-Thr-Leu-Asp-Leu-
 131 Gln-Gln-Val-Phe-Gln-Ile-Ala-Tyr-Val-Ile-
 141 Val-Lys-Ala-Ala-Asn-Ser-Pro-Arg-Pro-Gly-
 151 Asn-Trp-Ile-Leu-Glu-Arg-Ser-Leu-Asp-Asp-
 161 Val-Glu-Tyr-Lys-Pro-Trp-Gln-Tyr-His-Ala-
 171 Val-Thr-Asp-Thr-Glu-Cys-Leu-Thr-Leu-Tyr-
 181 Asn-Ile-Tyr-Pro-Arg-Thr-Gly-Pro-Pro-Ser-
 191 Tyr-Ala-Lys-Asp-Asp-Glu-Val-Ile-Cys-Thr-
 201 Ser-Phe-Tyr-Ser-Lys-Ile-His-Pro-Leu-Glu-
 211 Asn-Gly-Glu-Ile-His-Ile-Ser-Leu-Ile-Asn-
 221 Gly-Arg-Pro-Ser-Ala-Asp-Asp-Pro-Ser-Pro-
 231 Glu-Leu-Leu-Glu-Phe-Thr-Ser-Ala-Arg-Tyr-
 241 Ile-Arg-Leu-Arg-Phe-Gln-Arg-Ile-Arg-Thr-
 251 Leu-Asn-Ala-Asp-Leu-Met-Met-Phe-Ala-His-
 261 Lys-Asp-Pro-Arg-Glu-Ile-Asp-Pro-Ile-Val-
 271 Thr-Arg-Arg-Tyr-Tyr-Tyr-Ser-Val-Lys-Asp-
 281 Ile-Ser-Val-Gly-Gly-Met-Cys-Ile-Cys-Tyr-
 291 Gly-His-Ala-Arg-Ala-Cys-Pro-Leu-Asp-Pro-
 301 Ala-Thr-Asn-Lys-Ser-Arg-Cys-Glu-Cys-Glu-
 311 His-Asn-Thr-Cys-Gly-Asp-Ser-Cys-Asp-Gln-
 321 Cys-Cys-Pro-Gly-Phe-His-Gln-Lys-Pro-Tip-
 331 Arg-Ala-Gly-Thr-Phe-Leu-Thr-Lys-Thr-Glu-
 341 Cys-Glu-Ala-Cys-Asn-Cys-His-Gly-Lys-Ala-
 351 Glu-Glu-Cys-Tyr-Tyr-Asp-Glu-Asn-Val-Ala-
 361 Arg-Arg-Asn-Leu-Ser-Leu-Asn-Ile-Arg-Gly-
 371 Lys-Tyr-Ile-Gly-Gly-Val-Cys-Ile-Asn-
 381 Cys-Thr-Gln-Asn-Thr-Ala-Gly-Ile-Asn-Cys-

391 Glu-Thr-Cys-Thr-Asp-Gly-Phe-Phe-Arg-Pro-
 401 Lys-Gly-Val-Ser-Pro-Asn-Tyr-Pro-Arg-Pro-
 411 Cys-Gln-Pro-Cys-His-Cys-Asp-Pro-Ile-Gly-
 421 Ser-Leu-Asn-Glu-Val-Cys-Val-Lys-Asp-Glu-
 431 Lys-His-Ala-Arg-Arg-Gly-Leu-Ala-Pro-Gly-
 441 Ser-Cys-His-Cys-Lys-Thr-Gly-Phe-Gly-Gly-
 451 Val-Ser-Cys-Asp-Arg-Cys-Ala-Arg-Gly-Tyr-
 461 Thr-Gly-Tyr-Pro-Asp-Cys-Lys-Ala-Cys-Asp-
 471 Cys-Ser-Gly-Leu-Gly-Ser-Lys-Asn-Glu-Asp-
 481 Pro-Cys-Phe-Gly-Pro-Cys-Ile-Cys-Lys-Glu-
 491 Asn-Val-Glu-Gly-Gly-Asp-Cys-Ser-Arg-Cys-
 501 Lys-Ser-Gly-Phe-Phe-Asn-Leu-Gln-Glu-Asp-
 511 Asn-Trp-Lys-Gly-Cys-Asp-Glu-Cys-Phe-Cys-
 521 Ser-Gly-Val-Ser-Asn-Arg-Cys-Gln-Ser-Ser-
 531 Tyr-Trp-Thr-Tyr-Gly-Lys-Ile-Gln-Asp-Met-
 541 Ser-Gly-Trp-Tyr-Leu-Thr-Asp-Leu-Pro-Gly-
 551 Arg-Ile-Arg-Val-Ala-Pro-Gln-Gln-Asp-Asp-
 561 Leu-Asp-Ser-Pro-Gln-Gln-Ile-Ser-Ile-Ser-
 571 Asn-Ala-Glu-Ala-Arg-Gln-Ala-Leu-Pro-His-
 581 Ser-Tyr-Tyr-Trp-Ser-Ala-Pro-Ala-Pro-Tyr-
 591 Leu-Gly-Asn-Lys-Leu-Pro-Ala-Val-Gly-Gly-
 601 Gln-Leu-Thr-Phe-Thr-Ile-Ser-Tyr-Asp-Leu-
 611 Glu-Glu-Glu-Glu-Glu-Asp-Thr-Glu-Arg-Val-
 621 Leu-Gln-Leu-Met-Ile-Ile-Leu-Glu-Gly-Asn-
 631 Asp-Leu-Ser-Ile-Ser-Thr-Ala-Gln-Asp-Glu-
 641 Val-Tyr-Leu-His-Pro-Ser-Glu-Glu-His-Thr-
 651 Asn-Val-Leu-Leu-Lys-Glu-Glu-Ser-Phe-
 661 Thr-Ile-His-Gly-Thr-His-Phe-Pro-Val-Arg-
 671 Arg-Lys-Glu-Phe-Met-Thr-Val-Leu-Ala-Asn-
 681 Leu-Lys-Arg-Val-Leu-Leu-Gln-Ile-Thr-Tyr-
 691 Ser-Phe-Gly-Met-Asp-Ala-Ile-Phe-Arg-Leu-
 701 Ser-Ser-Val-Asn-Leu-Glu-Ser-Ala-Val-Ser-
 711 Tyr-Pro-Thr-Asp-Gly-Ser-Ile-Ala-Ala-Ala-
 721 Val-Glu-Val-Cys-Gln-Cys-Pro-Pro-Gly-Tyr-
 731 Thr-Gly-Ser-Ser-Cys-Glu-Ser-Cys-Trp-Pro-
 741 Arg-His-Arg-Arg-Val-Asn-Gly-Thr-Ile-Phe-
 751 Gly-Gly-Ile-Cys-Glu-Pro-Cys-Gln-Cys-Phe-
 761 Gly-His-Ala-Glu-Ser-Cys-Asp-Asp-Val-Thr-
 771 Gly-Glu-Cys-Leu-Asn-Cys-Lys-Asp-His-Thr-
 781 Gly-Gly-Pro-Tyr-Cys-Asp-Lys-Cys-Leu-Pro-
 791 Gly-Phe-Tyr-Gly-Glu-Pro-Thr-Lys-Gly-Thr-
 801 Ser-Glu-Asp-Cys-Gln-Pro-Cys-Ala-Cys-Pro-
 811 Leu-Asn-Ile-Pro-Ser-Asn-Asn-Phe-Ser-Pro-
 821 Thr-Cys-His-Leu-Asp-Arg-Ser-Leu-Gly-Leu-
 831 Ile-Cys-Asp-Gly-Cys-Pro-Val-Gly-Tyr-Thr-
 841 Gly-Pro-Arg-Cys-Glu-Arg-Cys-Ala-Glu-Gly-
 851 Tyr-Phe-Gly-Gln-Pro-Ser-Val-Pro-Gly-Gly-
 861 Ser-Cys-Gln-Pro-Cys-Gln-Cys-Asn-Asp-Asn-
 871 Leu-Asp-Phe-Ser-Ile-Pro-Gly-Ser-Cys-Asp-
 881 Ser-Leu-Ser-Gly-Ser-Cys-Leu-Ile-Cys-Lys-
 891 Pro-Gly-Thr-Thr-Gly-Arg-Tyr-Cys-Glu-Leu-
 901 Cys-Ala-Asp-Gly-Tyr-Phe-Gly-Asp-Ala-Val-
 911 Asp-Ala-Lys-Asn-Cys-Gln-Pro-Cys-Arg-Cys-
 921 Asn-Ala-Gly-Gly-Ser-Phe-Ser-Glu-Val-Cys-
 931 His-Ser-Gln-Thr-Gly-Gln-Cys-Glu-Cys-Arg-

941 Ala-Asn-Val-Gln-Gly-Gln-Arg-Cys-Asp-Lys-
951 Cys-Lys-Ala-Gly-Thr-Phe-Gly-Leu-Gln-Ser-
961 Ala-Arg-Gly-Cys-Val-Pro-Cys-Asn-Cys-Asn-
971 Ser-Phe-Gly-Ser-Lys-Ser-Phe-Asp-Cys-Glu-
981 Glu-Ser-Gly-Gln-Cys-Tyr-Cys-Gln-Pro-Gly-
991 Val-Thr-Gly-Lys-Lys-Cys-Asp-Arg-Cys-Ala-
1001 His-Gly-Tyr-Phe-Asn-Phe-Gln-Glu-Gly-Gly-
1011 Cys-Thr-Ala-Cys-Glu-Cys-Ser-His-Leu-Gly-
1021 Asn-Asn-Cys-Asp-Pro-Lys-Thr-Gly-Arg-Cys-
1031 Ile-Cys-Pro-Pro-Asn-Thr-Ile-Gly-Arg-Lys-
1041 Cys-Ser-Lys-Cys-Ala-Pro-Asn-Thr-Tyr-Gly-
1051 His-Ser-Ile-Thr-Thr-Gly-Cys-Lys-Ala-Cys-
1061 Asn-Cys-Ser-Thr-Val-Gly-Ser-Leu-Asp-Phe-
1071 Gln-Cys-Asn-Val-Asn-Thr-Gly-Gln-Cys-Asn-
1081 Cys-His-Pro-Lys-Phe-Ser-Gly-Ala-Lys-Cys-
1091 Thr-Glu-Cys-Ser-Arg-Gly-His-Tyr-Asn-Tyr-
1101 Pro-Arg-Cys-Asn-Leu-Cys-Asp-Cys-Phe-Leu-
1111 Pro-Gly-Thr-Asp-Ala-Thr-Thr-Cys-Asp-Ser-
1121 Glu-Thr-Lys-Lys-Cys-Ser-Cys-Ser-Asp-Gln-
1131 Thr-Gly-Gln-Cys-Thr-Cys-Lys-Val-Asn-Val-
1141 Glu-Gly-Ile-His-Cys-Asp-Arg-Cys-Arg-Pro-
1151 Gly-Lys-Phe-Gly-Leu-Asp-Ala-Lys-Asn-Pro-
1161 Leu-Gly-Cys-Ser-Cys-Tyr-Cys-Phe-Gly-
1171 Thr-Thr-Thr-Gln-Cys-Ser-Glu-Ala-Lys-Ala-
1181 Leu-Ile-Arg-Thr-Tyr-Val-Thr-Leu-Lys-Ala-
1191 Glu-Gln-Thr-Ile-Leu-Pro-Leu-Val-Asp-Glu-
1201 Ala-Leu-Gln-His-Thr-Thr-Thr-Lys-Gly-Ile-
1211 Val-Phe-Gln-His-Pro-Glu-Ile-Val-Ala-His-
1221 Met-Asp-Leu-Met-Arg-Glu-Asp-Leu-His-Leu-
1231 Glu-Pro-Phe-Tyr-Tyr-Lys-Leu-Pro-Glu-Gln-
1241 Phe-Gly-Gly-Lys-Lys-Leu-Met-Ala-Tyr-Gly-
1251 Gly-Lys-Leu-Lys-Tyr-Ala-Ile-Tyr-Phe-Glu-
1261 Ala-Arg-Glu-Glu-Thr-Gly-Phe-Ser-Thr-Tyr-
1271 Asn-Pro-Gln-Val-Ile-Ile-Arg-Gly-Gly-Thr-
1281 Pro-Thr-His-Ala-Arg-Ile-Ile-Val-Arg-His-
1291 Met-Ala-Ala-Pro-Leu-Ile-Gly-Gln-Leu-Thr-
1301 Arg-His-Glu-Ile-Glu-Met-Thr-Glu-Lys-Glu-
1311 Trp-Lys-Tyr-Tyr-Gly-Asp-Arg-Val-
1321 His-Arg-Thr-Val-Thr-Arg-Glu-Pro-Phe-Leu-
1331 Asp-Ile-Leu-Tyr-Asp-Ile-His-Tyr-Ile-Leu-
1341 Ile-Lys-Ala-Thr-Tyr-Gly-Asn-Phe-Met-Arg-
1351 Gln-Ser-Arg-Ile-Ser-Glu-Ile-Ser-Met-Glu-
1361 Val-Ala-Glu-Gln-Gly-Arg-Gly-Thr-Met-
1371 Thr-Pro-Pro-Ala-Asp-Leu-Ile-Glu-Lys-Cys-
1381 Asp-Cys-Pro-Leu-Gly-Tyr-Ser-Gly-Leu-Ser-
1391 Cys-Glu-Ala-Cys-Leu-Pro-Gly-Phe-Tyr-Arg-
1401 Leu-Arg-Ser-Gln-Pro-Gly-Gly-Arg-Thr-Pro-
1411 Gly-Pro-Thr-Leu-Gly-Thr-Cys-Val-Pro-Cys-
1421 Gln-Cys-Asn-Gly-His-Ser-Ser-Leu-Cys-Asp-
1431 Pro-Glu-Thr-Ser-Ile-Cys-Asn-Cys-Gln-
1441 His-His-Thr-Ala-Gly-Asp-Phe-Cys-Glu-Arg-
1451 Cys-Ala-Leu-Gly-Tyr-Tyr-Gly-Ile-Val-Lys-
1461 Gly-Leu-Pro-Asn-Asp-Cys-Gln-Gln-Cys-Ala-
1471 Cys-Pro-Leu-Ile-Ser-Ser-Asn-Asn-Phe-
1481 Ser-Pro-Ser-Cys-Val-Ala-Glu-Gly-Leu-Asp-
1491 Asp-Tyr-Arg-Cys-Thr-Ala-Cys-Pro-Arg-Gly-
1501 Tyr-Glu-Gly-Gln-Tyr-Cys-Glu-Arg-Cys-Ala-

1511 Pro-Gly-Tyr-Thr-Gly-Ser-Pro-Gly-Asn-Pro-
1521 Gly-Gly-Ser-Cys-Gln-Glu-Cys-Glu-Cys-Asp-
1531 Pro-Tyr-Gly-Ser-Leu-Pro-Val-Pro-Cys-Asp-
1541 Pro-Val-Thr-Gly-Phe-Cys-Thr-Cys-Arg-Pro-
1551 Gly-Ala-Thr-Gly-Arg-Lys-Cys-Asp-Gly-Cys-
1561 Lys-His-Tyr-His-Ala-Arg-Glu-Gly-Tyr-Glu-
1571 Cys-Val-Phe-Cys-Gly-Asp-Glu-Cys-Thr-Gly-
1581 Leu-Leu-Leu-Gly-Asp-Leu-Ala-Arg-Leu-Gly-
1591 Gln-Met-Val-Met-Ser-Ile-Asn-Leu-Thr-Gly-
1601 Pro-Leu-Pro-Ala-Pro-Tyr-Lys-Met-Leu-Tyr-
1611 Gly-Leu-Glu-Asn-Met-Thr-Gln-Glu-Lys-Lys-
1621 His-Leu-Leu-Ser-Pro-Gln-Arg-Ala-Pro-Glu-
1631 Arg-Leu-Ile-Gln-Leu-Ala-Glu-Gly-Asn-Leu-
1641 Asn-Thr-Leu-Val-Thr-Glu-Met-Asn-Glu-Leu-
1651 Leu-Thr-Arg-Ala-Thr-Lys-Val-Thr-Ala-Asp-
1661 Gly-Glu-Gln-Thr-Gly-Gln-Asp-Ala-Glu-Arg-
1671 Thr-Asn-Thr-Arg-Ala-Lys-Ser-Leu-Gly-Glu-
1681 Phe-Ile-Lys-Glu-Leu-Ala-Arg-Asp-Ala-Glu-
1691 Ala-Val-Asn-Glu-Lys-Ala-Ile-Lys-Leu-Asn-
1701 Glu-Thr-Leu-Gly-Thr-Arg-Asp-Glu-Ala-Phe-
1711 Glu-Arg-Asn-Leu-Glu-Gly-Leu-Gln-Lys-Glu-
1721 Lys-Asn-Gln-Met-Ile-Lys-Glu-Leu-Arg-Arg-
1731 Lys-Asn-Leu-Glu-Thr-Gln-Lys-Glu-Ile-Ala-
1741 Gly-Asp-Glu-Leu-Val-Ala-Ala-Phe-Gly-Glu-
1751 Leu-Lys-Lys-Val-Lys-Lys-Leu-Phe-Gly-Glu-
1761 Ser-Arg-Gly-Glu-Asn-Glu-Glu-Met-Glu-Lys-
1771 Asp-Leu-Arg-Glu-Lys-Leu-Ala-Asp-Tyr-Lys-
1781 Asn-Lys-Val-Asp-Asp-Ala-Tyr-Asp-Leu-Leu-
1791 Arg-Glu-Ala-Thr-Asp-Lys-Ile-Arg-Glu-Ala-
1801 Asn-Arg-Leu-Phe-Ala-Val-Asn-Gln-Lys-Asp-
1811 Met-Thr-Ala-Leu-Glu-Lys-Lys-Ile-Glu-Ala-
1821 Val-Glu-Ser-Gly-Lys-Arg-Gln-Ile-Glu-Asp-
1831 Thr-Leu-Lys-Glu-Gly-Asn-Asp-Ile-Leu-Asp-
1841 Glu-Ala-Asn-Arg-Leu-Ala-Asp-Glu-Ile-Asp-
1851 Ser-Ile-Ile-Asp-Tyr-Val-Glu-Asp-Ile-Gln-
1861 Thr-Lys-Leu-Pro-Pro-Met-Ser-Glu-Glu-Leu-
1871 Asn-Asp-Lys-Ile-Asp-Asp-Leu-Ser-Gln-Glu-
1881 Ile-Lys-Asp-Arg-Lys-Leu-Ala-Glu-Lys-Val-
1891 Ser-Gln-Ala-Glu-Ser-His-Ala-Ala-Gln-Leu-
1901 Asn-Asp-Ser-Ser-Ala-Val-Leu-Asp-Gly-Ile-
1911 Leu-Asp-Glu-Ala-Lys-Asn-Ile-Ser-Phe-Asn-
1921 Ala-Thr-Ala-Ala-Phe-Lys-Ala-Tyr-Ser-Asn-
1931 Ile-Lys-Asp-Tyr-Ile-Asp-Glu-Ala-Glu-Lys-
1941 Val-Ala-Lys-Glu-Ala-Lys-Asp-Leu-Ala-His-
1951 Gln-Ala-Thr-Lys-Leu-Ala-Thr-Gly-Pro-Arg-
1961 Gly-Leu-Leu-Lys-Glu-Asp-Ala-Lys-Gly-Cys-
1971 Leu-Gln-Lys-Ser-Phe-Arg-Ile-Leu-Asn-Glu-
1981 Ala-Lys-Lys-Leu-Ala-Asn-Asp-Val-Lys-Glu-
1991 Asn-Glu-Asp-His-Leu-Asn-Gly-Leu-Lys-Thr-
2001 Arg-Ile-Glu-Asn-Ala-Asp-Ala-Arg-Asn-Gly-
2011 Asp-Leu-Leu-Arg-Thr-Leu-Asn-Asp-Thr-Leu-
2021 Gly-Lys-Leu-Ser-Ala-Ile-Pro-Asn-Asp-Thr-
2031 Ala-Ala-Lys-Leu-Gln-Ala-Val-Lys-Asp-Lys-
2041 Ala-Arg-Gln-Ala-Asn-Asp-Thr-Ala-Lys-Asp-
2051 Val-Leu-Ala-Gln-Ile-Thr-Glu-Leu-His-Gln-
2061 Asn-Leu-Asp-Gly-Leu-Lys-Lys-Asn-Tyr-Asn-
2071 Lys-Leu-Ala-Asp-Ser-Val-Ala-Lys-Thr-Asn-

2089 Ala-Val-Ala-Lys-Asp-Pro-Ser-Lys-Lys
2090 1-le-Ile-Ala-Asp-Ala-Asp-Ala-Thr-Val-Lys
2101 Asp-Leu-Glu-Gln-Glu-Ala-Asp-Arg-Leu-Ile
2111 Asp-Lys-Leu-Lys-Pro-Ile-Lys-Glu-Leu-Glu
2121 Asp-Asn-Leu-Lys-Lys-Asn-Ile-Ser-Glu-Ile
2131 Lys-Glu-Leu-Ile-Asn-Gln-Ala-Lys-Ser
2141 Ala-Asn-Ser-Ile-Lys-Val-Ser-Val-Ser-Gln
2151 Gly-Ile-Lys-Cys-Ile-Arg-Thr-Tyr-Lys-Pro
2161 Glu-Ile-Lys-Lys-Gly-Ser-Tyr-Asn-Asn-Ile
2171 Val-Val-Asn-Val-Lys-Thr-Ala-Val-Ala-Asp
2181 Asn-Leu-Leu-Phe-Tyr-Leu-Gly-Ser-Ala-Lys
2191 Phe-Ile-Asp-Phe-Leu-Ala-Ile-Glu-Met-Arg
2201 Lys-Gly-Lys-Val-Ser-Phe-Leu-Tyr-Asp-Val
2211 Gly-Ser-Gly-Val-Gly-Arg-Val-Glu-Tyr-Pro
2221 Asp-Leu-Thr-Ile-Asp-Asp-Ser-Tyr-Tyr-Lys
2231 Arg-Ile-Ala-Ser-Arg-Thr-Gly-Arg-Asn
2241 Gly-Thr-Ile-Ser-Val-Arg-Ala-Leu-Asp-Gly
2251 Pro-Lys-Ala-Ser-Ile-Val-Pro-Ser-Thr-Ile
2261 His-Ser-Thr-Ser-Pro-Pro-Gly-Tyr-Thr-Ile
2271 Leu-Asp-Val-Asp-Ala-Asn-Ala-Phe-Leu-Phe
2281 Val-Gly-Gly-Leu-Thr-Gly-Lys-Leu-Lys-Lys
2291 Ala-Asp-Ala-Val-Arg-Val-Ile-Thr-Phe-Thr
2301 Gly-Cys-Met-Gly-Glu-Thr-Tyr-Phe-Asp-Asn
2311 Lys-Pro-Ile-Gly-Leu-Tyr-Asn-Phe-Arg-Glu
2321 Lys-Glu-Gly-Asp-Cys-Lys-Gly-Cys-Thr-Val
2331 Ser-Pro-Gln-Val-Glu-Asp-Ser-Glu-Gly-Thr
2341 Ile-Gln-Phe-Asp-Gly-Glu-Gly-Tyr-Ala-Leu
2351 Val-Ser-Arg-Pro-Ile-Arg-Tyr-Tyr-Pro-Asn
2361 Ile-Ser-Thr-Val-Met-Phe-Lys-Phe-Arg-Thr
2371 Phe-Ser-Ser-Ser-Ala-Leu-Leu-Phe-Tyr-Leu
2381 Ala-Thr-Arg-Asp-Leu-Arg-Asp-Phe-Met-Ser
2391 Val-Glu-Leu-Thr-Asp-Gly-His-Ile-Lys-Val
2401 Ser-Tyr-Asp-Leu-Gly-Ser-Gly-Met-Ala-Ser
2411 Val-Val-Ser-Asn-Gln-Asn-His-Asn-Asp-Gly
2421 Lys-Tyr-Lys-Ser-Phe-Thr-Leu-Ser-Arg-Ile
2431 Gln-Lys-Gln-Ala-Asn-Ile-Ser-Ile-Val-Asp
2441 Ile-Asp-Thr-Asn-Gln-Glu-Glu-Ala-Ile-Ala
2451 Asp-Leu-Ser-Ser-Gly-Asn-Asn-Phe-Gly-Leu
2461 Asp-Leu-Lys-Ala-Asp-Asp-Lys-Ile-Tyr-Phe

Modified-site 303..305	note	"rod-like structure"
Modified-site 363..365	note	"N-linked glycosylation site"
Modified-site 380..382	note	"N-linked glycosylation site"
Modified-site 470..472	note	"N-linked glycosylation site"
Domain		
328..1723	note	Domain IVb
	note	"Predicted to form globular structure"
Domain		
724..1175	label	Domain IIb
	note	"Contains ten and one half Cystein-rich EGF-like repeats, predicted to have 'rigid rod-like structure'"
Modified-site 746..748	note	"N-linked glycosylation site"
Modified-site 1061..1063	note	"N-linked glycosylation site"
Domain		Domain IVa
1176..1379	label	
	note	"Predicted to form globular structure"
Domain		
1180..1573	label	Domain IIIa
	note	"Contains four Cystein-rich EGF-like repeats, predicted to have rigid rod-like structure"
Domain		
1574..2151	label	Domain I+II
	note	"Forms two B-type chains, forms triple coiled-coil structure"
Modified-site 1597..1599	note	"N-linked glycosylation site"
Modified-site 1614..1616	note	"N-linked glycosylation site"
Modified-site 1700..1702	note	"N-linked glycosylation site"
Modified-site 1810..1812	note	"N-linked glycosylation site"
Modified-site 1901..1903	note	"N-linked glycosylation site"
Modified-site 1916..1918	note	"N-linked glycosylation site"
Modified-site 1920..1922	note	"N-linked glycosylation site"
Modified-site 2017..2019	note	"N-linked glycosylation site"
Modified-site 2028..2030	note	"N-linked glycosylation site"
Modified-site 2045..2047	note	"N-linked glycosylation site"
Modified-site 2126..2128	note	"N-linked glycosylation site"
Domain		Domain G
2154..3110	label	
	note	"Forms large globule at end of laminin long arm"
Modified-site 2240..2242	note	"N-linked glycosylation site"
Modified-site 2360..2362	note	"N-linked glycosylation site"
Modified-site 2435..2437	note	"N-linked glycosylation site"
Modified-site 2479..2480	note	"N-linked glycosylation site"
Modified-site 2551..2553	note	"N-linked glycosylation site"
Modified-site 2558..2560	note	"N-linked glycosylation site"
Modified-site 2648..2650	note	"N-linked glycosylation site"
Modified-site 2868..2870	note	"N-linked glycosylation site"
Modified-site 2893..2895	note	"N-linked glycosylation site"

L7 ANSWER 34 OF 36 GENIE COPYRIGHT 2004 The Thomson Corp on STN
 LN AAR82244 Protein GENIE
 TI Production of fibrinogen in transgenic mammals - by introducing DNA
 fragments into the germ line of a non-human mammal and collecting milk
 from female progeny.

IN Dalrymple M A; Foster D C; Garner I; Punkard D E
PA (PHAR-N) PHARM PROTEINS LTD.
PI (ZYMO) ZYMOGENETICS INC.
PI ***WO 9523868 A1 19950908 99p***
AI WO 1995-052648 19950301
PRAI US 1994-206176 19940303
DT Patent
LA English
OS 1995-320582 (41)
CR N-PSDB: AAT03853
DESC Human fibrinogen A-alpha chain protein.
AN AAB82244 Protein DSENE
AA 24 A; 42 R; 29 N; 35 D; 0 B; 9 C; 18 Q; 44 E; 0 Z; 72 G; 16 H; 19 I;
33 L; 40 K; 12 M; 20 F; 38 P; 91 S; 50 T; 11 W; 9 Y; 32 V; 0 Others
SQL
SEQ3 644

1 Met-Phe-Ser-Met-Arg-Ile-Val-Cys-Leu-Val-
11 Leu-Ser-Val-Val-Gly-Thr-Ala-Tip-Thr-Ala-
21 Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-
31 Gly-Gly-Gly-Val-Arg-Gly-Pro-Arg-Val-Val-
41 Glu-Arg-His-Gln-Ser-Ala-Cys-Lys-Asp-Ser-
51 Asp-Tip-Pro-Phe-Cys-Ser-Asp-Glu-Asp-Tip-
61 Asn-Tyr-Lys-Cys-Pro-Ser-Gly-Cys-Arg-Met-
71 Lys-Gly-Leu-Ile-Asp-Glu-Val-Asn-Gln-Asp-
81 Phe-Thr-Asn-Arg-Ile-Asn-Lys-Leu-Lys-Asn-
91 Ser-Leu-Phe-Glu-Tyr-Gln-Lys-Asn-Lys-
101 Asp-Ser-His-Ser-Leu-Thr-Thr-Asn-Ile-Met-
111 Glu-Ile-Leu-Arg-Gly-Asp-Phe-Ser-Ser-Ala-
121 Asn-Asn-Arg-Asp-Asn-Thr-Tyr-Asn-Arg-Val-
131 Ser-Glu-Asp-Arg-Leu-Arg-Ser-Arg-Ile-Glu-
141 Leu-Lys-Arg-Lys-Val-Ile-Glu-Lys-Val-Gln-
151 His-Ile-Gln-Leu-Leu-Gln-Lys-Asn-Val-Arg-
161 Ala-Gln-Leu-Val-Asp-Met-Lys-Arg-Leu-Glu-
171 Val-Asp-Ile-Asp-Ile-Lys-Ile-Arg-Ser-Cys-
181 Arg-Gly-Ser-Cys-Ser-Arg-Ala-Leu-Ala-Arg-
191 Glu-Val-Asp-Leu-Lys-Asp-Tyr-Glu-Asp-Gln-
201 Gln-Lys-Gln-Leu-Glu-Gln-Val-Ile-Ala-Lys-
211 Asp-Leu-Leu-Pro-Ser-Arg-Asp-Arg-Gln-His-
221 Leu-Pro-Leu-Ile-Lys-Met-Lys-Pro-Val-Pro-
231 Asp-Leu-Val-Pro-Gly-Asn-Phe-Lys-Ser-Gln-
241 Leu-Gln-Lys-Val-Pro-Pro-Glu-Tip-Lys-Ala-
251 Leu-Thr-Asp-Met-Pro-Gln-Met-Arg-Met-Glu-
261 Leu-Glu-Arg-Pro-Gly-Asn-Glu-Ile-Thr-
271 Arg-Gly-Gly-Ser-Thr-Ser-Tyr-Gly-Thr-Gly-
281 Ser-Glu-Thr-Glu-Ser-Pro-Arg-Asn-Pro-Ser-
291 Ser-Ala-Gly-Ser-Tip-Asn-Ser-Gly-Ser-Ser-
301 Gly-Pro-Gly-Ser-Thr-Gly-Asn-Arg-Ala-Thr-
311 Gly-Ser-Ser-Gly-Thr-Gly-Gly-Thr-Ala-Thr-
321 Tip-Lys-Pro-Gly-Ser-Ser-Gly-Pro-Gly-Ser-
331 Ala-Gly-Ser-Tip-Asn-Ser-Gly-Ser-Ser-Gly-
341 Thr-Gly-Ser-Thr-Gly-Asn-Gln-Asn-Pro-Gly-
351 Ser-Pro-Arg-Pro-Gly-Ser-Pro-Gly-Thr-Tip-
361 Asn-Pro-Gly-Ser-Ser-Glu-Arg-Gly-Ser-Ala-
371 Gly-His-Tip-Thr-Ser-Glu-Ser-Ser-Val-Ser-
381 Gly-Ser-Thr-Gly-Gln-Tip-His-Ser-Glu-Ser-

391 Gly-Ser-Phe-Arg-Pro-Asp-Ser-Pro-Gly-Ser-
401 Gly-Asn-Ala-Arg-Pro-Asn-Asn-Pro-Asp-Tip-
411 Gly-Thr-Phe-Glu-Glu-Val-Ser-Gly-Asn-Val-
421 Ser-Pro-Gly-Thr-Arg-Arg-Glu-Tyr-His-Thr-
431 Glu-Lys-Leu-Val-Thr-Ser-Lys-Gly-Asp-Lys-
441 Glu-Leu-Arg-Thr-Gly-Lys-Glu-Lys-Val-Thr-
451 Ser-Gly-Ser-Thr-Thr-Thr-Arg-Arg-Ser-
461 Cys-Ser-Lys-Thr-Val-Thr-Lys-Thr-Val-Ile-
471 Gly-Pro-Asp-Gly-His-Lys-Glu-Val-Thr-Lys-
481 Glu-Val-Val-Thr-Ser-Glu-Asp-Gly-Ser-Asp-
491 Cys-Pro-Glu-Ala-Met-Asp-Leu-Gly-Thr-Leu-
501 Ser-Gly-Ile-Gly-Thr-Leu-Asp-Gly-Phe-Arg-
511 His-Arg-His-Pro-Asp-Glu-Ala-Ala-Phe-Phe-
521 Asp-Thr-Ala-Ser-Thr-Gly-Lys-Thr-Phe-Pro-
531 Gly-Phe-Phe-Ser-Pro-Met-Leu-Gly-Glu-Phe-
541 Val-Ser-Glu-Thr-Glu-Ser-Arg-Gly-Ser-Glu-
551 Ser-Gly-Ile-Phe-Thr-Asn-Thr-Lys-Glu-Phe-
561 Ser-Ser-His-His-Pro-Gly-Ile-Ala-Glu-Phe-
571 Pro-Ser-Arg-Gly-Lys-Ser-Ser-Ser-Tyr-Ser-
581 Lys-Gln-Phe-Thr-Ser-Ser-Thr-Ser-Tyr-Asn-
591 Arg-Gly-Asp-Ser-Thr-Phe-Glu-Ser-Lys-Ser-
601 Tyr-Lys-Met-Ala-Asp-Glu-Ala-Gly-Ser-Glu-
611 Ala-Asp-His-Glu-Gly-Thr-His-Ser-Thr-Lys-
621 Arg-Gly-His-Ala-Lys-Ser-Arg-Pro-Val-Arg-
631 Gly-Ile-His-Thr-Ser-Pro-Leu-Gly-Lys-Pro-
641 Ser-Leu-Ser-Pro
HITS ATT: 55-62
L7 ANSWER 35 OF 36 DSENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAB80020 Protein DSENE
TI New hybrid proteins for use in tissue sealing and wound healing -
comprising a tissue-binding domain from a protein covalently linked to a
crosslinking domain of another protein
IN Itani M H ZYMOGENETICS INC.
PA (ZYMO) ***WO 9416085 A2 19940721 87p***
PI WO 1993-US12687 19931230
PRAI US 1992-998271 19921230
DT Patent
LA English
OS 1994-249231 (30)
CR N-PSDB: AAO70008
DSSC Fibrinectin.
AN AAB80020 Protein DSENE
AA 24 A; 42 R; 29 N; 35 D; 0 B; 8 C; 18 Q; 44 E; 0 Z; 72 G; 16 H; 19 I;
33 L; 40 K; 12 M; 20 F; 38 P; 90 S; 50 T; 12 W; 9 Y; 32 V; 0 Others
SQL
SEQ3 643

1 Met-Phe-Ser-Met-Arg-Ile-Val-Cys-Leu-Val-
11 Leu-Ser-Val-Val-Gly-Thr-Ala-Tip-Thr-Ala-
21 Asp-Ser-Gly-Glu-Gly-Asp-Phe-Leu-Ala-Glu-
31 Gly-Gly-Gly-Val-Arg-Gly-Pro-Arg-Val-Val-
41 Glu-Arg-His-Gln-Ser-Ala-Cys-Lys-Asp-Ser-
51 Asp-Tip-Pro-Phe-Cys-Ser-Asp-Glu-Asp-Tip-
61 Asn-Tyr-Lys-Cys-Pro-Ser-Gly-Cys-Arg-Met-

641 Leu-Ser-Pro
HITS AT: 55-62

HITS AT: 55-62

```
FEATURE TABLE:
Key      | Location | Qualifier
```

Domain	Label	cell-binding_domain
1357..1903	label	cell-binding_domain

Domain	1532..1631	label	cell-binding_domain
	note		"acts as tissue-binding domain"

			of hybrid protein"
--	--	--	--------------------

L7 ANSWER 36 OF 36 DGENE COPYRIGHT 2004 The Thomson Corp on STN
AN AAR56269 peptide DGENE
TI Synthetic peptide(s) and antibodies against fragment E - derived from

IN
fibrinolytic system
Kraus M. Stuber W

PA (BEHW) BEHRINGSWERKE AG. 33P***
PI ***DE 4242736 A1 19940623

PRAI DE 1992-4242736 19921217

LA German

DESC Peptide corresponding to C-terminal
2456360 peptide
2456360 peptide

AA	1	A	2	K	3	N	0	D	0	B	4	C	3	Q	3	E	0	Z	2	G	1	H	2	L	3
I	6	K	1	M	3	F	2	P	5	S	1	T	2	W	2	Y	1	V	0	Others					

5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
66
67
68
69
70
71
72
73
74
75
76
77
78
79
80
81
82
83
84
85
86
87
88
89
90
91
92
93
94
95
96
97
98
99
100

11 Pro-Phe-Cys-Ser-Asp-Glu-Asp-Trp-Asn-Tyr-

21 Lys-Cys-Pro-Ser-Gly-Cys-Arg-Met-Lys-Gly-

41 Asn-Arg-Ile-Asn-Lys
51 Phe-Glu-Tyr-Gln-Lys

02-CT .TV CITY

his v =

(FILE 'HOME' ENTERED AT 15:27:24 ON 07 OCT 2004

FILE 'DGENE' ENTERED AT 15:28:00 ON 07 OCT 2004

```

L1      RUN STATEMENT CREATED
-----

```

334 S L2

E WESCOTT/IN

L5 334 S L2
L6 300 S L2 NOT E4
L7 36 S L6 AND PY <=2001

=> log h
COST IN U.S. DOLLARS
FULL ESTIMATED COST
SINCE FILE
ENTRY
TOTAL
SESSION
387.53
387.74

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 15:34:21 ON 07 OCT 2004

Connecting via Winsock to STN

Welcome to STN International! Enter X:X

LOGINID:SSSPFA1653RAW

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * Welcome to STN International * * * * *

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America
NEWS 2 "Ask CAS" for self-help around the clock
NEWS 3 BEILSTEIN enhanced with new display and select options,
resulting in a closer connection to EBBS
NEWS 4 IFIRAI/IFIRUB/IFICDB relocated with new search and display
fields
NEWS 5 Caplus and CA patent records enhanced with European and Japan
Patent Office Classifications
NEWS 6 AUG 02 The Analysis Edition of STN Express with Discover!
(Version 7.01 for Windows) now available
NEWS 7 BIOTECBAS/BIOTECBDS: Two new display fields added for legal
status data from INPADOC
NEWS 8 AUG 27 INPADOC: New family current-awareness alert (SDI) available
NEWS 9 SEP 01 New pricing for the Save Answers for Scifinder Wizard within
STN Express with Discover!
NEWS 10 SEP 01 New pricing for the Save Answers for Scifinder Wizard within
STN Express with Discover!
NEWS 11 SEP 01 New display format, HTSTR, available in WPIDS/WPIDEX/WPIX
NEWS 12 SEP 14 STN Patent Forum to be held October 13, 2004, in Iselin, NJ
NEWS 13 SEP 27 STANDARDS will no longer be available on STN
NEWS 14 SEP 27 SWETSCAN will no longer be available on STN
NEWS EXPRESS
JULY 30 CURRENT WINDOWS VERSION IS V7.01, CURRENT
MACINTOSH VERSION IS V6.0C(ENG) AND V6.0C(UP),
AND CURRENT DISCOVER FILE IS DATED 11 AUGUST 2004
STN Operating Hours Plus Help Desk Availability
General Internet Information
NEWS HOURS
NEWS INTER
NEWS LOGIN
NEWS PHONE
NEWS WWW
CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that
specific topic.

All use of STN is subject to the provisions of the STN Customer
agreement. Please note that this agreement limits use to scientific
research. Use for software development or design or implementation
of commercial gateways or other similar uses is prohibited and may
result in loss of user privileges and other penalties.

* * * * * STN Columbus * * * * *

FILE 'HOME' ENTERED AT 18:58:54 ON 07 OCT 2004

=> file reg
COST IN U.S. DOLLARS

FULL ESTIMATED COST
SINCE FILE
ENTRY
TOTAL
SESSION
0.21
0.21

FILE 'REGISTRY' ENTERED AT 18:59:03 ON 07 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 6 OCT 2004 HIGHEST RN 757927-15-4
DICTIONARY FILE UPDATES: 6 OCT 2004 HIGHEST RN 757927-15-4

TSCA INFORMATION NOW CURRENT THROUGH MAY 21, 2004

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

Crossover limits have been increased. See HELP CROSSOVER for details.

Experimental and calculated property data are now available. For more
information enter HELP PROP at an arrow prompt in the file or refer
to the file summary sheet on the web at:
<http://www.cas.org/ONLINE/DBSS/registryss.html>

=> s C(PNOST)[ANDOIGLMPSTWV][ES][PDENOSTV][WLNOSTV][FW]/C/SCSP
L1 17 C(PNOST)[ANDOIGLMPSTWV][ES][PDENOSTV][WLNOSTV][FW]/C/SCSP

=> file caplus
COST IN U.S. DOLLARS

FULL ESTIMATED COST
SINCE FILE
ENTRY
TOTAL
SESSION
26.92
27.13

FILE 'CAPLUS' ENTERED AT 18:59:17 ON 07 OCT 2004
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2004 AMERICAN CHEMICAL SOCIETY (ACS)

Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available

for records published or updated in Chemical Abstracts after December 26, 1996), unless otherwise indicated in the original publications. The CA Lexicon is the copyrighted intellectual property of the American Chemical Society and is provided to assist you in searching databases on STN. Any dissemination, distribution, copying, or storing of this information, without the prior written consent of CAS, is strictly prohibited.

FILE COVERS 1907 - 7 Oct 2004 VOL 141 ISS 15
FILE LAST UPDATED: 6 Oct 2004 (20041006/ED)

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> s 11
L2 4 L1

=> s 12 and PK<=2001
21560072 PK<=2001
L3 0 L2 AND PK<=2001

=> log h
COST IN U.S. DOLLARS
FULL ESTIMATED COST

	SINCE FILE ENTRY	TOTAL SESSION
	2.26	29.39

SESSION WILL BE HELD FOR 60 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 18:59:47 ON 07 OCT 2004